gsk unite science technology talent get ahead disease together aim positively impact health billion people end decade successful growing company people thrive contents strategic report corporate governance investor information ahead together board gsk leadership financial record performance key team product development pipeline performance indicators chairs governance statement products competition chairs statement corporate governance architecture intellectual property ceos statement ahead together board oversight principal risks uncertainties business model continuous engagements key share capital control external environment decisions dividends prevention board committee reports financial calendar culture people remuneration committee chairs annual general meeting research development annual statement tax information shareholders commercial operations annual report remuneration shareholder services contacts performance vaccines directors report us law regulation performance specialty medicines group companies performance general medicines financial statements glossary terms operations manufacturing directors statement supply responsibilities responsible business independent auditors report risk management disclosure financial statements statements notes financial statements principal risks summary financial statements gsk plc climaterelated financial prepared uk gaap disclosures naturerelated financial disclosures nonfinancial sustainability information statement employees gender viability statement group financial review cautionary statement see inside back cover document cautionary statement regarding forwardlooking statements nonifrs measures use number adjusted noninternational financial reporting standards ifrs measures report performance business total reported results represent groups overall performance ifrs adjusted results nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages reconciliations nearest ifrs measures pages strategic report governance remuneration financial statements investor information gsk annual report focused biopharma company strong momentum big ambitions prevent treat disease vaccines committed getting ahead specialty general medicines focus issues matter society science immune system sustainability company use new platform data technologies including access healthcare diversity investing four core therapeutic areas equity inclusion health infectious diseases hiv respiratory planet 're sector leaders esg immunology oncology ahead performance making impact together strategy means intervening early societys urgent challenges prevent change course disease helping protect people support purpose puts people heart healthcare systems success core ahead together ambition make gsk place confident future talented people thrive culture strong momentum improving outlook ambitious patients accountable sustained growth decade impact right thing 're confident ability deliver foundation together deliver human health impact scale worldwide patients shareholders gsk people strategic report governance remuneration financial statements investor information gsk annual report performance key performance indicators financial delivered strong performance upgraded growth outlooks broadbased performance drove sales profits earnings growth group turnover bn turnover product area bn l vaccines bn aer bn aer cer cer l specialty medicines bn aer cer l general medicines bn growth excluding covid solutions aer cer aer cer total operating profit bn adjusted operating profit bn bn bn aer aer cer cer growth excluding covid solutions aer cer total continuing earnings per share p adjusted earnings per share p p p aer aer cer cer p p p p p p growth excluding covid solutions aer cer cash generated operations bn free cash flow bn bn bn use number adjusted nonifrs measures report performance business adjusted results nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages aer actual exchange rate cer constant exchange rate excluding covid solutions defined adjusted operating profit positive impact excluding covid solutions cer adjusted eps positive impact excluding covid solutions cer key performance indicator attributable continuing operations linked executive remuneration see pages details strategic report governance remuneration financial statements investor information gsk annual report performance key performance indicators continued research development continued strengthen latestage pipeline organic rd delivery targeted business development supporting future growth bn innovation sales products major approvals including infectious assets phase iiiregistration launched major lifecycle diseases hiv oncology innovation expansion last five years assets pipeline major business development deals least major product launches planned pipeline value progress reported externally commercial sensitivity responsible business continue recognised environmental sustainability leadership esg performance rating track based performance metrics met exceeded metrics cover six focus areas access healthcare global health health security environment diversity equity inclusion ethical standards product governance see pages st pharmaceuticals industry global health pipeline assets reduction operational sp global corporate sustainability progressed address priority world carbon emissions scope assessment score health organization diseases november culture culture progress ambitious patients accountable impact right thing measured employee surveys employee engagement score remained high read planned launches products nonrisk adjusted peak year sales billion see 'guidance outlooks assumptions basis preparation related guidance outlooks ' inside back cover fy results slides gskcom strategic report governance remuneration financial statements investor information gsk annual report chair 's statement gsk continued make significant progress strategic transformation programme change emma growth driven strong rd progress team delivering performance across areas executing companys latestage fundamentally improving gsks business especially vaccines pipeline strengthening earlier competitiveness sharpening specialty medicines including hiv stage rd technological operational execution cost respiratory company capabilities remains companys discipline strengthening pipeline built significant leadership number one priority continues enhancing groups capital positions competitive advantage receive significant attention allocation capacity shifting exceptional launch worlds board including science gsks culture combine high integrity first rsv vaccine arexvy us committee undertook detailed performance clear stand achievement reviews several year research areas including vaccines also clear report gsk rna technology antimicrobial developing distinctive role voice cost discipline across group resistance amr oligonucleotides prevention disease offering clear continues improve following antibodydrug conjugates adcs benefits patients healthcare period necessary investment liver disease nash systems wider society product launches management focused delivering improving rd productivity strategic progress improvements operating margin inevitably longterm programme saw evidence coming years pleased see good success transformation progress made year operationally gsk performing previously discussed organically targeted better crucially demerger haleon business development total consistently competitively fundamentally reset strengthened deployed approximately billion point last years gsks balance sheet rd business development including monetised billion holding group sales operating profits acquisitions partnerships haleon enable investment grew strongly well ahead year pipeline future growth outlooks company emma sets letter cagr excluding covid pages gsk significant solutions previously set also confirmed potentially valuable late period gsks progress commitment shareholder returns stage rd programmes vaccines momentum progressive dividend policy infectious diseases hiv respiratory upgraded outlooks board agreed pay shareholders specific areas oncology respectively increased dividend p per share p per share successful progression comparable basis programmes vital support groups growth outlook second half decade beyond see 'guidance outlooks assumptions basis preparation related guidance outlooks ' inside back cover fy results slides gskcom gsk group dividend p gsk related excludes dividend related consumer healthcare h strategic report governance remuneration financial statements investor information gsk annual report chair 's statement continued culture responsibility clear extensive meetings also pleased welcome julie believe one strongest discussions brown chief financial officer drivers gsks longterm shareholders year cfo may last year julie brings performance culture shift recognise significant performance huge experience life sciences emma team driving improvements cfo large ukbased companies delivered emphasis moved seeing significant change gsk board excellent shorterterm outlooks focus developing clear many cases worldleading experience medium term purpose strengthening leadership expertise including human upgraded outlooks given embedding businessrelevant genetics vaccines respiratory periods show confidence values behaviours infectious disease advanced board management technologies including ai ml ensuring environmental social gsks future biopharma commercial financial governance considerations also uncertainty around zantac expertise us payer hcp properly embedded strategy ranitidine litigation clearly patient understanding remains important impacted gsks share price delighted see company gsk performing better performance months ranked first sector sps done many years continue vigorously defend assessment corporate increasingly positive outlook remaining sustainability due energy commitment claims us including leadership emma team gsk also continues lead ongoing proceedings delaware support companys ambitious approach ensuring global access hope see greater clarity programme change products developing litigation new medicines vaccines finally would also like thank board evolution diseases malaria tb people partners customers composition maturity disproportionately affect shareholders support board continues improve ensure poorest countries world commitment last year relevant skills look forward another year also second year experience provide good oversight progress gsk operation new remuneration support constructively policy designed support challenge management gsks achievement outperformance business develops pure across strategic financial esg biopharma company goals believe helping pleased welcome wendy drive strong performance becker board october culture deep commitment sir jonathan symonds wendy highly experienced responsibility evident gsk chair nonexecutive director brings shareholder returns excellent business technology board remains focused life sciences experience delivering strong shareholder returns also succeed urs rohner valuation gsk long chair remuneration term committee steps may agm would like thank urs contribution gsk board particularly development new remuneration policy approved incentivise reward management performance consistent determined supporter gsk provided huge support emma strategic report governance remuneration financial statements investor information gsk annual report ceos statement gsk delivering commitments performing new standard excellent performance since also added shingles vaccine shingrix delivered provides us multiple new opportunities also delivered another strong clear momentum expect targeted business development performance billion deliver another year meaningful securing acquisitions sales specialty medicines growth continue alliances innovative assets hiv business grew strongly focus prevention changing new technologies cer driven acceleration oral course disease twodrug longacting injectable achieved whilst regimens treatment delivering commitments maintaining continued sharp focus prevention also saw good set series operating margins cash flow progress respiratory commitments shareholders mindful need invest marketleading il nucala including 'stepchange ' future deliver attractive cer lupus treatment benlysta performance following significant returns shareholders also major contributor cer transformation gsks structure strong performance overall sales new products strategy capital allocation set pages launched since contributed culture performance demonstrated billion since delivered progress sales excluding level performance helped us quarters consecutive sales growth covid solutions total generate free cash flow billion excluding covid solutions adjusted profits growing double consequence performance around twothirds sales digit levels cer momentum also pleased generated vaccines clear highlight year increase dividend year specialty medicines key strategic exceptional launch arexvy pence per share priority worlds first vaccine rsv pipeline strengthening time continued contributed billion sales rd continued make strengthen pipeline first year american progress organically vaccines medicines adults aged years older business development set clinical development majority vaccinated rsv pages delivered latestage assets highlighted twothirds four major product approvals moved forward positively vaccinated arexvy year arexvy apretude hiv time expect arexvy generate prevention ojjarra myelofibrosis annual sales billion jemperli firstline endometrial sales driven cancer assets phase iii penetration initial roll registrational studies looking vaccine europe japan forward significant late expansion arexvys indication stage rd milestones risk individuals aged years strategic report governance remuneration financial statements investor information gsk annual report ceo 's statement continued targeted business development also upgraded outlook longterm goals key continued strengthen pipeline sales grow metrics place areas support future growth activity adjusted profit overall performance rating included acquisition cagr basis track based bellus health aiolos bio believe deliver metrics met exceeded strengthen respiratory billion sales increase highlights year included pipeline signing licence billion versus estimate moving phase iii development agreements janssen hansoh gave billion lowcarbon ventolin inhaler pharma infectious diseases represents marked acceleration programme achieving leadership oncology effect expect reach diversity aspirations two years early original goal five gavi confirming roll upgrading outlooks years earlier malaria vaccine mosquirix expect another year countries africa details meaningful growth sales adjusted continue focus strongly set pages operating profit eps margin improvements retaining published standalone esg also upgraded outlooks flexibility invest growth performance report previously gave period keep working deliver important emphasise none clear momentum look ahead forecasts include anticipated conclusion gsk strong progress business development progress momentum improving outlooks made develop portfolio earlystage pipeline standalone biopharma company pipeline additional productivity improvements expertise developing innovative alongside current growth drivers vaccines medicines points strong outlook planning least enormous opportunity prevent gsk sustained growth major product launches change course disease decade next four hundreds millions people years building trust bodes well equally also committed making gsk includes new potential know much done place talented people vaccines meningitis influenza remain focused delivering thrive culture pneumococcal disease herpes potential continued ambitious patients accountable simplex virus hsv potential pace patients shareholders impact right thing medicines longacting hiv people positive engagement scores treatment prevention potential remain high latest finally ever people functional cure hepatitis b employee engagement survey fuel momentum want bepirovirsen new portfolio thank achieved potential antiinfective treatments operating responsibly remains core optimistic including gepotidacin also gsk aim continue delivering future excited potential new medicines respiratory sectorleading esg performance achieve get ahead disease diseases high burden unmet recognised latest ranking together need depemokimab camlipixant sector leaders sps global finally oncology corporate sustainability assessment potential indications reflects strong progress across jemperli potentially cd six core esg areas access targeting variety cancer types healthcare global health health emma walmsley security environment diversity equity chief executive officer inclusion ethical standards product governance closed early see 'guidance outlooks assumptions basis preparation related guidance outlooks ' inside back cover fy results slides gskcom strategic report governance remuneration financial statements investor information gsk annual report business model unite science technology talent get ahead disease together health impact shareholder returns thriving people central success people experts science technology manufacturing regulation intellectual property commercialisation gsk people countries worldwide suppliers working directly gsk bn rd investment manufacturing sites global rd centres aer cer us uk belgium italy identifying researching developing testing groundbreaking discoveries manufacturing commercialising vaccines specialty medicines general medicines broad vaccines portfolio targets specialty medicines prevent portfolio infectious diseases every stage treat diseases hiv primary care medicines including life helping protect people respiratory diseases immune inhaled medicines asthma meningitis shingles rsv flu polio inflammation diseases like lupus copd antibiotics infections many cancer many first bestinclass products prevent treat disease improving health millions people around world core therapeutic areas infectious diseases hiv respiratory oncology infectious diseases leaders hiv immunology emerging portfolio broadest focused ending pushing frontiers portfolio focused blood industry including global epidemic respiratory science women 's cancers hiv accounts two thirds industryleading harnessing science seeking pipeline pipeline driven patient immune system make transformative insights transform patient outcomes breakthroughs areas unmet need immunooncology based decades innovative research total rd expenditure includes intangible asset amortisation impairments plus immaterial amounts major restructuring costs strategic report governance remuneration financial statements investor information gsk annual report business model continued powered technology pipeline performance people productivity leveraging new platform use technology enable technology also core data technology every step productive efficient work ensure people rd process faster manufacturing processes supply chain tools analytical capabilities effective predictive reliability returns investment resources make datadriven discovering developing innovative decisions best work new medicines vaccines steered longterm priorities innovation performance trust develop launch new bold ambitions patients focus issues medicines vaccines reflected upgraded growth greatest impact reduce needed better outlooks pressure health systems including faster rd tackling health challenges inequities protecting environment taking action diversity equity inclusion creating value patients shareholders society bn p bn packs medicines per share dividend corporate income tax paid doses vaccines delivered addition pay duties levies transactional employment taxes economy disease prevention earlier intervention improve health lessen pressure health systems support economic productivity people support people grow well work really matters reinvestment returns make enable us reinvest discovering developing new vaccines medicines continue getting ahead disease company directors required law promote success organisation benefit shareholders wider stakeholders including employees suppliers community information issues factors stakeholders board considers relevant complying section f companies act section statement corporate governance section business model supported esg strategy described strategy supported robust framework monitoring managing risk see strategic report governance remuneration financial statements investor information gsk annual report external environment five major themes influenced external environment set mean us responding economic growth shows resilience pressure continues public finances global economy proved notable pockets public spending including health resilient expected strength americas economy grew remains strain governments recovery remained relatively buoyed sustained consumer face unprecedented pressure fragile uneven prospects spending robust government finances due string economic diverging regions spending associated shocks sustained sluggish growth infrastructure investment legislation higher debt higher interest rates many countries continued grapple passed making challenging persistent inflation driven resilience always mirrored service debts compelling factors including tight labour markets elsewhere example forecasts governments make tough choices several major central banks eurozone revised downwards direct spending responded increasing interest rates region continued feel adding burden rising costs impact weaker demand consumers businesses despite higher costs sticky inflation consequent tightening monetary policy amid rising levels debt political global economy continued expand volatility global growth prospects albeit slower rate remain tepid global growth forecast slow geopolitical tensions fuel shifting alliances fragmentation regionalisation countries look diversify de continued grow risk supply chains strategic ongoing conflicts ukraine sectors including biopharmaceuticals middle east focusing ever many looking towards india attention political alliances alternative supplier china august six yet backdrop activity countries invited join tensions china us china 's biopharmaceutical sector brics group remained new export controls resilient recognising acceleration combined economies investment screening mechanisms chinese innovation growth enlarged group would emerging sides particularly potential worth trillion focused critical minerals ai quarter semiconductors biotechnologies low middleincome world 's economy signs relations countries capitalised global policy improving two nations forums un general presidents meeting assembly set agenda issues first time year sidelines related health new technologies asiapacific economic industrial development cooperation summit diverse voices global platforms inequality seen critical issue new alliances also emerged governments must collectively potentially shifting weight make progress healthcare influence various blocs summit debates around best measure august saw brics group widening access attention countries widen membership equitable distribution first time since inviting six infrastructure capability know countries including saudi arabia make health products iran join protecting intellectual property rights efficient supply chains httpswwwimforgenblogsarticlesresilientglobaleconomystilllimpingalongwithgrowingdivergences httpswwwbbccouknewsworld strategic report governance remuneration financial statements investor information gsk annual report external environment continued changing demographics create opportunity innovation prevention pressures health systems continued savings health systems us look biopharma industry amid ongoing efforts progressed implementation driver innovation economic recover rebuild aftermath inflation reduction act ira growth us president 's state covid pandemic populations included selecting first drugs union address underlining ageing bringing complex potential price cuts new appetite better health needs chronic diseases programme enabling medicare treatments particularly cancer taking increasing toll infectious negotiate price highlights potential diseases remain significant threat costliest medicines could biopharma industry partner potentially limit future innovation recovery harnessing science individual impact changing access currently available technology provide solutions demographics disease patterns medicines ira bring help prevent change course extends societies economies meaningful benefits certain disease bring value individuals large poor health significant drag medicare patients access health systems societies economic growth every year poor vaccines without bear health costs around global real part cost gdp premature deaths lost bn productive potential among working eu also took forward legislation age people uk alone could test pharmaceutical million working days estimated innovation competitiveness societies ageing bringing lost year due illness meanwhile uk agreed fiveyear different health challenges deal aimed reducing medicine costs number people aged despite potential improve nhs setting annual limit years older worldwide individual outcomes boost allowed growth sales value projected double economic productivity branded medicines rising million investing health particularly billion prevention earlier intervention even governments sought ways governments continued look cost cut medicine costs continued balancing potential tech data appropriate use rapid advances science revolutions data technological consider contextspecific use ai technology continue shape life capabilities open new possibilities healthcare us uk sciences sector rd established patients advances drug continue consider place technologies small molecules discovery well enhancing appropriate guardrails around use vaccines remain key emerging manufacturing supply ai supporting innovation technologies maps medicines possibilities considering implications specific dnarna therapeutics including improving health outcomes need sectors landmark summit oligonucleotides gaining ground balanced appropriate regulation november uk eu us building market share major supports innovation ensures australia china agreed work biopharma companies continue responsible use develop together ai safety research increase focus artificial technology well intelligence machine learning ai use apply year ml accelerate drug discovery debate around regulation ai bn progress hinges diverse patient gathered pace governments data available stepped efforts examine computational research particular technologys promise risks last five years biopharma genomic data linked health entered collaborations first legislation kind eu information held clinical records ai companies passed ai act june taking estimated worth stringent approach billion wwwmckinseycomindustrieshealthcareourinsightshowprioritizinghealthcouldhelprebuildeconomies wwwcbiorgukmediacentrearticlesboostingworkforcehealthcanhelptheukachieveeconomicgrowthambitionssayscbi wwwunorgdevelopmentdesadspdwpcontentuploadssiteswsrchapterkeymessagespdf chapter key messageswsr unorg wwwaccenturecomcontentdamaccenturefinalaccenturecomdocumentaccenturetechvisionbiopharmaaccenturemerging atomsandbitsinlifesciencesvpdf strategic report governance remuneration financial statements investor information gsk annual report external environment continued pressure increasing climate nature action economic pressures political international climate 's also growing focus realignments influencing conference cop dubai countries limiting nature loss taskforce countries approach global challenges committed transition away naturerelated financial disclosures need collective action including fossil fuels triple renewable released final recommendations climate change nature loss energy capacity also saw providing risk management intergovernmental panel climate climatehealth agenda given disclosure framework change issued 'final warning ' prominence ever organisations report act march keep c degrees governments endorsing cop evolving naturerelated risks target within reach setting declaration climate health see responsible business section urgency sufficient swift climate companies continue take action naturerelated action regions see need reduce climate impact protect financial disclosures climate action opportunity business model taking steps use green policies lever ensure products supply chains growth example european remain resilient consequences commission set green deal climate change scientific evidence industrial plan make europe link climate change centre clean technology human health means continue evidence innovation see high expectations healthcare growing investor interest policy makers tackled rising sector reduce carbon emissions nature nature action inflation increased living costs respond health impacts aims mobilise institutional climate targets came pressure climate change year investors establish uk softened net zero policies biopharma companies stepped common agenda eu environment ministers commitments including strengthen corporate action nature increase target reducing locally led adaptation health focus eight sectors greenhouse gas emissions resilience programmes vulnerable including biotechnology opposition member communities affected climate pharmaceuticals countries change position challenging economic includes example advocating populations ageing infectious political landscape 's critical appropriate ip protections diseases still spreading invest pipeline vaccines balanced regulatory framework chronic diseases taking greater medicines prevent supports discovery delivery toll creating unsustainable change course disease vaccines medicines developed pressure health systems meet changing unmet healthcare emerging technologies ever believe getting ahead needs time reinforcing importance global disease best investment work governments regulators diversified supply chains patients carers communities health industry partners make sure systems economies pricing environment becomes medicines vaccines reach tougher believe well placed well continue work patients scale bringing value offer differentiated highvalue governments payers partners people need pipeline across prevention move towards new models care payers treatment disease built enable earlier action prevent scientific innovation critical lever using transformational new technology diagnose treat disease together improve health boost productivity techniques make rd opportunity rethink economic growth ease faster smarter demand data health treat sickness strain health systems continue realworld evidence support invest keeping people well work peers continued reimbursement new governments make sure products likely increase policy regulatory environment prevention continue work payers stimulates sustains innovation underpins purpose get ahead design innovative solutions disease see manage risk uncertainty also recognising full health social economic value httpssciencebasedtargetsorgblog ipccreleasesfinalwarningtokeep innovative medicines vaccines cwithinreach strategic report governance remuneration financial statements investor information gsk annual report gsk believe prevention best medicine prevention heart getting ahead disease preventing ill health first place stopping disease tracks prevention prevention mean us important preventing changing course opportunity prevent disease disease heart first place well change course health systems stretched mean getting ahead disease disease helping prevent health needs evolving together harnessing science slow progression illness limit demographics disease technology longterm complications patterns change prevention focus across pipeline portfolio including million vaccines premature deaths among weve built one broadest vaccine portfolios people could industry help protect people stages life avoided better childhood older age wide range prevention healthcare vaccine technologies like maps mrna adjuvants interventions across oecd take targeted approach allowing us develop countries amounts tailored vaccines different diseases individuals quarter deaths see source oecd hiv trillion decades weve transformed lives people living hiv making breakthroughs treatment loss productivity year prevention focusing research novel treatment g preventable options allow people living hiv take fewer conditions among people drugs take much less often weve also aged source ilcuk developed longacting regimen prevent hiv see trillion severe asthma us alone health spending decades experience respiratory care projected reach almost led us create treatments could bring patients trillion source cms closer ever remission severe asthma could free exacerbations attacks cause cumulative lung damage could potentially prevention earlier avoid hospitalisation removing need oral intervention offer solution corticosteroids stabilising lung function controlling challenges helping symptoms see improve people 's health outcomes bring benefits hepatitis b health systems using latest aiml techniques scientists economies identified biomarkers help work treatment combinations fit patients potentially trillion increases likelihood achieving 'functional cure ' virus longer present blood liver functions normalised stopping future could added global gdp damage see improving health around half annual economic benefits would come believe preventing want work patients policy larger healthier getting ahead disease best makers peers stop disease investment everyone patients tracks creating right conditions workforce source mckinsey carers communities health systems champion prevention enable economies timely proactive access preventative interventions strategic report governance remuneration financial statements investor information gsk annual report culture people purpose unite science technology talent get ahead disease together puts people heart success culture digital technology remain core purpose delivery ambitions built people 's skills committed making gsk place people area global events datacon thrive culture ambitious employees experience immersive sessions see first patients accountable impact right thing hand apply digital data tech tools including means support people things better generative ai become digitally fluent year faster focusing matters means setting clear employees took part every business objectives creating accountability results giving unit countries data academy employees everyone support space need succeed access resources online training 've run means everything responsibly integrity programmes develop senior leaders ' leadership care people patients around world count skills digital age 've also piloted career hub us culture embedded everything using ai match employees mentors projects recruitment onboarding training development potential job opportunities scale assessments performance promotion enhanced onboarding experience new code sets culture well commitments joiners introducing monthly live virtual sessions gsk people make deliver ceo senior leaders access senior ambition right way people sign global leaders beginning career us code annually personally commit im aim provide intimate connection gsk see code gskcom patients serve creating emotional connection purpose strategy culture complement ongoing helping people thrive local onboarding activities making gsk place people thrive core supporting people managers ahead together ambition thriving different individual common themes matter people managers play crucial role helping everyone firstly belief purpose desire teams thrive connecting contributions team live culture contribute delivering ambition makes patient gsk 's broader impact expect secondly feeling included able people managers motivate focus care develop opportunities keep growing support feedback teams deliver training anchored four space needed succeed finally feeling good areas vps invited attend four positive mental physical financial social wellbeing day inperson event called leading leaders programme means gsk place people feel help leaders bring best teams foster welcome valued environment including culture need succeed together also continue policies workplaces ways working enables invest growing next generation senior leaders supports deliver best support talent succession needs bespoke development interventions equipping leadership welcoming developing outstanding people skills future committed developing outstanding people giving opportunities grow expect people agreed development plan regardless grade role based conversation understand space support need succeed continue invest learning development initiatives everyone access keep growing campus training knowledge sharing platform httpswwwgskcomengbcompanygovernancecompliancethecode strategic report governance remuneration financial statements investor information gsk annual report culture people continued maintaining momentum diversity equity performance choice inclusion performance choice approach hybrid working continuing focus building diverse officebased roles quarter organisation equitable inclusive culture people allows right balance onsite remote everyone feels welcome valued included taking working clear expectations people take steps ensure equal opportunity nondiscrimination accountability spend enough time together person delivering ambition make leadership maintaining flexibility help us continue build teams diverse inclusive support sense community connectedness enable development numerous offerings development achieve ahead together ambitions employees including awardwinning leadership data annual employee survey shows broad development programme accelerating difference support approach expectations also people complete mandatory dei module recognising rewarding people part annual training year focused create inclusive workplace people thrive sharing success recognising rewarding people equitably progress made details dei aspirations see responsible made continues important part business section culture addition bonus scheme rewards performance across company year award health wellbeing volunteering people extra ahead together awards health wellbeing benefits support people delivering exceptional performance line different life stages fair inclusive include accountable impact ambitious patients global minimum standard weeks parental leave right thing identify people primary secondary carers forms family missed performance delivering global minimum standard care family member objectives living culture end life serious health emergencies insured benefits include samesex partners wherever possible mental people experience gsk health training available everyone also ensure continue listen people regularly enhanced financial wellbeing support employees measure experience gsk place work introducing nudge financial education platform includes annual survey employees featuring countries helping people manage finances questions engagement confidence inclusivity achieve financial goals culture focus areas trust priorities proud reignited volunteering across company engagement levels remained high focused ambition charitable investment themes also continue see high scores positive upward health people health planet innovators trends confidence delivery strategy future employees volunteer one two culture focus areas ambitious patients accountability days year taking part teambased handson impact right thing well measures together days skillsbased volunteering inclusion expanded analysis survey smaller number people volunteer four days understand differences employee experience across year selected skillsbased volunteering projects diverse characteristics continue make good progress creating culture workplace people feel sense belonging thrive measure effectiveness global managers teams provide feedback annual one survey managers receive anonymised aggregate feedback managers rated highly effective teams strategic report governance remuneration financial statements investor information gsk annual report research combine science immune system technology outstanding talent find development new ways prevent treat challenging diseases better faster strategic report governance remuneration financial statements investor information gsk annual report research development highlights vaccines medicines phase iiiregistration major approvals pipeline arexvy worlds first rsv vaccine older shingrix vaccine shingles approved adults approved us eu japan people risk japan positive data first efficacy trial adults aged apretude longacting preventative treatment china hiv approved first hiv prevention option europe positive phase iii data menabcwy vaccine candidate supporting filing ojjaaraomjjara approved us eu uk first treatment us fda fasttrack designation gonorrhoea newly diagnosed previously treated vaccine candidate myelofibrosis patients anaemia targeted business development including jemperli approved us eu uk acquisition bellus health aiolos bio frontline immunooncology respiratory licence agreements janssen treatment combination chemotherapy infectious diseases hansoh pharma patients dmmrmsih primary oncology advanced recurrent endometrial cancer rd approach focusing execution technology culture rd purpose unite science technology talent priorities rd get ahead disease discover execution accelerate pipeline including develop vaccines medicines transform business development deliver innovative vaccines peoples lives medicines see rd expenditure billion aer technology deliver innovation better faster cer driven investment across using new platform data technologies speed portfolio weve also strengthened pipeline discovery development improve chance technology capabilities business development success see seeking new differentiated opportunities diseases high patient need vaccines culture create agile innovative environment thats medicines development many potential ambitious patients attracts best people firstinclass bestinclass scientists partners see revolutionary era science technology making rapid advances drive discovery development vaccines medicines across prevention pipeline consider prevent disease underpins purpose get ahead first place also intervene treat earlier change disease see course preventing slowing progression illness limiting longerterm complications closed early strategic report governance remuneration financial statements investor information gsk annual report research development continued execution pipeline acceleration business development reinforced status world leader transformational vaccines medicines infectious diseases gained approvals us eu japan worldfirst respiratory syncytial virus broad portfolio pipeline based science rsv vaccine older adults arexvy japan immune system use new platform data shingles vaccine shingrix people risk technologies continues strengthen key milestones across core therapeutic areas positive hiv reshaping treatment prevention momentum together business development delivering longacting regimens apretude underpins confidence delivering upgraded growth approved europe hiv prevention oncology outlooks medium long term optimising portfolio focusing blood women 's cancers breakthroughs immunooncology across phases pipeline vaccines approvals ojjaara first treatment medicines modulate immune system specifically indicated myelofibrosis patients similar proportion based genetic evidence anaemia jemperli frontline treatment began eight phase programmes moved endometrial cancer also positive phase iii results assets phase ii three phase iii since blenrep treatment multiple myeloma development cycle times shortened business development critical contributor growth years median years compared creating extra value patients partners shareholders industry 's years major deals include acquisition bellus health investing heavily latestage pipeline aiolos bio new collaborations including janssen drive growth line therapeutic area strategies hansoh pharma believe bolster rigorously evaluate earlystage portfolio back existing strengths across therapeutic areas right programmes maximise impact health focus four therapeutic areas unlock pipeline value infectious diseases see reflecting progress planning least major product launches hiv see respiratoryimmunology see oncology see infectious diseases infectious diseases affect everyone everywhere years weve pioneered novel research methods putting major strain societies healthcare systems technologies help protect people infectious combined expertise vaccines medicines means diseases including chronic infections hepatitis b hiv focus prevention treatment shingles seasonal infections rsv influenza common infectious diseases resulting significant public health childhood diseases measles rare devastating benefits reduced deaths increased productivity two conditions meningitis range bacterial infections thirds vaccines medicines pipeline address made challenging antimicrobial resistance amr infectious diseases including hiv world well diseases predominantly affect lower leader area income countries malaria tb rotavirus billion people reach decade significant infectious diseases responsible estimated majority infectious disease portfolio one six deaths globally broadest industry around one billion people infected every year key highlights included approvals arexvy viruses like rsv influenza virus sarscov worldfirst rsv vaccine adults aged many need hospital treatment positive phase iii data pentavalent meningitis millions struggle bacterial fungal infections vaccine candidate live chronic viral conditions like hepatitis b hep b hiv vaccinepreventable diseases impose significant medical economic costs related treatment cover resulting productivity losses closed early strategic report governance remuneration financial statements investor information gsk annual report research development continued tackling rsv world 's first arexvy vaccine immunity make protecting older people infectious diseases challenging around older people year face hospital stays rsv shingrix approved japan prevention shingles people increased risk instance people underlying conditions like chronic obstructive due immune suppression immune deficiency pulmonary disease copd asthma diabetes heart vaccine approved japan people aged disease increased risk severe outcomes older since latest approval followed six rsv pneumonia clinical trials people aged older increased risk around people year die rsv us shingles including undergone stem cell eu figure closer transplants kidney transplants blood cancer solid tumours hiv regulatory application arexvy approved us eu japan patient group also accepted review china several countries prevention lower national medical products administration february respiratory tract disease caused rsv adults aged older followed positive phase iii data published reported data firstever efficacy trial new england journal medicine showed shingrix china demonstrated vaccine efficacy exceptional efficacy older people including results come phase iv trial zoster certain underlying medical conditions severe evaluated efficacy safety vaccine rsv reported data season two preventing shingles adults aged older ongoing phase iii trial showing vaccine efficacy two progressing towards meningitis vaccine complete rsv seasons clinical development programme continue evaluate longerterm followup around million people contract invasive optimal timing potential revaccination meningococcal disease imd year one six people diagnosed die us following approval us food drug administration fda us centers disease control least one five imd survivors longterm preventions advisory committee immunisation disabilities including brain damage deafness nervous practices recommended adults years age system problems older may receive single dose vaccine using shared meningitis acwy vaccine menveo meningitis b clinical decisionmaking vaccine bexsero together protect forms arexvy available across us canada multiple imd firstgeneration vaccine candidate european countries regulatory reviews countries combines vaccines aiming protect ongoing approvals launches expected serotypes cause disease globally single throughout beyond vaccine presented preliminary phase iii data european society paediatric infectious diseases also reported positive preliminary data showing vaccine candidate performed statistically clinical trial people aged increased risk rsv well bexsero menveo people aged showing noninferior immune responses compared adults currently investigational vaccine data aged older based data february show immunological effectiveness diverse us fda accepted regulatory application meningitis b invasive strains trial priority review extend vaccine 's indication adults aged increased risk regulatory submissions multivalent vaccines kind potential adults aged also accepted european support 's strategy eradicate meningitis medicines agency japanese ministry health also second generation vaccine labour welfare expect generate phase ii development aims improve protection data people aged older increased risk rsv b strains broader age groups well trials exploring coadministration trials investigational medicine chronic adult vaccines including shingles pneumococcal disease hepatitis b chb around million people living chb expanding use shingles vaccine one three people develop shingles lifetime people diagnosis sometimes serious consequences like longterm receive treatment almost million die year nerve pain loss vision currently patients take nucleosidenucleotide analogues shingrix vaccine protect people shingles na often life suppress virus launched countries people people rarely clear increased risk shingles shingrix specifically years weve leader hepatitis b vaccination designed combine one adjuvants antigen bepirovirsen tripleaction antisense oligonucleotide selected enhance protective immune response based potential cornerstone functional cure understanding virus causes shingles patients chb could eliminate need continued formulation helps overcome natural agerelated decline therapy ultimately reducing longterm risk developing liver complications strategic report governance remuneration financial statements investor information gsk annual report research development continued hope hepatitis b ' didnt know anything hepatitis b husband adopted daughter maren months old ' said maureen hepatitis b caregiver advocate 'my heart broke watched baby cry receiving injections endure resulting side effects doubt chronic hepatitis b scary stigma makes doesnt lifelong burden reason hope im energised ongoing research new treatment options could alleviate burden frequent often invasive treatments management chronic hepatitis b people including scientists gsk working towards finding functional cure ' maureen maren bepirovirsen single agent phase iii development maps potentially enables higher antibody responses shown clinically meaningful functional cure diseasecausing serotypes broader response patients chb receiving na therapy stronger protection see continue examine demonstrated bclear bsure clinical trials potential acceleration options plus valent well developing bepirovirsen phase iii trials programmes infants adults patients receiving nas also exploring potential herpes simplex virus sequential therapy options aim helping genital herpes chronic sexually transmitted infection patients achieve functional cure caused herpes simplex type hsv herpes october announced exclusive licence simplex type hsv viruses agreement phase ii small interfering rnabased worldwide estimated million people aged therapeutic originally developed arrowhead living hsv genital hsv infection pharmaceuticals provides opportunity develop potential novel sequential regimen many patients suffer frequent outbreaks along benefit broader group patients potentially psychological morbidity stigma threefold increase drive higher functional cure rates risk acquiring hiv infectious diseases gsk candidate hsv contains pneumococcal disease hsv antigens complemented adjuvant designed stimulate immune responses people already infected pneumococcal disease name illness caused hsv following successful completion phase first streptococcus pneumoniae bacterium timeinhumans study phase ii firsttimeinpatients proof leading cause acute bacterial diseases concept trial started late assessing two important area growing antimicrobial resistance formulations adults history genital herpes multiple licensed pneumococcal vaccines available outbreaks successful hope could help better however burden pneumococcal disease remains control symptomatic outbreaks viral shedding significant mitigating associated emotional burden improving quality life people living genital herpes us alone estimated pneumococcal pneumonia causes hospitalisations every year influenza estimates one million children die influenza remains one worlds greatest public pneumococcal disease every year health challenges novel valent vaccine candidate currently phase ii every year estimated one billion cases development plusvalent pneumococcal vaccine around world many resulting severe illness candidate currently preclinical development added death pipeline acquisition affinivax incorporate innovative maps platform technology strategic report governance remuneration financial statements investor information gsk annual report research development continued adjuvanted pandemic influenza vaccine moving towards potential treatment uncomplicated extensively studied consists eggbased antigen urinary tract infections urogenital gonorrhoea pandemic adjuvant agreements half women affected uncomplicated us canada europe provide least urinary tract infections uuti lifetime million doses pandemic influenza vaccine event quarter suffering recurring disease global health emergency despite concern rising resistance existing eggbased influenza vaccines backbone treatments theres new class antibiotics worldwide efforts limit impact seasonal influenza uuti two decades different platforms technologies continue investigational antibiotic gepotidacin novel needed future committed playing mechanism triazaacenaphthylene antibiotic uuti part meeting important patient need gonorrhoea discovered developed us exploring opportunities develop mrnabased partfunded partnership us biomedical influenza vaccines collaboration curevac advanced research development authority barda building positive phase results modified monovalent positive phase iii data showed potential mrna vaccine candidates target covid first new class oral antibiotics uuti monovalent flu developing nextgeneration years eagle eagle phase iii trials multivalent mrna flu vaccine protect multiple stopped early efficacy november influenza virus strains phase iii trials underway following planned interim analysis gepotidacin performed well nitrofurantoin existing firstline treatment covid uuti eagle trial gepotidacin demonstrated acute phase covid pandemic statistically significant superiority nitrofurantoin focus nextgeneration platforms combination vaccines potential protect treating complicated urinary tract infections multiple seasonal respiratory viruses tebipenem covid mrna development programme curevac partnership spero therapeutics inc progressed phase ii clinical trial recently exclusive licence agreement tebipenem hbr reported positive interim data monovalent latestage oral carbapenem antibiotic potential bivalent vaccine candidates treat complicated urinary tract infections cutis december first patient dosed pivotpo human papillomavirus pivotal phase iii trial tebipenem approved human papillomavirus hpv common sexually tebipenem hbr address unmet medical need transmitted infection affecting around million people novel oral antibiotic alternative intravenous year us alone often symptoms hospital therapy drugresistant cutis cause genital warts several types cancer hpv associated nearly cases cervical cancer vulvovaginal candidiasis fourth common cancer among women also signed exclusive licence agreement globally causes estimated deaths scynexis develop commercialise brexafemme year hpv also accounts cancers us fdaapproved firstinclass antifungal treatment worldwide including anal cancers vulvovaginal candidiasis vvc reducing oropharyngeal cancers working innovax incidence recurrent vvc brexafemme complements nextgeneration adjuvanted vaccine protect gepotidacin tebipenem reinforces types hpv commitment developing new antibiotic antifungal treatments areas high unmet medical need antibiotics antimicrobial resistance fasttracking gonorrhoea vaccine antimicrobial resistance amr one worlds top health threats estimated without action amr gonorrhoea secondmost prevalent bacterial including antifungal resistance could contribute million sexually transmitted infection worldwide deaths per year cause economic loss estimated million new cases year trillion across medicines vaccines pipeline amr gonorrhoea increased past years projects relevant amr rendering many classes antibiotics treat disease targeting pathogens deemed critical urgent ineffective making vaccine even important global effort tackle amr investigational neisseria gonorrhoeae ngg vaccine based generalised modules membrane antigens gmma technology aims protect people aged older currently ongoing phase iii efficacy trial ngg received fasttrack designation us fda accelerating path fda submission strategic report governance remuneration financial statements investor information gsk annual report research development continued hiv decades weve transformed lives people living transforming patients lives hiv making breakthroughs treatment longacting regimens prevention work develop longacting injectable cabenuva cabotegravir rilpivirine worlds first medicines means many need therapy times complete longacting injectable regimen treat hiv year instead day means patients treatment six times year estimates approximately million instead taking medicine orally every day solar new hiv infections globally burden study data announced showed cabenuva greatest subsaharan africa effective daily biktarvy tablets treating hiv month findings also showed nine ten participants us twothirds people living hiv switching biktarvy cabenuva preferred long virally suppressed new acting regimen diagnoses apretude longacting cabotegravir launched remains pressing need new approaches worlds first longacting injectable preexposure treatment prevention prophylaxis prep reduce risk sexually transmitted hiv two large phase iii studies demonstrated apretude work hiv viiv healthcare superior daily oral prep tdfftc men majority pfizer shionogi shareholders women open label phase given choice viiv healthcare company focused majority study participants chose apretude oral treatment prevention hiv goal tdfftc leave person living hiv behind european commission authorised apretude weve focused research transforming experience injectable tablet form followed positive opinion people living hiv novel treatment options european medicines agency 's ema committee allow take fewer drugs take much less medicinal products human use chmp apretude often weve also developed longacting regimen also approved australia south africa among prevent hiv many others looking future longacting treatment prevention new formulation reformulated cab focused progressing injectable doses every four months doubling todays interval cabotegravir treatment prep would halve visits clinic three times year year fight hiv official start aids epidemic considered june morbidity mortality weekly report noticed rare pneumonia seen previously healthy men sex men would several years hiv identified underlying cause marty st clair scientists burroughs wellcome predecessor company gsk urgently began search potential new medicine treat hiv aids group went develop zidovudine first medicine approved us nearly years marty continues work treat prevent hiv transmission role clinical director viiv healthcare optimistic outlook innovation hiv 'weve pretty much given people lives back ' said marty 'its hopeful time ' viiv positive action outreach strategic report governance remuneration financial statements investor information gsk annual report research development continued aim make reality prevention moving towards selfinjected longacting registrational study starting treatment aim treatment deliver evaluating possible combinations main aim develop worlds first long reformulated cab rilpivirine broadly neutralising acting treatment people living hiv inject antibody nls completed study allow individuals dose home combined nls halozymes recombinant reduce number clinic visits targeting dosing hyaluronidase ph technology allows delivery every two three months efficacy tolerability larger volume drug subcutaneous dosing similar cabenuva showed possible deliver single subcutaneous dose thats welltolerated last four months short goal develop new agents hiv treatment prevention reduce burden treatment beyond sixmonthly doses goal end allow people improved quality life decade partnering new integrase inhibitors vh vh newmechanismofaction agents capsid inhibitors respiratoryimmunology weve leaders delivering medicines help nucala firstinclass antiilbiologic monoclonal manage asthma copd years research antibody targets directly inhibits il looks harness science immune system treatment us europe indications four il develop medicines reduce signs symptoms mediated diseases severe asthma eosinophilic disease address treatment resistance slow phenotype crswnp egpa hes japanese progression immunemediated conditions include ministry labour health welfare accepted review lupus severe asthma eosinophilic phenotype supplementary new drug application nucala treat crswnp adults submission based data inflammatory diseases help millions people pivotal phase iii merit trial studying safety respiratory immune conditions worldwide efficacy nucala people crswnp current portfolio january china national medical products advancing science treatment il administration approved nucala addon maintenance mediated diseases treatment severe asthma eosinophilic phenotype years leaders researching nucala first targeted il treatment china adult roles eosinophils type white blood cell adolescent patients condition interleukin il play health disease depemokimab novel monoclonal antibody developed eosinophildriven diseases associated affinity il longacting inhibition il heightened levels eosinophils eosinophils pathological process includes suppression infiltrate certain tissues cause inflammation eosinophil activity first potential ultralongacting organ damage time affect patients day antiil biologic treats range il mediated today life diseases phase iii programme continues make progress across diseases including severe asthma crswnp il major cytokine responsible proliferation hes egpa activation survival eosinophils making proven treatment target patients higher levels currently approved il inhibitors dosed every four eosinophils eight weeks depemokimab designed administered every six months addressing challenges il mediated conditions encompass range diseases commonly associated frequent dosing including effective treatments adherence anxiety emotional burden include respiratory conditions like severe asthma eosinophilic phenotype copd chronic reaching broader range asthma patients rhinosinusitis nasal polyps crswnp rarer early acquired aiolos bio inc acquisition conditions like eosinophilic granulomatosis adds aio phase iiready longacting antibody polyangiitis egpa hypereosinophilic syndrome hes targets clinically validated tslp pathway research aims redefine treatment goals across respiratory pipeline could redefine standard care conditions going beyond optimal management daily asthma patients dosing every six months aio symptoms modify course disease could slow potential expand reach broader portion halt disease progression reduce risk organ asthma patients including severe asthma damage even mean people could achieve patients low inflammation treatment options clinical remission still needed addition treatment adult patients asthma aio also potential strategic report governance remuneration financial statements investor information gsk annual report research development continued additional indications including chronic rhinosinusitis systemic sclerosis ssc rare autoimmune disease nasal polyps causes atypical growth connective tissues affect musculoskeletal system heart lungs kidneys skin progress towards treatment refractory organs interstitial lung disease ild marked chronic cough camlipixant inflammation scar tissue buildup lungs affects approximately million people suffer chronic many half people living ssc current treatment cough million worldwide suffering options limited refractory chronic cough rcc year us fda granted orphan drug designation rcc cough persists eight weeks odd benlysta potential treatment ssc doesnt respond treatment underlying odd special status granted support development condition otherwise unexplained evaluation potential medicines treat diagnose prevent rare diseases disorders affecting fewer decades effective treatments people us began phase iiiii trial rcc patients often suffering depression urinary sscassociated ild exploring incontinence rib fractures loss sleep potential studies wider range potential indications acquired bellus health included camlipixant potential bestindisease highly selective benlysta remains first approved biologic oral px antagonist currently phase iii development systemic lupus erythematosus sle ln firstline treatment adults rcc current clinical data years robust efficacy longterm safety show selectively inhibiting px receptors recognised updated recommendations camlipixant may reduce cough frequency patients european alliance associations rheumatology suffering rcc relatively low incidence eular management sle ln endorsing dysgeusia taste disturbance associated earlier use treatment pathway plan phase iv medicines broadly target px receptor study early inform proactive expect data phase iii calm management lupus prevent organ damage development programme evaluating efficacy benlysta approved use countries safety camlipixant treat adults sle extended include treating systemic sclerosis benlysta children aged five older sle us japan eea countries uk countries continue work realise full potential benlysta antib lymphocyte stimulator blys monoclonal benlysta currently approved treat adults ln antibody people affected range immune us eea countries uk countries mediated conditions beyond lupus lupus nephritis ln us indication includes children aged five older benefit targeted mode action reassuring ln reviews continue countries safety profile remission could possible severe asthma shelby gorman gsk employee knows well negative impact severe asthma childs life doctor said us last time day felt good day shelby says daughter could remember one day felt well ever life many years frequently hospitalised due exacerbations shelbys daughter joelle received accurate diagnosis started appropriate targeted treatment first time able live life without respiratory infections daily antihistamines expertise respiratory disease deep understanding immune system scientists along global specialists developing solutions help people severe asthma achieve clinical remission shelby joelle strategic report governance remuneration financial statements investor information gsk annual report research development continued oncology cancer one worlds major causes death field blenrep treatment multiple myeloma patients needs still widely unmet treatment multiple myeloma third common blood options remain limited emerging portfolio cancer globally generally considered treatable oncology focused seeking solutions blood curable women 's cancers making transformative break approximately new cases multiple myeloma throughs immunooncology diagnosed globally year ojjaara momelotinib blenrep belantamab mafodotin jemperli dostarlimab zejula niraparib strong research new therapies needed multiple foundation work blood women 's cancers myeloma commonly becomes refractory available goal realise full potential existing medicines treatments well expand portfolio areas high unmet need blenrep antibodydrug conjugate treatment received approval us ojjaara relapsedrefractory multiple myeloma dreamm treatment myelofibrosis omjjaara approved driving excellence approaches multiple myeloma eu uk january also received approval clinical development programme continues evaluate us eu uk immunooncology therapy potential blenrep address unmet need early lines treatment combination novel therapies jemperli plus chemotherapy firstline treatment standard care treatments endometrial cancer patients certain biomarker november announced positive phase iii results continue evaluate dostarlimab studies dreamm trial showing potential blenrep reinforce ambition become backbone combination therapy benefit patients earlier treatment ongoing immunooncology research development lines interim analysis dreamm showed patients programme receiving blenrep combination bortezomib blood cancers dexamethasone bordex lived longer without disease progressing receiving daratumumab plus ojjaara helping myelofibrosis patients anaemia bordex existing standard care combination therapy myelofibrosis mf rare blood cancer affecting sharing data health authorities around people us scientific community await results nearly mf patients eventually develop anaemia dreamm another phase iii combination trial exploring requiring regular blood transfusions leading blenreps potential earlier therapy lines stop treatment established therapies also health authorities continued review addition anaemia patients experience existing monotherapy indications blenrep later therapy debilitating symptoms like night sweats fatigue lines based results previous studies included bone pain well enlarged spleen december ema recommending splenomegaly bringing pain inflammation renewal conditional marketing authorisation frequent infection risk existing fourth line later monotherapy indication ojjaara taken orally day medicine women 's cancers specifically indicated newly diagnosed previously jemperli backbone immunooncology therapy treated mf patients anaemia treats anaemia along constitutional symptoms enlarged spleen endometrial uterine cancer sixth common accompany disease means potentially offers cancer women worldwide estimated new standard care patients established treatments new cases deaths exacerbate anaemia endometrial cancer cases september fda granted broad lineagnostic biomarker known dmmrmsih approval ojjaara treatment primary patients type endometrial cancer faced secondary mf adults anaemia regardless significant unmet need typically experience poor previous mf therapy followed positive chmp longterm outcomes standard care chemotherapy opinion november approval european commission well mhra approval january jemperli became immunooncology weve also submitted new drug application japan treatment approved us eu uk frontline setting combination chemotherapy patients mismatch repair deficient microsatellite instabilityhigh dmmrmsih primary advanced recurrent endometrial cancer ruby trial supporting approvals jemperli plus chemotherapy showed reduction risk disease progression death compared chemotherapy alone strategic report governance remuneration financial statements investor information gsk annual report research development continued announced two additional positive data azur global openlabel phase ii clinical trial readouts ruby phase iii trial part trial investigate efficacy safety dostarlimab jemperli plus chemotherapy showed statistically significant monotherapy replacing chemotherapy radiation andor clinically meaningful overall survival benefit compared surgery treatmentnave patients dmmrmsih chemotherapy overall population patients locally advanced rectal cancer successful theres primary advanced recurrent endometrial cancer jemperli potential transform treatment patients immunooncology combination regimen locally advanced rectal cancer achieve part ruby trial evaluated trial aims confirm results generated separate jemperli plus chemotherapy followed jemperli plus ongoing investigatorinitiated trial researchers zejula treatment primary advanced recurrent memorial sloan kettering cancer center trial endometrial cancer demonstrated significantly improved reported participants treated dostarlimab progressionfree survival compared chemotherapy alone achieved clinical complete responses enabling overall mismatch repair proficient avoid surgery chemotherapy radiotherapy microsatellite stable mmrpmss patient populations also began azur trial phase iii trial jemperli also approved standalone treatment evaluates efficacy perioperative dostarlimab certain types endometrial cancer earlier monotherapy compared standard care adjuvant fda converted accelerated approval jemperli chemotherapy patients highrisk early stage dmmr secondline treatment full approval msih colon cancer approved could give patients monotherapy adult patients dmmr recurrent new chemotherapyfree option reduces risk advanced endometrial cancer determined fdaapproved test progressed following disease progression dostarlimab treatment prior platinumcontaining regimen setting neoadjuvant adjuvant settings arent candidates surgery radiation lung cancer european commission 's conditional approval lung cancer second common cancer globally jemperli monotherapy adult patients common cancer men patient population also converted full approval million new cases zejula parp inhibitor ovarian cancer beyond lung cancer worldwide continue develop zejula multiple pivotal trials assessing activity gynaecologic cancers solid majority lung cancers fall category called tumours evaluating several potential combinations nonsmall cell lung cancer nsclc form zejula therapeutics aiming address unmet lung cancer progresses slowly nsclc cases medical needs patients ongoing development spread beyond lungs diagnosis programme includes first phase iii trial assessing published data phase ii perla clinical potential niraparib combination dostarlimab trial showing favourable numerical trend overall survival firstline ovarian cancer maintenance zeal phase results dostarlimab plus chemotherapy compared iii trial evaluating niraparib combination standard pembrolizumab plus chemotherapy firstline metastatic care maintenance treatment firstline advanced nsclc data perla trial supports ambition nonsmall cell lung cancer addition based promising dostarlimab become backbone immunooncology early clinical data niraparib glioblastoma november therapy used alone combination standard exploring next steps clinical care future novel cancer therapies including targets development type cancer along cd axis cancers access antibodies targeting three known colorectal cancer cd checkpoints cd pvrig tigit goal cancers start colon rectum studying immune checkpoints combination distinct sections large intestine dostarlimab aimed increasing proportion classified colorectal cancers patients respond therapy improving durability response cd axis development colorectal cancer second leading cause cancer programme continued several earlyphase trials related death third common cancer underway including galaxies lung phase ii worldwide accounting approximately platform study firstline metastatic nsclc combines cancer cases dostarlimab belrestotug tigit antibody partnered estimated worldwide iteos therapeutics galaxies lung also million new cases colorectal cancer explore triplet combination dostarlimab belrestotug deaths gsk cd antibody january us fda granted dostarlimab fast addition two phase iii trials nsclc continued track designation treatment dmmrmsih locally readouts expected advanced rectal cancer costar lung phase iii randomised openlabel also started azur clinical trial programme studying threearm trial comparing investigational compound dostarlimab certain colorectal cancer indications cobolimab plus dostarlimab plus docetaxel strategic report governance remuneration financial statements investor information gsk annual report research development continued dostarlimab plus docetaxel docetaxel alone bh surface antigen overexpressed ovarian patients advanced nsclc progressed endometrial cancers often associated poor prior antipdl therapy chemotherapy prognosis well targeting bh hs uses clinically validated adc technologies zeal phase iii randomised doubleblind trial topoisomerase inhibitor payload topoi validated assessing niraparib combination standard care mechanism action approved anticancer medicines maintenance treatment firstline advanced nsclc proven standard care treating breast ovarian cancers pipeline growth business development december added oncology portfolio october announced exclusive licence clinicalstage adcs entering second exclusive licensing agreement chinese company hansoh pharma agreement hansoh pharma hs hs bhtargeted adc supports work developing treatments ovarian endometrial hs bh targeted adc also utilising clinically cancers well solid tumours validated topoi payload shown promising initial clinical activity lung cancer potential address unmet medical need broader solid tumour indications including colorectal cancer technology new platform data technology fundamentally expand ability identify novel vaccine transforming discover develop vaccines medicine options prevent medicines speeding discovery development treat diseases improving chance success investing platform technologies including technology makes us effective every stage multiple antigen presenting system maps allows discovery development process progress us develop multivalent vaccines complex bacterial vaccines medicines first best infections introducing tcell mediated diseasespecific kind early investment capabilities already antiprotein immunity potentially enables broader leading differentiated highimpact vaccines coverage certain disease types higher medicines including new vaccine rsv longacting immunogenicity current vaccines well higher hiv prevention prospect functional cure antibody responses developing maps chronic hepatitis b acquisition affinivax weve mainly directed maps combine power genetic data genomic preventing pneumococcal disease part insights speed scale ai make better valent pneumococcal vaccine candidate phase ii predictions increase probability new vaccines development see platform also shows medicines becoming available patients ai promise pathogens including team one largest industry works cause hospitalacquired infections genomics team improve select disease targets mrna enables protein synthesis human body determine best technology approach identify carrying information required cells produce groups patients treatment might work best proteins using mrna technology vaccine alone partner worlds development specific proteins antigens best minds across academia tech biotech produced bodys cells elicit humoral industries large companies small startups immune responses enabling human immune collaboration leads new ways thinking together system prevent fight disease developing mrna strive innovative solutions patients inhouse parallel collaboration curevac biopharmaceutical company developing therapies based using platform technologies discover mrna currently developing rna vaccines based develop novel vaccines medicines curevacs secondgeneration mrna backbone one major challenges addressing diseases monovalent bivalent covid vaccine candidates vaccines medicines currently exist phase ii multivalent seasonal influenza vaccine difficult treat small molecules biologics candidate protect multiple strains also phase iii see overcoming challenge investing innovation external collaborations develop small molecule design paired small molecule range platform technologies platform technology generative ai tools system advantage using pair disease targets best treatment modalities known chemical reactions building blocks create addressing diseases thought difficult large 'virtual libraries ' potential drug molecules target drug discovery specific biological targets strategic report governance remuneration financial statements investor information gsk annual report research development continued molecules comprising virtual libraries combined power biology technology profound advantage easily synthesised free many reshaping way science done example known problems associated small molecule generate data one quarter drugs since filtered series machinelearned companys year history end molecular property models based gsk historical data aim bring predictive realtime insight inform clean public sources progression development decisions research oligonucleotides short strands dna rna combining ai genetic genomics unexpected reduce restore modulate rna several possibilities mechanisms giving unique capability address built inhouse teams dedicated genomics wide range genomic targets multiple therapeutic areas ai including key rd sites london tel aviv first time oligonucleotides currently pipeline san francisco seattle philadelphia boston include bepirovirsen chronic hepatitis b gsk expertise helps us collect data generate ideas phase ii programme nonalcoholic arrive unexpected possibilities theyre bringing us steatohepatitis nash closer finding vaccines medicines diseases felt outside reach making research process also two collaborations build leading faster effective predictable oligonucleotide platform invested build worldclass research data entered collaboration wave life platform includes one worlds sciences pairs genetic expertise waves prism oligonucleotide platform offering three comprehensive large language models genetic disease rnatargeting modalities editing splicing silencing brings billion data points single place including sirna antisense collaboration helps map gene expression function activity enables us accelerate drug discovery newly identified targets scientists run experiments get answers matching best therapeutic modality questions matter hours process took weeks months announced partnership elsie biotechnologies inc collaboration combines genetics genomics expertise dna encoded library technologies using combination genetics functional elsie 's drug discovery platform throughout genomics genetic engineering techniques like crispr collaboration exercise option non clustered regularly interspaced short palindromic exclusive licence elsie discovery platform repeats enable us screen validate hundreds pv chemistry technologies use genetic targets parallel instead one time oligonucleotide drug discovery research screening process discover causal monoclonal antibodies produced single clone genes genomics link biomarkers may cells cell lines consist identical antibody molecules predict disease targets strong meant modulate patients immune system genetic evidence pipeline increase platforms needed make bestinclass monoclonal antibodies like nucala bispecific antibodies applying data tech clinical research antibodydrug conjugates like blenrep also clinical stage development aiml genomics developing generative design capabilities based helping us assess certain patient profiles might increased use next generation sequencing well respond well able make sure right public proprietary protein structure tools structures people right trials offers potential designed using tools realised using highly shorter less expensive clinical trials greater chances automated antibody synthesis isolation purification success processes example research antisense adjuvants substances enhance bodys immune oligonucleotide bepirovirsen chronic hepatitis b using response antigens use arexvy shingrix ml developed algorithms helped us categorise vaccines rsv shingles hsv vaccine patients five distinct subtypes based response candidate gsk also working xiamen treatment almost doubled ability correctly innovax biotech nextgeneration adjuvanted vaccine predict future patient outcomes compared using protect types hpv traditional methods significant help using genetic data better understand inform sequential combination therapy options disease choose right solutions potentially leading better outcomes ultimately right patients helping people living hepatitis b experience functional cure data technology combine aiml human genetics functional genomics understand patients human biology disease mechanisms makes us better choosing prioritising targets designing trials bringing new vaccines medicines patients strategic report governance remuneration financial statements investor information gsk annual report research development continued collaborating change course work complements technology biology projects disease patients underway laboratory genomic research cofounded researchers university working others achieve better faster california san francisco projects automating address disease areas high unmet need advancing crispr new discoveries disease many people possible mechanisms immunology oncology neurology collaborations uk biobank andme finngen collaborations helping make advances multiple given us access large genetic datasets deepen fields human health understanding diseases improve drug discovery also founding partner future health uk kings college london using tumour models initiative setting recruit five million people alongside digital pathology ai develop personalised capture genetic medical information work immunooncology treatments solid cancers genes health discover south africa make pathai working accelerate rd oncology sure diverse genetic representation diseases nash january also announced 'd joined alliance genomic discovery expanding established oxfordgsk institute molecular access diverse genetic datasets computational medicine imcm oxford university combines human genetics functional collaborations functional genomics give us insights genomics ml focus diseases including help select targets likely become amyotrophic lateral sclerosis als alzheimers medicines continue work genomics research parkinsons centres like broad institute affiliated mit harvard university boston altius institute work precision medicine company tempus seattle uk partners include consortium focused using data enable clinical trial open targets cofounded designs target selections oncology culture create agile innovative environment thats support weve taken steps focus even ambitious patients attracts best people intently core therapeutic areas strengthen scientists partners decisionmaking clearer ownership simplified agile governance embed technology deeply get ahead disease need best people work scientists researchers trial specialists technologists environment thrive weve created three research units dedicated vaccines make expertise inside company infectious diseases respiratory immunology partners rd people work together inclusive oncology reporting directly chief scientific officer environment foster new ideas make connections use expertise pick right targets right including scientists technologists data engineers patients leading clinical development phase ii working side side rd leadership team making recommendations phase iii programmes started roles past two years bringing years research teams complement ongoing research combined experience adding leadership hiv viiv healthcare delivering key priorities close collaboration rd commercial culture unites us ambitious patients manufacturing medical leaders makes sure match accountable impact always right thing scientific potential unmet patient need maximise culture encourages teams focus matters impact disease deliver competitive commercial take smart risks make informed decisions pace value weve also created one research technologies also helps take ownership objectives seize organisation bringing together platform data groups opportunities solve problems together create scaled engine identifying progressing targets partners strategic report governance remuneration financial statements investor information gsk annual report research development continued pipeline overview assets development latestage phase iiiregistration anticcl antibody osteoarthritis pain arexvy recombinant protein adjuvanted rsv older adults yoa antiil antibody atopic dermatitis gepotidacin bti inhibitor uncomplicated uti antisortilin antibody alzheimers disease bepirovirsen antisense oligonucleotide chronic hbv infection belrestotug antitigit antibody nonsmall cell lung cancer bexsero recombinant protein omv meningitis b infants us menabcwy vaccine recombinant protein omv conjugated vaccine hsdb sirna nonalcoholic steatohepatitis menabcwy stgen phase tebipenem pivoxil antibacterial carbapenem complicated uti bivalent conjugate salmonella typhoid paratyphoid ibrexafungerp antifungal glucan synthase inhibitor invasive candidiasis mtb cholesterol dependent inhibitor tuberculosis nucala antiil antibody copd crk inhibitor visceral leishmaniasis depemokimab longacting antiil antibody asthma proteasome inhibitor visceral leishmaniasis latozinemab antisortilin antibody frontotemporal dementia p falciparum whole cell inhibitor malaria camlipixant px receptor antagonist refractory chronic cough p falciparum whole cell inhibitor malaria low carbon version mdi ventolin beta adrenergic receptor fimh antagonist uncomplicated uti agonist asthma pik beta inhibitor viral copd exacerbations ojjaaraomjjara jak jak acvr inhibitor papdpapd inhibitor chronic hbv infection jemperli antipd antibody endometrial cancer tlr agonist chronic hbv infection zejula parp inhibitor ovarian cancer cabotegravir integrase inhibitor hiv blenrep antibcma adc multiple myeloma antiil antibody autoimmune disease cobolimab antitim antibody nonsmall cell lung cancer tg inhibitor pulmonary fibrosis linerixibat ibat inhibitor cholestatic pruritus primary biliary antiil antibody copd cholangitis rnaediting oligonucleotide alpha antitrypsin deficiency phase ii interferon pathway modulator systemic lupus recombinant protein adjuvanted malaria fractional dose erythematosus live attenuated mmrv new strain antipvrig antibody cancer gmma shigella anticd antibody cancer viral vector recombinant protein adjuvanted chronic xmt sting agonist adc cancer hbv infection belantamab antibcma antibody multiple myeloma recombinant protein omv conjugated vaccine dna polymerase theta inhibitor cancer menabcwy ndgen adctargeting bh gynecologic malignancies live attenuated varicella new strain dnmt inhibitor sickle cell disease maps adult pneumococcal disease valent maps paediatric pneumococcal disease valent assets ordered therapy area within phase infectious recombinant protein adjuvanted human papillomavirus diseases hiv respiratoryimmunology oncology opportunity gmma gonorrhoea driven advanced indications shown asset inlicence alliance relationship third party mrna seasonal flu additional indications candidates also investigation mrna covid registration adjuvanted recombinant subunit cytomegalovirus phase iii trial patients progranulin gene mutation recombinant protein adjuvanted therapeutic herpes metered dose inhaler simplex virus phase iii start expected hepatitis b virustargeted sirna chronic hbv infection approved us eu bivalent gmma invasive nontyphoidal salmonella phase iii study phase ii study start imminent ganfeborole leucyl trna synthetase inhibitor tuberculosis transition activities underway enable progression partner sanfetrinem cilexetil serine beta lactamase inhibitor tuberculosis gsk exclusive global licence option codevelop alpibectir bvlgsk ethionamide booster tuberculosis commercialise candidate broadly neutralizing antibody hiv rsv respiratory syncytial virus uti urinary tract infection hbv hepatitis b virus adc antibody drug conjugate copd chronic obstructive pulmonary maturation inhibitor hiv disease mmrv measles mumps rubella varicella omv outer membrane capsid protein inhibitor hiv vasicle sirna small interfering rna gmma generalised modules membrane antigens yoa years age capsid protein inhibitor hiv integrase inhibitor hiv benlysta antiblys antibody systemic sclerosis associated interstitial lung disease strategic report governance remuneration financial statements investor information gsk annual report commercial delivered strong sustained performance momentum successful operations commercial launches supported integrated global supply chain strategic report governance remuneration financial statements investor information gsk annual report commercial operations highlights bn total sales aer cer cer excluding covid sales contribution product area bn sales contribution region bn l vaccines l speciality medicines l general medicines l us l europe l international bar charts excluding covid solutions absolute values aer changes cer unless stated otherwise strong operational performance details performance drivers growth see 've continued focus operational vaccines performance performance strong growth across product areas specialty medicines performance regions builds good progress demonstrates strong sustained performance momentum general medicines performance means confident delivering upgraded growth outlooks period strong performance driven continued stepchange commercial execution underpinned focus leadership developing outstanding people building meaningful connections healthcare professionals hcps patients supported data technology give us strong insights best meet needs strategic report governance remuneration financial statements investor information gsk annual report performance vaccines broad vaccines portfolio targets infectious diseases every stage doubledigit growth vaccines life helping protect people meningitis shingles rsv flu polio successful launch arexvy us many continued strong uptake shingrix turnover international europe bn aer cer l established bn l shingles bn l meningitis bn l rsv bn l influenza l pandemic strategic report governance remuneration financial statements investor information gsk annual report performance vaccines continued key products product disease total revenue key information shingrix herpes zoster shingles bn aer cer marketleading recombinant adjuvanted vaccine indicated prevention shingles adults launched markets arexvy rsv bn world 's first approved rsv vaccine adults approved countries bexsero meningitis aer cer approved countries prevention invasive group b meningococcal disease imd caused neisseria meningitidis serogroup b boostrix diphtheria tetanus aer cer available countries market leader us acellular pertussis booster rotarix rotavirus aer cer marketleading pediatric vaccine countries increased share us since launch liquid formulation fluarix flulaval seasonal influenza aer cer quadrivalent influenza vaccines available countries infanrix pediarix diphtheria aer cer dtpa vaccine available countries pediarix one tetanus pertussis polio leading brands volume us hepatitis b haemophilus influenza type b engerix twinrix havrix hepatitis aer cer growing hepatitis portfolio leadership increased coverage strengthened recommendations menveo meningitis aer cer menveo helps protect imd caused neisseria group c w meningitidis serogroups c w available countries synflorix invasive disease aer cer synflorix available countries including pre pneumonia acute otitis qualification acquisition maps technology expected media enable greater serotypes disease coverage priorix priorix measles mumps rubella aer cer priorix continues gain share us priorix available tetra varilrix chickenpox countries varilrix countries priorix tetra countries cervarix human papilloma virus aer cer important option hpv cervarix twodose schedule girls aged launched china sales performance arexvy achieved billion sales driven strong uptake leading market share delivering vaccines sales grew aer cer billion total outstanding launch almost sales us aer cer billion excluding covid arexvy available major retail pharmacies solutions competitive contracting place shingrix grew aer cer billion increased influenza fluarixflulaval sales declined line demand favourable pricing q representing expectations aer cer million highest ever quarter sales growth driven driven competitive pressure lower market public funding expansion strong private uptake demand primarily us international europe established vaccines grew aer cer billion meningitis vaccine sales grew aer cer driven rotarix favourable us cdc stockpile movements billion largely delivered bexsero primarily driven mmrv vaccines increased supply international inclusion national immunisation programmes europe hepatitis vaccine performance related travel market menveo grew due favourable impact us cdc recovery center disease control stockpile replenishment strategic report governance remuneration financial statements investor information gsk annual report performance vaccines continued strategy growth shingrix continued grow available countries less penetration majority portfolio marketed vaccines one markets us million adults industrys broadest deliver approximately million recommended receive shingrix doses vaccines every day infants born vaccinated million people already protected year receive least one gsk vaccine vaccines shingrix ambition vaccinate portfolio targets infectious diseases every stage life million people support entered helping protect people rsv meningitis shingles exclusive agreement chongqing zhifei flu polio many biological products ltd zhifei value billion initial threeyear period copromote shingrix vaccines critical delivering growth plans china zhifei import distribute shingrix china focus strong execution key markets shingrix promoting vaccine network existing portfolio delivering value vaccination points partnership significantly extend pipeline new launches particularly worldfirst rsv availability shingrix supporting rapid expansion vaccine arexvy bring vaccines many patient access vaccine future potential patients possible indications vaccines complex highly technical develop continue lead meningitis market driven manufacture helps protect portfolio bexsero menb menveo menacwy prepare potential disruption new technologies theres transition pentavalent menabcwy vaccine established generic industry vaccines dont generally combines established vaccines continuing face socalled patent cliff longer lifecycle means invest bexsero remains integral strengthening vaccines remain use decades initial leadership securing key national immunisation authorisation example boostrix infanrix priorix programmes nip countries like germany engerix remain important parts portfolio terms switzerland well building realworld contribution performance evidence base helping improve immunisation rates globally focusing us adolescent population established platform technologies new improve competitiveness well look drive future platforms building maps mrna growth multiple lifecycle innovations coming technologies key part vaccines growth strategy years including launching menveo convenient liquid enabling us tackle complex diseases formulation additional countries birth throughout adulthood see established vaccines remain key priority growth drivers growth across portfolio representing third total vaccines business core launch arexvy supports market leadership vaccines continue grow strongly seek maximise ambition multibillionpound sales potential uptake need achieve approximately million million us adults aged prioritising specific segments growth opportunity older risk vaccinated arexvy return travel strengthened recommendations launches also underway across europe canada hepatitis adult segment increasing awareness vaccine approved japan several importance vaccination also working countries strengthening relationships maintain strong performance key markets making retailers given expertise older adult population sure resource teams success shingrix also drawing expertise deliver supply commitments respiratory diseases experience primary care sales force approvals launches expected meeting needs ageing populations increasing awareness impact rsv prioritising prevention adults increased risk look forward seeing focusing prevention reduce burden impact vaccine helping prevent disease create healthier thriving world vaccination severe consequences rsv globally critical element prevention infectious diseases especially children older adults age around immune system starts decline becomes less effective leading increased risk infectious diseases focus efforts helping keep older adults healthy moving sick care true healthcare prioritising prevention making adult immunisation standard care help vaccination adults remain active healthy participants society economy prolonging productivity contributing local economies reducing healthcare costs improve uptake adult immunisation working build investment case vaccination ease access increase belief importance vaccines strategic report governance remuneration financial statements investor information gsk annual report performance vaccines continued support healthcare professionals routinely initiate year commissioned research spotlights vaccination conversations patients build hyperlocal factors contributing inhibiting adult broader belief importance vaccination held immunisation uptake five diverse geographically vaccine virtual days bring together healthcare representative cities across world research builds professionals experts international vaccine upon existing global frameworks progresses vital community discuss present important updates initiatives un decade ageing data trends adult immunisation weve also agefriendly cities network continued series vaccinology master classes helping part coimmunity also supporting public better equip healthcare professionals conversations health efforts making data vaccination trends patients vaccines available vaccine track platform adult immunisation rates us still havent recovered sharing tools resources healthcare organisations fully covid pandemic help address gaps adult immunisation commissioned report published iqvia institute coimmunity initiative builds recent regulatory human data science global coalition aging industry changes us make vaccines estimated around million fewer doses available easier access medicare medicaid adult vaccines excluding covid solutions beneficiaries support community vaccine infrastructure administered anticipated help address launched coimmunity initiative us commits million grant funding national state local nonprofit organisations address longterm barriers immunisation particularly among older adults susceptible declining immune systems strategic report governance remuneration financial statements investor information gsk annual report performance specialty medicines continue global leaders specialty medicines growth excluding infectious diseases respiratory covid solutions aer cer hiv medicines emerging portfolio cancer continued growth momentum hiv medicines growth acceleration oncology turnover respiratoryimmunology bn aer cer l hiv bn l respiratoryimmunology bn l oncology l pandemic strategic report governance remuneration financial statements investor information gsk annual report performance specialty medicines continued key marketed products product disease total revenue key information dovato hiv treatment bn aer cer dolutegravirbased twodrug regimen launched markets nucala respiratory eosinophil bn aer cer treatment indicated us europe driven diseases use across four il mediated diseases see triumeq hiv treatment bn aer cer dolutegravirbased fixeddose combination tablets marketed countries tivicay hiv treatment bn flat aer cer dolutegravir tablet use combination antiretroviral agents marketed countries benlysta lupus lupus nephritis bn aer cer biologic approved treat sle ln us europe elsewhere cabenuva hiv treatment aer cer first complete longacting injectable regimen vocabria rekambys cabotegravir rilpivirine marketed countries europe japan juluca hiv treatment aer cer dolutegravirbased twodrug regimen marketed countries zejula ovarian cancer aer cer parp inhibitor commercially available l maintenance markets l maintenance markets apretude hiv prevention aer cer first longacting injectable cabotegravir hiv prevention launched us jemperli endometrial cancer aer cer pdblocking antibody available countries continuing investigated future monotherapy combination regimens multiple tumour types rukobia hiv treatment aer cer extendedrelease tablets people living multidrug resistant hiv use combination antiretrovirals launched markets xevudy covid treatment aer cer monoclonal antibody early treatment covid blenrep blood cancer multiple aer cer antibodydrug conjugate patients relapsed myeloma refractory multiple myeloma ojjaaraomjjara myelofibrosis approved us eu uk first treatment specifically indicated myelofibrosis patients anaemia jesduvroqduvroq anaemia due chronic aer cer approved us treatment anaemia kidney disease ckd chronic kidney disease ckd adult patients dialysis sales performance respiratoryimmunology sales aer cer billion consistent sustained double reported speciality medicines sales digit growth benlysta nucala nucala grew aer cer million total excluding covid billion continued strong growth regions solutions grew aer cer million reflecting high patient demand severe eosinophilic hiv sales grew aer cer billion primarily asthma new indications benlysta grew driven percentage point increase market share billion representing strong demand us europe within broadly flat global treatment market attributable continued market expansion patient demand oral twodrug regimen dovato oncology sales grew million driven strong juluca longacting medicines cabenuva apretude growth jemperli zejula uptake ojjaara post oral twodrug regimen longacting medicine sales us launch q partially offset impact grew billion representing total blenrep withdrawal us market november hiv portfolio growth jemperli continued accelerate particularly us following approval q zejula sales grew million strong growth regions us growth first line indication offset reduction use second line following update us prescribing information agreed fda q strategic report governance remuneration financial statements investor information gsk annual report performance specialty medicines continued strategy growth benlysta remains biologic approved systemic lupus erythematosus lupus nephritis portfolio specialty medicines focuses four benlysta saw consistent growth across major markets therapeutic areas infectious diseases hiv respiratory us patients starting therapy immunology oncology reinforcing strength focused helping identify treat patients leadership infectious diseases respiratory hiv earlier lupus progresses organ damage occurs building emerging capabilities oncology see drive growth oncology jemperli continues demonstrate potential sales come specialty medicines backbone ongoing immunooncologybased expect provide durable profitable growth research development programme used alone next five years drive growth accelerating pipeline combination standard care future novel cancer well prioritising business development targeting therapies potential transform patients lives acquisitions partnerships strengthen across multiple tumour types including endometrial cancer complement core therapy areas helping jemperli plus chemotherapy approved deliver beyond current longterm outlooks us eu uk first immunooncology acquisition bellus health announced april regimen treatment frontline primary advanced example builds respiratory expertise recurrent dmmrmsih endometrial cancer complements broader respiratory pipeline approvals significant driver performance increasingly confident major source sales growth oncology new longterm growth ojjaaraomjjara jak acvrinhibitor acquired drivers growth across portfolio purchase sierra oncology april hiv strategy growth built innovative approved us eu uk treat myelofibrosis portfolio medicines transforming hiv treatment anaemia makes ojjaara medicine prevention strong competitive execution specifically indicated newly diagnosed previously treated myelofibrosis patients anaemia launched dolutegravirbased oral twodrug addresses anaemia constitutional symptoms regimen dovato continues perform strongly enabling splenomegaly enlarged spleen hallmarks people living hiv remain virally suppressed complex blood cancer lineagnostic label fewer medicines broader anticipated expanding opportunity reach patients novel treatment option longacting portfolio medicines central additional regulatory filings initiated growth delivering strong results launch aim expand access patients markets across markets ovarian cancer zejula continues provide significant cabenuva worlds first complete longacting opportunity firstline maintenance therapy reaching regimen hiv treatment available us europe patients every month working japan china australia twomonthly cabenuva develop combination therapies zejula women 's addresses challenges associated daily oral therapy cancers solid tumours including fear disclosure adherence anxiety pill fatigue ensure focus areas make biggest impact patients weve withdrawn filing apretude worlds longacting medicine hiv jesduvroq eu stop filing markets prevention offering superior efficacy daily oral prevention medicines already available patients ftctdf tablets twomonthly dosing living anaemia ckd apretude expanded beyond us approval europe several subsaharan africa countries important lever end global epidemic respiratoryimmunology marketleading medicines nucala benlysta continued deliver doubledigit growth nucala targeted biologic therapy approved use across four il mediated diseases eosinophil disease continues drive growth consistent evidence across multiple indications combined marketleading safety data reinforce nucala biologic choice hcps severe asthma market continues grow us markets offer opportunities nucala help patients strategic report governance remuneration financial statements investor information gsk annual report performance general medicines antibiotics inhaled medicines asthma copd growth driven respiratory general medicines general medicine products many leaders ongoing strong demand trelegy class making life better regions anoro europe millions people worldwide international continued post pandemic recovery turnover antibiotic market europe international regions bn aer cer l respiratory bn l general medicines bn strategic report governance remuneration financial statements investor information gsk annual report performance general medicines continued key marketed products product disease total revenue key information trelegy ellipta copd asthma bn aer cer prescribed single inhaler triple therapy sitt worldwide reaching estimated million patients since launch seretideadvair asthma copd bn aer cer one marketleading icslaba treatments worldwide sales value relvarbreo ellipta asthma copd bn aer cer one leading icslaba treatments worldwide sales value ventolin asthma copd aer cer global marketleading saba reliever sales value augmentin common bacterial aer cer global leader oral antibiotics sales value available infections countries anoro ellipta copd aer cer global market leader lamalaba class volume unit sales approved countries avodart duodart benign prostatic aer cer market leaders sales value global dutasteride hyperplasia bph dutasteridetamsulosin fdc market respectively approved countries respectively avamysveramyst allergic rhinitis aer cer global leader inhaled corticosteroids prescription class sales value dermovate betnovate inflammatory skin aer cer global leader topical corticosteroids across markets cutivate eumovate conditions globally value sales excluding us icslaba inhaled corticosteroidlongacting beta agonists saba shortacting beta agonist labalama longacting beta agonistslongacting muscarinic antagonists fdc fixeddose combination key information source iqvia sales performance strategy impact general medicines sales grew aer cer billion reflecting growth trelegy single general medicines portfolio includes medicines inhaler triple therapy class across regions anoro typically prescribed primary care general europe international medicines contributed one third gsk 's sales helping fund growth investment rd returns trelegy grew aer cer billion growth shareholders delivered across regions reflecting increased patient demand growth sitt market penetration expect combination products class several market leaders positive impact lives hundreds millions patients seretideadvair sales decreased aer increased next years supply products cer billion primarily reflecting favourable us countries comprise total pricing however offset generic erosion impacts medicines vaccines supply volume every day europe certain international markets medicines improve health make life better millions general medicines decreased aer grew people world cer billion reflecting ongoing post pandemic demand antiinfectives europe international together respiratory infectious diseases therapeutics certain third party manufacturing arrangements generate general medicines revenue overall growth product group continues expected growth trelegy anoro established impacted ongoing generic competition products portfolio emerging markets committed positively impacting lives every day focus investment brands growing strongly maximise returns managing expected decline products mature markets lose exclusivity strategic report governance remuneration financial statements investor information gsk annual report performance general medicines continued drivers growth across portfolio augmentin global leader oral antibiotics sales value available countries reached main sources growth general medicines billion patients since launching years ago trelegy anoro augmentin continues grow strongly across regions augmentin trelegy sitt asthma copd delivered sales grew aer cer million strong ongoing billion first time trelegy demand across regions continued accelerate strongly growth regions since launch ventolin remains important including us third biggest growth driver medicine patients countries portfolio trelegy licensed countries copd significant proportion carbon emissions come dual indications asthma copd countries including us japan received several new ventolin metered dose inhalers mdis started rd programme redevelop ventolin mdis approvals expanding trelegys availability asthma patients turkey hong kong bahrain kuwait lower global warming potential gwp propellant clinical assessment successful could reduce trelegy number one sitt globally selling greenhouse gas emissions rescue mdis million packs twice volume nearest approximately competitor trelegy market leader two largest markets us japan market shares significantly exceeding nextlargest competitor respectively november global initiative chronic obstructive lung disease gold guidelines recommended triple therapy icslaba exacerbating patients helped continue growth sitt market six years first launch still growing year year expect trelegy key driver growth general medicines coming years anoro approved approximately countries treat symptomatic copd anoro remains global market leader lamalaba class volume unit sales continued growth global sales excluding us anoro robust clinical data profile includes headto head data lamalaba class versus common initial maintenance therapy options lama regulatory data file latest update august asthma july copd regulatory data file latest update august iqvia patient volume data october source iqvia strategic report governance remuneration financial statements investor information gsk annual report operations manufacturing supply global supply chain critical made significant progress bringing together vaccines medicines supply chains create one successful manufacture global supply chain integration helps drive efficiency supply vaccines medicines ensures capacity capabilities including best digital technology capabilities enables us deliver reliable deliver new products highquality products meet global network vaccines medicines patients needs maintain manufacturing sites delivered million vaccine performance doses billion packs medicines help make positive impact health millions people investing future productivity investing manufacturing supply chain increase productivity efficiency opened million adjuvant manufacturing facility hamilton us means produce qs adjuvant inhouse contributing rsv shingles malaria cervical cancer vaccines late opened manufacturing testing facility jurong singapore produce cytotoxic agent antibody drug conjugates needed nextgeneration cancer treatments tuas site also singapore weve begun building new vaccine manufacturing facility hepatitis b vaccines feature latest advanced technology sustainable design strategic report governance remuneration financial statements investor information gsk annual report operations manufacturing supply continued ware uk opened new oral solid dose facility supporting innovation bringing together rd supply chain specialists use global supply chain plays central role bringing new technologies rapid knowledge transfer deliver innovations patients quickly efficiently effectively new medicines faster efficiently possible teams involved early product wavre site belgium weve started building development working rd make sure million freezedrying centre using automation works clinical trials produced commercially robotics create capacity adult vaccines scale barnard castle uk multimillionpound q supplied rsv vaccine arexvy record time block smart manufacturing facility started commercial countries including us eu production immunology products canada following regulatory approvals shipped patients around world facility also bringing additional capacity deliver uses digital technology robotics make production jemperli patients around world following efficient regulatory approvals us europe exceeding targets ongoing programme worked external manufacturing partners productivity efficiency improvements year deliver supply chain excellence us launch ojjaara programme delivered million savings across medicines vaccines embracing technology data site productivity increased year harnessing power technology data transforming manufacturing supply chain promoting quality safety reliability identifying implementing best digital quality safety reliable supply critical meeting technology capabilities unlock growth patients patients needs creating competitive advantage shareholders people reliability remains strong ontime infull otif also working industrialise new platform measure specialty medicines technologies oligonucleotides medicines general medicines vaccines deviation mrna maps vaccines maps clinical trials rates improved medicines increased marginally continue new binney street site cambridge us vaccines clear action plans improvement plan scale production bring maps market information product governance see responsible using digital twins simulate processes anticipate business section issues use learn accelerate manufacturing weve also received external recognition technology helps increase production yields featured gartners top supply chain companies vaccines medicines based financial metrics esg criteria opinion also investing automation robotics sites industry analysts experts improving ergonomics increasing efficiency helping us deliver medicines vaccines patients around world increasing environmental sustainability manufacturing sites key role contribution net zero nature positive healthier planet environmental sustainability fundamental part global supply chain strategy see responsible business section information carbon emissions water use waste also investing plans improve natural habitats protect biodiversity improve soil water quality near sites approach sustainability progress made sites see esg performance report strategic report governance remuneration financial statements investor information gsk annual report responsible esg embedded strategy helps us deliver purpose supports business sustainable performance longterm growth strategic report governance remuneration financial statements investor information gsk annual report responsible business approach continue evolve esg performance rating ensure meets expectations stakeholders executive global biopharma company purpose leadership team board via corporate unite science technology talent get ahead responsibility committee review metrics make disease together deliver purpose need rating year ensure sufficiently consider esg impacts across everything lab challenging ambitious year removed two patient thats esg embedded strategy metrics relating access ethical standards added supports sustainable performance longterm one relating antimicrobial resistance amr met one growth helps us build trust generate value metrics relating access developing stakeholders reduce risk operations create publishing pricing access principles also positive social impact removed one ethical standards metrics tracks identified six esg focus areas address number employees leaving gsk misconduct increases material business issues matter decreases number could indicate either higher stakeholders focus areas core lower number breaches strongerweaker enforcement strategy greatest positive processes setting threshold effective impact societys urgent challenges measure success upholding standards continue including set un sustainable development monitor data internally publish externally goals un sdgs three additional metrics provide strong measure commitment ethical standards access healthcare added metric within global health health security global health health security focused amr amr urgent public health threat seen increased stakeholder interest approach environment updated biodiversity target achieved diversity equity inclusion dei new target focuses deforestation free sourcing paper palm oil ethical standards product governance assess performance gsk leadership team glt accountable focus areas informed recent delivering progress metrics regularly reviews materiality assessment reaffirmed performance along boards corporate material issues business well aligned responsibility committee crc individual metric six esg focus areas recognise assessed either track metric met exceeded responsible business static requirement track work least metric means continue evolve approach achieved track metric missed response rapidly changing operating environment strive continuous improvement ensure addition order calculate overall esg maintain strong esg performance performance rating performance across metrics aggregated single score illustrate whether esg performance rating track track work track rating defined esg performance rating helps us integrate esg delivery strategy allows us measure track metrics track verify progress making rating one track work metrics corporate kpis measures progress key metrics either track track work aligned six focus areas included metrics summarised esg performance track metrics track report esg performance rating esg performance rating track based assessment performance annual targets performance metrics met exceeded reviewed overall esg performance rating score subject independent limited assurance full details progress six focus areas esg performance rating metrics independent limited assurance reports see esg performance report strategic report governance remuneration financial statements investor information gsk annual report responsible business continued external benchmarking detailed perform key esg ratings ftsegood member ftsegood index since frequently asked investors cdp climate change water security access medicines ranked st access b forests palm oil b forests timber medicines index industry leader sustainalytics low risk rating antimicrobial resistance benchmark msci aa rating sp corporate sustainability assessment ranked st pharmaceuticals industry score moody 's analytics esg overall score november included djsi world sector average europe indices iss corporate rating b rating access aim positively impact health billion people providing access patients lower income countries end making vaccines collaborate global health partners including medicines available widely possible ngos generic manufacturers increase reach responsible pricing strategic access programmes patients lower income countries reached partnerships million people vaccines antiretrovirals lower income countries commitment make products available valuebased prices vaccines sustainable business implement access reserve lowest vaccine prices gavi vaccine strategies increase use medicines alliance similar organisations partnered vaccines treat protect underserved people gavi since foundation supplied one billion vaccine doses date lowest prices esg performance rating metric lowest income countries progress towards goal reaching billion people lower income countries products partnership significantly increased supply deliver around million doses cervarix progress critical vaccine lower income countries addressing putting right value innovation cervical cancer set responsible prices line benefits supplied around million doses bring patients health systems measured clinical pneumococcal vaccine synflorix eight gavieligible economic social outcomes compare offer countries lowest price vaccine rotavirus already available patients generate rotarix reaches children across gavieligible countries evidence clinical trials establish added value four former gavi countries offered vaccines provided medicines vaccines adjust civil society organisations serving refugees working pricing line socioeconomic status country emergency situations humanitarian ensure affordability availability mechanism since also longstanding supplier operate robust pricing approvals developing oral polio vaccines unicef alone access plans informed payers also work create supplied around million doses help eradicate polio stability predictability payers business neglected tropical diseases engaging proactively upcoming product launches donated million albendazole tablets help budget planning adjusting prices account tackle lymphatic filariasis lf soil transmitted helminths inflation us combined average net price echinococcosis taking total donated discounts rebates allowances billion pharmaceutical vaccines portfolio increased average list price increased compared remain committed supplying albendazole endemic list industry past five years countries lf eliminated everywhere far lf average net price products increased eliminated countries including bangladesh annually average list price rose lao pdr announced elimination disease compared list industry significant milestones collaborative effort get ahead disease together number tablets donating declining year given gradual eradication neglected tropical diseases ntds medicine targeting strategic report governance remuneration financial statements investor information gsk annual report responsible business continued programme benefited million people gsk partners mosquirix significant scientific since began according data breakthrough worlds first malaria vaccine first vaccine human parasite hiv aurobindo cipla viatris three generic july gavi announced nine african manufacturers signed sublicences viiv healthcares countries allocated doses mosquirix early licence medicines patent pool mpp develop committed supply total million manufacture supply generic versions cabotegravir doses gavieligible countries longacting hiv preexposure prophylaxis cabotegravir plan produce million doses annually la prep countries subject obtaining regulatory approvals viiv healthcare also works global health landmark study london school hygiene agencies ngos governments community partners tropical medicine showed combining mosquirix plan support introduction viivmanufactured antimalarial drugs areas africa seasonal malaria cabotegravir la prep introduction national reduced malaria cases deaths young children programmes late first orders cabotegravir period five years la prep delivered global partner programmatic use low middleincome countries findings confirm potential seasonal vaccination provide high level protection first five years viiv healthcare also voluntary licensing agreements life protection much needed generic manufacturers produce sell lowcost single fixeddose combination products containing helping strengthen healthcare systems hiv medicine dolutegravir adults agreements gsk viiv healthcare joined forces cover low middleincome countries one direct global fund pledge million three years create licence others via mpp similar gender equality fund support community agreements generic manufacturers children based led organisations working deliver covering countries well separate agreements lasting changes health policies programmes focusing enable greater access dolutegravir certain upper tb hiv malaria women girls middleincome countries total around million people diversity bill melinda gates foundation living hiv across countries access generic committed match donation also renewed product containing dolutegravir end partnership save children another five years people living hiv antiretrovirals building learnings last decade focusing genericaccessible low middleincome countries partnership reducing number zero dose children never received vaccine malaria ethiopia nigeria represent third date two million children ghana kenya zerodosed children africa malawi reached least one dose mosquirix rtssase whocoordinated full details progress six focus areas please see esg performance report malaria vaccine implementation programme developed global health health security want help address biggest health challenges progress faced people around world global health rd commitment viiv healthcare announced investment billion years accelerate global health rd develop novel products technologies treat end invested prevent priority diseases including pandemic threats progressed global health pipeline assets address esg performance rating metrics priority diseases including climateaggravated progress six global health pipeline assets address diseases disproportionate impact lower priority diseases income countries progress eight active rd projects address promising avenues tuberculosis prevention pathogens prioritised cdc posing treatment highest level concern due drug resistance gsk committed tackling tuberculosis tb one critical andor urgent threats worlds deadliest diseases developed promising candidate vaccine mase proof concept phase iib building longstanding successful history working external partners partnered bill melinda gates medical research institute mri development budget phasing linear across year period strategic report governance remuneration financial statements investor information gsk annual report responsible business continued gates mri well positioned lead large complex rd projects across medicines phase iii study required june wellcome vaccines relevant amr ranging early bill melinda gates foundation announced funding latestage development rd projects targeting million phase iii trials trials pathogens deemed critical urgent successful mase could first new vaccine us centers disease control prevention help prevent pulmonary tb century include gepotidacin could first novel breakthroughs malaria research treatment oral antibiotic treatment uncomplicated urinary tract august announced gsk scientists infections utis years positive phase iii data discovered strain naturally occurring bacterium eagle eagle trials presented could potentially help eradicate disease tres european congress clinical microbiology infectious cantos tc strain delftia tsuruhatensis bacterium diseases copenhagen april significantly reduces load p falciparum malaria march announced exclusive licence parasites mosquitoes could potentially inhibit agreement scynexis brexafemme ibrexafungerp transmission parasite humans continue tablets firstinclass antifungal treatment pursue groundbreaking research engaging vulvovaginal candidiasis vvc reduction global health institutions partners identify incidence recurrent vvc effective sustainable approach development mobilisation successful progressing vaccines enteric diseases reduce burden antimicrobial resistance supporting innovation capacity capability antimicrobial resistance amr major threat health building globally particularly prevalent lowresource africa open lab initiative launched settings continue progress candidate vaccines support earlycareer scientists based subsaharan africa several enteric diseases contribute focusing infectious diseases disproportionately burden amr including invasive nontyphoidal affect subsaharan populations malaria tb salmonella klebsiella shigella typhoid paratyphoid amr agreed grants ten researchers six fever announced partnering countries subsaharan africa announced limmatech biologics development call proposals november also working candidate vaccine shigellosis continue african academic institutions provide grantees develop another candidate vaccine disease supplemental training areas including epidemiology uses vaccine platform technology gmma statistics clinical research currently vaccines help prevent shigellosis strengthening health security disease causes deaths year many factors jeopardise health see rd pipeline security new emerging infectious diseases full details progress six focus areas please see esg rise amr primary contribution strengthening performance report health security innovation prevent mitigate infectious disease environment climate change nature loss urgent threat average percentage gsk sites suppliers human health well risk business resilience get compliant wastewater active pharmaceutical ahead disease help ensure longterm business ingredient limits percentage suppliers success need take action climate nature compliant amr industry alliance common antibiotic manufacturing framework discharge limits commitment percentage paper palm oil deforestation free commit net zero nature positive healthier planet ambitious goals set operational waste material reduction sites esg performance rating metrics operational emissions reduction scope market based emissions industrialisation lowcarbon ventolin initiated clinical nonclinical data available support regulatory submissions percentage carbon offset volume project pipeline metrics related esg performance rating outlined esg performance report also measure report performance public environmental sustainability targets publish gskcom strategic report governance remuneration financial statements investor information gsk annual report responsible business continued progress overall scope emissions lower baseline year although increase climate latest available data compared clear pathway net zero impact climate primarily driven higher sales metered dose ambitious goals inhaler mdi products although overall scope emissions science based targets initiative sbti increased period approved gsks net zero target line reduced upstream scope emissions suppliers corporate netzero standard worlds framework goods services buy make medicines corporate net zero target setting line climate vaccines additional upstream emissions account science approximately total emissions footprint value chain carbon footprint made supply chain emissions fell scope emissions operations use medicines vaccines makes total footprint propellant used scope emissions supply chain mdis asthma chronic obstructive pulmonary disease scope emissions patients using products copd mostly metereddose inhalers mdis gsks rescue mdi medication ventolin salbutamol scope emissions logistics essential medicine prescribed approximately million people respiratory conditions worldwide patient use scope emissions disposal products inhaler due current propellant accounts targets half carbon footprint investing lowcarbon programme potential reduce absolute reduction greenhouse gas emissions greenhouse gas emissions inhaler baseline across scopes investment transitioning next generation lower carbon propellant naturebased solutions remaining phase iii trials begin successful footprint regulatory submissions start imported renewable electricity supplement existing low carbon dry powder inhalers renewable electricity imported generated see pages disclosure climate risk scope resilience line task force climaterelated net zero greenhouse gas emissions across full value financial disclosures tcfd framework chain absolute reduction emissions baseline across scopes residual nature emissions neutralised shared detail plan contributing naturepositive world line goal global performance biodiversity framework halt reverse biodiversity loss reduced scope carbon emissions compared compared sets approach nature four focus baseline primarily energy efficiency areas freshwater land oceans atmosphere measures increasing amount renewable including biodiversity living species across electricity use member initiative areas aim deliver contribution three ways committed reach imported electricity avoiding reducing impact nature protecting renewable sources electricity restoring nature helping accelerate collaborative generate import renewable sources action approach aligned work reached imported renewable electricity taskforce naturerelated financial disclosures tnfd increase science based targets network sbtn signed power purchase agreement source may selected part first group renewable electricity cover electricity demand companies participate initial target validation sites europe mid two additional wind process sbtn set validated sciencebased targets turbines new solar farm manufacturing nature starting targets freshwater land facility irvine scotland began generating renewable followed targets oceans biodiversity energy already started implement final tnfd recommendations disclosure read based data target boundary includes biogenic landrelated emissions removals bioenergy feedstocks previously reported nature targets grouped water waste materials biodiversity updated target categories align four areas nature defined tnfd sbtn underlying targets waste materials targets remain strategic report governance remuneration financial statements investor information gsk annual report responsible business continued freshwater roadmaps place achieve sustainably continue work towards existing water targets sourced paper packaging palm oil paper packaging derived certified targets sources recycled raw materials core achieve good water stewardship sites palm oil materials certified thirdparties sustainable sources reduce overall water use operations working suppliers key part goal reduce impact nature appropriate also look opportunities reduce avoid use water neutral operations key natural materials including process efficiencies suppliers waterstressed regions synthetic alternatives example working zero impact api levels sites key suppliers process improvement deliver significant yield increase reducing nature impact improving supply resilience performance oceans achieved overall water reduction target continue deliver existing ocean target reduced overall water use operations set apply relevant sciencebased additional compared sites methodology oceans becomes available high water stress regions decrease target overall water use sites high water stress regions baseline marinederived materials sustainably sourced sites key suppliers located waterstressed areas developing catchmentlevel water performance replenishment restoration regeneration projects impacts dependencies oceans come primarily including partnering ngos deliver water marinederived materials critical part neutrality target manufacturing vaccines medicines example sites key suppliers compliant use horseshoe crab blood important substance amr alliance api wastewater discharge limits required regulators used primarily due scope pharmaceutical biomedical quality control processes expansion driven us expanding scope ensure quality safety medicines vaccines include api suppliers led decrease devices continue make progress volume percentage key suppliers confirmed reductions advancing pilot across five within wastewater api discharge limits sites test use nonanimal alternatives time engaging regulators support wider work strengthen responsible manufacturing uptake alternatives antibiotics highlighted example good practice report issue access medicine make progress reducing volumes moving foundations amr benchmark synthetic alternatives working suppliers improve sustainability new sustainable sourcing land standards include specific marine sustainable sourcing continue deliver existing land targets standard outlines requirements suppliers targets marinederived materials must adhere part positive impact biodiversity sites conducted physical site audits key suppliers atmosphere agricultural forestryderived materials sustainably sourced deforestation free air pollution significant risk human health particularly patients respiratory conditions like asthma copd performance performance completed baseline assessments six sites meaning assessed sites using approach air pollution includes reducing pollutants natural england biodiversity net positive methodology linked burning fossil fuels addressed via parallel plans place improve biodiversity sbtialigned climate targets set well nine manufacturing sites looking broadly air pollution footprint members alliance clean air clean air set ambitious new sustainable sourcing standards fund world economic forum done suppliers provide us materials highly initial assessment establish air pollution footprint dependent nature like lactose gelatine soy operations supply chain creating reduction plans aligned pathway net zero aim positive impact air quality predicted noeffect level gskowned sites strategic report governance remuneration financial statements investor information gsk annual report responsible business continued waste materials product stewardship overuse natural resources generation approach product stewardship across new waste pollution key drivers climate change existing products built scientific method nature loss environmental footprinting called life cycle assessment lca targets since completed lca analysis approach product stewardship means products using lca methodology enabled consider aim address impacts nature climate us identify need improve manufacturing every stage product lifecycle discovery design assess potential savings design changes design sourcing manufacturing product use provide productlevel information key customers disposal set target help accelerate specific products gsk sites manufacturing adoption approach pvcfree secondary tertiary packaging environmental impact reduction products waste packaging reduced operational waste since last also set targets reduce operational supply year total since increased amount chain waste materials recovered circular routes zero operational waste including eliminating single use maintained zero operational waste landfill plastics continue build longstanding operational waste reduction supply chain waste management programme identify opportunities find beneficial uses waste full details progress six focus areas please see esg performance report diversity equity inclusion want inclusive business people progress thrive ensures diversity clinical trials clinical trial diversity supports diverse communities continue make progress advancing clinical trial commitment diversity met objective phase iii interventional trials initiated proactive create diverse equitable inclusive workplace diversity plans also challenging actively enhance recruitment diverse patient populations monitor patient recruitment real time ensure clinical trials support diverse communities reach diversity goals esg performance rating metrics february published study years gsk phase iii trials initiated proactive viiv healthcare us clinical trial diversity data showed plans place designed enrol appropriately diverse trial enrolling participants clinical trials based real participants consistent disease epidemiology world disease epidemiology data rather census data improve yearonyear spend usbased certified would ensure trials reflect populations diverseowned suppliers affected different diseases publicly sharing research hope advance discussion around clinical update towards people aspirations fair trial diversity improve pharmaceutical sector equitable opportunities approaches issue clinical trial diversity aspire women hold least vpand roles globally end supporting diversity supply chains engaging mentoring small diverseowned aspire least ethnically diverse leaders businesses supply chain help identify roles vpandabove us end potential areas growth increased spend increase percentage black african annually usbased certified diverseowned suppliers american hispanic latinx vpandabove leaders year year year expanded successful us supplier diversity aspire least ethnically diverse leaders programme uk groups benefit roles vpandabove uk end programme include women ethnic minorities members increase percentage black vpand lgbtq community people disabilities leaders year year military veterans well small businesses high unemployment low income communities including reduction routine hazardous nonhazardous waste regulatory obligations allow excluding plastics critical product discovery development health safety strategic report governance remuneration financial statements investor information gsk annual report responsible business continued ensuring diversity workplaces addition within uk ethnicity pay gap report fundamentally committed equal employment also sharing pay gaps comparing average pay opportunity nondiscrimination employees white employees ethnic groupings want leadership reflect gsk people black mixed asian reference people reflect communities work hire uk governments recently published guidance provide granular view end women held vpandabove roles globally compared women made year added disability confidence training employees management first line leader training aimed people managers roles uk end ethnically training designed develop inclusive leaders diverse leaders vpandabove compared able promote disability confidence within teams black leaders vpandabove continue work make sure lgbtq compared us end colleagues feel welcome valued included ethnically diverse leaders vpandabove recognised gold employer stonewalls compared black african top global employers index american leaders vpandabove compared hispanic latinx leaders vpand also relaunched mental health matters training compared available globally designed help people spot signs poor mental health know start remain committed application fair conversation others signpost resources support equitable pay practices ensure equal opportunities everyones wellbeing equal pay equal work gender pay gap permanent ukbased gsk employees mean supporting diverse innovators future compared national average also uk launched million tenyear stem equity publishing second uk ethnicity pay gap comparing programme targeting yearold girls young average pay white ethnically diverse employees women black people people low socioeconomic uk ethnicity pay gap permanent ukbased backgrounds programme includes nationwide stem gsk employees mean compared mentoring delivered partnership established mentoring organisations first three years aim reach approximately young people programme full details progress six focus areas please see esg performance report ethical standards culture guides people behave ethical way progress right thing speak concerns supporting gsk people right thing expect everyone works us live code conduct code reflects purpose expect suppliers unite science technology talent get ahead commitment disease together sets commitments make company deliver purpose promote ethical behaviour across business ambition supporting employees right thing working suppliers share standards code supported additional global policies operate responsible way standards also accompanying global mandatory learning curriculum living code esg performance rating metrics people required complete employees complementary workers employees complementary workers completed complete gsks mandatory training training due yearend percentage employees believe also antibribery corruption abac training speak things dont feel right general industry benchmark people certain highrisk roles geographic regions helps identify mitigate potential direct highrisk suppliers achieve gsks abac risk especially thirdparty relationships minimum ecovadis score improvement recognise report manage conflicts interest plan place employees complementary workers completed training general industry benchmark according research kornferry strategic report governance remuneration financial statements investor information gsk annual report responsible business continued reporting investigating concerns visit sites person virtually help suppliers better saw overall decrease number understand control ehs risks year employees concerns raised conducted physical visits across priority suppliers employees disciplined policy violations open cases conducted supplier audits following industry year end reflective several factors including standard pharmaceutical supply chain initiative guidelines external geopolitical economic issues affecting trained supplier employees ehs countries changes nature concerns raised strengthened ehs contractual obligations worked internally continued emphasis appropriate suppliers help improve ecovadis scores management closure cases using data responsibly commitment human rights data essential foundation realising ambitions signatories un global compact patients advances artificial intelligence ai human rights position statement lays commitment machine learning ml technologies present tremendous un guiding principles business human rights opportunities technologies must approached crossbusiness human rights steering group correctly responsibly ethically increases volume reports glt boards corporate data processed aiml use resulted responsibility committee drives progress human greater focus data governance ethical use rights impacts risks across business personal information compliance data privacy laws take responsibility data privacy carried human rights training priority seriously exercise high standards integrity suppliers aimed ensuring good understanding dealing personal information human rights labour principles aligned international standards also continued human digital privacy governance board oversees rights training procurement thirdparty engagement overall data ethics privacy operating model supported leads better equip spot human rights issues digital privacy legal experts compliance visiting suppliers conduct audits site visits professionals monitor mitigate new emerging covering environment health safety ehs labour cyber threats protect cyber security risks rights priority suppliers top issues additional governance boards oversee identified supplier visits related policy use data research development manufacture wages compliance observations action plans supply products ensure follow regulations place drive improvement meet ethical obligations committed fair equitable pay ensuring created crossfunctional ai governance employees globally receive pay competitive council oversee ai strategy ensure responsible local markets sufficient support sustainable adoption aiml complemented internal standard living fair wage network certified policy ensure aiml adoption safe aligned gsk living wage employer reviewed global gsk 's culture establishing ai principles underpinned gap analysis conducted confirmed ethical standards set gsk code gsk workers paid living wage political engagement relevant markets also developed consistent gsk seek contribute public policy debate approach gsk manage global fair wage analysis especially relation life sciences healthcare annually well methodology fair wage committed highest ethical standards legislative network use continue assess us requirements political engagements working third parties make corporate political contributions sponsor expect third parties comply applicable laws party political meetings anywhere around world regulations adopt minimum abac full details progress six focus areas please see esg labour rights principles relevant comply performance report standards quality patient safety health safety environment performed assessments highrisk third parties across risk areas across organisation give additional support ehs risks largest suppliers including supply globally medicallycritical products well critical rd largest spend largest suppliers including supply globally medically critical products critical rd largest spend gsk maintains list globally medically critical products drug products approved treat lifethreatening disease medical condition adequately available alternative gsk provider ehs priority suppliers api suppliers medically rd revenuecritical gsk high spend suppliers strategic report governance remuneration financial statements investor information gsk annual report responsible business continued product governance commitment inspections recalls audit commit maintaining robust quality safety regulatory inspections processes using data new technologies manufacturing sites local operating companies responsibly compared received zero warning letters united states food drugs esg performance rating metrics administration fda critical findings medicines average number critical major findings per healthcare products regulatory agency mhra inspection fdamhraema regulators european medicines agency ema regulators respond learn inspection findings percentage inspections regulators taking necessary action address critical findings official action indicated number fda warning letters throughout two class product recalls fewer class ii recalls compared total number class iii external product recalls across necessary protect patients hesitate markets recall products voluntarily register disclose human subject research gsk quality management along supply chains products specifically register protocol summaries conducted quality audits contract studies initiated disclose results summaries manufacturers suppliers verify comply studies results due gsk standards comprehensive quality oversight progress model aligned quality management system maintaining quality across gsk uses riskbased approach assess qualify manage monitor thirdparty suppliers ongoing basis detailed specific quality framework driving continuous performance describes comply regulatory requirements standards across markets addresses global pharmacovigilance times local regulations across manufacturing distribution wellestablished rigorous worldwide system processes based principles defined monitor review safety products throughout international council harmonisation technical clinical development regulatory approval requirements pharmaceuticals human use expect partners meet high standards gsk quality function responsible managing quality safety governance conduct reviews thirdparty ensuring quality mindset embedded throughout safety systems monitoring contractual obligations organisation levels brings together extensive fostering collaboration lifecycle global network quality compliance professionals relationship within business units site level senior tackling counterfeit medicines vaccines management falsified products put health patients risk quality management depends upon comprehensive threaten brand reputation report cases ongoing patient safety quality process training confirmed counterfeit products relevant quality management system details training regulatory authorities actively participate legal required gsk people including induction hygiene safety proceedings illegal actors support customs technical skills training well good distribution local authorities regular training also monitor manufacturing practice training employees carry online marketplaces social media request takedowns specific qualitycritical sensitive activities subject sites illicitly selling prescriptiononly medicines additional training necessary clinical data transparency part commitment transparency made protocol summaries summaries results available since gsk trial register set also listed clinical trials data sharing via wwwvivliorg full details progress six focus areas please see esg performance report consider observations us fda major class recalls triggered reasonable probability use exposure violative product cause serious adverse health consequences death class ii recalls address use exposure violative product may cause temporary medically reversible adverse health consequences probability serious adverse health consequences remote class iii recalls relate use exposure violative product likely cause adverse health consequences gsk annual report risk management disclosure statements section risk management principal risks summary climaterelated financial disclosures naturerelated financial disclosures nonfinancial sustainability information statement employees gender viability statement strategic report governance remuneration financial statements investor information gsk annual report risk management deliver bold ambitions patients maintain wellembedded risk management internal control framework overseen evaluated board controls guidance manage risk effectively considering likelihood impact wellembedded risk management internal control timescale risks framework gives board ability evaluate enterprise risk assessment methodology oversee company manages principal emerging mechanism assess risk including risks line strategy longterm priorities principal risks enterprise risk assessment methodology companywide policy sets requirements roles considers likelihood impact risks responsibilities management governance timescale risk could occur based risks controls well supporting guidance probable scenario considering existing internal essential elements internal control framework controls impact assessments include considerations routinely evaluate risk management internal control across patient safety quality supply environment framework improvements health safety legal people regulatory reputation strategic objectives finance incorporating materiality board oversight setting 'tone top ' thresholds well considering current evolving risks board oversees system risk management evaluate emerging risks could affect ability internal control establishes risk appetite supported achieve longterm priorities threeyear horizon audit risk committee arc corporate line viability statement also define risks responsibility committee crc science committee emerging need know likely assess effectiveness risk management materialise impact would strategies fall within defined remits arc evaluate emerging risks impact board oversee cyber security risks company assess whether elevated details board committees responsibilities principal risk risk management compliance remit see risk oversight compliance boards levels identify emerging risks ongoing council rocc cochaired group general counsel basis rocc discusses evolving emerging risks chief compliance officer helps arc crc meeting time scan risk horizon science committee oversee risks strategies throughout year identify external trends may used address also risk management opportunities andor emerging risks monitor compliance boards rmcbs across group promote business activities internal environment rocc tone top establish risk culture oversee conducts annual risk review assess principal effectiveness risk management activities also emerging risks company review supported communicating information internal controls extensive analysis external trends insights management held accountable delivering seniorlevel interviews recommendations risk objectives line established risk appetite management compliance boards risk owners pertaining principal risks disclosure committee rocc shares annual review arc board responsibility considering materiality assessment agreement forming basis information determining disclosure following years risk management focus information timely way enterprise risk owner responsible principal risk overseen glt business strategy results operations financial member risk owners report risk mitigation rocc condition materially affected risks appropriate board committee quarter cyber security threats including result previous cyber significant risks issues also escalated glt security incidents provide assurance rmcb appropriate risk governance forum eg global materially affected future safety board throughout year needed legal risks future material incidents compliance support efforts advising business strategies activities risks controls audit assurance provides assessments adequacy effectiveness framework strategic report governance remuneration financial statements investor information gsk annual report risk management continued risk management internal control reporting current risks framework table starting shows current principal risk management internal control framework risks respective trends assessments mitigation aligned industry standards legal regulatory activities year order significance requirements defines essential elements expect full risk definitions potential impact context helps us identify assess manage report oversee mitigating activities see principal risks uncertainties risk relevant business activities framework helps risks level principal risks ensure risks proportionately managed line related esg including environmental sustainability risk appetite throughout year timely climate change managed six focus areas transparent manner support strategic objectives described esg performance report additional information climaterelated risk management principal risks include information cyber climaterelated financial disclosures security define enterprise risk plans include description risk context assessment risk changes risks appetite treat risk actions december annual risk review arc agreed businesses take line internal control roccs recommendation principal risks framework mitigate risk plans enable remain largely unchanged emerging risk data board committees assess effectiveness risk management continue evaluated year management strategies report principal risks emerging risks rocc respective board viability statement see arc report see committees every quarter drive dynamic data internal control framework see driven discussions agile risk management strategies legal proceedings see environment see oversight report existing control measures climaterelated financial disclosures see implementation emerging risks external insights key risk indicators risk reporting thresholds aligned risk appetite include risks mitigations associated relevant events around us geopolitical tensions code sets overarching expectations employees complementary workers aim right thing integrity care part culture risk management framework complements culture speak processes making sure identify mitigate risks effectively monitor important risks take action address issues annual confirmation exercise general managers site directors senior leaders glt checks key risks well managed actions place address gaps principal risks include controls responding problems within risk plans also business continuity planning embedded framework critical processes continue business operations event crisis strategic report governance remuneration financial statements investor information gsk annual report principal risks summary trend versus risk prior year assessment mitigation activities patient external risk environment remains stable pharmacovigilance function like across safety industry contends challenging legal regulatory environment even external optimised stateoftheart pharmacovigilance system predict issues impacting safety efficacy could potentially result regulatory action andor litigation particularly true issues based robust scientific evidence ongoing benefitrisk assessment products internal risk environment remains stable continue focus ensuring optimised benefitrisk profile vaccines medicines appropriate safety expertise gsk oversight successfully completed significant transition simplified thirdparty support model global pharmacovigilance operational activities product external risk environment stable yet remains high may regulatory agencies ended quality emergency covid measures resumed onsite inspections sites planned external unannounced make sure meet product quality expectations increased nationalism following pandemic driven broader spectrum regulatory requirements continues rapidly evolve new pharmaceutical chemical environmental expectations products focus data governance data integrity remains application aiml improve manufacturing quality infancy uncertainty regulated gxp arena us fda working industry understand application develop guidance risk exposure remains stable ongoing inspection readiness programme ensures preparedness regulatory authority inspections continue invest technology gsk strengthen data management controls modernise quality processes proactive anticipating regulatory expectations continue work industry level refine quality standards build new competencies assure product quality legal external risk environment increasing wideranging regulatory environment remains matters challenging due uncertainty volatility sometimes conflicting requirements influencing external ability determine exact requirements market government agencies notably us increasingly looking use competition law tackle perceived issues access medicine pricing acquisitions governments continuing enforce anticorruption laws regulations including nationwide oneyear campaign fight corruption healthcare china sanctions continue complex current geopolitical environment particularly concerning russia risk exposure stable due robust internal systems processes monitoring ensure proactive timely response changes adapting internal controls designed gsk accommodate external regulatory fluctuations changing risks financial external risk environment remains challenging due political uncertainty proposed controls increases obligations directors auditors increasing threats cyber attacks external reporting fraud increasing disclosure requirements including esg nonfinancial information risk exposure remains stable due ongoing focus resilience personnel testing internal control framework implement optimal risk mitigation gsk transformational programmes technology centralised processes risk control assessments maintain effective tax treasury strategies continually strengthen control frameworks collaborate external bodies setting standards commercial external risk environment stable governments remain focused initiatives drive practices medicine vaccine costs consumers passing us inflation reduction act ira external introduces new medicare inflationbased drug rebates drug pricing negotiation programme could overall negative effect us also macroeconomic factors inflationary pressure contribute challenging environment stakeholders competitive pressure remains intense across therapy areas market segments risk exposure remains stable mature robust control environment evolved match competitive enhancements commercial digital practices gsk including significantly higher volumes engagement healthcare professionals supported embedding endtoend speaker engagement system eliminating zerovalue contracts enhanced case study training medical commercial interface implementing new tenders procedure implementing enhanced interactive digital media channel oversight strategic report governance remuneration financial statements investor information gsk annual report principal risks summary continued trend versus risk prior year assessment mitigation activities scientific external risk environment changing diversity engagement platforms continues patient increase digital health technologies generative ai advance rapidly also external engagement environment continues characterised complex dynamic disease areas treatments increased volume patientcentric activities phases product lifecycle risk exposure remains stable continue build innovative digital capability improve engagement practices internal controls mitigate risk rapidly evolving gsk environment use data systems monitor emerging risks associated scientific patient engagement activities data ethics external risk environment continues increase global landscape data protection privacy privacy cyber laws develops given current pace technologyfocused innovation external expected continue companies need mindful relevant potential legislation regulations increasing trend data sovereignty could affect healthcare companies ability drive medical innovation operate internationally global regulators eu uk us china also introducing legislation around use ai ml closely aligned privacy regulations regulations play key role safeguarding privacy ensuring responsible data usage transparency ethical use data preventing biases managing international data flows internal risk exposure increasing given focus data uncertain external environment data ethics privacy operating model transformed make sure gsk flexible enough adapt emerging privacy laws us eu uk china india including addressing restrictions imposed regulators relation international data transfer mechanisms focused simplifying principles processes allowing flexibility around deployment model different territories business functions research external risk environment increasing technologyfocused innovation accelerates practices discovery development medicines vaccines advances technology expanded use external data digital footprints sophisticated cyber security threats rising trend data sovereignty developing global landscape quality standards data protection privacy cyber laws new entrants sector continue influence environment companies consider relevant emerging legislation regulations impact ability drive innovation operate internationally risk exposure increasing adopt new technologies scale adoption ai discovery development medicines vaccines continue adapt internal gsk business processes enable innovation meet ethical societal regulatory expectations environment external risk environment remains stable currently external ehs risk factors health reduce ability discover manufacture vaccines medicines safely external safety ehs risk exposure remains stable 've continued safety leadership training embedding life saving rules adhering ehs standards initiated contractor safety gsk programme deliver improvements reduce risk profile associated using contractors across business units strengthening driver safety programmes information external risk continues rise digital footprints increase threats cyber security cyber become sophisticated including threat actors access sophisticated ai external security capabilities continued geopolitical conflicts also increased cyber security risk large corporations risk exposure continues increase adopt new technologies scale adoption ai across gsk remain track deliver multiyear cyber maturity programme cmp gsk risk mitigation programmes including china high risk jurisdiction processes accountabilities data management improve controls governance identify protect detect respond recover cyber security incidents strategic report governance remuneration financial statements investor information gsk annual report principal risks summary continued supply external risk environment remains stable cyber attacks two continuity thirdparty logistics providers tested business continuity planning external constraints seen sourcing bioscience materials abated however new constraint emerging thirdparty sterile manufacturing capacity increases competition contract manufacturing operations extreme weather events continue present challenges across industry facilities worldwide risk exposure remains stable maintained combination welldefined supply chain management processes clear escalation pathways ensure supply continuity clear gsk succession plans place critical supply chain roles supply chain initiative integration medicines vaccines supply chains one organisation demonstrate commitment evolving technology platforms product portfolio without affecting supply continuity remains consistently high strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures climaterelated financial disclosures consistent managements role assessing managing climate recommendations recommended disclosures related risks opportunities task force climaterelated financial disclosures tcfd gsk leadership team glt including tcfd allsector guidance compliance glt meets regularly giving members opportunity requirements lr r uk listing rules discuss strategic financial reputational matters disclosures compliance companies strategic report climaterelated financial disclosure president global supply chain glt member regulations company act management responsibility environmental sustainability updated risk assessments reflect changes includes climate change responsible supply chain progression sustainability governance oversight risks opportunities transformation programme makes sure effective framework manage risks opportunities across business units governance along delivering commitments net zero boards oversight climaterelated risks nature positive healthier planet ambitious goals set opportunities across entire value chain board glt reviewed discussed midyear board considers climaterelated matters throughout performance key environmental metrics including year includes assessing risk management processes climaterelated ones see part reviewing challenging endorsing business plan budgets gsks esg performance rating including overseeing major capital expenditures gsk sustainability council acquisitions divestments board approved progression next phase development low sustainability council held quarterly attended carbon ventolin programme senior leaders across business members include leaders procurement finance hr compliance rd corporate responsibility committee crc exercises manufacturing corporate affairs council co oversight provides guidance reviews esg chaired president global supply chain vp performance including climaterelated risks sustainability supported global sustainability opportunities environmental performance team external third parties provide specialist targets expertise advice business crc receives quarterly updates environmental council sustainability including climate regular attendees include ceo president global supply chain approved annual targets climate key see details board architecture performance indicators kpi sustainability programme crc reviewed approved gsks twin goals reviewed monthly performance escalations climate nature following demerger potential concerns issues consumer healthcare business july crc approved gsk would submit updated refreshed approved annual climate risk review approach targets science based targets initiative sbti risk disclosure aligned c pathway align sbti net agreed newly formed esg reporting hub zero standard reduce carbon emissions would accountable assurance environmental data crc met five times discussed climate reviewed progress core programmes improve related issues three separate occasions sustainability supply chain management focused reviewed progress towards securing portfolio carbon credits support commitment progress delivering climate ambitions including low carbon ventolin nature plan updates implications geopolitical landscape key milestones decisions required achieve net zero targets midyear performance key environmental metrics including climaterelated metrics part reviewing interim esg performance rating approved climate disclosure statement final esg performance rating public environmental reporting disclosures strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued business support long term ten years enable us explore sustainability council supported assessing uncertainties changes weather disease patterns managing climaterelated risks opportunities societal responses climate change across globe sustainability programme steering team chaired vp sustainability meets monthly identified prioritised climaterelated coordinates sustainability programme risks opportunities associated workstreams team monitors programme risks performance progress enablers required deliver sustainability programme changes regulations governing supply high global warming potential gwp substances eu sustainability councils within business meet uk us governments could restrict ability quarterly review business unit performance manufacture metered dose inhalers delivery company sustainability ambition chaired senior leaders within business future regulatory policy responses address climate also attend gsk sustainability council change could lead imposition carbon taxes countries manufacture source goods metered dose inhaler steering team third parties attended senior leaders across commercial supply chain regulatory rd businesses aligned increasing levels water stress could lead interruptions respiratory business team chaired supply water thirdparty supply sites president global supply chain also chairs increasing frequency impact extreme weather sustainability council decisionmaking body events could disrupt gsk thirdparty programme reduce climate impact metered supplier sites dose inhalers contribute approximately gsks total ghg emissions naturebased projects might deliver sufficient volumes carbon credits offset million tonnes coe capital allocations board cab chaired per year requiring us buy additional credits cfo includes group financial controller higher cost reviews climaterelated capital expenditure part annual planning capital allocation process opportunities esg reporting hub established cop countries committed provides oversight assurance esg performance provide lowcarbon healthcare systems could lead data including carbon emissions data increasing demand lowcarbon medicines carbon offset programme steering committee vaccines includes group financial controller vp several reports exploring impact climate change sustainability also attends sustainability council health shown climate change affects reviews due diligence outcomes potential carbon water vectorborne diseases could lead offset projects performance established increasing demand new medicines vaccines investments makes new investment decisions processes identifying assessing climaterelated crossfunctional team sustainability finance risks opportunities set risk management supply chain procurement functions performs section continue monitor emerging risks annual review climate risks monitor previously new data include future assessments identified climate risk escalate new emerging climate risks sustainability council impact climaterelated risks opportunities business strategy financial planning results climate scenario modelling shared business unit risk management control boards rmcb commitment work towards net zero nature positive healthier planet ambitious goals set strategy embedded strategic longterm priorities always climaterelated risks opportunities considering social environmental governance identified short medium long term impacts everything laboratory patient climaterelated risks opportunities considered nearterm carbon reduction target reduction three different time horizons scope scope carbon emissions longterm carbon reduction target reduction short term less three years aligning financial scope scope carbon emissions planning timeframes targets measured baseline medium term three ten years aligning longterm targets aligned c pathway business forecasting timeframes approved science based targets initiative sbti strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued transition plan energize programme encourage use taking action reduce emissions across full renewable energy throughout pharmaceutical sectors supply chain value chain prioritising highestimpact areas invest around billion deliver emissions manufacture initiative encourage suppliers reductions removals achieve targets though measure manage reduce emissions activities outlined pharma lca consortium group eight global beyond expect left harder pharmaceutical come together via totackle emissions across supply chain pharmaceutical environment group support operations logistics disposal many cases sustainable markets initiative codevelop shared addressing residual emissions likely depend way measuring reporting environmental technologies infrastructure regulatory frameworks product footprints require broad publicprivate collaboration risks uncertainties decarbonisation plan interdependent broader economic transition follows similar timeframe pharmaceutical manufacturing processes highly regulated different agencies across world may progress reducing carbon emissions found slow implementation decarbonisation initiatives direct operations supply chains complex involve several order continue reducing scope emissions across intermediate stages production highly product operations focusing specific volume demand specific materials quite low reduce ability influence maximising energy efficiency sites purchase small share supplier 's production longstanding energy efficiency programme transitioning imported renewable electricity many suppliers based regions renewable investing power purchase agreements electricity heat less available elsewhere supplemented purchase energy attribute measuring scope emissions complex challenging certificates lack primary data suppliers increasing use electric vehicles sales fleet methodologies involve using spendbased estimates mixed activitybased data industry average data risks uncertainties extrapolations based subjective choices judgments markets operate singapore data systems processes controls mature accessing renewable electricity challenging primary data becomes available may need limited generation capacity market boundary restate reported emissions data future rules governing imported electricity product impact uncertainties transition renewable heat use products makes carbon hightemperature heat produced electricity footprint patient use gsks rescue metered dose inhaler generally commercially available today biogas replace mdi medication ventolin salbutamol accounts natural gas without introducing major changes facilities half carbon footprint investing widely available locations rd programme large factory upgrade project operate use biomass fuel could introduce issues redevelop inhaler transitioning lowercarbon land use change impacts local air quality propellant recent data early clinical trials supported decision progress phase iii dosing transition electric vehicles could first patients planned first half restricted vehicle availability lack charging successful regulatory submissions begin infrastructure sourcing key materials battery production risks uncertainties supply chain metered dose inhalers complex devices new sustainable procurement programme requires medical propellant must meet specific range technical suppliers disclose emissions set carbon reduction performance characteristics safe efficacious targets aligned c reduction pathway also patients work suppliers particularly largest engaging medical regulators us footprint encourage adopt new sustainability food drug administration fda european medicines measures agency ema uk medicines healthcare supply chain emissions shared challenge across products regulatory agency mhra advances sector working peers collaborative pharmaceutical product design reduce initiatives environmental impact medicines activate programme help active pharmaceutical ingredients api suppliers accelerate decarbonisation initiatives strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued carbon credits net zero scenario ssp rcp focused emissions reductions meet scenario sets narrow achievable pathway carbon targets also investing high quality nature global energy sector achieve net zero co emissions protection restoration projects support net rely emissions reduction zero nature positive goals deliver cobenefits outside energy sector achieve goal scenario human health generate carbon credits offset annually consistent limiting global temperature rise c baseline value chain carbon footprint without temperature overshoot net zero means huge volume credits required taper declines use coal oil gas shift continue reduce emissions aiming achieve renewable energy sources net zero emissions across full value chain lowcarbon scenario ssp rcp criteria high quality projects include avoidance scenario current net zero pledges achieved harm transparency additionality permanence mitigation full extensive efforts realise nearterm leakage project monitoring reporting verification emissions reductions advanced economies reach net zero claims avoidance double counting emissions china around target prioritising carbon removal countries latest scenario consistent credits also secure proportion carbon limiting global temperature rise c avoidance reductions credits recognition level net negative emissions critical role conserving existing carbon stocks temperature rise could reduced c protecting nature net zero target current trajectory scenario ssp rcp aim secure carbon removal credits scenario sets show extent announced risks uncertainties ambitions targets path deliver recognise fastmoving field emissions reductions required achieve net zero emissions methodologies guidelines likely evolve temperature rise exceed c implement plans commit remaining flexible noticeable shift happen latter half transparent progress learning century net zero pledge emissions within scenario necessarily mean co emissions risk naturebased projects deliver energy sector need reach net zero sufficient volumes carbon credits meet needs allocation carbon offsetting within pledges given year may need purchase credits higher cost breach planetary boundaries scenarios ssp rcp scenario aligned pledges laid climate scenarios paris agreement one countries unable use climate scenarios inform management meet united nations sustainable development goals climate risks reporting results risk management scenario severe physical control boards rmcb business well consequences planet temperature rise sustainability council exceed c leading high loss biodiversity developed modelling tools support species extinction third parties enable us model impacts physical risk management transition risks sites supply chains located example modelled probability processes identifying assessing climaterelated interruption extreme weather event key risks sites supplier sites subsequent financial impact nature risks opportunities climate interruption assuming inventory levels carried change depends physical aspects climate existing business continuity plans modelled change also regulatory commercial changes impact future carbon taxes direct taxes markets operate including pressures reduce energyrelated emissions emissions trading schemes climate impact metered dose inhaler medicines taxes carbon border adjustment mechanisms assuming deliver carbon reduction glidepath risk management policies designed address beyond types risks including group principal risks uncertainties climate risk management follows reviewed updated climate scenarios policy framework risks climate change group first developed intend review scenarios level fall governance crc support make sure 'll remain date sustainability council individual risks climate change raised appropriate business unit iea net zero emissions scenario httpswwwieaorgreportsglobal functional risk management control boards make sure energyandclimatemodelnetzeroemissionsbyscenarionze integrate risks business risk management last accessed november processes iea world energy outlook chapter p download report httpswwwieaorgreportsworldenergyoutlookoverview last accessed november iea announced pledges httpswwwieaorgreportsglobalenergy andclimatemodelannouncedpledgesscenarioaps last accessed november strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued specific dedicated environmental sustainability risk communications government affairs team management plan put place risk manages corporate reputation identifying management plan covers expectations monitoring climaterelated issues undertaking addressing impact environment proactive reactive engagement relevant environment increasing impacts operational stakeholder groups communicate position resilience access energy water natural details manage prioritised risks resources used products along anticipated cost risk table increases regulatory changes environmental taxes review developments policy regulations global processes identifying assessing managing national level receiving quarterly monitoring reports climate related risks integrated overall risk management procedures identify risks climate change factors evolve example assess climate annual basis crossfunctional team impact merger acquisition activity sustainability finance supply chain procurement construction new buildings use shadow carbon functions reviews climate risks climaterelated risks price per tonne coe inform decisionmaking considered strategic operational perspective investments major capital expenditure understand make sure maintain comprehensive view implications potential carbon offset costs carbon different types climate risks face different emissions value chain value based time horizons may affect us team review recommendation carbon pricing leadership previously identified climate risks plus new emerging risks coalition concluded explicit carbon opportunities make recommendations paper price level required drive change restrict temperature sustainability council risk assessment papers increases c least ustco prepared prioritised risks considering likelihood monitor value used internal carbon pricing financial impact us risk different estimates future costs carbon credits climate scenarios processes managing climaterelated risk risk opportunity analysed understand managing metrics targets used purposes disclosure differentiate potential impact total profit using low 'physical ' 'transition ' climaterelated risks million medium million million high physical risks typically identified asset project million threshold level managed depending level risk impact assessments approved vp assessed use climate scenario analysis model sustainability finance vp global supply potential impacts prioritised physical risks helps chain business unit results shared business us understand resilience supply chains unit risk management compliance boards rmcb climate change finance rmcb make sure risks transition risks typically risks associated changes contextualised business risks managed regulations societal expectations transition appropriately allows management take holistic lowercarbon economy identified enterprise view optimise risk mitigation responses ensure level market level manage transition risks responses climaterelated risks properly integrated investment decisions sustainability relevant business unit function activities transformation programme procedures resilience strategy considering different climate example manage risks may arise product related scenarios including c lower scenario claims based environmental performance using external accreditation processes organisations used climate scenarios described stress review evidence used support claims test resilience organisation considering impacts potential physical transition risks opportunities locations operate described table modelling identify material impact business resilience report highlevel commission carbon prices carbon pricing leadership coalition p https wwwcarbonpricingleadershiporgreportofthehighlevelcommission oncarbonprices strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued potential physical risk financial impact description gsk response scenario timeframe metrics targets risk identified three water basins water current medium sites achieve increasing levels stressed areas algeria india pakistan trajectory achieved good water water stress leading manufacturing sites water stewardship interruptions supply aim water neutral long term stewardship water sites manufacturing facility nashik india years total supplied sites thirdparty supply built plants rainwater harvesting water sites climate scenario analysis identified reduce thirdparty number sites supplier sites located overall water suppliers use water basins could become water stressed use freshwater main added watch breach medium operations source water list monitor changes risk levels planetary manufacture medicines update site water risk assessments boundaries water vaccines water appropriately long term neutral availability financial impact assumes manage years restricted factory inventory supply chain levels operations operations would water stress could lead key interrupted threemonth supply interruption worst suppliers water case stressed regions increasing frequency climate scenario modelling indicated current medium business extreme weather seven physical perils flood rainfall trajectory continuity climate events causing presents highest likelihood acute scenario plans related risks disruption interruption however risk flooding long term reviewed business thirdparty supplier rainfall extreme weather years annually continuity sites events expected remain low identified extreme weather performed risk assessments taken events one manufacturing operations action precipitation rainfall business continuity plans review mitigate flood annually respond impacts extreme risk precipitation riverine weather events including adopting flood extreme wind appropriate mitigation plans breach medium wildfire extreme wellestablished loss prevention planetary heat result short risk engineering programme identify boundaries term interruptions range risks could impact sites scenario long term manufacturing flood risks exist taken action years supplier sites mitigate financial impact assumes manage inventory supply chain levels extreme weather event could lead threemonth supply interruption worst case potential transitional risk financial impact description gsk response scenario timeframe metrics targets regulations governing investing rd programme current high onoff track use high gwp large manufacturing site upgrade project trajectory substances redevelop ventolin salbutamol inhaler scenario medium term delivery key absolute updated eu transitioning lowercarbon propellant years milestones reduction uk updated could potentially reduce carbon emissions rd recently us clinical trials programme greenhouse could lead successful plan gas emissions increasing costs restrict ability already portfolio dry powder baseline manufacture inhaler products use propellants across metered dose inhaler affected risk scopes mdi products financial impact assumes use high gwp reformulated product approved propellant hfaa respectively regulators launched according plan strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued potential transitional risk selected financial impact description gsk response scenario timeframe metrics targets future regulatory managing risk reducing value net zero medium scope policy responses chain carbon emissions line transition mm carbon address climate plan described medium emissions absolute change could lead financial impact assumes deliver years long scope reduction imposition reduction carbon emissions term years carbon carbon taxes assumes carbon tax values per iea emissions greenhouse countries scenarios supplemented data policy gas manufacture pledges small number countries lowcarbon medium emissions source goods mm third parties medium term year baseline falling low across mlong scopes term years respectively current low trajectory medium term years long term years naturebased projects established governance framework lowerthan low fail deliver manage project external partners anticipated medium term development anticipated volumes issues escalated carbon offset growth years absolute carbon credits programme steering committee scenario reduction lowerthanexpected growth result assume future cost per tonne co e natural medium greenhouse natural catastrophe catastrophe gas could lead lowerthananticipated growth scenario scenario medium term emissions buying carbon assume underdelivery single year years credits higher cost issues identified early baseline make enough take preventative actions across shortfall natural catastrophe scenario assume scopes projects affected impact last five years respectively potential profit impact opportunities gsk response scenario timeframe metrics targets cop november reducing scope carbon net zero scope emissions turn reduces scope countries committed footprint customers suppliers carbon absolute provide lowcarbon ecodesign programme reduce emissions reduction healthcare systems impacts products packaging total waste could lead investing rd programme reduce greenhouse increasing demand greenhouse gas emissions metered dose low materials gas l ao nw c va ar cb co inn e sedicines hn ah va ele mrs u ds ee g oto dtr e pa rot ga rs et sh sm toa w rd sc ro efp od rm un ld ting low carbon l yeo rg term fe rm omiss aio ns alternative gas could potentially reduce baseline climate impact clinical across trials successful scopes portfolio dry powder inhaler products low carbon footprints part consortium eight global respectively pharmaceutical companies codevelop current zero shared way measuring reporting trajectory operational environmental product footprints waste financial impact based research performed us details published commitments transition lowcarbon healthcare major markets strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued metrics targets metrics use assess climaterelated risks opportunities line strategy risk management process disclose considered key metrics following tcfd guidance tables well metrics metrics used consistent crossindustry climaterelated metrics based strategic metrics organisation scope emissions marketbased locationbased approach described table assess climate risks scope emissions described table opportunities line strategy renewably sourced electricity described table risk management total supplied water described table process total waste materials described table esg composite metric part senior leaders remuneration policy see sites achieved water stewardship described table esg performance report includes metrics used support strategic metrics listed b disclose scope energy carbon emissions see table applicable scope scope emissions energy ghg emissions scope emissions sources related risks scope emissions marketbased scope emissions locationbased scope emissions metrics scope emissions intensity metrics prioritised physical transition risks included risk table c describe targets targets measured baseline applicable used organisation absolute reduction greenhouse gas emissions baseline across scopes manage climate investment naturebased solutions remaining footprint related risks net zero greenhouse gas emissions across full value chain absolute reduction emissions opportunities baseline across scopes residual emissions neutralised performance targets renewable electricity scope achieve good water stewardship sites reduce overall water use operations zero operational waste including eliminating single use plastics water neutral operations key suppliers waterstressed regions performance targets including reduction routine hazardous nonhazardous waste regulatory obligations allow excluding plastics critical product discovery development health safety see basis reporting esg resources section gskcom httpswwwgskcomengbresponsibilityesgresources detailed methodologies measuring reporting gsk environmental kpis commit net zero nature positive healthier planet ambitious goals set across entire value chain report progress reducing scope carbon emissions scope carbon emissions energy use water waste annually towards targets esg performance report public responses cdp climate water forest questionnaires strategic report governance remuneration financial statements investor information gsk annual report climaterelated financial disclosures continued metrics data carbon emissions carbon emissions tonnes coe scope emissions energy scope emissions scope emissions marketbased scope emissions locationbased scope emissions uk scope emissions metrics scope emissions energysales revenue tonnes coem scope emissions energyfte tonnes coefte total energy used gwh uk energy used gwh renewably sourced electricity total supplied water million total supplied water areas high water stress million total waste materials metric tonne sites achieved water stewardship data reported excludes previous consumer healthcare business unless otherwise specified carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition use marketbased scope emissions reporting purposes report scope emissions across categories esg performance report ask external assurance providers deloitte provide limited assurance isae energy scope selected scope carbon emission data water wastewater data methodologies reporting measurements provided basis reporting esg resources section gskcom httpswwwgskcomengbresponsibilityesgresources refers emissions sales force vehicles propellant emissions released manufacture inhalers majority propellant emissions released patient use included scope carbon emissions onsite waste wastewater treatment refrigerant gas losses collect publish scope data across categories recent scope data available process compiling data yet complete except scope emissions patient use inhalers disclosed esg performance report publish data becomes available included esg performance report data restated see esg performance report naturerelated financial disclosures gsk committed playing part minimise governance impact dependencies nature well helping boards oversight naturerelated dependencies protect restore nature impacts risks opportunities human health relies fundamentals nature clean described air fresh water nature loss range negative impacts health example reduced air quality managements role assessing managing nature increases incidence severity respiratory diseases related dependencies impacts risks opportunities habitat degradation deforestation increasing addition disclosure sustainability risk new human pathogens pandemics council reviewed gsks nature strategy ensuring alignment protect human health get ahead disease ways working required science based targets need protect nature nature sbtn longer term budgetary gsk active member working groups requirements considered taskforce naturerelated financial disclosures tnfd human rights policies engagement activities committed make full disclosure oversight respect indigenous peoples local tnfd framework early based data communities affected stakeholders however making initial disclosure fully compliant framework show progress position human rights published gskcom nature programme responsibility respect human rights engagements patients employees suppliers communities live operate strategic report governance remuneration financial statements investor information gsk annual report naturerelated financial disclosures continued beginning nature journey concerns longterm exposure working formalise policies procedures related pharmaceuticals environment pose risk stakeholders engagement human rights specifically environmental species including aquatic life presence relation assessment impacts action antibiotics environment potential impact nature driving antibiotic resistance well reducing microbial biodiversity growing concern many stakeholders protecting restoring nature key part active area research climate nature strategy nature investments always context dependant key us work clinical agricultural practices generally expert partners ngos ensure project recognised dominant sources antibiotics entering implementation includes local experts local environment unregulated manufacturing practices may communities also contribute antimicrobial resistance make decisions protection restoration land projects run human rights assessment part primary dependency land due natural broader due diligence assessment allows us materials source derive agricultural understand local context history process commodities key driver deforestation land use partners use plan use engage involve local change globally supply chains communities including free prior informed consent commodities often long complex may many fpic grievance mechanisms benefits tiers removed direct engagement operational shared land holdings relatively small although two rd connection nature projects health sites one belgium one spain located key benefits consistently included nature biodiversity areas projects worked thirdparty experts develop publish toolkit enable project oceans developers investors impacts dependencies oceans come primarily marinederived materials critical part strategy manufacturing vaccines medicines includes naturerelated dependencies impacts risks example horseshoe crab blood important opportunities identified short medium substance required regulators used long term pharmaceutical biomedical quality control processes impacts dependencies ensure quality safety medicines vaccines devices water water essential production vaccines atmosphere medicines mapped water footprint leader medicines vaccines respiratory health calculated volume water use value chain want play part improving air quality operations improved done initial assessment establish air pollution understanding world footprint operations supply chain biggest impact water showed directly relatively low impact air quality largest proportion primary operational impact water availability emissions sits supply chain manufacturing sites located areas water stress using water risk data world waste materials resources institute world wildlife fund approach product stewardship means identified five sites located waterstressed areas across consider aim address impacts nature climate algeria india pakistan face increasing water every stage product lifecycle discovery availability quality risks design sourcing manufacturing product releases active pharmaceutical ingredients priority use disposal set target help accelerate focus us regarding water quality pharmaceutical adoption approach residues may sometimes pass environment effect naturerelated dependencies impacts risks part normal biological process following patient use opportunities business model value chain lesser extent pharmaceuticals also enter strategy financial planning well transition environment unused medical products factory plans analysis place discharges committed net positive impact nature reducing environmental impacts across water waste materials biodiversity investing nature protection restoration set targets focus realms nature well supportive information see public policy httpswwwgskcom targets waste materials report progress mediagskpositiononpharmaceuticalsintheenvironment nature plan targets annually marchpdf read position antimicrobial resistance public policy strategic report governance remuneration financial statements investor information gsk annual report naturerelated financial disclosures continued selected one first group since deepened understanding companies work science based targets full value chain nature impacts dependencies network sbtn pilot develop set validated continued align evolving practices guidance sciencebased targets nature starting targets following tnfd leap locate evaluate assess freshwater land followed targets oceans prepare methodology better understand biodiversity targets focus locations naturerelated risks opportunities involved across value chain nature particularly pilot working science based targets network pressure aim pilot sciencebased targets sbtn set validated sciencebased targets nature nature starting targets freshwater land followed targets oceans biodiversity resilience strategy naturerelated risks opportunities taking consideration different scenarios processes managing naturerelated dependencies impacts risks opportunities manage organisational resilience nature related risks implementation sustainability set targets focus realms programme delivery plan evolve external nature well supportive targets waste materials guidance continues evolve report progress nature plan targets annually locations direct operations meet criteria priority locations water across sites maintain high quality water freshwater infrastructure ensure leakage reduce identified three initial water basins water overall water use waterefficiency projects stressed areas manufacturing sites including behaviour change programmes introducing including across india pakistan algeria waterefficient cleaning procedures prioritised investment water neutrality achieve measurable positive impact waterstressed today gsk sites complete gsk water stewardship basins availability quality accessibility assessment aligned alliance water stewardship aws standard implement action plans comply land standard sites located waterstressed operational land holdings relatively small although areas aim secure certification aws two rd sites one belgium one spain standard located key biodiversity areas land piloted approach biodiversity work avoiding reducing impact assessing baseline assessment action plans three sites opportunities improve efficiency material changes improving habitats protecting species improving soil switching alternatives set ambitious standards water quality commenced biodiversity suppliers provide us materials highly uplift projects three largest rd facilities dependent nature sugar paper palm oil stevenage uk upper providence upper lactose gelatine soy merion pennsylvania us standards developed collaboration third addressing critical agricultural forestry party experts aim support suppliers assess marinederived materials engaged improve verify approach addressing range associated suppliers external independent experts nature impacts associated climate social map full supply chains involved understand existing impacts including land use water stewardship sustainability standards identify gaps establish biodiversity improvement plans first stage addressing critical oceans materials including paper palm oil roadmaps committed restore mangroves indonesia place aim achieve sustainable sourced communityled projects mangroves play crucial role paper palm oil engaged climate regulation climate change mitigation associated suppliers map full supply chains involved carbon sequestration potential mangroves make understand existing sustainability standards identify gaps local population resilient flooding improve establish action plans local fish ecosystem water quality contribute health livelihood local communities committed positive impact biodiversity operational sites used integrated risk impact management biodiversity assessment tool ibat worked processes identifying assessing prioritising ecological experts complete mapping baseline naturerelated dependencies impacts risks biodiversity assessments sites opportunities direct operations value chain implementing biodiversity action plans across estate aim improve habitats protect species improve soil water quality strategic report governance remuneration financial statements investor information gsk annual report naturerelated financial disclosures continued oceans collective measurement direct value chain reduce impact oceans implementing emissions across clean air fund membership aims marine sustainable sourcing standard outlines build picture activities give rise poor air specific requirements suppliers marinederived quality globally intends enable policy makers materials must adhere industries make informed decisions considering broader global impacts health poor air quality part approach product stewardship working reduce volume marinederived materials waste materials example process efficiencies longer term embedding approach product stewardship reduce seeking transition alternatives marine impact nature means working minimise waste derived materials wherever possible technical materials used waste pollution generated regulatory perspective delivering medicines vaccines across full product lifecycle already achieved zero atmosphere operational waste landfill continue build outcome initial air quality assessment highlighted longstanding operational waste management programme opportunities reductions emissions linked onsite identify opportunities achieve beneficial use electricity generation use solid fuels car use waste however risk circular routes move electric fleet well indicating opportunities recovery waste streams may still exist value chain sourcing plastic glass products supply chain working waste footprint assessment help supplier engagement waste creating reduction plans around key areas reduction product design build aligned pathway net zero aim circularity reduce waste design positive impact air quality processes identifying assessing prioritising conducting additional air quality assessment monitoring naturerelated risks integrated working stockholm environment institute sei inform overall risk management processes university york broadening suite air pollutants taken consideration understand impact part first group companies working across value chain connection human science based targets network sbtn set health validated sciencebased targets nature starting targets freshwater land followed targets help accelerate collective action air pollution oceans biodiversity targets focus members alliance clean air clean air locations across value chain nature particularly fund caf world economic forum aims pressure aim sciencebased targets drive corporate action clean air accelerate climate nature action create healthy communities around world continue work towards existing targets work sbtn pilot delivery plan continue evolve go sbtn target validation external guidance continues evolve data developed primarily greater supply chain traceability metrics targets report performance existing targets using metrics water use waste materials see table realm key performance indicator freshwater average percentage gsk sites suppliers compliant wastewater active pharmaceutical ingredient limits percentage suppliers compliant amr industry alliance common antibiotic manufacturing framework discharge limits land percentage paper palm oil deforestation free waste materials reduction routine operational hazardous nonhazardous waste strategic report governance remuneration financial statements investor information gsk annual report naturerelated financial disclosures continued gsk sets following targets managing nature commitments focus area target freshwater sites achieve good water stewardship reduce overall water use water neutral operations key suppliers waterstressed regions zero impact active pharmaceutical ingredient levels sites key suppliers land positive impact biodiversity sites agricultural forestry derived materials sustainably sourced deforestation free oceans marinederived materials sustainably sourced atmosphere renewable electricity scope reduction carbon emissions across full value chain net zero carbon emissions across full value chain waste materials zero operational waste including eliminating single use plastics waste reduction supply chain environmental impact reduction products packaging predicted noeffect level linked remuneration senior leaders gsk sites target updated december reflect priority materials including reduction routine hazardous nonhazardous waste regulatory obligations allow excluding plastics critical product discovery development health safety strategic report governance remuneration financial statements investor information gsk annual report nonfinancial sustainability information statement following aligns nonfinancial reporting requirements contained sections ca cb companies act description business model human rights policy due diligence outcomes business model human rights risk management social matters working third parties viability statement access data engagement audit risk committee report global health health security antibribery corruption principal risks uncertainties employees ethical standards nonfinancial key performance indicators culture people reporting investigating concerns performance key employee engagement performance indicators environmental matters wellbeing development policies environment diversity equity inclusion public policies codes climaterelated financial gender pay gap standards available gskcom disclosures ethical standards naturerelated financial disclosures board diversity employees gender male female total board management employees headcounts december senior managers defined companies act strategic report directors report regulations total calculated fulltime equivalent employees ftes december male female calculated applying employees gender diversity percentages total fte number strategic report governance remuneration financial statements investor information gsk annual report viability statement accordance provision revision downside scenarios consider gsks cash flows code gsk assessed prospects group sustainability dividends funding strategy insurance longer period months required going provision recovery well key financial ratios concern provision directors confirm period metrics subject reasonable expectation gsk continue operate sensitivity analysis involves flexing number meet liabilities fall due next three main assumptions underlying forecasts individually years directors assessment made combination along mitigating actions reference gsks current position prospects could realistically taken avoid reduce impact strategy boards risk appetite gsks principal risks occurrence underlying risk managed detailed pages following hypothetical downside scenarios strategic report evaluated board reviews internal controls risk scenario business performance risks include key management policies approves governance performance risks including lower sales new products structure code conduct also appraises greater adverse impact generic competition approves major financing investment licensing competitive launches gsk products well decisions evaluates monitors performance possible supply manufacturing challenges prospects gsk whole focus largely improving longterm financial performance scenario external macroeconomic risks scenario delivery companys business strategies aligned reflects incremental risks business driven outside priorities factors intense competition increased pricing pressure us europe well potential board reviews gsks strategy makes significant impact material negative changes macro capital investment decisions longterm time horizon economic healthcare environment based multiyear assessment return capital performance company market opportunities scenario principal risks scenario includes severe medicines vaccines approach aligned assessment potential loss impact principal gsks model achieving balanced growth investing risks related patient safety product quality supply chain high quality innovative products patients healthcare continuity information cyber security providers however since many internal external environmental harm well antibribery corruption parameters become increasingly unpredictable longer consequent regulatory actions fines significant time horizons gsk focuses detailed bottomup plan litigation could fundamentally threaten threeyear cycle plan reviewed least annually operations risks managed mitigating directors approve business forecasts showing activities described pages expected financial impact directors believe scenario put option exercise scenario evaluates threeyear assessment period viability statement additional funding requirements assuming earliest appropriate aligns groups well potential exercise outstanding put option held established business planning processes balance pfizer inc longterm nature investments medicines vaccines assessment period analysis threeyear review also makes certain assumptions nearterm business performance realistically visible normal level capital recycling likely occur considers whether additional financing facilities plan stress tested series robust required respective level funding flexibility operational principal risk downside scenarios part headroom boards review risk plan assumes next several years challenging healthcare industry results stress testing show certain continued pressure pricing pharmaceuticals combinations hypothetical scenarios could increase uncertain economic conditions prevailing across many funding demands gsk require mitigating changes markets gsk operates gsk assumes premature groups funding strategy however light loss exclusivity key products period liquidity available group based analysis anticipated launches proceed planned directors reasonable expectation even severe stress tests group able continue operation meet liabilities fall due threeyear period assessment gsk annual report group financial review section summary full year results financial performance summary reporting framework financial performance adjusting items cash generation conversion financial position resources approach tax treasury policies critical accounting policies strategic report governance remuneration financial statements investor information gsk annual report group financial review summary full year results full year growth growth full year full year aer cer results summary turnover turnover excluding covid solutions total continuing operating profit total operating margin ppts ppts total continuing eps p p p adjusted operating profit adjusted operating margin ppts ppts adjusted eps p p p cash flow cash generated operations free cash flow financial results unless otherwise stated growth commentary cer ex covid excluding covid solutions defined gsk delivered excellent performance sales billion double digit adjusted operating profit adjusted eps per share growth cer consequence performance also pleased increase dividend year expect another year meaningful growth gsk driven continued focus execution strengthening pipeline capital allocation delivering stepchange financial total continuing eps grew reflecting strong profit growth lower charges related remeasurement performance contingent consideration liabilities partly offset fair value sales million increase loss retained stake haleon plc compared fair overall reflecting continued strong business performance value gain period prior year addition strong growth vaccines arexvy shingrix hiv unfavourable comparison due upfront income excluding covid solutions sales grew total operating received settlement gilead sciences inc profit increased million driven overall adjusted eps grew overall positive impact performance favourable contingent consideration excluding covid solutions benefiting lower liabilities ccl movements adjusted operating profit grew net finance expense decreased following debt million positive impact restructuring effective adjusted tax rate line excluding covid solutions adjusted operating margin guidance increased driven largely favourable product mix operational efficiencies well increased royalties improved operating margins reconciliation total adjusted results included total operating profit margin higher due profitable growth across portfolio favourable movements total adjusted cost sales percentage sales contingent consideration liabilities partly offset decreased full year reflecting reduced sales lower unfavourable comparison due upfront income received margin xevudy compared total adjusted sga settlement gilead sciences inc growth focused investment vaccines including adjusted operating profit margin improved primarily due disease awareness launch arexvy together reduced sales lowermargin xevudy excluding covid shingrix longacting hiv jemperli ojjaara rd costs solutions adjusted operating profit margin improved due increased due investment latestage programmes product mix productivity improvements increased royalty vaccines respiratoryimmunology infectious diseases income growth sga reflected investment vaccines including disease awareness launch arexvy together shingrix longacting hiv jemperli ojjaara royalty income also contributed margin improvement strategic report governance remuneration financial statements investor information gsk annual report group financial review continued cash flow performance net debt improvement total full year cash generated operations net debt position decreased billion end increased million despite annualising gilead look deploy funds enhance growth deliver sciences inc settlement quarter billion due attractive shareholder returns started year net higher adjusted operating profit favourable timing xevudy debt billion strong free cash generation cash flows lower uk pension contributions partly offset addition monetisation stake haleon plc higher receivables arexvy sales net capital investment supported billion investment targeted business increased primarily due lower proceeds asset development capital expenditure billion disposals resulting free cash flow returned shareholders via dividend continuing operations increasing million capital deployment supports business growth shareholder returns free cash flow fcf bn including capital expenditure net disposal proceeds plant property equipment intangibles bn bn includes dividend distribution income exchange net debt financing items capital allocation framework support capital allocation framework support investment returns investment returns priority invest growth coupled attractive capital allocation framework means first priority shareholder returns remains invest business capital allocated towards development pipeline organic targeted business development also remain committed delivering attractive returns shareholders pursuing progressive dividend policy guided percent payout ratio investment cycle setting dividend policy gsk considers priorities group investment strategy growth alongside sustainability dividend consistent reflecting strong business performance year gsk expects declare increased dividend p per share full year expected dividend p event surplus cash excess would returned shareholders remain committed maintaining balance sheet strong investment grade credit rating gsk group dividend gsk related excludes dividend related consumer healthcare h fy dividend pshare strategic report governance remuneration financial statements investor information gsk annual report group financial review continued guidance cer excluding covid outlooks cer solutions january gsk announced upgraded outlooks expect another year meaningful growth previously given period gsk guidance provided cer excludes impact period gsk expects sales grow covid solutions sales expected increase cagr basis adjusted operating profit per cent adjusted operating profit expected increase basis compares increase per cent adjusted earnings per previous outlooks share expected increase per cent respectively adjusted operating profit margin expected guidance supported following turnover expectations full year gsk expects achieve sales billion riskadjusted basis cer gsk expects vaccines expect high single digit low double maintain continued strong focus margin improvements digit percent growth retaining flexibility invest future growth specialty medicines expect low doubledigit per recognising gsk likely face loss exclusivity cent growth dolutegravir us eu majority impact gsk stated expects general medicines expect sales decrease operating margins broadly stable period midsingledigit per cent gsk expects effective transition within hiv portfolio adjusted operating profit expected grow towards new longacting treatment prevention therapies per cent cer despite percentage point impact margin mix benefit growth higher operating margin operating profit growth following loss gardasil royalties vaccine specialty medicine products continued effective beginning gsk expects deliver focus achievable productivity gains notably supply leverage gross margin level due improved product mix chain sga vaccines specialty medicines growth expectations guidance outlooks regarding future continued operational efficiencies addition gsk performance dividend payments read together anticipates leverage operating profit due step guidance outlooks assumptions cautionary sga growth low singledigit increase rd statements inside back cover expected increase broadly line sales support growth pipeline adjusted earnings per share expected increase per cent cer reflecting higher operating profit favourable net finance costs expectations noncontrolling interests remain unchanged relative gsk anticipates previously communicated increase adjusted effective tax rate around following implementation global minimum corporate income tax rate aligned organisation economic cooperation development pillar initiative covid solutions anticipate future revenue covid solutions reduce sales growth adjusted operating profit growth currency impact exchange rates hold closing rates january yen rest estimated impact sterling turnover growth gsk would exchange gains losses recognised level estimated impact sterling adjusted operating profit growth gsk would strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance summary total results group set growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit net finance costs share tax profitslosses associates joint ventures profitloss disposal interest associates joint ventures profit taxation taxation profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interests discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations pence p p earnings per share discontinued operations pence p total earnings per share pence p p earnings per ads continuing operations us earnings per ads discontinued operations us total earnings per ads us adjusted results group set reconciliations total results adjusted results set pages growth turnover turnover cer turnover cost sales selling general administration research development royalty income adjusted operating profit adjusted profit attributable noncontrolling interest adjusted profit attributable shareholders adjusted profit taxation adjusted earnings per share p p p strategic report governance remuneration financial statements investor information gsk annual report group financial review continued reporting framework total adjusted results costs ordinary course smaller scale restructuring legal charges expenses retained within total group financial review discusses operating adjusted results financial performance group cash flows financial position resources results year adjusted results include benefits major restructuring compared primarily results preceding year programmes exclude significant costs amortisation intangible assets except computer software total results capitalised development costs significant legal major total reported results represent groups overall restructuring transaction items performance regarded complete picture groups financial performance presented total results gsk also uses number adjusted nonifrs measures exclusion adjusting items may result adjusted report performance business adjusted results earnings materially higher lower total earnings nonifrs measures may considered addition particular significant impairments restructuring charges substitute superior information presented legal costs excluded adjusted earnings higher accordance ifrs adjusted results defined total earnings nonifrs measures defined gsk undertaken number major restructuring gsk believes adjusted results considered together programmes response significant changes groups total results provide investors analysts trading environment overall strategy following material stakeholders helpful complementary information acquisitions within pharmaceuticals sector highly understand better financial performance position regulated manufacturing operations supply chains group period period allow groups long lifecycle business mean restructuring performance easily compared majority programmes particularly involve rationalisation peer companies measures also used closure manufacturing rd sites likely take management planning reporting purposes several years complete costs cash noncash determining compensation may directly programmes provided individual elements comparable similarly described measures used approved meet accounting recognition criteria companies result charges may incurred number years gsk encourages investors analysts rely following initiation major restructuring programme single financial measure review gsks annual reports significant legal charges expenses arising including financial statements notes entirety settlement litigation government investigations adjusted results normal course materially larger regularly occurring individual matters also include adjusted results exclude profits discontinued certain major legacy matters operations consumer healthcare business see details following items relation reconciliations total adjusted results providing continuing operations total results together tax information key adjusting items effects items set pages amortisation intangible assets excluding computer gsk provides earnings guidance investor community software capitalised development costs basis adjusted results practice line peer impairment intangible assets excluding computer companies expectations investor community software goodwill supporting easier comparison groups performance major restructuring costs include impairments peers gsk able give guidance total results tangible assets computer software specific reliably forecast certain material elements total board approved programmes structural results particularly future fair value movements significant scale costs individual related contingent consideration put options projects exceed million including integration costs given rise significant adjustments driven external factors following material acquisitions currency movements capital markets transactionrelated accounting adjustments related significant acquisitions proceeds costs disposals associates products businesses significant settlement income significant legal charges net insurance recoveries expenses settlement litigation government investigations operating income royalty income items strategic report governance remuneration financial statements investor information gsk annual report group financial review continued reporting framework continued historical record adjusting items reconciliations total adjusted operating profit continuing operations last three years summarised follows total operating profit continuing operations intangible amortisation intangible impairment major restructuring transactionrelated items divestments significant legal items adjusted results analysis impact transactionrelated items operating profit last three years follows contingent consideration former shionogiviiv healthcare jv including shionogi preferential dividends viiv healthcare put options pfizer preferential dividends contingent consideration former novartis vaccines business contingent consideration acquisition affinivax adjustments transactionrelated items full reconciliations total adjusted results including continuing discontinued operations set pages explanations adjusting items reported nonifrs measures return capital employed return capital employed calculated total profit free cash flow taxation percentage average net assets year free cash flow defined net cash inflowoutflow total net debt continuing operating activities less capital expenditure net debt defined total borrowings less cash cash property plant equipment intangible assets equivalents liquid investments shortterm loans third contingent consideration payments net finance costs parties subject insignificant risk change dividends paid noncontrolling interests contributions value please see note net debt calculation net noncontrolling interests plus proceeds sale debt property plant equipment intangible assets dividends received joint ventures associates total operating margin attributable continuing operations used total operating margin operating profit divided turnover management planning reporting purposes discussions presentations investment analysts adjusted operating margin rating agencies free cash flow growth calculated adjusted operating margin adjusted operating profit divided reported basis reconciliation net cash inflow turnover continuing operations free cash flow continuing operations set compound annual growth rate cagr working capital cagr defined compound annual growth rate shows annualised average rate revenue growth working capital represents inventory trade receivables number given years assuming growth takes place less trade payables exponentially compounded rate cer aer growth order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used comparative period cer represents growth constant exchange rates aer represents growth actual exchange rates strategic report governance remuneration financial statements investor information gsk annual report group financial review continued reporting framework continued noncontrolling interests viiv healthcare cash payments reflected cash flow statement partly operating cash flows partly within investing trading profit allocations activities tax relief payments reflected viiv healthcare subsidiary group groups adjusting items part tax charge part operating results turnover operating profit profit payment relating original estimate fair value tax included within group income statement contingent consideration acquisition portion earnings allocated noncontrolling shionogiviiv healthcare joint venture million interests owned shareholders line reported within investing activities cash flow statement respective equity shareholdings pfizer inc pfizer part payment relating increase shionogi co ltd shionogi shareholders liability since acquisition reported within operating cash including gsk also entitled preferential dividends flows determined performance certain products movements contingent consideration payable shionogi shareholder contributed relative performance follows products changes time proportion overall earnings allocated shareholder also changes particular increasing proportion sales dolutegravir cabotegravircontaining products favourable contingent consideration beginning impact proportion preferential dividends year allocated gsk adjusting items allocated remeasurement income statement shareholders based equity interests gsk entitled movements approximately total earnings cash payments operating cash flows adjusted earnings viiv healthcare cash payments investing activities contingent consideration end year remeasurements liabilities preferential dividends allocated pfizer shionogi included within operating incomeexpenses contingent consideration payable posttax basis shionogi december million december acquisitionrelated arrangements million expected paid within one year consideration acquisition shionogis interest exit rights former shionogiviiv healthcare joint venture shionogi received equity stake viiv healthcare viiv pfizer may request ipo viiv healthcare time healthcare also agreed pay additional future cash either gsk consent ipo offering consideration shionogi contingent future sales completed within nine months pfizer could require gsk performance products developed joint acquire shareholding original agreements gsk venture dolutegravir cabotegravir ifrs business unconditional right long made subsequent combinations gsk required provide estimated distribution shareholders withhold consent fair value contingent consideration time exercise pfizer put option result accordance acquisition required update liability latest ifrs gsk recognise liability put option estimate fair value subsequent period end balance sheet however q gsk notified pfizer liability contingent consideration recognised irrevocably given right accordingly balance sheet date acquisition million recognised liability put option groups subsequent remeasurements reflected within balance sheet q initial value operating incomeexpenses within adjusting items million consistent revised treatment end q income statement period gsk also recognised liabilities future preferential dividends anticipated become payable pfizer cash payments settle contingent consideration shionogi groups balance sheet made shionogi viiv healthcare quarter based actual sales performance income relevant pfizer right require gsk acquire shareholding products previous quarter payments reduce viiv healthcare certain circumstances time put balance sheet liability hence recorded option liability therefore recorded groups balance income statement included cash flow cash sheet current liability measured gross payments made shionogi viiv healthcare redemption basis derived internal valuation viiv million healthcare business liability required recorded fair value closing balances liabilities related pfizers estimated future payments significant timing shareholding follows difference charges recorded total income statement reflect movements fair value liability actual cash payments made settle pfizer put option liability strategic report governance remuneration financial statements investor information gsk annual report group financial review continued reporting framework continued original agreements shionogi could also specialty medicines requested gsk acquire shareholding viiv healthcare specialty medicines typically prescription medicines used sixmonth windows commencing gsk treat complex rare chronic conditions gsk unconditional right long made subsequent comprises medicines infectious diseases hiv oncology distribution shareholders withhold consent respiratoryimmunology exercise shionogi put option result gsk recognise liability put option balance sheet share consolidation however q gsk notified shionogi following completion consumer healthcare business irrevocably given right accordingly recognised demerger july gsk plc ordinary shares liability put option groups balance sheet consolidated maintain share price comparability q initial value million q shionogi demerger shareholders received new ordinary shares irrevocably agreed waive put option result gsk nominal value pence every existing derecognised liability put option groups ordinary shares nominal value pence balance sheet directly equity value liability earnings per share diluted earnings per share adjusted million derecognised earnings per share dividends per share retrospectively gsk also call option shionogis shareholding viiv adjusted reflect share consolidation periods healthcare original agreements presented exercisable sixmonth windows commencing earnings per share gsk irrevocably agreed waive first two exercise windows last sixmonth window earnings per share retrospectively adjusted remains call option fair value value share consolidation july applying ratio new accounting purposes ordinary shares every existing ordinary shares reporting definitions total earnings per share unless otherwise stated total earnings per share refers total covid solutions basic earnings per share covid solutions include sales pandemic adjuvant rar returns rebates covid solutions including vaccine manufacturing xevudy associated costs gsk sells customers commercial government include reinvestment rd categorisation used mandated contracts reimbursement arrangements management believe helpful investors include rebates chargebacks right return certain providing clarity results group showing pharmaceutical products principally us revenue contribution growth covid solutions recognition reflects grosstonet sales adjustments result adjustments known rar accruals turnover excluding covid solutions source significant estimation uncertainty fluctuation turnover excluding covid solutions excludes impact material impact reported revenue sales pandemic adjuvant within vaccines xevudy within one accounting period next specialty medicines related covid pandemic total operating margin management believes exclusion impact covid solutions sales aids comparability reporting total operating margin total operating profit divided periods understanding gsks growth including region turnover versus prior periods also guidance excludes adjusted operating margin contributions covid solutions adjusted operating margin adjusted operating profit divided adjusted operating profit excluding covid turnover solutions discontinued operations adjusted operating profit excludes impact commercial consumer healthcare presented discontinued operations covid solutions xevudy pandemic operation q demerger consumer adjuvant healthcare completed july group income adjusted earnings per share excluding covid statement group cash flow statement distinguish solutions discontinued operations continuing operations adjusted earnings per share excludes impact percentage points commercial operations covid solutions xevudy percentage points growth abbreviated ppts pandemic adjuvant noncontrolling interest general medicines noncontrolling interest equity subsidiary general medicines usually prescribed primary attributable directly indirectly parent care community settings general healthcare practitioners gsk includes medicines inhaled respiratory brand names partner acknowledgements dermatology antibiotics diseases brand names appearing italics throughout document trademarks gsk associated companies used licence group strategic report governance remuneration financial statements investor information gsk annual report financial performance group turnover vaccines group turnover million year turnover bn aer cer sales grew aer cer aer growth cer growth excluding covid solutions bn group turnover business l vaccines group turnover bn aer growth cer growth l speciality medicines bn aer decline cer decline vaccines turnover l general medicines vaccines turnover excluding covid solutions bn bn aer growth cer growth aer growth cer growth pandemic turnover bn group turnover geographic region aer growth cer growth l us bn doubledigit growth vaccines full year driven successful launch arexvy us continued strong aer growth cer growth uptake shingrix international europe pandemic l europe vaccines sales mostly include gsks share contracted bn european volumes related covid booster vaccine co developed sanofi aer growth cer growth shingles l international bn growth growth cer aer decline cer growth shingles shingrix vaccine herpes zoster shingles grew gsk reports results two segments namely commercial aer cer increased demand favourable pricing operations total rd see note 'turnover segment growth driven public funding expansion strong information ' consolidated financial statements private uptake international europe regions details represented global turnover compared third commercial operations segment three product groups shingrix launched markets outside us vaccines specialty medicines general medicines cumulative immunisation rates international sales driven launch uptake across several vaccines products includes sales shingrix markets strong momentum channel inventory build arexvy china due transition distributors new public programme australia sales europe included deliveries specialty medicines products includes gsks marketed uk national immunisation programme began products hiv oncology respiratoryimmunology offering shingrix vaccination september us specialty medicines including nucala retail demand grew overall sales declined versus general medicines products include products challenging comparator period higher previously reported established pharmaceuticals sales nonretail purchasing us cumulative immunisation trelegy ellipta anoro ellipta previously reported within penetration end q reached respiratory category specialty products million us adults currently recommended products typically accessed patients primary receive shingrix percentage points since time care settings last year united states census bureau international database year strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued meningitis specialty medicines growth growth cer turnover bn meningitis bn aer decline cer decline doubledigit meningitis vaccine sales growth largely delivered bexsero vaccine meningitis b primarily driven inclusion national immunisation programmes group turnover europe menveo vaccine meningitis acwy grew due favourable impact us cdc center disease control stockpile borrow q replenishment q meningitis growth benefitted favourable impact cdc stockpile movements percentage points rsv growth growth specialty medicines turnover cer rsv arexvy specialty turnover excluding covid solutions bn arexvy worlds first approved respiratory syncytial virus aer growth cer growth rsv vaccine older adults achieved billion sales driven strong uptake leading market share pandemic turnover delivering outstanding launch almost sales bn us arexvy available major retail pharmacies aer decline cer decline competitive contracting place retailers administered doses arexvy achieved twothirds specialty medicines growth excluding covid solutions share retail vaccinations approximately million aer cer reflected continued growth momentum million us adults aged older risk hiv portfolio growth acceleration oncology vaccinated arexvy respiratoryimmunology covid solutions negatively impacted growth percentage points influenza hiv growth growth cer growth growth influenza cer hiv fluarixflulaval sales declined line expectations growth hiv primarily driven percentage point driven competitive pressure lower market demand increase market share within broadly flat global treatment primarily us market attributable patient demand oral dr established vaccines dovato juluca longacting medicines cabenuva apretude growth driven patient demand ten growth growth percentage points remainder favourable pricing cer dynamics tender growth dovato continues established vaccines highest selling product hiv portfolio established vaccines growth driven rotarix favourable oral dr long acting us cdc stockpile movements mmrv vaccines increased growth growth supply international hepatitis vaccine performance cer related travel market recovery established vaccines oral dr long acting growth excluding impact cdc stockpile movements oral dr dovato juluca longacting medicine cabenuva apretude sales growth continues end year represented total hiv portfolio compared q driven market share growth united states census bureau international database year percentage points versus q strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued respiratoryimmunology general medicines growth growth cer turnover bn respiratoryimmunology aer growth cer growth bn therapy area includes sales nucala benlysta jesduvroq us duvroq japan patients anaemia due chronic kidney disease consistent group turnover sustained doubledigit growth benlysta nucala nucala growth growth cer nucala nucala il antagonist monoclonal antibody treatment severe asthma additional indications including chronic growth driven respiratory general rhinosinusitis nasal polyps eosinophilic granulomatosis medicines ongoing strong demand trelegy polyangiitis egpa hypereosinophilic syndrome hes regions anoro europe international continued continued strong growth regions reflected high patient post pandemic recovery antibiotic market europe demand severe eosinophilic asthma additionally international regions increasing sales growth contributions new respiratory indications growth growth benlysta cer growth growth respiratory cer performance reflected growth trelegy single inhaled benlysta triple therapy class across regions anoro europe benlysta monoclonal antibody treatment lupus continues international show consistent growth representing strong demand us trelegy europe bio penetration volume uptake certain international markets particularly japan china growth growth cer oncology trelegy growth growth trelegy prescribed single inhaler triple therapy sitt cer treatment worldwide copd asthma strong growth oncology delivered across regions reflecting increased patient oncology demonstrated strong growth driven jemperli demand growth sitt market penetration zejula performance uptake ojjaara post us launch class growth momentum continues supported outputs q partially offset impact blenrep withdrawal recently updated primary care guidelines global us market november initiative chronic obstructive lung disease zejula seretideadvair growth growth growth growth cer cer zejula seretideadvair zejula parp inhibitor treatment ovarian cancer grew seretideadvair icslaba treatment asthma strong growth regions us growth first copd seretideadvair sales growth increased primarily line indication offsetting reduction use reflecting favourable us pricing however offset second line following update us prescribing information generic erosion impacts europe certain international agreed fda q markets us growth impacted unfavourable rar adjustments impact us channel inventory reduction ahead price changes general medicines growth growth cer general medicines decline aer reflects adverse currency impacts low single digit growth reflected ongoing post pandemic demand antiinfectives europe international certain third party manufacturing arrangements overall growth product group continues impacted ongoing generic competition strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued turnover regions international us growth growth cer growth growth total cer excluding covid total excluding covid covid solutions impacted growth percentage points excluding impact covid solutions international continued grow aer cer strong growth sales growth adversely impacted percentage points across product groups due decreased sales xevudy vaccines double digit growth driven shingrix launch vaccines grew strongly driven arexvy launch uptake uptake across several markets strong momentum channel leading market share partly offset competition lower inventory build china new public programme market demand influenza vaccines growth benefitted australia established meningitis vaccines also contributed favourable us cdc stockpile movements percentage growth points specialty medicines grew hiv nucala benlysta zejula specialty medicines grew driven strong hiv performance benlysta nucala continued growth strong oncology general medicines growth driven trelegy growth growth despite partial offset impact withdrawal across established respiratory general medicines blenrep november growth driven augmentin strong post pandemic antibiotic demand general medicines growth largely driven trelegy increased patient demand growth sitt market partially offset established respiratory general medicines europe growth growth cer total excluding covid covid solutions impacted growth percentage points excluding impact covid solutions europe delivered strong growth aer cer vaccines growth reflected shingrix national immunisation programme initiation uk launch uptake across several markets together bexsero national immunisation campaigns france spain ongoing travel vaccine recovery specialty medicines double digit growth driven growth hiv oncology benlysta nucala including impact new indication launches general medicines low single digit growth maintained strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued cost sales late stage increased investment vaccines driven continued acceleration progression pipeline growth growth including rsv pneumococcal mrna therapeutic hsv cer vaccines total cost sales sales respiratoryimmunology investment continued adjusted cost sales depemokimab phase iii programmes asthma nasal polyps together camlipixant new asset sales refractory chronic cough nucala copd paediatric benlysta ccl osteo arthritic pain offset decreased total adjusted cost sales percentage sales expense completion clinical programme decreased primarily reflecting lower sales lower margin otilimab xevudy compared excluding xevudy year benefitted increasing margin contribution infectious diseases investment bepirovirsen treatment vaccines sales particularly launch arexvy q chronic hepatitis b increased support monotherapy us shingrix outside us addition specialty combination programmes investment key assets oncology medicines particularly hiv contributed improved margin continued jemperli ojjaara offset well continued operational efficiencies partly reduction terminated cell gene therapy programme offset adverse inventory provision adjustments year well inflationary impact input costs earlystages investment increased il atopic dermatitis hiv portfolio focused next generation selling general administration longacting treatments preventative medicines growth growth total rd included higher impairment charges compared cer total selling general administration royalty income sales growth growth adjusted selling general cer administration total royalty income sales adjusted royalty income growth total adjusted sga primarily reflected growth total adjusted royalty income primarily related increased investment growth vaccines including disease gardasil royalties million well awareness launch global market expansion arexvy kesimpta biktarvy royalties overwhelming majority investment behind global market expansion disease income gardasil royalties ceased end awareness shingrix specialty medicines increased operating incomeexpense investment targeted behind longacting injectables hiv launch ojjaara myelofibrosis oncology growth growth partly offset continuing benefit restructuring cer tight control ongoing costs also reflected zejula operating income royalty dispute q total sga also included expenses increase significant legal costs see details operating expenses reflected charge million research development million arising remeasurement growth growth contingent consideration liabilities liabilities cer pfizer put option fair value loss million total research million gain retained stake haleon plc partly offset development million million net income primarily sales related equity investments milestone income including adjusted research million dividends received retained investment development haleon plc q upfront income billion sales received settlement gilead sciences inc rd operating expense growth driven investment across portfolio strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued operating profit share tax profits associates joint growth growth ventures cer share tax loss associates joint ventures total operating profit million million share loss sales adjusted operating profit profit disposal interest associates sales group also reported profit disposal interests associates joint ventures million total operating profit margin higher due profitable growth across portfolio well favourable profit tax movements contingent consideration liabilities partly offset taking account net finance costs share profits unfavourable comparison due billion upfront losses associates profit loss disposal interest income received settlement gilead sciences inc associates profit taxation million compared q million adjusted operating profit benefitted strong sales taxation favourable product mix increased royalty income partly offset increased investment behind product launches rd also included increased legal charges primarily relating zejula royalty dispute uk current year charge rest world current year charge adverse impact lower sales covid solutions chargecredit respect prior periods percentage points total operating profit growth aer percentage points cer impact total total current taxation operating profit margin percentage points total deferred taxation taxation total profits adverse impact lower sales covid solutions percentage points adjusted operating profit growth charge million represented effective tax rate impact adjusted operating profit margin total results reflected different percentage points tax effects various adjusting items tax adjusted profit adjusted operating profit business amounted million represented effective adjusted tax rate issues related growth growth taxation described note 'taxation ' financial cer statements group continues believe made commercial operations adequate provision liabilities likely arise periods sales open yet agreed tax authorities rd ultimate liability matters may vary amounts provided dependent upon outcome agreements commercial operations adjusted operating profit benefitted relevant tax authorities strong sales favourable product mix minimal xevudy sales increased royalty income partly offset noncontrolling interests nci increased investment growth launch assets well growth growth increase legal provisions cer rd segment operating expenses growth driven total continuing progression late stage vaccines respiratory adjusted immunology infectious diseases included pneumococcal mrna programmes together decrease total profit continuing operations newly acquired camlipixant ongoing investment key allocated ncis primarily driven lower viiv healthcare programmes depemokimab bepirovirsen profits allocation million million well lower net profits group 's entities net finance costs decrease adjusted profit continuing operations growth growth allocated ncis reflected lower net profits cer group 's entities ncis partly offset higher profits total net finance cost viiv healthcare allocation million adjusted finance cost million total net finance costs million compared million adjusted net finance costs million compared million decrease mainly driven net savings maturing bonds including sterling notes repurchase q higher interest income cash partly offset higher interest shortterm financing strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued earnings per share continuing operations dividends growth growth board declared four interim dividends resulting p cer total dividend year p per share total continuing earnings dividend per share p retrospectively adjusted per share p p share consolidation gsk group dividend adjusted earnings per share p p p per share gsk related excludes dividend related consumer healthcare h please increase total continuing eps primarily reflected refer note 'dividends ' financial statements lower charges related remeasurement contingent consideration liabilities partly offset fair value loss dividend policy retained stake haleon plc compared fair value gain period last year addition unfavourable dividends remain essential component total shareholder comparison due upfront income received settlement return gsk recognises importance dividends gilead sciences inc q shareholders june gsk investor update gsk set progressive dividend policy adjusted eps reflected growth adjusted operating profit implemented guided percent payout ratio well lower finance costs growth also reflected investment cycle consistent favourable benefit lower noncontrolling interests reflecting strong business performance year gsk lower sales lower margin covid solutions reduced declared increased dividend p q adjusted eps six percentage points p per share full year expected dividend p setting dividend policy gsk considers currency impact results capital allocation priorities group investment growth growth strategy growth alongside sustainability dividend mp mp cer turnover total continuing earnings per share p p adjusted earnings per share p p adverse currency impact primarily reflected weakening emerging market currencies yen sterling strengthening sterling us dollar partly offset weakening sterling euro exchange gains losses settlement intercompany transactions minimal impact adjusted eps strategic report governance remuneration financial statements investor information gsk annual report group financial review continued adjusting items adjusted results reconciliation divestments intangible intangible significant december total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax losses associates joint ventures profitloss disposal interest associates profit taxation taxation tax rate profit taxation continuing operations profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations earnings per share continuing operations p p p p p p p weighted average number shares millions strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued adjusted results reconciliation divestments profit intangible intangible significant december total discontinued asset asset major transaction legal adjusted results operations amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interest discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations p p p p p p p earnings per share discontinued operations p p total earnings per share p p p p p p p p weighted average number shares millions strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued adjusted results reconciliation divestments profit intangible intangible significant december total discontinued asset asset major transaction legal adjusted results operations amortisation impairment restructuring related items results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs loss disposal interest associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation continuing operations profit taxation discontinued operations gainslosses demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interest discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders earnings per share continuing operations p p p p p p p earnings per share discontinued operations p p total earnings per share p p p p p p p p weighted average number shares millions strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial performance continued intangible asset amortisation transactionrelated adjustments see description information intangible transactionrelated adjustments continuing operations asset amortisation resulted net charge million million majority related chargescredits intangible asset impairment remeasurement contingent consideration liabilities see description information intangible liabilities pfizer put option pfizer shionogi asset impairment individual intangible asset accounted preferential dividends viiv healthcare material impairment major restructuring integration chargecredit within pharmaceuticals sector highly regulated contingent consideration former shionogiviiv healthcare joint venture manufacturing operations supply chains long life cycle including shionogi preferential dividends business mean restructuring programmes particularly involve rationalisation closure viiv healthcare put options pfizer manufacturing rd sites likely take several years preferential dividends complete contingent consideration former novartis vaccines business major restructuring costs related specific board approved major restructuring programmes excluded contingent consideration acquisition adjusted results major restructuring programmes affinivax including integration costs following material acquisitions adjustments structural significant scale total transactionrelated charges costs individual related projects exceed million ordinary course smallerscale restructuring costs retained million charge relating contingent within total adjusted results consideration former shionogiviiv healthcare joint venture represented increase valuation total major restructuring charges incurred contingent consideration due shionogi driven million million analysed follows million updated future sales forecasts exchange rates unwind discount million non non million credit relating viiv healthcare put cash cash total cash cash total option pfizer preferential dividends represented reduction valuation put option result updated separation exchange rates sales forecasts cash balances viiv preparation restructuring healthcare contingent consideration liability fair valued programme ifrs explanation accounting non controlling interests viiv healthcare set significant acquisitions million credit relating contingent consideration legacy programmes former novartis vaccines business primarily relates changes future sales forecasts million charge relating contingent consideration separation preparation programme incurred cash charges acquisition affinivax primarily relates unwind million primarily restructuring discount commercial administrative functions well global supply chain noncash charges million primarily divestments significant legal charges reflected writedown assets administrative items manufacturing locations divestments significant legal charges items primarily benefit year restructuring programmes included million net income dividends billion primarily relating separation preparation milestones related investments including million restructuring programme programme largely dividends received retained investment haleon plc complete delivered target billion annual partly offset million fair value losses investment savings total costs still expected billion slightly haleon plc legal charges provide significant legal higher cash charges billion lower noncash charges matters including zantac broken separately billion litigation investigation significant legal charges year primarily reflected increased legal charges zantac costs significant acquisitions relate integration costs vast majority relate prospective legal costs sierra oncology inc sierra affinivax inc affinivax defence litigation acquired q bellus health inc acquired q strategic report governance remuneration financial statements investor information gsk annual report group financial review continued cash generation conversion summary consolidated cash flow statement set capital expenditure financial investment cash payments tangible intangible fixed assets amounted million million disposals realised million million cash payments total net cash inflow operating activities acquire equity investments amounted million total net cash outflow investing million sales equity investments realised activities million million total net cash inflowoutflow financing free cash flow activities free cash flow amount cash generated group decrease cash bank overdrafts meeting obligations contingent consideration cash bank overdrafts beginning year interest tax dividends paid noncontrolling interests exchange adjustments capital expenditure property plant equipment decrease cash bank overdrafts intangible assets cash bank overdrafts end year cash bank overdrafts end year comprise free cash inflow cash cash equivalents total cash payments shionogi relation viiv overdrafts healthcare contingent consideration liability year million million recognised cash flows operating activities payments reconciliation net cash inflow continuing deductible tax purposes operating activities free cash inflow future cash flow reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow long term expect future cash generated shown operations sufficient fund operating debt servicing costs normal levels capital expenditure obligations existing licensing agreements expenditure arising restructuring programmes routine outflows including net cash inflow continuing operating tax pension contributions dividends subject activities principal risks uncertainties discussed pages purchase property plant equipment may time time additional demands finance acquisitions access multiple purchase intangible assets sources liquidity short longterm capital markets proceeds sale property plant financial institutions needs addition cash equipment flow operations proceeds sale intangible assets net finance costs dividends disposal proceeds joint ventures associates contingent consideration paid reported investing activities contribution noncontrolling interests distributions noncontrolling interests free cash inflow strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources property plant equipment assets business sciencebased technologyintensive highly regulated governmental authorities allocate significant noncurrent assets financial resources renewal maintenance property plant equipment property plant equipment vehicles minimise risks right use assets interruption production ensure compliance goodwill regulatory standards number processes use hazardous intangible assets materials investments associates joint ventures total cost property plant equipment investments december million net book value deferred tax assets million land buildings represented noncurrent assets million plant equipment vehicles million assets total noncurrent assets construction million invested million new property plant equipment mainly current assets related large number projects renewal inventories improvement expansion facilities various worldwide current tax recoverable sites support new product development launches well trade receivables improve efficiency existing supply chains property derivative financial instruments mainly held freehold new investment financed liquid current equity investments resources december contractual liquid investments commitments future capital expenditure million cash cash equivalents believe property plant facilities adequate assets held sale current requirements total current assets right use assets total assets right use assets amounted million december liabilities compared million december current liabilities increase year reflected impact additions shortterm borrowings business combinations million additions million partly offset depreciation million disposals contingent consideration liabilities impairments amounting million trade payables derivative financial instruments goodwill current tax payable goodwill decreased million december shortterm provisions million primarily result exchange rate loss total current liabilities million partially offset increase million acquisitionsrelated transactions noncurrent liabilities longterm borrowings intangible assets corporation tax payable intangible assets include cost intangibles acquired deferred tax liabilities third parties computer software net book value pensions postemployment benefits intangible assets december provisions million million increase primarily reflected contingent consideration liabilities additions net disposals writeoffs million partly noncurrent liabilities offset impairment losses net reversals amortisation total noncurrent liabilities million exchange rate losses million total liabilities net assets total equity strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources continued investments associates joint ventures trade payables held investments associates joint ventures december trade payables carrying value december million million compared million december million see note 'investments associates joint decrease primarily driven lower accruals relating ventures ' financial statements details profit share collaborations partly offset higher customer return rebates accruals see note 'trade current equity investments payables ' financial statements current equity investments amounted million provisions december million current equity investments comprise equity investments group holds carried deferred tax provisions shortterm intention sell may sell short term noncurrent provisions million december acquired intention measured fair million provisions yearend included value profit loss fvtpl initially million million related legal recorded fair value plus transaction costs disputes million million related major remeasured subsequent reporting dates fair value restructuring programmes provision made legal unrealised gains losses recognised income disputes indemnified disposal liabilities employee statement investment million related liabilities costs restructuring programme million represents shares held haleon plc extent balance sheet date legal demerger disposals haleon plc shares resulted constructive obligation existed could reliably estimated gross proceeds million nil pensions postemployment benefits investments account pension postemployment december held investments carrying arrangements accordance ias net deficits value million million significant million million pension arrangements investments held december crispr million million unfunded post therapeutics ag vir biotechnology inc sr one capital employment liabilities see note 'pensions post fund ib lp investments fair value employment benefits ' financial statements december million million noncurrent liabilities million million million million respectively investments included equity stakes noncurrent liabilities amounted million companies research collaborations december million provide access biotechnology developments potential interest interests companies arise contingent consideration liabilities business divestments contingent consideration amounted million december million million derivative financial instruments assets million represented estimated present value held current derivative financial assets fair value amounts payable shionogi relating viiv healthcare million million majority financial million million represented estimated instruments related foreign exchange contracts present value contingent consideration payable former designated designated accounting hedges shareholders affinivax million million represented estimated present value contingent inventories consideration payable novartis related vaccines inventories amounted million million acquisition december liability due shionogi million respect trade receivables preferential dividends explanation accounting noncontrolling interests viiv healthcare set trade receivables amounted million million december increase mainly driven arexvy sales us total contingent consideration payable posttax basis december million million deferred tax assets expected paid within one year shionogi deferred tax assets amounted million consideration payable expected paid number million december years result total estimated liabilities discounted present values posttax basis using posttax discount derivative financial instruments liabilities rates held current derivative financial liabilities fair value shionogiviiv healthcare contingent consideration liability million million primarily related discounted affinivax contingent consideration foreign exchange contracts designated liability discounted novartis vaccines designated accounting hedges contingent consideration liability discounted partly partly strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources continued maturity profile bond debt equivalent usd bonds eur bonds gbp bonds jpy bonds net debt cash liquid investments billion billion held centrally december analysis cash gross debt effects hedging liquid investments follows cash cash equivalents short term borrowings long term borrowings liquid investments net debt end year cash cash equivalents gross debt fixed december net debt billion compared floating billion december comprising gross debt net debt billion cash liquid investments billion net debt decreased billion primarily due billion movements net debt free cash inflow billion proceeds disposal investments including partial sale retained stake haleon plc net favourable exchange impacts billion translation nonsterling denominated debt total net debt beginning year partly offset dividends paid shareholders decrease cash bank overdrafts billion net acquisition cost bellus health inc decrease liquid investments billion net decreaseincrease longterm loans december gsk shortterm borrowings net decrease shortterm loans including overdrafts lease liabilities repayable within repayment lease liabilities months billion billion repayable debt subsidiary undertaking acquired subsequent year exchange adjustments december gsks cash liquid investments noncash movements held follows decreaseincrease net debt continuing operations decreaseincrease net debt bank balances deposits discontinued operations us treasury treasury repo money total net debt end year market funds liquidity funds cash cash equivalents liquid investments government securities strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources continued total equity contractual obligations commitments december total equity increased financial commitments summarised note million december million 'commitments ' financial statements summary movements equity set following table sets contractual obligations commitments december fall due payment total equity beginning year total yr yrs yrs yrs total comprehensive income year noncash distribution noncontrolling loans interests interest loans deconsolidation former subsidiaries finance lease dividends shareholders obligations ordinary shares issued future finance changes noncontrolling interests charges leases noncash dividends shareholders lease contracts yet hedging gainloss transferred nonfinancial assets commenced intangible assets sharebased incentive plans tax sharebased incentive plans property plant equipment contributions noncontrolling interests investments distributions noncontrolling interests purchase total equity end year commitments total share purchases december gsk held million shares treasury commitments respect loans future interest payable shares million shares cost million loans disclosed taking account effect million deducted retained derivatives earnings entered number research collaborations ordinary shares repurchased period january develop new compounds pharmaceutical february company expect companies terms arrangements include make ordinary share repurchases remainder upfront fees equity investments loans commitments million treasury shares transferred fund specified levels research addition often agree employee share ownership plan esop trusts shares held make payments future milestones achieved trusts satisfy future exercises options awards agreements relate compounds early group share option award schemes stages development potential obligation make proportion shares held trusts respect milestone payments continue number years awards rules scheme require gsk satisfy compounds move successfully development exercises market purchases rather issue process generally closer product marketing new shares shares held trusts matched approval greater probability success amounts options awards granted shown within intangible assets represent maximum would paid milestones achieved december esop trusts held million increase commitments mainly million gsk shares future exercise attributable new rd collaborations resulting higher share options share awards executive intangible assets commitments supplemental savings plan carrying value million million deducted reserves market value shares million million strategic report governance remuneration financial statements investor information gsk annual report group financial review continued financial position resources continued connection demerger consumer healthcare normal course business provided various december pension scheme valuations identified cash indemnification guarantees respect business disposals funding technical provisions deficits three gsk uk pension legal disputes subsequently arisen schemes scottish limited partnerships slps established provision made outflow resources considered provide funding mechanism gsks uk defined probable reliable estimate made likely benefit pension schemes slps together held shares outcome dispute included note 'other representing total issued share capital haleon provisions ' financial statements plc provide outcome tax legal disputes pension scheme slp interest entitled outflow resources considered probable receive distribution slp amount equal reliable estimate outflow may made december net proceeds sales haleon plc shares receive disputes provision dividend income haleon plc shares received made possible make reliable estimate aggregate amount equal agreed threshold proceeds potential outflow funds might required settle threshold proceeds thresholds total million disputes possibility outflow increased notional interest remaining balance remote time time payment amount would fully fund ultimate liability matters may vary significantly cash funding technical provisions deficits three amounts provided dependent upon schemes shown december valuations negotiations relevant tax authorities outcome proceeds threshold reached gskcontrolled litigation proceedings relevant discussed general partner slp entitled sell remaining principal risks uncertainties pages haleon plc shares held slp distribute proceeds note 'legal proceedings ' financial statements gsk december total cash contributions totalling million million made towards proceeds threshold leaving outstanding amount due uk pension schemes cash contributions included million distributions dividends haleon plc shares slps schemes contingent liabilities contingent liabilities set note 'contingent liabilities ' financial statements following table sets contingent liabilities comprising performance guarantees letters credit items arising normal course business expected expire total yr yrs yrs yrs guarantees contingent liabilities total strategic report governance remuneration financial statements investor information gsk annual report group financial review continued approach tax business makes major contribution public purse tax risk countries operate managed tax contribution includes direct taxes robust internal policies processes training compliance corporate income tax indirect taxes vat programmes board directors audit risk customs duties well taxes employment committee responsible approving tax policies taxes property taxes therefore important risk management arrangements part wider internal companies explain approach tax helps inform control framework dialogue tax tax policy seek maintain open constructive relationships supportive efforts ensure companies tax authorities worldwide meeting regularly discuss tax appropriately transparent tax affairs affairs real time business updates wherever possible managed part tax strategy set detail also monitor government debate tax policy key within public policies section website jurisdictions understand share informed support exchange countrybycountry reporting point view regarding potential future changes tax law cbcr data tax authorities validated support transparent sustainable tax system existing information held taxpayers support ability relevant provide pragmatic constructive business input ensure multinational groups pay right amount tax tax policy makers either directly industry trade right places bodies advocating reform support economic growth job creation well needs patients key global biopharmaceutical company substantial stakeholders business employment presence many countries around world pay significant amount tax includes group corporate tax charge million corporate income tax business taxes tax million profits tax million associated employees also collect significant million representing effective tax rate amount tax behalf governments along supply made cash tax payments million chain including employees year million addition taxes pay profits pay duties levies transactional subject taxation throughout supply chain employment taxes worldwide nature operations means cross border supply routes necessary ensure supplies medicines groups total tax rate numerous countries result conflicting claims tax lower adjusted tax rate reflecting different tax authorities profits taxed individual countries effects various adjusting items lead double taxation profits taxed adjusted tax rate one country rate benefited innovation incentives available key profits recognised territories reference activities territories operate uk belgium performed value generate ensure patent box regimes uk government enacted profits recognised jurisdictions aligned activity legislation introducing global minimum corporate income tax undertaken line current oecd guidelines rate effect line organisation base transfer pricing policy arms length principle economic cooperation developments oecd pillar two support transfer prices economic analysis model framework anticipate rules restrict reports ability benefit innovation incentives consequentially effective adjusted tax rate forecast increase around engage artificial tax arrangements without business commercial substance seek avoid tax use tax havens transactions would details corporate tax charges year fully disclose tax authority zerotolerance set note 'taxation ' financial statements approach tax evasion facilitation tax evasion strategic report governance remuneration financial statements investor information gsk annual report group financial review continued treasury policies report sterling pay dividends sterling cash interest rate risk management flows role treasury monitor manage gsks objective minimise effective net interest cost groups external internal funding requirements balance mix debt fixed floating interest rates financial risks support strategic objectives gsk time policy interest rate risk management limits operates global basis primarily subsidiary net amount floating rate debt specific cap reviewed companies manage capital ensure agreed less annually board subsidiaries able operate going concerns optimise returns shareholders appropriate foreign exchange risk management balance debt equity treasury activities governed objective minimise exposure overseas operating policies approved annually board directors subsidiaries transaction risk matching local currency recently october treasury management group income local currency costs possible foreign tmg meeting chaired chief financial officer takes currency transaction exposures arising external internal place regular basis review treasury activities trade flows selectively hedged gsks internal trading members receive management information relating transactions matched centrally manage inter activities company payment terms reduce foreign currency risk treasury operations possible manage cash surpluses borrowing requirements subsidiary companies centrally using forward objective gsks treasury activities minimise contracts hedge future repayments back originating posttax net cost financial operations reduce volatility currency order benefit earnings cash flows gsk uses variety financial instruments finance operations derivative order reduce foreign currency translation exposure financial instruments manage market risks seek denominate borrowings currencies principal operations derivatives principally comprise foreign exchange assets cash flows primarily denominated us forward contracts swaps used swap dollars euros sterling borrowings liquid assets currencies required group borrowings swapped currencies required purposes well interest rate swaps used borrowings denominated swapped foreign currencies manage exposure financial risks changes interest match investments overseas group assets may rates treated hedge relevant assets forward derivatives used exclusively hedging purposes relation contracts major currencies also used reduce exposure underlying business activities trading groups investment overseas group assets tmg speculative instruments reviews ratio borrowings assets major currencies regularly capital management commodity risk management gsks financial strategy implemented groups financial architecture supports gsks strategic priorities objective minimise income statement volatility arising regularly reviewed board manage capital fluctuations commodity prices practical cost structure group appropriate mix debt effective tmg authorised approve equity continue manage financial policies credit execution certain financial derivatives hedge commodity profile particularly targets ratings least aa price exposures moody'ssp cycle counterparty risk management gsks longterm credit rating standard poors set global counterparty limits banking stable outlook moodys investor services moodys investment counterparties based longterm credit ratings stable outlook shortterm credit ratings moodys standard poors usage limits p standard poors moodys respectively actively monitored breach limits would liquidity risk management reported chief financial officer immediately gsks policy borrow centrally order meet anticipated addition relationship banks credit ratings funding requirements cash flow forecasts funding reviewed regularly changes ratings occur requirements monitored tmg regular basis changes made investment levels authority limits strategy diversify liquidity sources using range facilities appropriate banking counterparty limits reviewed maintain broad access financial markets least annually day sweep cash number global subsidiaries central treasury accounts liquidity management purposes strategic report governance remuneration financial statements investor information gsk annual report group financial review continued critical accounting policies group consolidated financial statements us medicaid programme stateadministered prepared accordance ukadopted international programme providing assistance certain poor accounting standards conformity requirements vulnerable patients medicaid drug rebate companies act international financial program established reduce state federal reporting standards ifrs issued international expenditure prescription drugs patient accounting standard board iasb protection affordable care act became law participate providing rebates states accruals required make estimates assumptions medicaid rebates calculated based specific terms affect amounts assets liabilities revenue expenses relevant regulations patient protection reported financial statements actual amounts results affordable care act could differ estimates cash discounts offered customers encourage critical accounting policies relate following areas prompt payment accrued time invoicing adjusted subsequently reflect actual turnover experience taxation note record accrual estimated sales returns applying legal disputes notes historical experience customer returns amounts invoiced together marketrelated information contingent liabilities note stock levels wholesalers anticipated price increases pensions postemployment benefits note competitor activity information judgements estimates made areas given note 'critical accounting judgements reconciliation gross turnover net turnover us key sources estimation uncertainty ' financial commercial operations follows statements turnover margin margin margin respect turnover accounting policy largest gross turnover business us commercial operations us market complex arrangements rebates discounts marketdriven allowances following briefly describes nature segments arrangements existence us commercial operations government arrangements certain indirect customers mandated whereby customer able buy products state programmes wholesalers reduced prices chargeback represents cash discounts difference invoice price wholesaler customer returns indirect customers contractual discounted price accruals prior year estimating chargebacks calculated based adjustments terms agreement historical experience product growth rates items customer rebates offered key managed care total deductions group purchasing organisations direct net turnover indirect customers arrangements require customer achieve certain formulary status performance targets marketdriven segments consist primarily managed care relating value product purchased predetermined medicare plans negotiate contract pricing market shares relative competitors accrual honoured via rebates chargebacks mandated segments customer rebates estimated based specific terms consist primarily medicaid federal government agreement historical experience product growth programmes receive governmentmandated pricing via rates rebates chargebacks strategic report governance remuneration financial statements investor information gsk annual report group financial review continued critical accounting policies continued overall sales deduction percentage sales consistent may become involved significant legal proceedings year year sales growth coming primarily trelegy respect possible meaningfully assess arexvy specialty products including hiv deductions within whether outcome result probable outflow year split approximately follows general medicines quantify reliably estimate liability could result specialty medicines vaccines ultimate resolution proceedings cases appropriate disclosure cases would included december total accrual discounts rebates annual report provision would made allowances returns us commercial operations amounted million million position could change time therefore monthly process operated monitor inventory levels assurance losses result outcome wholesalers abnormal movements process uses legal proceedings exceed material amount gross sales volumes prescription volumes based third party amount provisions reported groups financial data sources information received key wholesalers statements aim maintain inventories consistent level like many pharmaceutical companies faced year year based pattern consumption various complex product liability antitrust patent litigation basis us commercial operations inventory levels well investigations operations conducted various wholesalers distribution channels december governmental regulatory agencies throughout year estimated amount approximately four weeks general counsel group head groups legal turnover calculation uses third party information function supported senior vice president head accuracy totally verified believed global litigation group responsible sufficiently reliable purpose litigation government investigations routinely brief chief executive officer chief financial officer legal disputes board directors significant litigation pending respect accounting policy legal disputes group governmental investigations group following briefly describes process meetings appropriate detail status significant determine level provision necessary litigation government investigations review matters accordance requirements ias provisions number claims notified us information contingent liabilities contingent assets provide potential claims yet notified assessment validity anticipated settlement costs outflow resources claims progress made settling claims recent settlement considered probable reliable estimate may made levels potential reimbursement insurers likely outcome dispute legal expenses meetings also include assessment whether arising claims group sufficient information available us able make reliable estimate potential outcomes disputes often external counsel assisting us various litigation matters investigations also assist briefing board senior management following discussions matters possible make reliable estimate amount provision may required level provision legal disputes reviewed adjusted appropriate matters discussed note 'legal proceedings ' financial statements strategic report strategic report approved board directors february julie brown chief financial officer february gsk annual report corporate governance section board gsk leadership team chairs governance statement corporate governance architecture ahead together board oversight continuous engagement key decisions board committee reports remuneration committee chair 's annual statement annual report remuneration directors report strategic report governance remuneration financial statements investor information gsk annual report board sir jonathan symonds cbe skills experience nonexecutive chair jon extensive international financial life sciences governance experience jon served independent nonexecutive director hsbc holdings plc april age chairman group audit committee september deputy group chairman nationality british august retirement board february previously appointed september chairman hsbc bank plc chief financial officer novartis ag partner managing n director goldman sachs chief financial officer astrazeneca plc partner kpmg jon fellow institute chartered accountants england wales external appointments nonexecutive director genomics england limited previously served chairman nonexecutive chair energy aspects member european round table industry senior advisor chatham house dame emma walmsley skills experience chief executive officer appointed gsks ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma joined gsk age loreal worked years variety roles paris london new york nationality british shanghai emma previously nonexecutive director diageo plc emmas position appointed january independent director microsoft inc supplements technology cyber security chief executive officer experience brings board april emma holds classics modern languages oxford university external appointments independent director microsoft inc julie brown skills experience chief financial officer julie extensive financial life sciences background group cfo smith nephew serving nonexecutive director audit chair age roche holding ag julie interim group cfo astrazeneca nationality british plc worked wide range commercial strategic financial positions across three appointed april continents year period julie also chief operating officer cfo executive chief financial officer may director burberry group plc responsibilities included finance transformation information technology oversight cyber security julie fellow institute chartered accountants institute tax external appointments cochair cfo leadership network accounting sustainability part king charles iii charitable fund group companies patron oxford university women business non executive director chair audit committee diageo plc effective august elizabeth liz mckee anderson skills experience independent nonexecutive director liz brings significant experience commercial biopharmaceuticals seasoned biotech board member significant experience commercial biopharmaceuticals operationally age board level well deep understanding biotechnology sector nationality american application technology invaluable gsk pure biopharma company appointed september current roles liz served worldwide vice president commercial leader infectious diseases vaccines also immunology oncology janssen r pharmaceuticals vice president general manager wyeth vaccines liz also previously board member huntsworth plc board member chair science technology investment committee bavarian nordic liz degree engineering technical management mba finance external appointments board member biomarin pharmaceutical inc board member revolution medicines inc board member insmed inc trustee wistar institute director aro biotherapeutics company private company key committee chair c corporate responsibility science n nominations corporate governance audit risk r remuneration strategic report governance remuneration financial statements investor information gsk annual report board continued charles bancroft skills experience senior independent nonexecutive director charlie wealth financial management experience global biopharma charlie retired successful career bristol myers squibb bms march age held number leadership roles commercial strategy finance beginning career nationality american bms held positions increasing responsibility within finance organisation appointed may commercial operational responsibility latin america middle east africa canada japan senior independent nonexecutive director several pacific rim countries appointed chief financial officer chief july financial officer executive vice president global business operations executive vice president head integration strategy business development chief n r financial officer charlie line management responsibility information technology including cyber security charlie successfully steered bms period strategic transformation including billion acquisition celgene charlie also served member board colgatepalmolive company march external appointments board member kodiak sciences inc board member biovector inc advisory board member drexel universitys lebow college business board determined charlie recent relevant financial experience agreed appropriate qualifications background audit committee financial expert dr hal barron skills experience nonexecutive director hal distinguished career biosciences strong track record research development rd joined board gsk chief scientific officer president age rd brought new approach rd focused science related immune nationality american system use human genetics advanced technologies help identify next appointed january generation transformational medicines august transitioned nonindependent chief scientific officer nonexecutive director additional responsibilities support rd president rd april joining gsk hal president rd calico llc california life company transitioned role nonexecutive alphabetfunded company uses advanced technologies increase understanding director august lifespan biology hal previously executive vice president head global product development chief medical officer roche responsible products combined portfolio roche genentech genentech senior vice president development chief medical officer hal nonexecutive director chair science technology committee juno therapeutics inc march acquired celgene corporation previously served nonexecutive board director grail inc advisory board member verily life sciences llc external appointments ceo board cochair altos labs inc associate adjunct professor epidemiology biostatistics university california san francisco dr anne beal skills experience independent nonexecutive director anne brings extensive healthcare experience board physician entrepreneur combines passion patient advocacy recognised health policy expert age development global national programmes improving healthcare access patient nationality american groups ensuring voice patients reflected research programmes appointed may current roles anne spent six years harvard medical school massachusetts general hospital instructor paediatrics also held leadership roles c n r commonwealth fund aetna foundation anne previously deputy executive director chief engagement officer patientcentered outcomes research institute us chief patient officer global head patient solutions sanofi external appointments founder ceo absolutejoi skincare board member academyhealth board member prolacta bioscience key committee chair c corporate responsibility science n nominations corporate governance audit risk r remuneration strategic report governance remuneration financial statements investor information gsk annual report board continued wendy becker skills experience independent nonexecutive director wendy highly experienced nonexecutive director held significant leadership positions wide range global businesses public private nonprofit sectors age possesses wealth strategic consumer marketing expertise particular across nationality american technology life sciences sectors appointed october wendy strong executive management experience chief executive officer jack wills limited group chief marketing officer vodafone group plc partner r mckinsey company wendys interest science healthcare medical research dates time mckinsey worked range healthcare clients us europe furthered years served board cancer research uk recently wendy spent time nonexecutive director nhs england chair british heart foundation wendy held several nonexecutive director roles amongst others chair remuneration committees great portland estates plc ocado group plc member remuneration audit committees whitbread plc current prior roles technology companies wendy adds boards experience cyber security external appointments chair logitech international sa board member chair compensation committee sony group corporation senior independent director chair remuneration committee oxford nanopore technologies plc member governing bodies university oxford dr harry hal c dietz skills experience independent nonexecutive director hal brings extensive experience field human genetics central gsks approach scientific medical expert rd former president american society human genetics recognised worlds leading authority genetic disorder known marfan syndrome also age brings experience developing novel therapies particularly relation diseasemodifying nationality american treatments fibrotic neurodegenerative diseases total hal authored original appointed january publications peerreviewed journals career physician scientist dedicated entire career care study individuals heritable connective tissue disorders primary perturbations extracellular matrix homeostasis function lab identified genes many conditions uses model systems explain disease mechanisms hal received many prestigious awards including curt stern award american society human genetics colonel harland sanders lifetime achievement award medical genetics taubman prize excellence translational medical science harrington prize american society clinical investigation harrington discovery institute pasarow award cardiovascular research inbevbaillet latour health prize belgium research achievement award american heart association inductee american society clinical investigation american association advancement science association american physicians national academy medicine national academy sciences external appointments victor mckusick professor paediatrics medicine molecular biology genetics department genetic medicine johns hopkins university school medicine investigator howard hughes medical institute nonexecutive board director altius institute biomedical sciences independent chair gsks human genetics scientific advisory board key committee chair c corporate responsibility science n nominations corporate governance audit risk r remuneration strategic report governance remuneration financial statements investor information gsk annual report board continued dr jesse goodman skills experience independent nonexecutive director jesse brings scientific public health expertise boards deliberations wealth scientific medical expert experience spanning science medicine vaccines regulation public health proven record addressing pressing public health needs academic federal sectors age jesse previously served senior leadership positions us food drug administration nationality american fda including recently fdas chief scientist previously deputy appointed january commissioner science public health director center biologics evaluation research cber c jesse played leadership role developing fdas regulatory science medical countermeasures initiatives worked collaboratively industry academia government global public health regulatory partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn influenza pandemic served senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovations cepi external appointments professor medicine attending physician infectious diseases georgetown university directs georgetown university center medical product access safety stewardship compass board member formerly president united states pharmacopeia usp board member scientific counselors infectious diseases centers disease control prevention cdc board member intellia therapeutics inc member us national academy medicine board member adaptive phage therapeutics inc urs rohner skills experience independent nonexecutive director urs broad business banking legal background extensive senior level experience multinational companies age urs served chairman number boards recently credit suisse group nationality swiss april joining credit suisse urs served chairman executive appointed january board ceo prosieben prosiebensat media ag followed number years private practice major law firms switzerland us admitted bars r n canton zurich switzerland state new york us founding partner chair vega cyber associates ag brings current technology cybersecurity experience board supplemented digital transformation time chair credit suisse external appointments member international advisory board investcorp chair vega cyber associates ag dr vishal sikka skills experience independent nonexecutive director vishal distinguished background technology particularly artificial intelligence ai machine learning ml central gsks approach rd also brings deep age understanding cyber security board founder ceo vianai systems inc nationality american silicon valleybased company provides advanced technological software services ai appointed july ml large enterprises around world founding vianai systems vishal served ceo infosys limited led c innovative strategy help clients renew existing landscapes using automation design thinking nextgeneration technologies transform customer experiences also served member executive board sap se prior chief technology officer vishal phd ai stanford university coauthored several research abstracts related ai technology database management external appointments founder ceo vianai systems inc board member oracle corporation member supervisory board bmw ag member advisory board stanford university 's ai center center humancentered artificial intelligence key committee chair c corporate responsibility science n nominations corporate governance audit risk r remuneration directors departing iain mackay january may stepped board may retired company december strategic report governance remuneration financial statements investor information gsk annual report gsk leadership team glt skills experience emma walmsley emma joined gsk glt see board biographies pages chief executive officer julie brown julie joined gsk glt see board biographies pages chief financial officer diana conrad diana appointed chief people officer member glt april chief people officer previously senior vice president hr pharmaceuticals rd played key strategic role leader rd people culture agenda support transformation diana joined gsk canadas hr team held several roles increasing responsibility becoming senior vice president hr consumer healthcare prior joining gsk held hr roles companies including ge capital gennum corporation zenon environmental laboratories diana honours bachelor arts mcmaster university canada james ford james joined glt appointed senior vice president group general svp group general counsel counsel later taking responsibility compliance corporate security investigations legal compliance joined gsk served general counsel consumer healthcare general counsel global pharmaceuticals vice president corporate legal acting head global ethics compliance prior gsk james solicitor clifford chance dla holds law degree university east anglia diploma competition law king 's college qualified solicitor england wales attorney new york state bar james based london practised law lived us singapore hong kong james cochair usbased civil justice reform group director european general counsel association association corporate counsel sally jackson sally joined glt march senior vice president global communications ceo svp global communications office leads communications government affairs function globally also ceo office ceos chief staff prior sally senior vice president office ceo cfo previously served head investor relations joined gsk sally holds degree natural sciences university cambridge luke miels luke joined gsk glt chief commercial officer responsible chief commercial officer commercial portfolio medicines vaccines luke also cochairs portfolio investment board tony wood member viiv healthcare board outside gsk luke member singapore economic development board previously worked astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affairs corporate affairs head asia roche based shanghai singapore prior held roles increasing seniority roche sanofiaventis us europe asia luke holds bachelor science degree biology flinders university adelaide mba macquarie university sydney shobie ramakrishnan shobie joined glt appointed chief digital technology officer chief digital technology officer joined gsk deep broad experience biotech hitech companies recently led digital technology gsks global commercial organisation transforming companys capabilities digital data analytics playing pivotal role establishing agile commercial operating model joining gsk shobie held senior technology leadership roles organisations including astrazeneca salesforce genentech roche nonexecutive director deliveroo board member emeritus sustainableitorg formerly member board directors remediant shobie holds bachelors degree electronics engineering vellore institute technology university madras india strategic report governance remuneration financial statements investor information gsk annual report gsk leadership team glt continued skills experience david redfern david joined glt chief strategy officer responsible corporate president corporate development development strategic planning previously senior vice president northern europe responsibility gsks pharmaceutical businesses region senior vice president central eastern europe joined gsk david appointed chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis joined glt became president pharmaceuticals supply chain president global supply chain responsible manufacturing supply gsks medicines vaccines addition leads quality environment health safety sustainability corporate level regis joined gsk site director france rising become senior vice president global pharmaceuticals manufacturing current role previously held senior positions sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer holds mba phil thomson phil joined glt appointed president global affairs president global affairs responsibility groups strategic approach stakeholder engagement reputation policy development previously phil senior vice president communications government affairs joined glaxo wellcome commercial trainee phil holds degree english history russian studies durham university deborah waterhouse deborah appointed glt january became chief executive officer viiv ceo viiv healthcare president healthcare april addition viiv deborah also leads gsks global health gsk global health organisation deborah joined gsk prior viiv senior vice president primary care within gsks us business strong track record performance specialty primary care deborah led hiv business uk heading hiv centre excellence pharma europe held roles general manager australia new zealand senior vice president central eastern europe deborah nonexecutive director schroders plc holds degree economic history english literature liverpool university tony wood tony appointed chief scientific officer cso head rd member glt chief scientific officer august following appointment cso designate january joined gsk pfizer senior vice president medicinal science technology responsible science technology platforms driving delivery new innovation tony led largescale global organisations drug discovery development multiple therapeutic areas including immunology oncology infectious diseases time pfizer tony responsible invention new antiretroviral medication used treat hiv infection fellow academy medical sciences honorary fellow royal society chemistry rsc highest honour given rsc fellow royal society biology tony bsc chemistry phd organic synthesis university newcastle postdoctoral fellow imperial college london also currently visiting professor imcm oxford glt members departing iain mackay member glt cfo may stepped board may retired company december strategic report governance remuneration financial statements investor information gsk annual report chairs governance statement gsk continued make significant progress pure biopharma company board skills capabilities challenge support gsks performance longterm success board evolution board succession boards composition continue evolve two succession processes began urs rohner tailored pure biopharma company chaired remuneration committee since may reaches relevant skills experience deep industry nine years service agm scientific expertise well broad pharma business succeeded following agm wendy becker joined commercial experience board october wendy strong background science life sciences technology also heart business science choices make experienced remuneration committee chair well equipped drs hal dietz hal barron jesse understanding global corporates oversee next goodman provide breadth depth scientific iteration remuneration policy presented knowledge combines well vishal sikkas deep agm expertise technology artificial intelligence machine learning aiml liz anderson provides strong commercial second succession planning focus continued expertise dr anne beal brings strong focus patients refreshment boards scientific expertise dr laurie patient experience charlie bancrofts extensive glimcher stepped board october expertise pharma company executive cfo means replaced unsure precisely board meets needs gsk today additional skills needed focus deepens rna oligonucleotides undertaken detailed search management level transitioned cfo iain scientist deep experience rna mackay guided us separation haleon julie brown deep industry expertise successor dr jesse goodman due retire nine years service agm sought board industry experience expertise public health infectious diseases regulation invaluable necessary board priorities focus gsk delivering meaningful consistent improvement performance needs sustained effective capital allocation strategic choices reflected recent upgrade longerterm outlooks announced beginning year pharmalife tech finance consumerother sciences board management agendas completely aligned clear focus three time periods management l prebiopharma board communicate financial performance pipeline l biopharma board progress business development support growth ambitions science technologies nonexecutive director tenure support longterm growth business beyond primary focus boards work building confidence growth outlooks significant opportunities come aiml theme running every board meeting l years l years l years l years board priorities focus value creation governance oversight ahead together strategy delivery performance targets execution rd pipeline business development longterm rd strategy approach endtoend business impact aitechnology peopletalentculture esg leadership zantac litigation defence mitigation focus shareholder value creation strategic report governance remuneration financial statements investor information gsk annual report chairs governance statement continued board supported modular communication plan similarly wherever go gsk year travels included included deep insights vaccines infectious us china middle east europe take disease hiv respiratory immunology oncology board opportunity meet local employees levels small reviewed strategies priorities prior groups impressive hear meet talk pride communication market revised outlooks presented purpose mission towards prevention improved annual results also reviewed extensively human health second half year along longerterm strategic esg continues right heart gsk plan terms business development board science ambition particularly proud progress committee work alongside emma management team making dei terms people diversity understand scientific rationale competitiveness clinical trials asset consideration potential returns value creation significant activity board shareholder perspectives engagement board visits important element board programme board believe importance maintaining march board spent three days visiting vaccines site continuous level engagement shareholders wavre belgium board members deep immersion year continued meet range investors combined vaccines business work site inspired represented approximately share register passion commitment group around year nonexecutive board members attended employees spent time visit similarly annual governance meeting hear shareholders views first board holding march meeting north hand feedback shareholders provide invaluable carolina immersive briefing hiv business shaping boards work appreciate clarity efficiency direct engagement brings continue rd progress technology welcome opportunity engage investors directly longerterm future company comes deep aspects gsk boards work sustainable productivity internal externally sourced rd welcome approach taken financial reporting investment technology path set council updated uk corporate governance code five years ago routed commitment transform encourage boards bolder choosing right approach productivity use technology business explaining important last year boards rd updates centred antibody drug necessary conjugates oligonucleotides amr vaccines rna shareholder value liver disease discussions supported validated prior deepdives science committee made progress always key improved returns consistency embracing potential aiml every part business performance consistency communication crucial medium longterm success deliberately believe management delivered wealth tech experience board ranging dr translated sustained shareholder value creation hal barrons rd experience verily google vishal acutely aware happened yet sikkas unique tech vantage point expertise ai ml ceo also brings unique insights role microsoft terms zantac litigation board deeply involved along experience use technology overall strategy ceo general counsel biotechs uks national genomics programmes addition every quarter audit risk committee reviews collectively deep appreciation tremendous potential disclosures auditor ensure complete technology unlock give us reassurance execute fair accounting judgments appropriate confidence biggest investment course believe year significant progress across rd every part gsk technology built time periods beyond optimising priorities clear aligned work programme board culture responsibility different two years ago really delighted progress emma board receives regular briefings people talent management team made performance culture every board interaction wherever board board meets members local employee talent enables us get first hand impression culture encourage read board colleagues ' committee mood employees hear views company updates follow pages provide greater detail work thank continued support look forward connecting year whether annual general meeting may otherwise sir jonathan symonds chair february strategic report governance remuneration financial statements investor information gsk annual report corporate governance architecture corporate governance architecture framework designed improve board 's effectiveness support oversight gsk leadership team glt delivers company 's strategy framework continues evolve support infrastructure priorities pure biopharma business gsks internal control risk management arrangements integral overall corporate governance framework described pages pages ensure framework 's optimal effectiveness clear division responsibilities individual collective board roles described appropriate distribution workload board committee requisite focus skills highly committed board directors motivated carry roles responsibilities success company committee roles committee report committee role focus membership chairs acts behalf board scheduled meetings take decisions urgent sir jonathan symonds matters accordance matters authority delegated board time company chair time senior independent director chairs board 's committees corporate considers gsk 's trust priority oversight responsible business approach dr anne beal chair responsibility esg strategy performance reporting reflects important issues dr jesse goodman responsible sustainable business growth oversight views interests dr vishal sikka internal external stakeholders reviews issues could serious impact gsks business reputation science supports board understanding business development transactions key dr hal dietz chair strategic themes company 's rd strategy based reviewing underlying dr jesse goodman scientific assumptions detail giving board technical assurance indepth dr hal barron oversight rdrelated risks nominations reviews structure size composition board appointment members sir jonathan symonds corporate board committees appointment corporate officers makes recommendations chair governance board appropriate plans assesses orderly succession executive non charles bancroft executive directors reviews management 's succession plan ensure adequacy dr anne beal urs rohner responsible overseeing monitoring making recommendations board corporate governance arrangements reviews board glt conflicts interest audit risk reviews financial reporting process integrity companys financial statements charles bancroft external internal audit process system internal control identification chair management risks information cyber security companys elizabeth mckee process monitoring compliance laws regulations ethical codes practice anderson wendy becker oversees esg data reporting assurance initiates audit tenders selection urs rohner appointment external auditor setting auditor 's remuneration overseeing work remuneration sets companys remuneration policy regard gsks workforce remuneration urs rohner chair gsk able recruit retain motivate executives wendy becker chair designate regularly reviews remuneration policy make sure consistent charles bancroft companys scale scope operations supports business strategy growth plans dr anne beal aligned wider workforce helps drive creation shareholder value elizabeth mckee chair ceo responsible evaluating making recommendations anderson board remuneration arrangements policy nonexecutive directors board committee written terms reference approved board reviewed least annually make sure comply latest legal regulatory requirements reflect best practice developments terms reference board committee available gskcom strategic report governance remuneration financial statements investor information gsk annual report corporate governance architecture continued leadership independent oversight rigorous challenge chair senior independent director jonathan symonds charles bancroft leads manages business board acts sounding board chair trusted provides direction focus intermediary directors ensures clear structure board together nonexecutive directors leads committees operate effectively annual review chairs performance taking maintains dialogue shareholders account views executive directors governance company discusses results chairs effectiveness review sets board agenda ensures sufficient time chair allocated promote effective debate support sound leads search appointment process makes decisionmaking recommendation board new chair ensures board receives accurate timely clear acts additional point contact shareholders information maintains understanding issues concerns meets regularly nonexecutive director meetings shareholders briefings discuss individual contributions performance company secretary investor relations training development needs gsk 's senior independent nonexecutive directors role description shares peer feedback provided part available gskcom board evaluation process meets regularly nonexecutive directors nonexecutive directors independently executive directors provide strong independent element board chairs role description available gskcom constructively support challenge management scrutinise performance achieving agreed deliverables chief executive officer emma walmsley shape proposals strategy offer specialist advice management manages group business letter appointment setting terms develops groups strategic direction board 's conditions directorship consideration approval devote time necessary proper implements agreed strategy performance duties supported glt expected attend meetings required maintains continuous dialogue shareholders respect companys performance independence statement chief executive officers role description available gskcom board considers nonexecutive directors identified pages except dr hal barron independent assessed provision financial reporting council 's frc uk corporate governance code code gsk 's nonexecutive directors ' role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chairs plan future agendas annual programmes ensures information made available board members timely fashion supports chair design deliver board inductions coordinates continuing business awareness training nonexecutive directors undertakes internal board committee evaluations chair 's request advises directors board practice procedures corporate governance matters chairs group 's disclosure committee operates boardapproved appointments policy reflects board external appointment requirements code point contact shareholders corporate governance matters strategic report governance remuneration financial statements investor information gsk annual report corporate governance architecture continued board committee attendance nominations corporate corporate board chairs responsibility science governance audit risk remuneration total number routine meetings current members attended attended attended attended attended attended attended sir jonathan symonds emma walmsley julie brown may elizabeth mckee anderson dr hal barron charles bancroft dr anne beal wendy becker october dr harry dietz dr jesse goodman urs rohner dr vishal sikka retired members iain mackay may number additional meetings directors served part year numbers brackets show number meetings directors eligible attend details committee members skills experience included biographies pages high attendance record scheduled board committee meetings directors served set january urs rohner reached nine years service step board agm planned continues demonstrate characteristics independence expected board carrying role board dr vishal sikka joined board july first year board unable attend two board meetings preexisting external board commitments contributed fully boards work met regularly chair provide input board committee materials inputted technology ai discussions audit risk committee also spent time chief digital technology officer team year sharing expertise perspectives frc uk corporate governance code financial experience members audit risk committee also financial industry experience details found accordance frc 's code board determined biographies pages charles bancroft recent relevant financial experience also agreed appropriate compliance statement qualifications background audit committee board pleased report full financial expert defined sarbanesoxley act alignment provisions frc 's code determined independent within meaning securities exchange act amended board also pleased report consistently applied principles frc 's code set pages corporate governance report copy code available frcs website wwwfrcorguk board appointments policy nonexecutive directors expected devote time necessary performance duties director required attend minimum scheduled board committee meetings however recognised may rare occasions possible explained attendance table special allowance also given first year board membership calendars aligned board directors external appointments governed boardapproved policy considered external appointments help board glt members widen expertise knowledge hence perform roles effectively proposing new nonexecutive director appointments board approval board considers demands individuals time appointed board individual required disclose significant commitments may indication time involved subsequently additional prospective external appointments serving board directors considered approved board noting nature role type organisation time commitment potential conflicts could arise company secretary maintains register commitments potential conflicts board satisfied given directors interests sufficient time carry role gsk executive nonexecutive directors may undertake maximum one four listedcompany directorships respectively strategic report governance remuneration financial statements investor information gsk annual report ahead together board oversight board carries responsibilities annual programme meetings board seeks optimise effectiveness setting annual meeting programme focus priorities agreed year support delivery company 's short medium longterm strategy board committees ' programmes work set complement avoid unnecessary duplication year board received papers presentations actively discussed progress management people materials discussions help board make effective decisions contribute oversight business performance ensure good governance key areas board considered highlighted areas focus board 's work included building overseeing gsk pure biopharma business delivery performance included momentum setting approving board 's priorities pure biopharma company discussing scrutinising strategic plans gsk assessing potential upgrade longerterm outlook scrutinising updates rd strategy progress progression company 's pipeline discussing gsk 's overall commercial strategy particular china discussing endtoend business opportunities impact ai advanced technologies performance patients ahead together overseeing fundamentals commercial execution costbase management capital allocation pipeline culture included receiving regular reports ceo cfo cso including assessment delivery performance targets strengthening receiving updates rd strategy approach pipeline progress fundamentals assessing product area strategy reports vaccines speciality care including hiv oncology general medicines value creation reviewing gsk 's capital allocation priorities ensure investment growth deliver improved returns shareholders evaluating business development transactions acquisitions strategic partnerships third parties including bellus health zhifei hansoh aiolos bio arrowhead pharmaceuticals janssen pharmaceuticals scrutinising group 's financial performance shareholder value creation development investor relations roadmap reviewing zantac litigation strategy approving monetisation retained shares haleon post demerger consumer healthcare business enhancing overseeing culture embedding esg core included esg leadership assessing esg performance reviewed plans lowcarbon ventolin including clinical nonclinical data available support regulatory submissions approving esg performance report oversight company 's pricing access policy principles reviewing stakeholder perception research regular boards programme governance included corporate reviewing quarterly financial results dividend proposals earnings guidance investor materials results announcements governance annual report form f receiving related reports external auditor oversight setting annual budget forwardlooking threeyear plan longrange forecast conducting annual review enterprise risk responsibility framework enterprisewide risks undertaking annual board evaluation implementing agreed outcomes receiving reports board committee work reviewing continuing evolve boards governance architecture evaluating ceos performance setting objectives reviewing culture talent succession plans annually engaging gsk 's stakeholders people gather understand views companys activities operations culture reviewing employee pulse survey results receiving reports wider corporate governance regulatory developments company secretarys report approving company 's modern slavery statement gender pay gap positioning strategic report governance remuneration financial statements investor information gsk annual report ahead together board oversight continued board performance board committee evaluations review board committees focused potential board evaluates performance opportunities support gsk 's momentum pure committees every year biopharma company help remove duplication support delivery board 's priorities identified evaluation normally carried externally every third addition committee reviewed committee members ' year recent external evaluation facilitated tenure expertise diversity jan hall business advisory company connection gsk committee considered operated effectively following enhancements agreed board committee evaluation conducted internally company secretary corporate responsibility committee wide remit performing well consideration would given provided questionnaire board members additional routes identify potential emerging issues within drew together responses themes responses committee 's area responsibility review discuss outcomes recommendations addition committee would continue seek external committee chair perspectives provide challenge science committee working effectively opportunities following discussion committee board enhance effectiveness considered particular whole identified areas focus improvement committee 's programme would focus rd 's board committees set tech strategy capacity undertake deep dives action points specific areas rd activity input earlier new projects would explored due consideration discussion following action nominations corporate governance committee points improve performance agreed working effectively successor dr jesse goodman key priorities board 's focus programme sought ahead retirement board meetings year ahead committee would undertake review board committee architecture membership ensure given fundamental importance culture board remained aligned board priorities wished ensure fully embodied gsk 's culture audit risk committee considered effective would therefore undertake culture training provided work appropriately streamline material reviewed employees committee made good progress continue additional opportunities increase informal engagement area opportunity year ahead committee board management also continue give focus tech cyber security use ai removal unnecessary duplication board remuneration committee operated effectively committees ' work would continued programme aims despite challenging environment focus simplify papers create time deeper would determine right business imperatives discussions meetings gsk 's next remuneration policy ensure globally competitive rewarded delivery outperformance chair 's evaluation senior independent director sid carried chair 's evaluation sought feedback chair 's performance directors individually collectively review concluded chair leading board appropriately effectively chair sid discussed results review strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions prioritising continuous engagement stakeholders rightly high expectations us ongoing basis encouraged report company 's dynamic operating environment presents many board experiences relevant material challenges opportunities board aim make sure engaging people commercially successful balanced aligned meeting stakeholders expectations upholding wellestablished strong engagement mechanisms reputation maintaining licence operate building employees described pages trust engage briefed stakeholders ' board monitors regularly four key governance views make sure identify respond channels help board understand people expectations effectively appropriately thinking engage main stakeholder groups including regular board updates chief people officer patients shareholders consumers customers people ceo culture talent across company covered pages strategic feedback annual employee engagement survey report including questions engagement confidence patients people two stakeholders heart inclusivity culture people ambitious patients range pulse surveys differentsized employee groups accountable outcomes committed right help check sentiment quicker frequent thing culture described pages basis provide valuable insights impact major strategic report initiatives events communications direct engagement board influence importance different stakeholder groups vary depending matter considered certain workforce engagement company 's demerger stakeholders interests conflict meaning board reviewed formal workforce engagement board need make balanced judgements arrangements decided move specific workforce engagement director model apply continuous stakeholder engagement feedback helps us alternative arrangement three methods set identify emerging issues also enables us make decisions frcs code context relevant important given new gsk board recently refreshed terms principal board committees glt undertake tenure half independent nonexecutive engagement boards behalf according remit directors served less three years given means build detailed understanding gsk 's renewed purpose focus global biopharma actions plans affecting might affect stakeholders company considered important adopt collective insights shared board board engagement model agreed particular board receives briefings stakeholders effective approach ensure newer board members meet perspectives work corporate responsibility employees hear views committee discussed pages new model operated board members regularly receive direct inperson receptions local employees ceos board report board site visits including wavre belgium one specific external stakeholder insights report provides two global vaccines hubs boston us global strategic insights based analysis key developments headquarters brentford achievements risks affecting reputation chair 's site visits including wavre singapore perceptions external stakeholders vaccine manufacturing sites philadelphia regular investor relations report summarises investor commercial site perceptions chair 's attendance management meetings including regular corporate governance litigation regulatory china commercial employees commercial core updates leadership team uk china regional general managers commercial talent saudi arabia general board also learns stakeholders ' views management team engagement feedback events quarterly investor chair corporate responsibility committee chair results calls annual general meeting employee survey convene attend ongoing meetings leaders reports boards workforce engagement activities company 's employee resource groups talk experts presenting board committee meetings chair experience gsk think dei agenda also holds regular investor checkin meetings sid ambitions progressing sharing suggestions charlie bancroft sometimes joins available individual enhance dei agenda meetings investors utilising variety bespoke engagements enabled broad open dialogue facilitated first opportunities board members also gain wider hand engagement discussions neds stakeholder views annual strategy meeting people individually part small groups glt part yearly review strategy budget encompassing perspectives strategy purpose planning processes also includes review specific ahead together culture dei aspects companys policies strategy addition board members encouraged meet individually employees shareholders key stakeholders induction strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions continued engaging shareholders annual governance meeting board aim directly engage directly years hybrid meeting held central london accountable institutional investors private retail institutional shareholders key investment industry bodies shareholders several ways including regular proxy advisory firms invited representatives various communications annual governance meeting annual institutional shareholders proxy advisers attended general meeting work investor relations event comprising approximately company 's share team chair jonathan symonds company register secretary victoria whyte sid charlie bancroft another meeting new format make interactive point contact shareholders possible began jon sharing investors board 's quarter ceo emma walmsley cfo julie brown priorities focus beyond charlie give results presentations institutional investors analysts providing reflections year jon charlie non media webcast also regularly joined executive directors held informal open discussion cso chief commercial officer cco ceo viiv issues shareholders ' minds helped foster able provide investors detailed insights richer dialogue specific areas responsibility key themes covered included regular meetings ongoing board changes succession planning arrangements active dialogue institutional shareholders work challenges board last year company 's performance plans objectives company 's current future momentum excellent ceo engagements representing company 's execution key priorities share register harnessing digital technology talent driven current previous cfo engagements ahead together purpose comprising register positive signs influence culture cso engagements representing register ambitious patients accountable impact cco engagements representing register right thing ceo viiv engagements register meeting new format well received chair maintains consistent dialogue shareholders shareholder feedback shared full board including fund portfolio managers regularly annual general meeting engages governance esg professionals pleased hold company 's hybrid agm date publication annual report jon sofitel heathrow may shareholders joined held individual engagements range meeting person shareholders joined virtually via institutional shareholders make approximately lumi platform watch listen updates chair companys share register enables gain current ceo vote shareholders able ask questions understanding shareholders ' views insights perspectives meeting person virtually proposed company also discusses continual evolution resolutions approved shareholders majorities many aspects board governance performance oversight ranging succession hybrid agm year held new venue royal year chair ceo rest board key glt lancaster hotel central london located close members focused communicating strong ongoing new global headquarters details see performance gsk global biopharma business successful launch arexvy world 's first rsv vaccine progressing pipeline across core therapy areas infectious diseases hiv respiratoryimmunologyand oncology strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions continued section statement board members required law promote success company benefit shareholders wider stakeholders including employees suppliers society statement meets requirement set section section cza companies act act summarises directors addressed matters set section f act performing duties board considers statement focuses risks opportunities strategically important gsk consistent groups size complexity allows properly understand potential effects decisions makes stakeholders details engagement main stakeholder groups including patients shareholders consumers customers employees across organisation summarised generally throughout pages strategic report board 's continuous engagement company 's shareholders people particular set section pages corporate governance architecture processes summarised pages board seeks consider relevant matters making decisions especially continue drive performance momentum gsk future longterm results likely consequences decision long term challenging economic political landscape directors proposed choice highlighting relevant stakeholder recognise criticality investing pipeline vaccines impacts proposal consideration whether positive medicines prevent disease well meeting changing andor negative directors relevant unmet healthcare needs support gsks purpose factors consideration decisionmaking process ahead together strategy ultimately longterm success papersinformation relevant duty normally submitted sustainability gsk time gsk works ceo cfo chief scientific officer chief commercial governments regulators industry partners ensure officer president corporate development president global medicines vaccines reach patients scale bringing affairs glt members andor direct reports value patients need payers input challenge decision awareness directors directors appreciate assessing consequences matters considered directors include longterm decisions environment multifaceted finely balanced invariably involves trade pipeline progression reviews competing stakeholder interests budget planning support decisionmaking directors provided business development deals papersinformation minimum describe longterm proposal consideration comment capital allocation priorities fits withstrengthens otherwise impacts business commercial vaccines general meds specialty reviews strategy budget threeyear plan relevant dividend policy aligned ahead together ambition outlooks esg ambitions including six areas esg focus directors also apprised success risk factors appropriate alternatives considered rationale specific details see ahead together business model disclosures pages b workforce interests people directors understand people core matters considered directors include ahead together ambition helping power purpose culture progress delivering strategy seek create oversee environment gsk outstanding people thrive talent pipeline positive employee experience critical attract retain diversity equity inclusion ambitions motivate best people ethnicity gender pay gap data trends reporting papersinformation relevant duty normally submitted board chief people officer head reward employee engagement practices feedback input challenge decision awareness directors health safety risks pay fairness benefits performance choice workplace environment specific details see culture people diversity equity inclusion engaging people disclosures pages strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions continued c business relationships importance developing groups business relationships suppliers customers others patients placed gsk heart purpose matters considered directors include culture ambitious patients accountable access healthcare impact right thing ethical standards suppliers key stakeholders including governments ngos healthcare authorities healthcare global health health security professionals rd joint venture partners affiliate companies others help us research develop manufacture regulate human rights provide access distribute medicines vaccines modern slavery act statement products patients need product governance key imperative directors custodians responsible business ensure company develops scientific patient engagement monitors relationships partnerships ultimately supplier payment policy serve patients line code conduct suppliers expected meet antibribery corruption thirdparty risk management programme labour rights standards comply standards working third parties policy quality health safety environment explored detail helping foster good specific details see responsible business relations suppliers offer preferential payment terms disclosures pages designated smaller suppliers uk us papersinformation relevant duty normally submitted ceo cfo president global supply chain chief commercial officer chief scientific officer president global affairs andor direct reports input challenge decision awareness directors community environment impact groups operations community environment environment one principal esg focus areas esg papersinformation relevant duty normally submitted embedded strategy fundamental success president global affairs president global supply get ahead disease help ensure longterm success chief people officer andor direct reports input directors recognise responsible business need challenge decision awareness directors consider esg impacts across everything extends matters considered directors include lab patients taking action climate nature community investment donations policy manufacturing sites key role contribution net zero nature positive healthier planet environmental clinical trial diversity planning enrolment sustainability fundamental part global supply chain diversity equity inclusion strategy strategy supplier action turn help gsk achieve environmental goals climate nature embodied environment net zero nature positive goals gsks sustainable procurement programme first full year operation seen suppliers take action carbon environment health safety risks power heat transport water waste sustainable emerging climate environmental legislativeregulatory deforestationfree sourcing materials support reviews environmental sustainability goals specific details see responsible business directors believe company reflective climate naturerelated financial disclosures pages support diversity local communities serve strengthening early stem education investments support longterm diverse talent pool increase positive impact volunteering activities within communities also investing plans improve natural habitats protect biodiversity improve soil water quality near manufacturing sites strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions continued e reputation desire maintain reputation high standards business conduct responsible company gsk seeks force good matters considered directors include ambitious targets positive impact health audit assurance plan people society planet company manages risks effectively takes action things go wrong seeks respect code conduct human rights directors periodically review continuing corporate financial statements appropriateness frameworks underpinning high standards business code conduct including corporate governance regulatory updates range policies standards architecture corporate governance arrangements enterprise risk assessments papersinformation relevant duty normally submitted esg ambitions including six areas esg focus ceo cfo general counsel chief commercial officer emerging esg legislativeregulatory reviews president global affairs chief people officer chief digital technology officer chief compliance officer company internal control risk effectiveness reviews secretary head audit assurance input challenge speak internal investigations decision awareness directors specific details see responsible business corporate governance architecture disclosures pages separate esg performance report f fairness shareholders aim act fairly members group directors seek act fairly interests matters considered directors include shareholders major retail shareholders alike annual general meeting regular constructive dialogue shareholders communicate strategy performance receive investor annual governance meeting views perspectives promote investor confidence ensure capital markets days meet management events continued access capital inform directors ' decisionmaking strategic matters group individual director shareholder meetings directors navigate weigh range shareholder opinion arrive decisions support longterm investor analysts perception surveys success company investor relations plan papersinformation relevant duty normally submitted remuneration policy proposals ceo cfo president global affairs head investor relations company secretary input challenge specific details see shareholder engagement decision awareness directors shareholder information disclosures pages strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions continued key decisions decisionmaking board focuses gsk 's priorities pure biopharma company strong momentum big ambitions whilst balancing interests stakeholders selected examples key decisions taken board january drive purpose momentum strategy include stakeholder groups decision boardcommittee regarded stakeholder interests section duties considered upgraded ambition june gsk articulated shareholders outlook period stakeholders patients growth given gsks improved performance strong momentum focused employees biopharma company board audit risk committee agreed investors board considered update investor expectations appropriate duties upgrades new longterm results longterm ambitions gsk january following thorough review gsk published new upgraded outlooks workforce fairness investing market sales grow adjusted profit shareholders business future delivering cagr basis deliver sales relationships attractive returns billion represents increase billion versus estimate given shareholders marked sales acceleration also provided clear visibility shareholders people key stakeholders building blocks future growth company progressive dividend board recognises importance dividends shareholders december stakeholders policy audit risk committee board considered gsk 's progressive investors patients dividend policy best applied line agreed capital allocation workforce board audit risk priorities group investment strategy growth alongside duties committee considered sustainability dividend longterm results application progressive dividend policy line workforce business capital allocation priorities resulted increased dividend p q q p relationships reputation p full year p expected dividend p fairness shareholders capital allocation board approved updated capital allocation framework priority stakeholders patients framework investing business focussed towards development pipeline employees organic rd portfolio targeted business development investors board considered achieved increased focus roi investments duties updated capital allocation longterm results framework best support ultimately board determined updated framework would continue workforce fairness growth sustainable support investing growth delivering sustainable returns shareholders shareholders business returns shareholders underpinned strong balance sheet also consistent gsk 's strategic relationships priorities supports company 's commitment deliver longterm profitable growth business development board support science committee commercial reviews stakeholders patients late stage assets reviewed many business development opportunities employees science committee year leading concluded transactions included investors considered scientific duties merits business development opportunities licence agreements hansoh pharma two antibodydrug conjugates longterm results relevant late potential across several solid tumour indications support work workforce business stage assets commercial developing cancer treatments relationships reviews prior board 's agreement chongqing zhifei biological products copromote shingrix review approval china significantly extend availability vaccine support patient access acquisitions bellus health aiolos bio expand strengthen gsk 's respiratory portfolio deals considered context potential help gsk deliver transformational medicines patients drive growth accelerating pipeline strategic report governance remuneration financial statements investor information gsk annual report continuous engagement key decisions continued stakeholder groups decision boardcommittee regarded stakeholder interests section duties considered artificial intelligence board reviewed provided feedback strategy integrate stakeholders patients workforce culture responsibly scale ai across business accelerate pipeline amplify employees performance drive productivity duties board considered longterm results approach impact board recognises significant potential ai particularly context workforce adopting ai endto interpreting datasets develop medicines higher probability success business relationships end basis across business however support audit risk committee board also considered associated risks ai described pages board approved establishment ai governance council cochaired general counsel cdto help manage risks across group close attention also paid impact adopting ai workforce including wellbeing gains enabled increased efficiency benefits upskilling building ai capabilities lowcarbon ventolin year corporate responsibility committee endorsed board stakeholders patients strategy reviewed approved plans progress transition metered dose employees inhaler newgeneration lowcarbon inhalers significantly contribute gsk 's investors corporate responsibility carbon reduction targets phase iii trials begin duties committee board successful programme potential reduce greenhouse gas emissions longterm results reviewed plans use inhaler approximately workforce business progression next phase relationships development low carbon ventolin programme board corporate responsibility committee carefully considered needs patients rely ventolin complexity clinical development process well investment required new manufacturing facilities successful programme could lead regulatory submissions supporting health asthma copd patients making significant positive impact gsk 's transition environmentally sustainable future strategic report governance remuneration financial statements investor information gsk annual report board committee reports discussed management steps needed help corporate responsibility committee report leverage leadership position conjunction support expertise science committee included growing dr anne beal business development strategy improving pathogen surveillance capabilities given amr urgent public threat corporate responsibility committee stakeholders increasingly interested gsks approach pleased present report second chair agreed appropriate include amr one corporate responsibility committee committee esg performance rating metrics first time first full year gsk operating global environment biopharma company renewed purpose unite science carbon reduction plan strong case making technology talent get ahead disease together transition lowcarbon inhalers salbutamol essential deliver purpose company needs consider esg rescuereliever medicine gsk 's ventolin salbutamol impacts across everything committee oversees metered dose inhaler mdi used million patients six esg focus areas address material globally use inhaler due high global warming business issues matter stakeholders potential gwp current propellent accounts half worked programme activities year gsks carbon footprint management updated committee committees focus ask management fundamental developing proposed plans transition inhaler questions concerning nextgeneration lowcarbon propellant successful significantly contribute gsk 's carbon reduction targets well company performing making however developing lowcarbon inhaler impact six esg areas embedded companys complex involves clinical nonclinical programmes strategy well establishing new manufacturing facilities supports sustainable performance long examined key considerations behind term growth investing lowcarbon transition programme could improvements identified reduce greenhouse gas emissions inhaler implemented endorsed managements rd mdi transition programme investment case board submitted readouts support undertook number esg performance latest early clinical data received deepdives evaluated supported boards decision november progress phase iii trials trials successful access could lead regulatory submissions committee reviewed progress towards companys aim nature plan review committee received update improve health billion people current performance companys nature positive ensuring access vaccines medicines including goal achieved reducing reaching billion people lowermiddle income countries companys environmental impacts across water waste llmics particular discussed materials biodiversity investing protecting flexible tailored operating model driving access restoring nature committee satisfied nature llmics depending need goals targets remain appropriate industry leading working partners right capabilities also noted standards assessing verifying geographical footprint deliver interventions may companies ' nature approach continued strengthen include donations affordable supply licensing make pleased gsk actively helping shape sure people access vaccines medicines environment source competitive advantage science need based targets network nature sbtn set first science based targets nature framework validate companies investing billion years global health rd nature targets similar regulatory approach pipeline contributing building resilient health systems previously adopted climatebased targets given relative global health security maturity nature positive programme company pleased selected first group companies antimicrobial resistance amr committee reviewed globally go target validation process accredit external amr landscape trends major threat nature targets sbtn methodology finalised globally considered companys holistic innovative additionally gsk also committed disclosing investment approach addressing amr threat arrangements taskforce naturerelated pleased note approach resulted largest financial disclosures framework annual report relevant amr vaccine rd pipeline industry diversity equity inclusion delivery people dei aspiration committee heard chief people officer cpo progress companys workstreams drive increased leadership diversity build diverse talent pipeline foster inclusive culture pleased excellent progress made date discussed challenges opportunities maintain future progress areas strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued clinical trial diversity chief scientific officer cso science committee report outlined approach broadening clinical trial diversity connects patient impact committee strongly agreed companys clinical trials must dr hal dietz accessible inclusive ensure clinical development science committee programmes reflect diversity patient populations impacted disease study including limited pleased present first report chair science age race ethnicity sex gender noted committee committee activities importance reflecting epidemiological profile rather joined committee january succeeded census profile benchmark plan dr jesse goodman chair january appropriate patient representation working community groups build trust awareness participation jesse chair committee since created clinical trials seven years ago made outstanding contribution defining implementing committees role remains esg performance rating important member committee offers vital insights esg performance rating rating helps us integrate esg work delivery strategy allows us measure committees key activities split three verify progress making second year important areas rating used committee continues oversee evolution make sure meets expectations pipeline reviews monitoring gsks pipeline key stakeholders business development undertaking technical reviews discussed management rationale removing one assurance underlying science potential business esg metrics relating access also scrutinised development transactions new amr metric formulated reviewed set scientific deepdives discussing analysing key make sure suitably stretching strategically scientific technology themes drive companys relevant metric joined cpo cso discuss rd strategy status five dei metrics measures needed progress performance metrics pipeline progress separately committee kept informed work committee continued monitor progress led cfo assure data underlying esg metrics rd cso dr tony wood provided regular updates rating overseen audit risk progress across companys four therapeutic areas committee infectious diseases hiv respiratoryimmunology oncology monitored evaluated companys progress particular pipeline highlight launch metrics rating half full year arexvy gsks worldfirst rsv vaccine older adults recommended board publishing final 'on track ' esg year vaccine gained approvals us eu japan performance rating alongside esg disclosures several countries arexvy marked turning point annual report esg performance report efforts reduce burden rsv respiratory virus evaded prevention therapeutic advances details see strategic report years also heralds next wave vaccine innovation esg performance report available gsk gskcom oncology jemperli combination chemotherapy dr anne beal received approval us eu first new frontline corporate responsibility committee chair treatment option decades patients dmmrmsih february primary advanced recurrent endometrial cancer approvals reinforced potential jemperli redefine cancer treatment backbone immunooncology therapy number key regulatory milestones also achieved year shingrix vaccine shingles approved people risk japan positive data first efficacy trial china apretude longacting preventative treatment hiv approved first hiv prevention option europe ojjaaraomjjara approved us eu uk first treatment newly diagnosed previously treated myelofibrosis patients anaemia gonorrhoea vaccine candidate received us fda fasttrack designation strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued committee pleased progress made deepdives innovative science accelerate pipeline year terms investment latestage pipeline drive growth well year committee continued undertake rigorous decisionmaking early stage pipeline scientific deepdives highly innovative maximise potential impact patients technologies currently explored cso team deepdives undertaken included limited rd leadership changes liver disease oligonucleotide strategy continuing accelerate pipeline relies attracting gsks expertise infectious disease immunology human best people fostering culture ambitious genetics driven research chronic hepatitis b patients accountable impact always right new data presented bepirovirsen improved thing committee pleased rd understanding heterogeneous nature hepatitis b leadership changes made year including creating three infections insights bclear btogether phase dedicated research units vaccines infectious diseases iib trials bepirovirsen help gsk progress towards respiratory immunology oncology hiv research comprehensive functional cure people living chronic operates part global specialist hiv company viiv hepatitis b common cause chronic liver disease healthcare deepdive oligonucleotidebased therapeutic changes mean company better focus core strategies positions gsk achieve leadership field therapeutic areas easily identify targets oligonucleotides unique ability address wide range best outcomes patients supporting new genomic targets across many therapeutic areas teams single research technologies organisation means offer enormous potential help patients brings together platform data groups integrate diseases historically difficult treat technology effectively across gsk 's workflow companys collaboration wave life sciences initiated business development transactions brought together waves prismtm platform gsks since demerger cso team worked hard expertise genetics genomics progress eight accelerate business development complement gsks organic preclinical programmes collaboration also granted gsk pipeline called upon committee devote nearly twice exclusive licence waves preclinical programme treat much time meetings critically vet business alpha antitrypsin deficiency complementing gsks development proposals transactions compared last clinicalphase oligonucleotides including bepirovirsen year committee changes transactions reviewed committee year since became chair changes include committees composition work underway bellus health acquisition bellus latestage nominations corporate governance committee refresh biopharmaceutical company working better lives boards scientific expertise including successor dr jesse patients suffering refractory chronic cough rcc goodman due retire board look acquisition provided gsk access camlipixant forward providing update next year potential bestinclass treatment phase iii development dr hal dietz firstline treatment rcc acquisition aligned gsks science committee chair expertise prioritisation respiratory medicines february hansoh pharma two exclusive licence agreements antibodydrug conjugates hs bestinclass potential ovarian endometrial cancer hs promising initial clinical activity lung cancer potential address unmet medical need broader solid tumour indications aiolos bio acquisition aiolos closed february adds aio gsk 's respiratory biologics portfolio aio phase iiready longacting antibody could redefine standard care asthma patients dosing every six months also potential expand company 's reach broader range asthma patients arrowhead pharmaceuticals janssen pharmaceuticals transfer exclusive worldwide rights development commercialisation investigational therapeutic treat chronic hepatitis b gsk plans evaluate drug sequential regimen bepirovirsen gsks investigational antisense oligonucleotide treatment chronic hepatitis b transaction potential redefine treatment paradigm chronic hepatitis b enabling patients achieve functional cure committee confident transactions strong scientific justification look forward seeing develop next years strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued nominations corporate governance board glt diversity committee report committed diversity board committees gsk committed equal opportunities jonathan symonds employees every level company board management seek support encourage diverse nominations corporate governance committee inclusive culture throughout company pleased present fifth report chair effective board includes range balance skills nominations corporate governance committee experience knowledge well diversity ethnicity committee gender sexual orientation professional socialeconomic evolving board pipeline talent background disability age independence individuals prepared challenge collaboratively corporate governance statement discussed mix complemented diversity personal board important board appointment processes attributes including character intellect judgement honesty undertaken recently julie brown new cfo appointed courage september joined board wendy becker new remuneration committee chair designate committee responsible developing measurable appointed joined board second half objectives line relevant regulatory best practice transition process underway enable wendy succeed urs targets monitoring progress part rohner remuneration committee chair close implementing boards diversity policy policy includes agm appointments tailored biopharma gender ethnicity diversity targets applying company board committees minimum seek align policy objectives financial conduct authority fca ftse committee seeks follow best practice searches women leaders review parker review diversity targets makes appointments recommends board regulatory best practice targets ensure agreeing criteria role appropriate diverse consistent public dei aspirations currently interview panel considering comprehensive diverse meet exceed policy objectives regulatory longlist candidates shortlisted candidates interviewed best practice targets shown next assessed chosen criteria due diligence undertaken committee makes final board glt diversity data collection recommendation executive search firms appointed year diversity data gathered directly self according companys procurement policy based identified basis follows expertise relative role board members using questionnaire committee engages search firms signatories voluntary code conduct executive search firms glt members individual election held gsk 's hr database gender diversity best practice diversity data published following section report committee worked number executive search firms december date publication also provided additional consultancy services also continue oversee developing pipeline direct company korn ferry general recruitment executive search reports glt gender ethnically diverse assessment services hrrelated services egon backgrounds zehnder executive search assessment coaching services specific senior executives russell reynolds executive full details gsks representation women ethnically search services diverse leaders covered part diversity global workforce pleasing progress dei committee reviewed potential conflicts interest commitments including gender ethnicity illustrated judged appropriate safeguards esg performance report gskcom good progress conflicts look forward reporting committee 's boosted since introducing dei measure continued work progress evolve board next part annual bonus arrangements executive year 's report directors glt members committee also continues review diverse talent sir jonathan symonds succession pipelines development plans key nominations corporate governance committee chair management roles successors year february undertook deepdive emerging senior talent glt identified people exceeding expectations exceptionally talented potential take glt role future included reviewing strategic approach talent development planning board seeks meet individuals employee receptions board engagement opportunities strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued diversity equity inclusion ethnicity gender female composition current post agm l ethnically diverse l currenthistoric l white l expected target female representation board data gsk annual report published first quarter year current female representation includes one allfemale executive boards running ftse company expected rise may urs rohner retires board board glt diversity objectives least status objective performance board positions held women met two directors one woman senior board position ceo cfo sid andor chair end exceeded ceo cfo glt positions held women exceeded one board director ethnically diverse exceeded two directors one glt member ethnically diverse end met one glt member fca uk listing rule diversity reporting number senior positions board percentage number board percentage ceo cfo sid number executive executive members board chair management management gender identity sex men women specifiedpreferred say ethnic background white british white including minority white groups mixedmultiple ethnic groups asianasian british blackafricancaribbeanblack british ethnic group including arab specifiedpreferred say strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued audit risk committee report technology data privacy ethics rapidly evolving principal risk committees oversight number privacy laws charles bancroft regulations often based eu general data protection audit risk committee regulations increasing number territories around world consequently committee interested pleased present report third chair understand regulatory approaches adopted audit risk committee committee biggest markets including us india china following pages aim share insights activities may affect gsks operations including rd undertaken overseen committee year operations gsks first full year focused global biopharma committee receives regular reports robust company committee reviewed key operational features integrated governance framework gsk operates monitor risks governance platform underpin purpose govern use data generally gsk 's framework made unite science technology talent get ahead disease specialist governance boards include representative together also pleased report progress members relevant internal functions framework committee 's expanded remit oversee review esg data augmented team legal assurance compliance function expertise advise global digital committee continues primary oversight privacy cyber security matters zantac litigation regular legally privileged updates committee discussed tenets new enhanced review related accounting disclosure flexible data privacy model introduced expected communication requirements committee also reviews comprise global privacy principles standardised global current indicative timeline cases report summarise controls meeting eu standards reward would key matters board awareness input decision flexibility adopt different standards local laws continue defend claims brought vigorously based incompatible gsk 's standardised global controls provided science meet gsk 's global privacy principles based work committee done inspected gsk details measures taken year mitigate continues exhibit strong compliance culture risk described consistent tone engagement top runs throughout organisation financial reporting information cyber security principal risk gsk controls framework remains robust required area remains standing agenda item fundamental changes year discussed scheduled meetings science chief digital technology officer cdto chief information security officer ciso chief compliance strategic vaccine partnership china q officer cco present updates information cyber company entered exclusive agreement chongqing security well assessments status associated zhifei biological products ltd zhifei copromote shingrix key risk indicators china support accelerated market penetration innovative vaccine committee scrutinised cdtos skills experience especially related arrangement concluded significant amount cyber security set ciso spent time resources devoted due diligence career building leading technology teams across several arrangement key controls introduced ensure functional areas including cyber security infrastructure compliance expectations would met mitigate risks digital communications healthcare companies also responsible establishing cyber security function committee satisfied ongoing governance haleon plc prior demerger framework monthly reviews monitoring arrangements appropriate experienced compliance cco focuses ensuring consistent cohesive personnel also allocated support partnership approach information cyber security operates across aspects business enterprise risk management chief patient officer new role chief patient officer cco also responsible risk analytics monitoring established beginning committee organisation previous experience creating assessed controls governance arrangements dedicated global risk office combines enterprise risk new role chief patient officer 's primary role provide management reporting activities gsk medical leadership part one overarching gsk asset disease strategy chief patient officer reports chief year committee reviewed progress commercial officer ensure patients treated gsk first full year updated multiyear cyber security plan products benefit robust compliant scientific information plan benchmarked national institute line commitment patients standards technology cyber security framework nist csf end help validate companys also satisfied key areas medical ethics capabilities improved committee examined results safety execution clinical trials clear lines internal nist assessment undertaken jointly escalation chief medical officer enhanced tech audit assurance functions building companys internal control framework independent assessment committee review scheduled business monitoring protocols external nist review specialist independent cyber experts look forward providing update results independent review report next year strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued committee also closely following esg data assurance development finalisation introduction securities committee oversaw creation implementation q exchange commissions sec new cyber security rules rules new dedicated esg data assurance hub effective end satisfied finance organisation formally established consistent company foreign private issuer taken necessary approach governance processes controls governance steps ensure compliance developed improve assurance esg data requirements support companys performance key esg metrics committee assesses adequacy gsk 's insurance risk meanwhile corporate responsibility committee behalf coverage arrangements annually including information board continues oversee esg strategy performance cyber security risk part insurance risk programme assessment reporting review communicate committees recommendation hub 's initial focus environmental data later board implementation processes capabilities develop hub look social also agenda cyber security training glt governance areas soon committee also included cyber security simulation exercises learnings oversee development implementation technology wider workforce discussed mandatory training solutions automate information gathering supplement new joiners regular phishingsimulation exercises level process control standards surround esg performance data highlighted previously relevant cyber security expertise board colleague dr vishal sikka brings deliberations looking forward committee continue review looking strengthen oversight area upcoming regulations might affect future esg running bespoke cyber incident training sessions assurance reporting obligations directors cyberrelated experience included highlighted hubs horizonscanning activities board biographies pages particular committee discussed initial results ongoing impact assessment underway corporate details measures taken year sustainability reporting directive directive could become mitigate risk described partially effective reporting year would artificial intelligence ai rapid advancement ai fully effective consolidated reporting level gsk particular generative technology potential application also aware reporting arrangements reflect across company presents significant opportunities drive published sec climate regulations expected become innovation growth productivity effective financial year accelerate purpose end board reviewing internal control framework opportunities scale use ai potential competitive advantage balanced awareness board recognises obligation present fair balanced lack harmonisation new emerging regulations understandable assessment gsks current position govern ethical responsible use ai new trends prospects accountable evaluating approving may impact risk profile research practices scientific effectiveness gsks internal controls including financial patient engagement data ethics privacy operational compliance controls risk management information cyber security principal risks could processes future impact gsks value chain therefore ensure reliability financial reporting developments monitored closely compliance laws regulations internal management committee control framework comprehensive enterprisewide risk end board approved establishment ai management model supports board identify governance council council cochaired general evaluate manage groups principal emerging risks counsel cdto comprising crossfunctional experts required frcs code framework designed particular council assessing business activities manage risk gsk achieving business objectives current risk environment internal control fitforpurpose framework complemented corporate framework importantly council fully connected key culture speak processes ensures risks data management boards data ethics privacy associated business activities actively information cyber security pleased report effectively controlled line agreed risk appetite council approved implemented suite written believe gsks framework provides reasonable absolute standards controls adopting new ai tools training assurance material misstatement loss tailored developers procurers users ai board mandates groups risk oversight committee auditor shared goal leverage compliance council rocc senior leaders support technology appropriate particularly interested committee overseeing risk management internal control discussed auditor use ai deliver activities also provides business framework risk increased effectiveness efficiency audit management escalation significant risks risk also keen better understand opportunities gsk use management compliance boards rmcbs across scalable aienabled innovations improve speed group promote tone top establish risk performance tracking detection capabilities culture ensure effective oversight internal controls key part staying ahead increasingly sophisticated risk management processes threats group third parties area continue focus strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued principal risk assigned risk owner drawn committee receive regular reports principal risk senior management accountable managing owners compliance aa areas significant risk principal risk oversight glt member includes group related internal controls reports assess setting implementing risk mitigation plans risk owners internal control environment within principal risk area report quarterly respective risk management approach including enhancements strengthen controls progress rocc appropriate board considered reports committee reports annually committee compliance function assists rocc board effectiveness gsks internal controls rmcbs compliance responsible advancing enterprise authority delegated committee wide risk management developing riskbased board conducted robust assessment groups principal ethically sound working practices also actively promotes risks assessment line frcs code included ethical behaviours enabling employees operate line consideration nature extent risk board culture comply applicable laws willing take achieve gsks strategic objectives regulations board via committee also oversaw effectiveness audit assurance aa function provides independent internal control environment risk management assurance senior management board processes across group whole year effectiveness risk management groupwide line approval date annual report agreed assurance plan helps senior management board meet oversight advisory responsibilities detail review groups risk management fulfil gsks strategic objectives build trust patients approach discussed risk management section stakeholders aa dual reporting line cfo strategic report pages committee management principal risk explained principal risks uncertainties pages groups viability discussed strategic report strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued significant issues relating financial statements considering gsks quarterly financial results announcements financial results annual report committee reviewed significant issues management judgements determining results reviewed management papers setting key areas risk actions taken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table summary financial outcomes appropriate committee external auditor discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly yearend financial statements reviews current forecast net debt positions various financing facilities options available group committee also considered managements review impacts current economic environment climate change following consideration assessments included stress testing viability scenarios sources liquidity funding forecasts estimates committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition rebates rar accruals revenue accruals customer returns rebates rar accrual us commercial operations billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us commercial operations determining level accrual necessary set critical accounting policies pages provisions legal matters including committee received detailed reports actual potential litigation investigations groups internal external legal counsel including zantac litigation together commercial practices number detailed updates investigations groups commercial practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion see note financial statements provisions details provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment losses million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement necessary relation viiv healthcare increase liability pay contingent consideration primarily result updated exchange rate assumptions well increases sales forecasts unwind discount cash payments nearly billion year december group 's balance sheet included contingent consideration liability billion relation viiv healthcare see note financial statements contingent consideration liabilities details viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued effectiveness quality external audit auditors reappointment process external auditor committee committed making sure gsk receives external auditor appointment highquality effective external audit evaluating last tender maydecember deloittes performance prior making recommendation reappointment early transition year committee reviewed effectiveness performance first shareholder approval current may criteria agreed management auditor beginning first audited annual report fyear ending december detailed criteria used judge deloitte 's effectiveness new lead audit engagement partner external auditor available gskcom based audit approach strategy ensuring highquality next audit tender required take effect regulations independent audit effective partnership value money committee monitors engagements external contractual similar obligations restricting stakeholders relevant areas oversight including groups choice external auditor frc securities exchange commission audit partner rotation sought ensure deloitte would deliver smooth thorough efficiently executed audit external auditor required rotate audit engagement considered partner gsk every five years overall quality audit previous audit partner stepped march independence deloitte audit gsks financial statements concluded whether deloitte showed appropriate level challenge robust review process committee together scepticism work former cfo new audit partner selected committee approved appointment effect deloittes length tenure taken account start financial year assessing independence objectivity given commenced role auditor however committee satisfied deloitte managed orderly handover consider effectively assumed role auditor new audit engagement partner resulted committee also considered feedback external seamless transition maintenance high levels audit audit survey committee members quality effectiveness throughout reporting year financial management team corporate business unit level survey covered audit tender effectiveness auditors challenge committee considers company complied mandatory audit processes audit integrity deloitte committee responsibility provisions competition transparency reporting management markets authority statutory audit services order committee auditor 's effective use technology deloitte continues maintain independence clarity auditors communications ways working objectivity committee remains satisfied quality audit teams leadership performance gsk intend tender external skills experience audit team auditor contract end current required period years identified considers best committee chair regularly meet independently interests shareholders committee mindful audit partner also meet auditor privately appointments new cfo gsk audit partner end committee meeting discuss progress deloitte financial year helpful appropriate mitigating risks overfamiliarity company auditor reviewed feedback noted areas improvement implemented audit team committee satisfied effectiveness auditor external audit process auditors independence qualifications objectivity expertise resources agreed recommend board deloitte 's reappointment next agm free influence third party strategic report governance remuneration financial statements investor information gsk annual report board committee reports continued nonaudit services audit services comparison management operates presumption accountancy firms ordinarily provide nonaudit services gsk however external auditors skills experience make suitable supplier nonaudit support auditrelated matters tax services may used best interests company line gsks nonaudit services policy committee ensures auditor objectivity independence safeguarded reviewing preapproving external auditors provision services company policy complies frcs revised ethical standard sarbanesoxley act observes following core l audit services policy features engaging external auditor nonaudit services l assurance services gsk nonaudit services policy key features fees payable deloitte nonaudit services relating consumer healthcare demerger million process nonaudit services put million set annual report competitive tender financial services providers annual report respectively fee line groups procurement process unless million paid auditor respect gsk pension schemes skills experience external auditor make suitable supplier fees paid company 's auditor associates safeguards adequate safeguards established set details given note objectivity independence group audit threatened compromised financial statements operating profit fee cap total fee payable nonaudit services committee considered level nonaudit services exceed annual audit fee except special incurred part annual review deloittes independence circumstances would clear advantage set previous satisfied auditor auditor undertaking additional work continued independent exercised objectivity prohibitions gsks policy includes whitelist permitted nonaudit throughout services line relevant regulations service list prohibited fair balanced understandable assessment preapproval nonaudit services require preapproval set need annual report fair balanced table ensure services approved understandable one key compliance requirements consistent gsks nonaudit policy permissible companys financial statements ensure gsks annual services process ensures services fall within report meets requirement wellestablished scope services permitted preapproved documented process governing coordination review committee represent delegation groupwide contributions publication runs parallel authority preapproval process followed external auditor value preapprover committee received summary managements approach committee chair cfo gsks annual report ensure met requirements frcs code enabled committee board group financial controller confirm gsks annual report whole fair balanced understandable provides necessary designate group information shareholders assess companys position financial controller performance business model strategy code conduct reporting lines number wellestablished policies including new code conduct available gskcom together details confidential speak lines reporting investigating unlawful conduct charles bancroft audit risk committee chair february strategic report governance remuneration financial statements investor information gsk annual report remuneration report committee chair 's annual statement dear shareholder longterm incentive lti awards behalf remuneration committee pleased grant performance share plan present remuneration report includes psp award vested based performance end annual statement explaining committees work year award vested three four measures annual report remuneration summary full vesting pipeline progress measure remuneration policy approved shareholders almost full vesting innovation sales measure agm available pages respectively cash flow measure also vested annual report gskcom full context remuneration outcomes remain disappointed yet achieved vesting outlined earlier report gsk delivered strong relative tsr measure part reflects adverse performance sales adjusted operating profit share price reaction zantac litigation period adjusted eps growing doubledigit levels year also recognise relative concerns excluding covid solutions also strong pipeline strength companys pipeline confident progress four major product approvals including progress making develop portfolio together world 's first rsv vaccine arexvy improving longerterm outlooks growth increasingly reflected gsks valuation overall company delivering step change performance commitments previously made summary incentive outcomes shareholders following review contextual factors including previous payouts committee believes outcomes second year operation company 's new appropriately reflect performance round remuneration policy fundamental part considered experience stakeholders including architecture gsk postseparation ensure build shareholders employees performance culture generate sustained delivery shareholder value incentive awards relation made accordance remuneration policy also confirm policy better links executive remuneration delivery following careful review committee deem outperformance annual bonus opportunity necessary exercise discretion significantly reduced target performance increased exceptional outperformance new remuneration policy implementation scheme increase bonus opportunity annual bonus lti increase potential cash reward executives incremental award delivered form shares deferred committee determined changes made three years bonus lti measures total sales growth adjusted operating profit growth targets exclude annual bonus commercial benefit covid solutions delivery committee reviewed bonus annual bonus measures continue based outcomes ceo cfo annual total sales growth terms two financial measures company delivered sales growth adjusted operating profit growth annual adjusted operating profit growth excluding covid solutions significantly higher guidance company provided personal performance strategic operational start year market expectations strongly measures supports delivery gsks growth outlooks period esg diversity equity inclusion dei psp measures remain strong performance led overall payout financial elements bonus salary relative tsr targets set consideration analyst consensus total sales growth three years committee comfortable payout representative strong performance adjusted operating profit growth three years committee also reviewed performance non pipeline progress financial measures previously disclosed together esg environment composite scorecard executives delivery specific individual strategic operational measures performance targets also calibrated consider number internal external reference points particular performance combined overall payout analyst consensus used challenge metrics maximum salary ceo input science corporate responsibility salary delivered deferred shares committees relevant committee therefore salary cfo salary proration satisfied targets set suitably stretching period employed salary delivered deferred shares salary committee noted increase agreed wider workforce uk careful consideration including review market ceo cfos competitive positioning agreed receive salary increases strategic report governance remuneration financial statements investor information gsk annual report committee chair 's annual statement continued workforce fairness thank setting executive pay important committee would like take opportunity thank fellow good understanding groups wider workforce committee members shareholders support approach pay emphasis fairness equity engagement tenure committee chair end annual basis meet senior human welcome feedback look forward receiving resources leaders across company understand support report annual general meeting perspectives pay gsks remuneration may arrangements wider workforce globally year fifth annual meeting held details important urs rohner check given remuneration committee chair february board changes announced september julie brown joined board may cfo point iain mackay stepped board details joining leaving arrangements transition described last years report remuneration committee chair succession finally retiring nonexecutive director gsk agm therefore final report chair committee delighted welcome wendy becker joined committee october since wendy working smooth transition handover succeeds committee chair may wealth experience chairing remuneration committees looking forward chairing committee leading policy review committee planning undertake review effectiveness remuneration arrangements advance scheduled policy renewal agm wendy jonathan symonds chair looking forward engaging investors ensure clear perspectives work update remuneration policy strategic report governance remuneration financial statements investor information gsk annual report remuneration glance total remuneration emma walmsley ceo pay performance annual bonus outcome financial measures target delivered total sales growth adjusted operating profit growth overall strategic operational esg nonfinancial measures measures dei emma walmsley exceeded met full julie brown exceeded met full annual bonus delivery ceo cfo overall bonus overall bonus salary salary julie brown cfo may l shares deferred years service employment l cash april psp outcome adjusted free relative tsr cash flow overall vesting see details cfo joining arrangements l fixed pay salary benefits pensions pipeline progress innovation sales l performance pay annual bonus vested ltis l vested l lapsed remuneration implementation base salary increase uk employees executive directors benefits pensions changes pay performance annual ltis bonus lti measures remain follows alignment strategy bonus psp total sales growth line sales growth ambitions adjusted operating profit growth line adjusted operating profit growth ambitions strategic operational individual accountability delivery strategy public ambitions emphasis innovation rewards acceleration strengthening pipeline pipeline relative total shareholder return alignment shareholders nature climate ambitions esg ambitions dei priorities excluding covid solutions strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration total remuneration audited fixed pay pay performance salary lti awards total pension annual bonus psp award vesting remuneration benefits read pages pages following sections provide details element total remuneration committee implemented companys shareholderapproved remuneration policy year terms fixed performance pay total remuneration audited emma walmsley ceo julie brown cfo iain mackay former cfo may may fixed pay salary benefits pension total fixed pay pay performance annual bonus vesting psp lti awards total pay performance total remuneration represents sum paid julie brown cfo part buyout arrangements relation leaving burberry set full annual report setting buyout arrangements staged two year period committee sought ensure compensated likeforlike basis far possible fulfilment arrangements cfo purchased shares june deferred annual bonus plan dabp mandatory dabp bonus deferrals set annual bonus bonus payment iain mackay represents bonus earned respect period january may details bonus paid respect remainder year found leaving directors section bonus payment julie brown represents bonus earned respect period may december bonus full period employment shown psp vesting total remuneration figure ceo included vesting topup award made may vest may final actual value received updated bringing total value million previously reported million psp vesting ceo figure valued based vesting prices february share price february date grant vested amounts executive directors value attributable share price appreciation performance period committee exercise discretion relation vesting awards share price changes psp vesting value former cfo unreduced illustrative amount award vest january accordance terms executive senior management recoupment policy recoupment policy award remain subject twoyear holding period started original vesting date award february actual value received updated annual report details former cfos leaving arrangements set leaving directors section ceo cfo contribute maximum month share save plan buy shares share reward plan respectively details hm revenue customs hmrc approved allemployee plans set malus clawback committee may specific circumstances line stated principles apply malusclawback determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect ceo cfo former cfo strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued total remuneration audited continued fixed pay audited salary committee aware sensitivity amongst stakeholders levels pay setting reviewing salary considered average increases awarded employees executive directors multiplier effect increases base salaries total remuneration opportunity committee considered wider economic context individual performance market positioning increases awarded table sets base salaries increases agreed executive directors compared increases uk workforce salary change effective date uk employees april emma walmsley january julie brown may julie brown 's salary announcement appointment september set line predecessor given extensive experience cfo salary upon joining increased reflect increases awarded uk employees ceo early benefits benefits table provides analysis total benefits grossed tax received executive directors emma walmsley uk remuneration reporting regulations require benefits available employees company add executive directors total benefits items deemed tax authorities taxable businessrelated services benefit include employee benefits well total benefits businessrelated services provided employees assist enable carry role tax authority julie brown deemed taxable benefit individual benefits available employees business expenses company meets tax businessrelated services arises therefore items shown grossed tax total benefits pensions january pension arrangements executive directors aligned wider workforce received gsk pension contributions cash supplements base salary matching contributions first salary march first salary rest table shows breakdown pension values included total remuneration calculated set uk large mediumsized companies groups accounts reports regulations amended remuneration regulations emma walmsley julie brown may pension remuneration values uk defined contribution employer cash contributions pension strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited annual bonus adjusted strategic total sales esg operating profit operational growth dei annual bonus growth measures l financial measures l nonfinancial measures annual bonus performance following table shows annual bonuses earned compared bonus opportunity bonus bonus opportunity outcome paid shares target maximum salary maximum dabp bonus salary salary bonus salary cash award emma walmsley julie brown details mandatory deferral executive directors dabp bonus set see details iain mackay 's bonus arrangements following retirement company julie brown 's bonus prorated reflect period employed table provides details bonus may became executive director financial measures total sales growth adjusted operating profit growth targets set following consideration analyst consensus well internal budgets threshold maximum performance target growth respectively total sales growth adjusted operating profit growth targets outcomes purposes annual bonus calculation based cer excluding commercial benefit covid solutions overview performance financial performance measures gsk delivered strong performance sales adjusted operating profit adjusted eps growing double digit levels year excluding covid solutions significantly higher guidance provided start year strongly supports delivery gsks growth outlooks period delivered fullyear reported group sales billion aer cer excluding covid solutions vaccines growth aer cer arexvy sales billion since launch q specialty growth aer cer excluding covid solutions adjusted group operating profit cer growth excluding covid solutions driven higher sales supported prioritised increased investment rd new product launches adjusted eps p aer cer excluding covid solutions ahead updated guidance strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued strategic operational measures committee received considered performance assessment report executive director showing extent achievement individual personal strategic operational measures agreed committee support delivery strategic commitments financial elements annual bonus committee satisfied scale executive directors achievements year excellent achievements focus pipeline commercial execution continued evolution culture achievement performance assessment emma walmsley innovation delivered pipeline progression target four major product approvals rsv prevention hiv exceeded prevention oncology delivered innovation sales successful launches including arexvy new products launched since contributed billion sales upgraded longterm outlooks sales profits outlooks sales adjusted operating profit growth cagr excluding covid solutions sales outlook increased billion cer using average rates performance delivered financial plan exceeding guidance set sales excluding covid exceeded solutions adjusted operating profit positive impact excluding covid solutions adjusted eps grew positive impact excluding covid solutions cer group sales billion trust sector leader sp global corporate sustainability assessment exceeded access global health million people lower income countries reached access partnerships malaria vaccine roll countries global health pipeline assets progressing environmental sustainability progress kpis including progression low carbon ventolin inhaler programme phase iii development diversity equity inclusion aspirations gender diversity uk us ethnicity aspirations vp achieved culture annual survey employee engagement reported increase exceeded committee determined ceo clearly exceeded individual objectives maximum attributed overall bonus julie brown demonstrate deep review pipeline forecasting support upgrading longterm outlooks beyond exceeded financial design new investor engagement programme including development investor relations leadership roadmap communication longterm outlooks cost discipline deep review capital allocation pipeline value unlocks support investment organic rd exceeded cash flow business development maximise returns shareholders management initiated work drive pl efficiency focus sga operating margin improvement demonstrate successfully integrated gsk established strong partnership working ceo members met strong glt notable output support rd commercial organisations culture leadership committee determined cfo clearly met individual objectives maximum attributed overall bonus esg dei aspirations emma walmsley julie brown payout level enterprise targets met directorate targets met nil enterprise targets met directorate targets personal directorate targets met target enterprise directorate targets met maximum outcome achieved maximum payout maximum payout overview performance dei aspirations esg dei measure reinforces delivery commitment create diverse equitable inclusive workplace broader dei commitments set part effort meet aspirational targets diversity senior leadership committee agreed interim annual aspirational targets including global gender representation us uk race ethnicity representation aspirations enterprise level ceo directorate level cfo internal governance team audited performance aspirations committee delivery interim aspirations met year end gsk enterprise performance gender representation us ethnicity uk ethnicity vp employee population julie brown 's directorate also met aspirations strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued vesting psp lti awards pipeline innovation adjusted free relative total progress sales cash flow shareholder return total vested lti overview performance line committees agreed principles actual performance measure carefully reviewed adjustments made appropriate ensures vesting outcome reflects genuine underlying business performance delivered line culture values committee deem necessary exercise discretion relation vesting awards due share price changes overall psp awards vested targets set performance period significant progress achieved accelerating delivery pipeline near full vesting achieved innovation sales reflecting increases performance trelegy nucala dovato benlysta period strong performance evidenced full vesting adjusted free cash flow pipeline progress elements however disappointingly nilvesting relative tsr percentage award values vesting rounded whole numbers presentational purposes psp outcomes outcome vesting level performance measures relative weighting performance targets outcome maximum award pipeline progress targets strengthening pipeline progression high quality assets pivotal trials achievement regulatory approvals major markets points allocated achievement two equally weighted elements threshold maximum measure pivotal trial starts points major regulatory approval milestones points innovation sales recognises importance launching new products successfully billion driving performance key commercial success measure aggregates threeyear sales new innovative products launched three year performance period preceding two years ie innovation sales billion vesting maximum threshold adjusted free line companys agreed principles afcf figures included billion cash flow afcf adjustments number material distorting items including legal settlements exchange rate movements special pension contributions revised target billion vesting maximum threshold revised target adjusted since annual report noted relative tsr tsr ranking within comparator ranked th group companies vesting maximum st nd rd th th threshold median th th median vesting threshold falls two companies relative tsr comparator group set total vesting respect psp awards afcf measure target threshold associated vesting scales psp awards adjusted since restated annual report net overall impact increase revised target billion billion psp awards adjustment takes account revised timings restructuring payments linked future ready programme strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued psp vesting value vested shares granted vested emma walmsley number shares vested value represented vesting includes dividend reinvestments performance period based vesting price february psp award dr hal barron vested adjusted time worked performance period including dividend reinvestments shares vested value million shares sold tax held two years terms recoupment policy committee aware guidance investor bodies regarding potential executive benefit arising share award grants around time stock market fall onset covid march remuneration policy contains sufficient flexibility reduce vesting awards required reduction required respect awards granted february making determination committee considered share price time february award final quarter time previous award february whilst upward downward movements gsk 's share price period taking points consideration committee satisfied risk windfall gains lti grants dabp awards respect deferral bonus psp awards set dabp awards psp awards face value face value total number award award level number award bonus deferred shares base salary shares emma walmsley julie brown iain mackay face value dabp awards calculated based share price closing price february day grant nilcost options executive directors performance conditions attached dabp awards reflect mandatory threeyear deferrals respect annual bonus face values psp awards calculated based share price emma walmsley julie brown closing price february april respectively days respective grants unreduced psp award julie brown granted conjunction joining arrangements detailed annual report conditional shares based performance measures iain mackay receive psp award due retirement company performance period psp awards january december awards vest maximum threshold performance please see directors remuneration report details measures targets awards historical vesting lti plans following table summarises lti vesting performance measure gsk last ten years relative tsr adjusted free cash flow innovation sales previously rd new product pipeline progress business diversification total vested allemployee share plans executive directors may participate hmrc approved allemployee share plans namely companys share save share reward plans along wider uk workforce participants share save plan may save month three years option buy gsk shares discount share price start savings contract participants share reward plan contribute month purchase gsk shares company matches oneforone basis malus clawback policy existing policy malus clawback provided remuneration policy report annual report available gskcom committee reviews discloses whether recoupment committee exercised malus clawback disclosure made matter subject public reports misconduct fully resolved legally permissible disclose made without unduly prejudicing company therefore shareholders line disclosure guidelines matters report administrative amendment malus clawback section remuneration policy described annual report approved shareholders agm committee adopted additional clawback policy accordance us securities exchange commission 's new clawback rules effective november details existing policies recruitment remuneration loss office termination payments please refer remuneration policy report pages annual report available gskcom strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued pay performance annual bonus performance measures changes operation annual bonus plan full details policy please refer pages annual report bonus opportunity salary target maximum emma walmsley julie brown equivalent first salary deferred portion excess deferred full weighting performance measures weighting performance measures adjusted operating profit strategic operational esg diversity equity total sales growth growth measures inclusion emma walmsley julie brown inevitably targets linked directly financial strategic plan commercially sensitive committee consider appropriate disclose annual bonus targets year may result competitive harm however details performance targets usual disclosed retrospective basis annual report lti awards table provides details mandatory deferral dabp annual bonus payments associated awards granted shares awarded performance conditions must held three years regardless continued employment awards granted psp dabp awards psp awards bonus deferred number face value face value award shares salary shares award base salary number shares emma walmsley julie brown strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued pay performance audited continued lti performance measures measures weightings awards remain unchanged used awards measure weighting innovation pipeline progress performance relative tsr total sales growth adjusted operating profit growth trust esg environment innovation performance pipeline progress measure seeks reward acceleration relative tsr continue measured gsks strengthening pipeline based two equally global pharmaceutical comparator group see weighted elements key assets indications measured total sales growth adjusted operating profit growth threeyear performance period measures recognise importance commercial ambitions targets total sales growth adjusted points allocated successful assets submeasure operating profit growth commercially sensitive based upon forecast commercial value peak year sales time grant end performance period submeasures award vest follows trust pivotal trial starts esg environment measure based climate nature goals see targets award focuses mainly phase iii registrational trial starts may focus nature goals relating water waste materials also include phase ii starts reduction biodiversity impact climate goals incorporate scope emission reduction targets carbon performance level points payout offsetting industrialisation availability green threshold nil ventolin threshold achieve vesting targets two measures achieved end one climate one nature maximum vesting targets four measures achieved end major regulatory approvals vesting six measures must met targets performance level points payout vesting two six measures least one threshold nil climate one nature must exceeded threshold targets maximum pipeline progress measure commercially sensitive time grant end performance period provide disclosure achieved strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors pay wider setting internal context comparison remuneration structure employees executive directors element wider workforce executive director pay salary market competitiveness base salaries across company assessed local market level competitiveness roles kept regular review increases may also made reflect change scope individuals role responsibilities experience executive directors following performance review increases base salaries considered line market practice average increase wider employee population comparator tools agreeing increases executive directors committee mindful multiplier effect individuals total remuneration benefits company seeks provide appropriate benefits pensions package aligned competitive pensions market practices countries company operates employees executive directors based annual exception sales force participate separate arrangements wider workforce bonus participates plan based performance four business financial measures structured reflect priorities specific business area plan designed reward employees collective contribution business achievement separate mechanisms place recognise outstanding individual performance address performance executive directors participate plan follows bonus salary paid cash shares deferred three years bonus earned excess maximum salary would delivered fully shares deferred three years clawback andor malus provisions apply lti plans senior vice president svp vice president vp employees participate performance share plan executive directors clawback andor malus provisions apply svp vp employees together directors managers glt receive annual share value plan awards restricted shares share ukbased employees participate hmrc approved share save share reward employee share ownership plans dilution limits awards made plans incorporate dilution limits consistent guidelines published investment association limits rolling tenyear period plans rolling tenyear period executive share plans granted senior executives estimated dilution existing awards made last ten years december follows gsk employee share plans executive share plans strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors ' pay wider setting continued ceo wider employee pay ratio lower quartile median upper quartile financial year p p p gsk continues use option methodology robust statistically accurate way calculate three ratios options available remuneration regulations pay ratio higher influenced company 's strong performance delivered increased bonus ceo vest also much higher previous years due improvement gsk share price award granted vested pay ratios calculated using actual earnings ceo uk employees ceos total single figure remuneration million million detailed total remuneration uk fulltime equivalent employees december calculated line single figure methodology reflects actual earnings received excluding business expenses used produce percentile calculation option remuneration regulations business expenses excluded reimbursed employees sufficiently substantial value significantly impact ratios table shows salary total pay benefits percentiles p p p salary total pay benefits committee believes median pay ratio consistent companys pay reward progression policies base salaries employees including executive directors set reference range factors including market practice experience performance role relative importance spend pay table shows total employee pay dividends paid figures table reflecting payments made shareholders year impact movements exchange rates set pages however cash dividends change declared respect million million decrease please see note financial total employee pay statements details dividends paid year total employee pay based employees average number people employed see note financial statements details last share repurchase made company strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors ' pay wider setting continued external context target ceo total remuneration positioning comparator groups reviewing ceos remuneration committees european crossindustry comparator group primary comparator group european crossindustry committee 's primary comparator group ceo cfo comparator group also references pay global global pharmaceutical comparator group secondary pharmaceutical comparator group group ceo also used measure relative tsr performance european crossindustry comparator group roche holding ag linde deutsche telekom novartis sanofi kering lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adidas loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser remuneration includes salary expected value incentives based global pharmaceutical comparator group committees agreed benchmarking methodology france us sanofi abbvie historic ceo remuneration amgen switzerland bristolmyers squibb emma walmsley novartis eli lilly roche holdings johnson johnson merck co reo mta ul n eration u ak strazeneca pfizer maximum abbvie amgen included remuneration benchmarking annual bonus included relative tsr performance comparator group award vesting lti tsr performance graph awards following graph sets performance company sir andrew witty relative ftse index global pharmaceutical performance comparator group tenyear period total remuneration december indices selected comparison purposes reflect primary index gsk maximum constituent industry gsk operates annual bonus award vesting lti awards emma walmsleys total remuneration includes pay period january march became ceo sir andrew witty received prorata payment lieu variable bonus opportunity accordance remuneration policy psp dabp awards sir andrew witty granted vest april accordance terms recoupment policy strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued remuneration governance committee role membership principal proxy advisory firms also consulted regularly details available incorporated also invited annual governance meeting reference report chair ceo chief people sent engagement letters committee company officer head reward group financial controller chairs company secretary assisted committee year agm voting adviser committee details voting levels respect remuneration independent willis towers watson plc wtw arrangements set adviser wtw member remuneration consultants votes group operates code conduct executive remuneration consulting uk total votes total votes total votes withheld cast billion million accessed wwwremunerationconsultantsgroupcom agm appointed december following tender process remuneration report advice provided committee comfortable wtw amendments engagement partner team provides remuneration policy remuneration advice committee agm connections company directors may impair independence remuneration report fees charged time materials basis remuneration policy one month conflicts wtw provides market data hr consulting interest services company committee regularly reviews arrangements potential conflicts appropriate ensures safeguards place statement consideration shareholder views committee engages regular dialogue shareholders holds regular meetings gsks largest investors discuss take feedback remuneration policy practices governance matters ongoing engagement details extensive consultation committee company chairs regarding remuneration matters prior agm vote continuing engagement shareholders afterwards set shareholder engagement investor share capital events dates participation represented meetings held prior january april investors agm meetings held may investors agm february publication annual report annual governance meeting invitations november investors attendance december investors strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued remuneration governance continued committee focus items discussed remuneration policy prepared agreed proposed administrative amendments remuneration policy continued engagement shareholders reviewed considered shareholder proxy advisor feedback fixed pay considered executive director glt performance benchmarking competitiveness gsk comparator groups reviewed glt company secretary salary recommendations executive director salary review recommendations reviewed company chairs fees pay performance annual bonus executive director glt bonus recommendations set executive directors bonus objectives lti plans considered lti performance outcomes award vesting ceo executive directors glt confirmed lti grants executive directors glt governance remuneration considerations committee programme areas focus committee evaluation annual review terms reference approved remuneration report confirmed group budget remuneration purposes considered agm remuneration report feedback external remuneration environment performance target disclosure incentive plans agreed committee 's key messages annual governance meeting committee chair consulted employee representatives wider workforce pay practices pay generally leaving directors support cfo succession transition process announced september set annual report stepping board iain mackay continued receive remuneration left gsk december line current remuneration policy base salary increased whilst serving executive director may received total benefits comprising benefits available employees businessrelated services value pension may totalled comprising uk defined contribution employer cash contributions see explanation employee end remained eligible receive bonus executive bonus plan based delivery measures described reviewed committee determined total year comprising cash delivered gsk shares deferred three years dabp plan bonus value respect period served executive director eligible therefore receive psp awards given due leave gsk vesting existing lti awards accordance recoupment policy regard psp award ordinary shares vest january award shares inclusive dividends vest accordance performance described illustrative unreduced value award disclosed single figure table value time vesting updated annual report since executive service contract ended december required satisfy postemployment share ownership requirement set payments audited past directors loss office payments made past directors loss office payments made strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued nonexecutive directors fees company aims provide chair nonexecutive directors fees competitive paid companies equivalent size complexity subject limits contained articles association nonexecutive directors fees nonexecutive directors fees applied set table together fees per annum chair fee standard ned annual fee supplemental fees chair audit risk committee senior independent director scientific medical experts chairs remuneration corporate responsibility science committees appointed workforce engagement director science committee members undertaking significant additional responsibilities behalf gsk following review approval committee end determined chair 's fee increased effect january chair ceo also recommended board approve increase nonexecutive directors ' standard annual fee effect january line increase awarded wider uk workforce total fees audited audited table sets value fees benefits received nonexecutive directors form cash shares ads nonexecutive directors ' fees paid currency sterling converted using average exchange rate reviewed time time average exchange rates updated nonexecutive directors fees converted us dollars using exchange rate benefits comprise grossed cash value travel subsistence costs incurred normal course business relation attendance board committee meetings fulfilling role fixed fees fixed fees nonexecutive directors emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay sir jonathan symonds elizabeth anderson charles bancroft dr hal barron dr anne beal wendy becker dr hal dietz dr jesse goodman urs rohner dr vishal sikka nonexecutive director section remuneration policy agm shareholders approved administrative amendment nonexecutive director section remuneration policy allow notional shares ads previously allocated nonexecutive director plan delivered chair nonexecutive directors time committee board considered appropriate applicable tax withholding chair mr rohner 's notional shares released agm expected nonexecutive directors holdings released following company 's agm may company expect make significant changes fee structure chair nonexecutive directors remainder remuneration policy period strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors interests shares audited executive directors interests shares interests executive directors company office persons closely associated pca shown table december date retirement unvested share plan interests subject total directors interests beneficial interests subject performance performance december february date retirement shares shares options shares emma walmsley julie brown iain mackay none directors hold vested unexercised options total directors interests includes beneficial interests unvested share plan interests subject performance emma walmsley balance february includes shares awarded psp dabp vested february less sold satisfy tax liabilities vested amounts relevant shares awarded psp dabp iain mackay vest january accordance terms recoupment policy executive directors shareholdings sor outlined beneficial interests includes shares held executive directors pcas emma walmsley julie brown includes shares shares respectively purchased share reward plan unvested shares subject performance represent psp shares vested subject additional twoyear holding period unvested options subject performance represent bonus deferrals dabp awarded nilcost options described note figure excludes options options held emma walmsley julie brown respectively share save plan unvested shares subject performance represent unvested psp awards iain mackay retired board may dabp table shows bonus deferrals subsequent reinvestment dividends dabp amounts represent gross share balances prior sale shares satisfy tax liabilities vesting december dabp bonus deferrals february date retirement january emma walmsley julie brown iain mackay following table sets details nilcost options exercised executive directors number shares date market price gain exercise date grant option exercise grant price exercise emma walmsley iain mackay nilcost options awarded dabp represent bonus deferred executive director recorded remuneration annual bonus total remuneration table number shares option includes initial award together reinvested dividends accrued date exercise executive directors ' share ownership requirements sor audited align interests executive directors shareholders required build maintain significant holdings shares gsk time executive directors required continue satisfy sor holding sor first months leaving gsk less sor months thereafter shares subject performance conditions excluded sor calculation end performance period vested shares included extent performance conditions met value holdings calculated posttax basis iain mackay exceeded sor date retirement board continues maintain sor value holdings salary sor february december salary emma walmsley julie brown strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors interest shares audited continued nonexecutive directors interests shares interests nonexecutive directors office persons closely associated pca shown table prior ned share allocation plan total directors interests number sharesads beneficial dividends elected ned sor interests reinvested allocated february february december december december january year end year shares sir jonathan symonds met wendy becker progress urs rohner met ads elizabeth anderson progress charles bancroft met dr hal barron met dr anne beal progress dr hal dietz progress dr jesse goodman met vishal sikka met ned share ownership requirements since july company operated minimum nonexecutive director share ownership requirement ned sor least one times standard ned annual fee chairs fee maintained retirement board chair nonexecutive directors transitioned previous ned share allocation plan ned plan purchasing shares adss market net fees spend minimum net fees purchasing gsk shares adss market total directors interests include beneficial interests notional sharesads received part fees previously operated ned plan dividends received notional sharesads prior ned plan year january converted notional sharesads january dr hal barron includes psp award vested february see total interests dr barron reduced since december following vesting psp dabp awards granted former executive capacity cso details vesting level psp shown dabp vest relates deferral shares annual bonus addition vesting shares sold meet executive 's tax liabilities details transition cso non executive director given annual report beneficial interests includes sharesads held nonexecutive directors pcas notional sharesads allocated year ned plan relates dividends reinvested year strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued percentage change remuneration directors percentage change percentage change percentage change percentage change salary salary salary salary fees benefits bonus fees benefits bonus fees benefits bonus fees benefits bonus uk employees executive directors emma walmsley julie brown nonexecutive directors sir jonathan symonds elizabeth mckee anderson charles bancroft dr hal barron dr anne beal wendy becker dr hal dietz dr jesse goodman urs rohner dr vishal sikka retired executive directors iain mackay table provided accordance schedule companies directors remuneration policy directors remuneration report regulations uk employee population considered relevant comparison closely reflects economic environment encountered executive directors percentage changes calculated based total remuneration table executive directors total fees table nonexecutive directors information executive directors salary benefits found dr hal barron transitioned nonexecutive director role august fees nonexecutive directors include fees received cash form shares ads directors senior management information provided compensation interests directors senior management group group purpose group defined executive nonexecutive directors members glt company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various lti plans set table align interests senior management shareholders executive directors glt members required build maintain significant holdings shares gsk time glt members required hold shares equivalent multiple two times base salary must continue satisfy share ownership requirements minimum months leaving gsk awards dividend reinvestment awards awarded shares ads shares ads performance share plan deferred investment awards share value plan notional shares ads executive directors eligible receive deferred investment awards participate share value plan strategic report governance remuneration financial statements investor information gsk annual report annual report remuneration continued directors senior management continued february group pcas following interests shares ads company interests awarded various lti plans described note financial statements employee share schemes pages interests february shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awards share value plan notional shares executive directors eligible receive deferred investment awards participate share value plan executive directors external appointments company recognises executive directors may invited become nonexecutive directors companies appointments broaden knowledge experience benefit company executive directors entitled retain fees received appointments emma walmsley independent nonexecutive director microsoft corporation year whilst iain mackay director gsk also independent nonexecutive director national grid plc service contracts letters appointment table sets dates executive directors service contracts available companys registered office gskcom date contract effective date expiry date emma walmsley julie brown na nonexecutive directors letters appointment also available view companys registered office nonexecutive director expected serve board end agm following third anniversary appointment provided elected subsequently reelected annually subject mutual agreement may serve one two three year terms depending needs board remuneration policy continues reflect provision uk corporate governance code code companys remuneration policy approved may gsks annual general meeting operated intended terms company performance quantum since approval full policy available gskcom investors section two administrative amendments approved shareholders gsk 's annual general meeting described annual report clarity simplicity remuneration arrangements executive directors set clear simple way risk operate deferral postvesting holding arrangements addition operating malus clawback provisions committee discretion adjust award outcomes predictability proportionality policy defines maximum limits total annual bonus longterm incentive opportunities payouts elements linked fulfilment performance conditions support companys publicly stated ambitions strategy alignment culture gsks purpose strategy culture continue directly reflected performance conditions set annual bonus longterm incentive strategic report governance remuneration financial statements investor information gsk annual report operation scope remuneration policy remuneration policy policy set pages ii policy came effect provided terms annual report available governance payment consistent shareholderapproved section gskcom intended policy gsks remuneration policy force time agreed executive nonexecutive directors operate period iii time relevant individual director three years date approval companys company opinion committee annual general meeting may payment consideration individual becoming committee wrote policy principally relation director company purposes payments remuneration arrangements executive directors whilst includes committee satisfying awards variable taking account possible recruitment replacement remuneration relation award shares ads additional executive director operation terms payment agreed time award policy committee intends policy operate granted period set entirety however may due performance share plan psp awards subject terms consideration seek change policy period psp plan rules award granted believes appropriate longterm committee may adjust amend awards success company consultation shareholders accordance provisions plan rules includes sought shareholder approval general meeting making adjustments reflect oneoff corporate events committee reserves right make remuneration change companys capital structure payments andor payments loss office including committee may also make minor amendments exercising discretions available connection policy regulatory exchange control tax administrative payments notwithstanding line purposes take account change legislation without policy terms payment agreed obtaining shareholder approval amendments agm may date companys first shareholderapproved directors remuneration policy came effect basis preparation annual report remuneration prepared accordance companies act large mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts annual report remuneration subject audit total remuneration figures executive directors including details element remuneration salary benefits pension annual bonus longterm incentive awards non executive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections annual report remuneration approved board directors signed behalf urs rohner remuneration committee chair february strategic report governance remuneration financial statements investor information gsk annual report directors ' report directors ' powers independent advice gsk directors powers determined uk legislation company agreed procedure directors take articles association contain rules independent legal andor financial advice companys appointment replacement provide directors expense deem necessary may appointed ordinary resolution members indemnification directors resolution board appointed board director must retire next annual general meeting qualifying third party indemnity provisions defined elected shareholders companies act force benefit directors former directors held office articles also provide directors required seek approval signature annual report reelection annually annual general meeting accordance frc 's code change control essential contracts director cease director contracts arrangements individually fundamental ability business becomes bankrupt operate effectively neither company party ceases director virtue companies act material agreements would take effect altered articles terminate upon change control following takeover bid suffers mental physical ill health board resolves agreements director would shall cease director provide compensation loss office employment resulting missed directors meetings continuous period six takeover except provisions companys share months without permission board resolves plans may cause options awards granted plans shall cease director vest takeover otherwise prohibited director law details termination provisions executive directors resigns offers resign board accepts offer service contracts given full version companys required resign board remuneration policy available gskcom directors conflicts interest investors section directors duty companies act content directors report avoid situation could direct indirect conflict interest possible conflict purposes uk companies act directors company articles provide general power board report gsk plc year ended december authorise conflicts comprises board reviews new potential actual conflict directors report recorded company secretary directors counted quorum authorisation actual section pages potential conflicts nominations corporate governance corporate governance report committee reviews register potential conflicts employee engagement annual basis board subsequently approves directors statements responsibilities continuing basis directors responsible informing company secretary new actual investor information potential conflicts may arise changes strategic report sets matters required circumstances may affect authorisation previously disclosed directors report considered given even provided authorisation director strategic importance absolved statutory duty promote success company actual conflict arises postauthorisation strategic report board may choose exclude director receipt relevant information participation debate section pages suspend director board last resort require risk management objectives policies director resign nominations corporate governance committee likely future developments company reviewed register potential conflict authorisations research development activities register potential conflicts january committee business relationships reported board conflicts appropriately authorised process authorisation continued diversity operate effectively committee recommended provision information consultations approval register potential conflicts board employees subsequently approved except described note carbon emissions financial statements related party transactions end financial year director person closely section statement associated material interest contract significance group company articles prohibit director voting resolution concerning appointment terms termination appointment strategic report governance remuneration financial statements investor information gsk annual report directors ' report continued following information also incorporated directors report location annual report interest capitalised financial statements notes particulars important postbalance financial statements sheet events company note subsidiaries publication unaudited financial group financial review information details longterm incentive remuneration report schemes waiver emoluments director applicable waiver future emoluments directornot applicable non preemptive issues equity cash applicable non preemptive issues equity cash applicable unlisted major subsidiary undertaking parent company participation placing applicable listed subsidiary provision services controlling applicable shareholder shareholder waiver dividends financial statements notes shareholder waiver future dividends financial statements notes agreements controlling shareholders applicable directors report drawn presented accordance reliance upon english company law liabilities directors connection report shall subject limitations restrictions provided law approved board directors february signed behalf sir jonathan symonds chair february gsk annual report financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements gsk plc prepared uk gaap strategic report governance remuneration financial statements investor information gsk annual report directors ' statement responsibilities directors responsible preparing annual report directors responsible keeping adequate accounting remuneration report group parent company records sufficient show explain companys financial statements accordance applicable law transactions disclose reasonable accuracy regulations time financial position group enable ensure group financial statements uk company law requires directors prepare financial remuneration report comply companies act statements financial year directors required also responsible safeguarding assets prepare group consolidated financial statements group hence taking reasonable steps prevention accordance ukadopted international accounting detection fraud irregularities standards conformity requirements companies act international financial reporting group financial statements year ended standards ifrs issued international accounting december comprising principal statements standards board iasb directors elected prepare supporting notes set financial statements parent company financial statements accordance pages report parent company financial united kingdom accounting standards applicable law statements year ended december comprising united kingdom generally accepted accounting practice balance sheet statement changes equity financial reporting standard reduced disclosure year ended december supporting notes framework company law directors must set pages approve financial statements unless satisfied responsibilities auditor relation financial give true fair view state affairs group statements set independent auditors report profit loss period preparing financial pages statements directors required financial statements year ended december select suitable accounting policies apply included annual report published printed consistently form made available website directors make judgements accounting estimates responsible maintenance integrity corporate reasonable prudent financial information included companys website state group financial statements comply ifrs legislation united kingdom governing preparation issued iasb conformity dissemination financial statements may differ requirements companies act legislation jurisdictions state regard parent company financial statements applicable uk accounting standards current directors whose names functions followed subject material departures disclosed listed corporate governance section annual explained parent company financial statements report confirms best knowledge group financial statements prepared prepare financial statements going concern basis accordance applicable set accounting standards unless inappropriate presume group conformity requirements companies act parent company continue business give true fair view assets liabilities preparing group financial statements international financial position profit group accounting standard requires directors properly select strategic report risk sections annual report apply accounting policies present information including represent management report include fair accounting policies manner provides relevant review development performance business reliable comparable understandable information provide position company group taken additional disclosures compliance specific whole together description principal risks requirements ifrs standards insufficient enable users uncertainties faces understand impact particular transactions annual report financial statement taken whole events conditions entitys financial position fair balanced understandable provide financial performance make assessment information necessary shareholders assess companys ability continue going concern companys position performance business model strategy strategic report governance remuneration financial statements investor information gsk annual report directors ' statement responsibilities continued disclosure information auditor uk corporate governance code directors office date annual report board considers gsk plc applies principles confirmed complies provisions uk corporate governance code maintained financial reporting council far aware relevant audit described corporate governance section pages information companys auditor unaware board considers annual report taken taken steps ought whole fair balanced understandable provides taken director make aware information necessary shareholders assess relevant audit information establish groups position performance business model companys auditor aware information strategy confirmation given interpreted required financial conduct authoritys listing rules accordance provisions section companies auditor considered directors statement act compliance relation points uk corporate going concern basis governance code specified review pages pages contain information annual report performance group financial position cash flows net annual report year ended december debt position borrowing facilities climate related risks comprising report directors remuneration information including treasury risk management report financial statements additional information policies exposures market credit risk hedging investors approved board directors activities given note 'financial instruments related signed behalf disclosures ' financial statements assessed principal risks matters considered connection viability statement directors considered appropriate adopt going concern basis accounting preparing financial statements sir jonathan symonds internal control chair february board audit risk committee reviewed assessment risks internal control framework operates gsk considered effectiveness system internal control operation group year covered annual report date approval board directors detail review internal controls set governance report strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report members gsk plc report audit financial statements opinion basis opinion opinion conducted audit accordance international standards auditing uk isas uk applicable law financial statements gsk plc parent company responsibilities standards described subsidiaries group give true fair view auditors responsibilities audit financial state groups parent companys affairs statements section report december groups profit year ended independent group parent company group financial statements properly prepared accordance ethical requirements relevant accordance united kingdom adopted international audit financial statements uk including accounting standards international financial reporting financial reporting councils frcs ethical standard standards ifrss issued international accounting applied listed public interest entities fulfilled standards board iasb ethical responsibilities accordance parent company financial statements requirements confirm provided non properly prepared accordance united kingdom audit services prohibited frcs ethical standard generally accepted accounting practice including frs group parent company noted audit risk reduced disclosure framework committee report within corporate governance section financial statements prepared accordance annual report disclosure provided requirements companies act note regarding fees payable groups auditor audited financial statements comprise believe audit evidence obtained sufficient appropriate provide basis opinion group consolidated balance sheet december summary audit approach consolidated income statement year ended key audit matters consolidated statement comprehensive income year ended key audit matters identified current year consolidated statement changes equity year ended valuation viiv healthcare shionogi contingent consideration liability consolidated cash flow statement year ended valuation us returns rebates rar accruals valuation intangible assets notes financial statements includes material accounting policy information valuation uncertain tax positions including transfer pricing parent company valuation contingent liabilities significant legal proceedings balance sheet december statement changes equity year ended materiality materiality used group financial notes l financial statements includes statement million million material accounting policy information determined basis statutory profit tax adjusted profit tax revenue net cash flows financial reporting framework applied operations preparation group financial statements applicable law united kingdom adopted international accounting standards scoping ifrss issued iasb financial reporting following components subject audit procedures framework applied preparation well assessment effectiveness internal parent company financial statements applicable law controls financial reporting belgium canada china united kingdom accounting standards including frs france germany italy japan united kingdom reduced disclosure framework united kingdom generally united states accepted accounting practice audit scope addressed groups revenue groups profit tax groups total assets significant changes approach removed key audit matters relating consumer healthcare demerger systems impact financial reporting strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued conclusions relating going concern key audit matters auditing financial statements concluded key audit matters matters professional directors use going concern basis accounting judgement significance audit preparation financial statements appropriate financial statements current period include significant assessed risks material misstatement whether evaluation directors assessment groups due fraud identified matters included parent companys ability continue adopt going greatest effect overall audit concern basis accounting included strategy allocation resources audit directing efforts engagement team enquiries group directors management regarding assumptions used going concern models including matters addressed context audit potential impact climate change financial statements whole forming opinion evaluating groups existing access sources financial statements whole provide financing including undrawn committed bank facilities separate opinion matters including impact changes interest rates removed two key audit matters consumer profitability healthcare demerger key audit matter following reading analyst reports industry data external completion demerger prior year key audit information including understanding macroeconomic matter relating systems impact financial reporting environment determine provided corroborative following remediation control deficiencies relating contradictory evidence relation assumptions used governance operation infrastructure privileged access comparing forecasted sales recent historical financial management prior year information testing underlying data generated prepare forecast scenarios determined whether adequate support assumptions underlying forecast evaluating groups disclosures going concern requirements ias based work performed identified material uncertainties relating events conditions individually collectively may cast significant doubt groups parent companys ability continue going concern period least twelve months financial statements authorised issue relation reporting group applied uk corporate governance code nothing material add draw attention relation directors statement financial statements whether directors considered appropriate adopt going concern basis accounting responsibilities responsibilities directors respect going concern described relevant sections report strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation viiv healthcare shionogi contingent audit procedures performed consideration liability performed following audit procedures amongst others group completed number significant transactions related primarily sales forecasts resulted recognition material contingent tested controls key inputs assumptions consideration liabilities key source estimation used valuation contingent consideration uncertainty significant liabilities viiv liability including review controls sales forecasts healthcare shionogi contingent consideration liability viiv treatment product portfolio used value viiv ccl ccl obtained groups assessment key inputs group completed acquisition remaining assumptions used sales forecasts challenged interest shionogiviiv healthcare joint venture reasonableness including enquiries key upon completion group recognised contingent individuals senior leadership team commercial consideration liability fair value expected future strategy team key personnel involved budgeting payments made shionogi december forecasting process inspection supporting liability valued million evidence challenged us volume assumptions made group identified viiv ccl key audit matter estimate sales forecasts involved benchmarking significant estimates assumptions relating sales forecast market share data external data forecasts used valuing viiv ccl sensitivity total prescription volumes new patient prescription valuation inputs significant relate volumes order assess sources contradictory sales forecasts united states us certain products evidence treatment prevention portfolio forecasts challenged reasonableness us pricing assumptions based assessment expected launch dates group comparing forecasted returns pipeline assets ability shift market practice rebates rate product current rate prescriber behaviour towards longacting injectable assessing forecasted returns rebates treatments drug regimens size longacting comparable products considering expected changes prevention market subsequent sales volumes payer policy incremental challenge forecasting sales associated considered results clinical studies undertaken recently launched products due lack historical actual year group key competitors order assess data sales forecasts also required significant audit effort whether corroborative contradictory perform appropriate audit procedures challenge assumptions used product portfolio sales forecasts evaluate reasonableness forecasts us contingent consideration liabilities including viiv ccl benchmarked groups sales forecasts disclosed key source estimation uncertainty note included reports nine analysts considered sales group financial statements disclosures forecasts total viiv basis individual provided note matter also discussed audit product basis assessing identified contradictory risk committee report within corporate governance data section annual report together valuations specialists assessed reasonableness overall valuation methodology including benchmarking discount rate used testing valuation model mechanical accuracy key observations communicated audit risk committee sales forecasts used valuation reasonable line relevant supporting information satisfied sales forecasts appropriately reflect trends overall hiv treatment prevention markets including impacts competition healthcare reform predicted shift towards longacting injectable products approach valuing viiv ccl consistent prior periods overall satisfied valuation liability reasonable consistent ifrs strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation us returns rebates rar accruals audit procedures performed us group sells customers various performed following audit procedures amongst others commercial government mandated contracts related estimates rar accruals reimbursement arrangements include rebates tested key controls estimation rar accruals chargebacks right return certain pharmaceutical including controls associated forecasting products revenue recognition reflects grosstonet utilisation rates process monthend accrual review sales adjustments adjustments known controls returns rebates rar accruals source challenged assumptions selection utilisation rates significant estimation uncertainty could material focusing certain products concluded impact reported revenue accrual sensitive assumptions us commercial business million rar challenge included comparison historical utilisation rates deductions made gross revenue million consideration historical accuracy assessment resulting net revenue million balance sheet market changes impact competition new accrual december us commercial business product launches changes government legislation amounted million macroeconomic factors appropriately reflected rar accruals four significant payer channels also referred supplemented substantive analytical procedures buying groups rar accrual relates managed developing independent expectation accrual healthcare organisations medicaid ryan white medicare balance key segments based historical part claims received adjusted reflect market changes two main causes significant estimation uncertainty period including assessment time lag initial point sale claim receipt utilisation rate portion total sales compared independent expectation recorded made payer channel estimated evaluate appropriateness year ending accrual recording accruals utilisation assumption position challenging key assumptions used derive considered historical accuracy estimates accrual given influenced market demand evaluated whether forecast assumptions factors outside control group appropriately updated selection cases time lag point sale point actual rebate claims differed amount accrued exact rebate amounts known group upon evaluated appropriateness completeness receipt claim payer channels longest periodend adjustments liability made part time lag result greater accrued period therefore ongoing review estimated accrual greater level estimation uncertainty estimating periodend accrual performed audit procedures actual rebate payments made year agreeing relevant level estimation uncertainty also impacted contract assess whether rebate payments line significant shifts channel mix driven changes contractual terms competitive landscape including competitor generic key observations communicated audit risk product launches changes government legislation committee macroeconomic factors focus utilisation assumptions products deem level satisfied estimated liability rar accruals estimation uncertainty significant yearend appropriate observed level prudence estimate assessing also focus periodend adjustments made independent expectations accordance rar accruals adjustments reflected updates made requirements ifrs revenue contracts initial assumptions included within forecasted rar customers limit risk significant reversal revenue rates view present greatest opportunity fraud revenue recognition notwithstanding existence internal controls us commercial operations returns rebates disclosed key source estimation uncertainty note group financial statements disclosures provided note matter also discussed audit risk committee report within corporate governance section annual report strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation intangible assets audit procedures performed december group held million performed following audit procedures amongst others intangible assets including licenses patents trademarks forecast sales pricing volume growth rates trade names excluding goodwill computer probability technical regulatory success profit margin software includes million intangible assets levels discount rates used assessment acquired part acquisition bellus health valuation intangible assets acquired year part groups acquisition bellus health intangible assets indevelopment available tested review controls key inputs assumptions use tested least annually impairment used valuation intangible assets controls irrespective whether indication impairment exists encompass review valuation models contain number assumptions probability technical carrying amount individual intangible asset regulatory success launch dates plus revenue cashgenerating unit intangible asset belongs cost assumptions exceeds recoverable amount impairment occurs inquired key individuals corporate recoverability intangible asset derived certain development team commercial forecasting leads key assumptions estimates future trading performance personnel involved assets research development create significant estimation uncertainty process used outcome inquiries evaluate underlying assumptions include forecast sales pricing groups evidence support key assumptions volume growth rates probability technical overall sales forecasts peak year sales including regulatory success ongoing clinical trials includes anticipated market share volume uptake alongside assumptions timing cash flows determined price points required foreseeable competitive anticipated launch year peak year sales subsequent sales landscape growth rates probability regulatory erosion due generic product competition profit margin technical success margins levels addition due impact uncertainty driven evaluated key inputs assumptions applied ongoing global macroeconomic volatility valuation estimating sales profit margin forecasts including intangible assets also affected discount rate benchmarking forecasts external market data assumptions made group included independent market research therapeutic area price points price growth rates anticipated impairment charges million competitor market landscape currently time recorded primarily full impairments due forecast regulatory approval plus assessment cessation research development dictated negative sources contradictory evidence clinical trial readouts lack commercial attractiveness compared forecast sales profit margin levels identified valuation intangible assets key plan data asset asset internal forecasts approved audit matter due inherent judgements involved gsk leadership team board directors estimating future cash flows auditing assumptions indevelopment intangible asset forecast estimates required extensive audit effort challenge launch within next year period evaluate reasonableness forecasts management assessed historical accuracy sales forecasts judgements performing retrospective reviews across marketed assets within business disclosures relating intangible assets including engaged fair valuation specialists assess acquired part business combinations included reasonableness discount rates valuation note note group financial statements methodology applied well performing mechanical matter also discussed audit risk committee report accuracy checks within corporate governance section annual report considered whether events transactions occurred balance sheet date reporting date affect conclusions reached carrying values assets associated disclosures key observations communicated audit risk committee intangible assets acquired period part bellus health business acquisition concluded assumptions underpinning fair value intangible assets reflected purchase price allocations reasonable accordance ifrs intangible assets indevelopment subject impairment reviews concluded judgements made management reasonable accordance ifrs strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation uncertain tax positions including transfer pricing audit procedures performed group operates numerous jurisdictions support tax specialists assessed open tax transfer pricing matters exposures uk appropriateness uncertain tax provisions focused us overseas tax authorities give rise uncertain tax jurisdictions group greatest potential positions wide range possible outcomes exposure highest level judgement required provisions contingencies certain judgements respect performing following audit procedures amongst others estimates tax exposures contingencies required tested key controls preparation review reporting order assess adequacy tax provisions judgmental tax balances transactions include sometimes complex result considerations required provisions uncertain tax provisions multiple tax laws regulations assessed assumptions judgements december group recorded provisions required determine range possible outcomes million respect uncertain tax positions recognition measurement provisions uncertain tax positions compliance requirements ifric valuation uncertain tax positions disclosed key source uncertainty income tax treatments estimation uncertainty note group financial involved transfer pricing specialists evaluate statements disclosures included note transfer pricing methodology group associated matter also discussed audit risk committee report approach provision recognition measurement within corporate governance section annual report considered evidence actual results recent tax authority audits enquiries thirdparty tax advice obtained group tax specialists knowledge market practice relevant jurisdictions key observations communicated audit risk committee satisfied estimates relation uncertain tax positions related disclosures accordance ifrs work concluded consistent approach applied estimating uncertain tax provisions appropriate accordance ifric strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation contingent liabilities significant legal audit procedures performed proceedings performed following audit procedures group operates environment subject tested groups controls completeness significant legal administrative proceedings including provisions robustness provision product liability intellectual property tax antitrust consumer requirements ias appropriateness judgements fraud governmental regulations used determine best estimate completeness group currently exposed number regulatory accuracy data used process litigation matters groups provision matters evaluated assessment provisions associated million december matters disclosed probabilities potential outcomes accordance contingent liabilities criteria recognising ias provision ias provisions contingent liabilities contingent assets met including zantac litigation evaluated methodology data significant described note judgements assumptions used valuation provisions appropriate context applicable significant judgement required group determining financial reporting framework whether ias provisions contingent liabilities contingent assets particular relation zantac inquired inspected correspondence litigation groups internal external counsel assess litigation matter evaluate groups significant judgements whether outcome result probable outflow assumptions particularly outcome litigation uncertain subject additional court proceedings provision made actual expected trial outcomes settlements evaluated groups conclusion determination reliable estimate made supportive contradictory evidence amounts obligation requirements ias particularly respect nature extent contingent liabilities zantac litigation underlying significant estimation uncertainties disclosed read board minutes settlement agreements contingent liabilities significant legal proceedings evaluate managements approach respect disclosed notes respectively key audit matter litigation agreed terms conditions discussed within corporate governance section arrangements payments made evaluate provisions annual report already recorded whether requirement additional provisions respect zantac litigation inspected evidence presented relevant scientific studies outcomes product liability litigation jurisdictions alongside entitys assessment possible outcomes ongoing trial expectation trials go ahead per schedule future trials evaluated whether disclosures made financial statements appropriately reflect facts critical accounting judgements key observations communicated audit risk committee satisfied estimation provisions contingent liability disclosures consistent requirements ias strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued application materiality set performance materiality level lower materiality define materiality magnitude misstatement reduce probability aggregate uncorrected financial statements makes probable economic undetected misstatements exceed materiality decisions reasonably knowledgeable person would financial statements whole group parent company changed influenced use materiality planning performance materiality set group parent scope audit work evaluating results materiality respectively audit work determining performance materiality considered factors based professional judgement determined including materiality financial statements whole follows risk assessment including assessment groups parent company overall control environment consider group financial statements financial statements appropriate rely controls number business materiality million million processes million million basis determining benchmark materiality past experience audit indicated low determining materiality considered determined using number corrected uncorrected misstatements materiality metrics used investors total assets identified prior periods readers financial benchmark capped agreed audit risk committee would statements particular report committee audit differences excess considered statutory profit group materiality tax adjusted profit materiality million million well differences tax revenue net cash flows represents threshold view warranted reporting qualitative operations total assets grounds also report audit risk committee disclosure matters identified assessing overall using professional judgement presentation financial statements determined materiality million see materiality compares benchmark metrics metric statutory profit tax adjusted profit tax revenue net cash inflow operating activities reconciliation statutory profit tax adjusted profit tax detailed adjusting items section strategic report rationale given importance strength metrics used investors balance sheet benchmark readers financial key measure applied statements concluded financial health statutory profit tax important primary benchmark shareholders since adjusted profit tax primary concern revenue net cash inflow parent company operating activities payment used supporting dividends using benchmarks benchmark total assets therefore component materiality appropriate metric allocated inscope components ranged current year million million materiality million increased reflect million size scale nature parent company account balances audited purpose consolidated financial statements lower component materiality used strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued audit scope execution structured approach audit reflect audit work performed global shared service centres group organised ensured audit effective significant amount groups operational processes risk focused cover financial reporting undertaken shared service centres group audit team included senior individuals central control common systems throughout group responsible global processes coordinated enables us deploy utilise technology data analytics audit work shared service centres utilising live across breadth group enabling detailed global project management platform structure enables understanding flow transactions enabling us focus us develop good understanding endtoend risk assessment design targeted audit testing processes supported material account balances classes procedures transactions disclosures within group financial embed technology throughout audit improve quality statements evaluated effectiveness internal effectiveness including areas planning controls financial reporting processes scoping project management risks controls assessment considered implications remainder audit substantive testing reporting insights management work audit risk committee piloted use audit work executed component level individual legal artificial intelligence powered tools continue invest entities following components subject audit use technology across audit procedures well assessment effectiveness internal controls financial reporting belgium canada audit approach summarised following china france germany italy japan united kingdom areas enabled us obtain evidence required form united states group audit team active opinion group parent company financial dialogue throughout audit component audit statements teams responsible audit work direction risk assessment audit planning group level risk supervision group audit team included assessment procedures considered amongst factors determining whether work planned performed impact climate change wider macroeconomic accordance overall group audit strategy environment account balances disclosures requirements group audit instructions company practices data analytical tools allow us components part supervising work scrutinise large transactional data sets unusual trends components senior group audit team members visited characteristics outliers transaction flows support belgium usa uk china well shared service identification audit risks example analysed us rar centre audits malaysia poland satisfy data product payment channel identify products oversight supervision appropriate high values total rebate deductions performed reviews audit working papers increased recognised significant differences rebate frequency length reviews depending rates offered payers qualitative factors significance risk component continued impacted brands see section valuation us returns attend planning clearance meetings components rebates rar accruals also used data analytics audit procedures undertaken group level determine products regions valuation parent company addition also performed viiv healthcare shionogi contingent consideration liability audit work group parent company financial sensitive assumptions used see section statements including limited consolidation valuation viiv healthcare shionogi contingent groups results preparation financial consideration liability appointed partners statements certain disclosures within directors group audit team lead global audit operating remuneration report litigation provisions exposures segments commercial operations research addition entity level oversight controls relevant development addition partners responsible financial reporting components legal entities component legal entity audits country annual revenue greater total segment partners met regularly senior segment group revenue included audit scope management understand strategy performance components legal entities covered audit scope matters arose throughout year could subject analytical procedures confirming impacted financial reporting addition held significant risks material misstatement regular meetings members internal audit aggregated financial information internal legal counsel global ethics compliance teams understand work review reports internal controls testing approach tested enhance risk assessment effectiveness internal controls financial reporting across inscope entities entity level controls group level common systems allowed relevant controls tested centrally across components utilised automated controls testing tool leveraged support testing controls automated business controls able place reliance controls planned audit scope addressed group 's revenue group 's profit tax group 's total assets strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued impact climate change audit consultation climate change specialists climate change potential impact group conducted detailed risk assessment procedures across number ways set strategic report pages scope balances transactions determine risks annual report notes pages material misstatement financial statements financial statements group applying expected impact climate change committed net zero greenhouse gas emissions across understanding business groups full value chain challenged appropriateness groups assessment planning audit considered potential potential impact climate change impact impact climate change groups business financial statements including area financial statements intangible assets sought understand groups identification used assessment impact climate change assessment potential impacts climate change challenge groups assessment going concern risks influence groups strategy implications including considering potential impact future financial statements performance availability financing groups assessment focused impacts part audit procedures required read frequent extreme weather conditions water scarcity changes consider disclosures consider whether political landscape media focus materially inconsistent financial statements propensity cause changes consumer market knowledge obtained audit identify behaviour volatility costs availability materials material inconsistencies result procedures resources could impact future financial performance asset valuations strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued information information comprises information included identify material inconsistencies apparent material annual report financial statements misstatements required determine whether gives auditors report thereon directors responsible rise material misstatement financial statements information contained within annual report based work performed conclude material misstatement opinion financial statements cover information required report fact information except extent otherwise explicitly stated report express form assurance summarise work relation areas conclusion thereon information including areas upon specifically required report responsibility read information consider whether information materially inconsistent financial statements knowledge obtained course audit otherwise appears materially misstated matters specifically required report responsibility reporting principal risks viability statement set corporate governance statement section nothing material report add review confirmation description light knowledge draw attention respect matters gathered audit considering directors processes support statements made challenging key judgements estimates consideration historical forecasting accuracy evaluating macroeconomic assumptions consider statements aligned relevant provisions code directors remuneration report set opinions matters prescribed report whether part directors remuneration report companies act section opinion audited properly prepared disclosures specified part directors remuneration report companies act made audited prepared accordance companies act strategic report directors report set opinions matters prescribed report whether consistent audited financial statements companies act section opinion prepared accordance applicable legal requirements based work undertaken course report identified material misstatements either report audit information reports consistent light knowledge understanding group audited financial statements parent company environment obtained course audit prepared accordance applicable legal requirements referenced provided limited assurance accordance international standards assurance engagements isae isae selected metrics strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued reporting information responsibility reporting alternative performance measures apms opinion apms measures defined generally accepted accounting practice gaap therefore typically included financial use calculation disclosure apms statement part annual report group use apms consistent groups published definitions adjusted profit free cash flow constant currency growth rates policies reporting financial performance use apms groups reporting results consistent guidelines produced esma reviewed assessed calculation reporting frc metrics assess consistency groups published definitions appropriate balance use policies items statutory metrics apms together clear also considered assessed whether use apms definitions reconciliation apms used groups reporting results consistent guidelines produced financial reporting regulators european securities markets authority esma guidelines use apms frc alternative performance measures thematic review published october also considered whether appropriate balance use statutory metrics apms addition whether clear definitions reconciliation apms used financial reporting provided dividends distribution policy opinion dividends policy appropriately consider whether dividends policy transparent dividends disclosed dividends paid consistent paid consistent policy outlined strategic report policy responsibilities directors auditors responsibilities audit financial statements explained fully directors responsibilities statement directors responsible preparation objectives obtain reasonable assurance financial statements satisfied give whether financial statements whole free true fair view internal control directors material misstatement whether due fraud error determine necessary enable preparation financial issue auditors report includes opinion reasonable statements free material misstatement whether assurance high level assurance guarantee due fraud error audit conducted accordance isas uk always detect material misstatement exists preparing financial statements directors misstatements arise fraud error considered responsible assessing groups parent companys material individually aggregate could ability continue going concern disclosing applicable reasonably expected influence economic decisions matters related going concern using going concern users taken basis financial statements basis accounting unless directors either intend liquidate group parent company cease description responsibilities audit operations realistic alternative financial statements located frcs website wwwfrcorgukauditorsresponsibilities description forms part auditors report strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued audit response risks identified extent audit considered capable detecting irregularities including fraud result performing identified valuation us returns rebates accruals key audit matter related potential risk fraud key audit matters irregularities including fraud instances noncompliance section report explains matter detail also laws regulations design procedures line describes specific procedures response key audit responsibilities outlined detect material matter common audits isas uk also misstatements respect irregularities including fraud required perform specific procedures respond risk extent procedures capable detecting management override irregularities including fraud detailed addition procedures respond risks identifying assessing potential risks related identified included following irregularities identifying assessing risks material misstatement reviewing financial statement disclosures testing respect irregularities including fraud noncompliance supporting documentation assess compliance laws regulations considered following provisions relevant laws regulations described direct effect financial statements nature industry sector control environment enquiring senior leadership team audit risk business performance including design committee inhouse external legal counsel groups remuneration policies key drivers directors concerning actual potential litigation claims remuneration bonus levels performance targets performing analytical procedures identify unusual results enquiries senior leadership team internal unexpected relationships may indicate risks material audit audit risk committee including obtaining misstatement due fraud reviewing supporting documentation concerning reading minutes meetings charged groups policies procedures relating governance reviewing internal audit reports identifying evaluating complying laws correspondence regulators regulations whether aware instances addressing risk fraud management override noncompliance controls testing appropriateness journal entries detecting responding risks fraud whether adjustments assessing whether judgements made knowledge actual suspected alleged making accounting estimates indicative potential fraud bias evaluating business rationale significant internal controls established mitigate risks related transactions unusual outside normal course fraud noncompliance laws regulations business matters discussed among engagement team also communicated relevant identified laws regulations including significant component audit teams involving potential fraud risks engagement team members relevant internal specialists including tax valuations significant component audit teams remained alert pensions industry specialists regarding indications fraud noncompliance laws fraud might occur financial statements regulations throughout audit potential indicators fraud report legal regulatory obtained understanding legal regulatory frameworks group operates focusing provisions requirements laws regulations direct effect determination material amounts disclosures opinions matters prescribed financial statements key laws regulations companies act considered context included provisions uk companies act pensions legislation tax legislation opinion part directors remuneration report also considered key laws regulations audited properly prepared accordance fundamental effect operations group including companies act good clinical practice fda regulations general data protection requirements antibribery corruption policy opinion based work undertaken course foreign corrupt practices act audit information given strategic report directors report financial year financial statements prepared consistent financial statements strategic report directors report prepared accordance applicable legal requirements light knowledge understanding group parent company environment obtained course audit identified material misstatements strategic report directors report strategic report governance remuneration financial statements investor information gsk annual report independent auditor 's report continued report audit financial statements continued directors remuneration corporate governance statement companies act also required report listing rules require us review directors statement opinion certain disclosures directors remuneration relation going concern longerterm viability part made part directors remuneration corporate governance statement relating groups report audited agreement accounting compliance provisions uk corporate records returns governance code specified review nothing report respect matters based work undertaken part audit matters required concluded following elements corporate governance statement materially consistent address financial statements knowledge obtained audit auditor tenure following recommendation audit risk committee directors statement regards appropriateness effect january appointed adopting going concern basis accounting board directors audit financial statements year material uncertainties identified set ended december subsequent financial periods directors explanation assessment groups period total uninterrupted engagement firm six prospects period assessment covers years period appropriate set directors statement fair balanced consistency audit report additional report understandable annual report set audit risk committee boards confirmation carried robust audit opinion consistent additional report assessment emerging principal risks set audit risk committee required provide pages accordance isas uk section annual report describes review effectiveness risk management internal control use report systems set pages section describing work audit risk report made solely parent companys members committee set body accordance chapter part companies act audit work undertaken matters required report might state parent companys members exception matters required state auditors report purpose fullest extent permitted law adequacy explanations received accounting accept assume responsibility anyone records parent company parent companys members body audit work report opinions companies act required report formed opinion required financial conduct authority fca disclosure received information explanations guidance transparency rule dtr rdtr r require audit financial statements form part electronic adequate accounting records kept format annual financial report filed national storage parent company returns adequate audit mechanism fca accordance dtr rdtr received branches visited us r auditor 's report provides assurance whether parent company financial statements electronic format annual financial report agreement accounting records returns prepared compliance dtr rdtr r nothing report respect matters parent company passed resolution accordance section companies act senior statutory auditors name stated deloitte llp statutory auditor london united kingdom february strategic report governance remuneration financial statements investor information gsk annual report consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating incomeexpense operating profit finance income finance expense share tax profitloss associates joint ventures profitloss disposal interests associates joint ventures profit taxation taxation profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations total profit taxation year profit attributable noncontrolling interests continuing operations profit attributable shareholders continuing operations profit attributable noncontrolling interests discontinued operations profit attributable shareholders discontinued operations total profit attributable noncontrolling interests total profit attributable shareholders basic earnings per share pence continuing operations p p p basic earnings per share pence discontinued operations p p total basic earnings per share pence p p p diluted earnings per share pence continued operations p p p diluted earnings per share pence discontinued operations p p total diluted earnings per share pence p p p consolidated statement comprehensive income year ended december notes total profit year comprehensive incomeexpense year items may reclassified subsequently continuing operations income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates fair value movements cash flow hedges deferred tax fair value movements cash flow hedges reclassification cash flow hedges income statement items reclassified continuing operations income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments fair value movements cash flow hedges remeasurement gainslosses defined benefit plans tax remeasurement lossesgains defined benefit plans comprehensive income expense year continuing operations comprehensive income year discontinued operations total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year strategic report governance remuneration financial statements investor information gsk annual report consolidated balance sheet december notes noncurrent assets property plant equipment right use assets goodwill intangible assets investments associates joint ventures investments deferred tax assets noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments current equity investments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board february signed behalf sir jonathan symonds chair strategic report governance remuneration financial statements investor information gsk annual report consolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity december profit year comprehensive incomeexpense year total comprehensive incomeexpense year distributions noncontrolling interests contributions noncontrolling interests dividends shareholders shares issued realised tax profits disposal equity investments share associates joint ventures realised profits disposal equity investments writedown shares held esop trusts sharebased incentive plans transaction noncontrolling interests tax sharebased incentive plans december profit year comprehensive incomeexpense year total comprehensive incomeexpense year distributions noncontrolling interests noncash distribution noncontrolling interests contributions noncontrolling interests changes noncontrolling interests deconsolidation former subsidiaries dividends shareholders noncash dividend shareholders realised tax losses disposal liquidation equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts shares acquired esop trusts sharebased incentive plans tax sharebased incentive plans hedging gain taxation transferred nonfinancial assets december profit year comprehensive incomeexpense year total comprehensive incomeexpense year distributions noncontrolling interests contributions noncontrolling interests dividends shareholders realised tax losses disposal liquidation equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts shares acquired esop trusts sharebased incentive plans hedging gainloss taxation transferred nonfinancial assets tax sharebased incentive plans december analysis reserves presented part note movements equity strategic report governance remuneration financial statements investor information gsk annual report consolidated cash flow statement year ended december notes cash flow operating activities profit taxation continuing operations year adjustments reconciling profit tax operating cash flows cash generated operations attributable continuing operations taxation paid net cash inflowoutflow continuing operating activities cash generated operations attributable discontinued operations taxation paid discontinued operations net operating cash flows attributable discontinued operations total net cash inflowoutflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments increasedecrease liquid investments purchase businesses net cash acquired proceeds sale equity investments contingent consideration paid disposal businesses investments associates joint ventures proceeds disposal associates joint ventures interest received dividend distributions investments dividends associates joint ventures net cash inflowoutflow continuing investing activities net investing cash flows attributable discontinued operations total net cash inflowoutflow investing activities cash flow financing activities issue share capital repayment longterm loans issue longterm notes repayment shortterm loans net increase inrepayment shortterm loans repayment lease liabilities interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing items net cash inflowoutflow continuing financing activities net financing cash flows attributable discontinued operations total net cash inflowoutflow financing activities increasedecrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments increasedecrease cash bank overdrafts year cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents overdrafts strategic report governance remuneration financial statements investor information gsk annual report notes financial statements presentation financial statements description business preparing consolidated financial statements group considered impact physical transitional gsk global biopharma group prevents treats climate change risks well plans mitigate disease vaccines specialty general medicines gsk current valuation assets liabilities focuses science immune system use particularly context risks identified task force new platform data technologies investing four core climaterelated financial disclosures tcfd therapeutic areas infectious diseases hiv respiratory immunology oncology group believe material impact judgements estimates relation climaterelated risks compliance applicable law ifrs result valuation assets liabilities financial statements prepared accordance significantly impacted december ukadopted international accounting standards group reviewed recoverable values property plant conformity requirements companies act equipment inventories goodwill intangible assets international financial reporting standards issued material balances impacted climaterelated iasb risks groups transition plans mitigate risks composition financial statements one climaterelated risks identified relates metered dose inhalers mdi group addressing risk consolidated financial statements drawn sterling transitioning lowercarbon propellant transition functional currency gsk plc accordance ifrs expected material impact recoverable accounting presentation financial statements comprise amount estimated useful lives related property plant consolidated income statement equipment see note 'property plant equipment ' details consolidated statement comprehensive income consolidated balance sheet whilst currently significant mediumterm impact consolidated statement changes equity expected group aware everchanging risks consolidated cash flow statement attached climate change continues assess impact notes financial statements judgements estimates preparation consolidated financial statements composition group parent company financial statements list subsidiaries associates opinion directors principally affected amount profit net financial statements parent company gsk plc assets group given note principal group prepared accordance uk gaap uk companies accounting presentation company balance sheet presented accounting policies given financial period pages financial statements cover financial year january december comparative figures financial years january december appropriate january december accounting principles policies financial statements prepared using historical cost convention modified revaluation certain items stated accounting policies going concern basis financial statements prepared accordance groups accounting policies approved board described note accounting principles policies information application accounting policies including areas estimation judgement given note critical accounting judgements key sources estimation uncertainty preparation financial statements conformity generally accepted accounting principles requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period actual results could differ estimates strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued accounting principles policies consolidation part payment relating original estimate fair value contingent consideration acquisition consolidated financial statements include reported within investing activities cash flow statement assets liabilities results cash flows part payment relating increase company subsidiaries including esop trusts liability since acquisition date reported within operating groups share results net assets associates cash flows joint ventures consideration transferred together non groups share assets liabilities revenue expenses controlling interest exceeds fair value net assets joint operations liabilities contingent liabilities acquired excess recorded goodwill costs effecting acquisition financial statements entities consolidated made charged income statement period december year incurred entities group power direct goodwill capitalised separate item case relevant activities affect returns group subsidiaries part cost investment case generally control financial operating joint ventures associates goodwill denominated policies accounted subsidiaries currency operation acquired group ability exercise joint control cost acquisition groups interest rights net assets entities entities net assets acquired difference recognised directly accounted joint ventures group ability income statement exercise joint control arrangement rights specified assets obligations specified liabilities equity subsidiary acquired non arrangement arrangement accounted joint controlling interest recognised either fair value operation group ability exercise noncontrolling interests share net assets significant influence entities accounted subsidiary casebycase basis changes groups associates results assets liabilities associates ownership percentage subsidiaries accounted within joint ventures incorporated consolidated equity financial statements using equity method accounting assets liabilities revenue expenses joint operations foreign currency translation included consolidated financial statements foreign currency transactions booked functional accordance groups rights obligations interests currency group company exchange rate ruling acquired entities consolidated date group date transaction foreign currency monetary assets acquires control interests sold deconsolidated liabilities retranslated functional currency rates date control ceases exchange ruling balance sheet date exchange transactions balances subsidiaries eliminated differences included income statement profit tax taken sales subsidiaries consolidation assets liabilities including related products sold customers outside group goodwill overseas subsidiaries associates joint ventures relevant proportion profits transactions joint ventures translated sterling rates exchange ruling joint operations associates also deferred balance sheet date results cash flows overseas products sold third parties transactions non subsidiaries associates joint ventures translated controlling interests recorded directly equity deferred tax sterling using average rates exchange relief unrealised intragroup profit accounted extent considered recoverable exchange adjustments arising opening net assets profits year retained overseas subsidiaries business combinations associates joint ventures translated sterling less business combinations accounted using acquisition exchange differences arising related foreign currency accounting method identifiable assets liabilities borrowings hedge groups net investment contingent liabilities acquired measured fair value operations taken separate component equity within acquisition date consideration transferred measured retained earnings fair value includes fair value contingent translating sterling assets liabilities results consideration cash flows overseas subsidiaries associates joint fair value contingent consideration liabilities ventures reported currencies hyperinflationary reassessed balance sheet date changes economies adjustments made material reflect recognised income statement payments contingent current price levels loss net monetary assets charged consideration reduce balance sheet liability result consolidated income statement recorded income statement strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued accounting principles policies continued revenue operating income royalty income gsk enters development marketing collaborations turnover outlicences groups compounds products group receives revenue supply goods external parties contracts give rise fixed variable customers orders received majority contracts consideration upfront payments development milestones gsk enters relate sales orders containing single salesbased milestones royalties performance obligations delivery pharmaceutical vaccine products average duration sales order less income dependent achievement development months milestone recognised highly probable significant reversal amount cumulative revenue product revenue recognised control goods recognised occur usually related passed customer point control passes event occurs salesbased milestone income recognised determined customer arrangement generally highly probable sales threshold reached occurs delivery customer salesbased royalties licence intellectual property product revenue represents net invoice value including fixed recognised relevant product sale occurs variable consideration variable consideration arises sale goods result discounts allowances given revenue time recognition revenue accruals estimated future returns rebates revenue payment customer expected recognised full highly probable significant one year impact material amount reversal amount cumulative revenue recognised consideration discounted using appropriate discount rates occur methodology assumptions used estimate value added tax sales taxes excluded rebates returns monitored adjusted regularly revenue light contractual legal obligations historical trends past experience projected market conditions estimates expenditure associated returns rebates revisited expenditure recognised respect goods services reporting date resolved revenue received supplied accordance contractual terms adjusted accordingly please refer note 'critical provision made obligation exists future liability accounting judgements key sources estimation respect past event amount uncertainty ' details rebates discounts obligation reliably estimated manufacturing startup allowances costs validation achievement normal group entered collaborative agreements typically production expensed incurred pharmaceutical biotechnology companies advertising promotion expenditure charged develop produce market drug candidates vaccines income statement incurred qualify joint arrangements gsk control commercialisation activities group shipment costs intercompany transfers charged cost recognises turnover cost sales gross basis profit sales distribution costs sales customers included sharing amounts royalties due counterparty selling general administration expenditure recorded within cost sales cost sales includes net restructuring costs recognised provided recoveries cost million cost million appropriate respect direct expenditure business cost million profit sharing arrangements reorganisation plans sufficiently detailed well royalties due counterparty counterparty advanced appropriate communication controls commercialisation activities records sale affected undertaken group principal customer contract instead records share gross profit copromotion software service saas configuration costs expensed income net basis within turnover nature co incurred software configured promotion activities group records costs controlled saas provider sales commercial operations turnover includes copromotion research development revenue million million million reimbursements counterparty research development expenditure charged collaboration agreements selling general income statement period incurred administration research development costs development expenditure capitalised criteria recorded net respective lines consolidated income recognising asset met usually regulatory filing statement made major market approval considered highly probable property plant equipment used research development capitalised depreciated accordance groups policy strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued accounting principles policies continued legal disputes employee share plans provision made anticipated settlement costs legal incentives form shares provided employees disputes group outflow share option share award schemes resources considered probable reliable estimate fair values options awards calculated made likely outcome respect product liability grant dates using blackscholes option pricing model claims related certain products provision made charged income statement relevant vesting sufficient history claims made settlements enable periods management make reliable estimate provision required cover asserted unasserted claims group provides finance esop trusts purchase company shares meet obligation provide shares certain cases incurred reported ibnr actuarial employees exercise options awards costs running technique used determine estimate addition esop trusts charged income statement provision made legal expenses arising claims received disputes shares held esop trusts deducted reserves transfer made reserves group may become involved legal proceedings retained earnings vesting periods related share respect possible meaningfully assess options awards reflect ultimate proceeds receivable whether outcome result probable outflow employees exercise quantify reliably estimate liability cases appropriate disclosure cases included property plant equipment provision made property plant equipment ppe stated cost costs associated claims made group third purchase construction less provisions depreciation parties charged income statement impairment financing costs capitalised within cost incurred qualifying assets construction pensions postemployment benefits depreciation calculated write cost less residual value ppe excluding freehold land using straightline costs providing pensions defined benefit schemes basis expected useful life residual values lives calculated using projected unit credit method reviewed appropriate adjusted annually spread period benefit expected normal expected useful lives major categories ppe derived employees services consistent advice qualified actuaries pension obligations measured present value freehold buildings years estimated future cash flows discounted rates reflecting leasehold land buildings lease term years yields highquality corporate bonds pension scheme assets plant machinery years measured fair value balance sheet date equipment vehicles years costs postemployment liabilities calculated similar way defined benefit pension schemes spread disposal ppe cost related accumulated period benefit expected derived depreciation impairments removed financial employees services accordance advice statements net amount less proceeds taken qualified actuaries income statement service cost providing retirement benefits employees leases year together cost curtailment charged operating profit year group recognises right use assets lease actuarial gains losses effect changes arrangements lessee except shortterm actuarial assumptions recognised statement leases defined leases lease term months less comprehensive income year arise leases low value assets rights use assets owned third parties lease agreements capitalised groups contributions defined contribution plans inception lease recognised consolidated charged income statement incurred balance sheet corresponding liability lessor recognised lease obligation within short longterm borrowings carrying amount subsequently increased reflect interest lease liability reduced lease payments made calculating discounted lease liability leases annual payments million implicit rate lease used available incremental borrowing rate lease specific adjustment used neither available leases annual payments less million incremental borrowing rate used incremental borrowing rate rate interest gsk would able borrow similar term similar security funds necessary obtain similar asset similar market strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued accounting principles policies continued finance costs charged income statement contingent milestone payments recognised point produce constant periodic rate charge remaining contingent event becomes probable development balance obligations accounting period costs incurred group associated acquired licences patents knowhow marketing rights written variable rents part lease liability right income statement incurred unless criteria use asset payments charged income recognition internally generated intangible asset met statement incurred lease rental costs shortterm usually regulatory filing made major lowvalue leases capitalised also charged market approval considered highly probable income statement incurred acquired process rd marketed products valued nonlease components accounted separately independently part fair value businesses acquired lease components plant equipment leases third parties value substantial separately accounted land buildings vehicle long term assets either contractual leases legal nature sold separately rest modifications reassessments lease obligations occur businesses acquired lease liability right use asset remeasured costs acquiring developing computer software right use assets title expected pass gsk internal use internet sites external use capitalised point future depreciated basis consistent intangible fixed assets software site supports similar owned assets cases right use assets significant business system expenditure leads depreciated shorter useful life asset creation durable asset controlled group erp lease term systems software amortised seven ten years computer software three five years using straight goodwill line basis goodwill stated cost less impairments goodwill deemed impairment noncurrent assets indefinite useful life tested impairment least annually carrying values noncurrent assets reviewed impairment either standalone basis part larger fair value interest acquired entitys cash generating unit indication assets assets liabilities contingent liabilities exceeds might impaired additionally goodwill intangible assets consideration paid excess recognised immediately yet available use tested impairment gain income statement annually provision impairment charged income intangible assets statement year concerned intangible assets stated cost less provisions impairments goodwill reversed impairment losses amortisation impairments noncurrent assets reversed change estimates used determine recoverable amounts licences patents knowhow marketing rights separately extent revised recoverable amounts acquired acquired part business combination exceed carrying values would existed net amortised estimated useful lives generally depreciation amortisation impairments exceeding years using straightline basis time recognised available use estimated useful lives determining amortisation charge take account patent investments associates joint ventures lives exclusivity period applicable well value joint operations obtained periods nonexclusivity pharmaceutical intangible assets depending characteristics competitive investments associates joint ventures carried environment estimated longterm profits asset consolidated balance sheet groups share net book value amortised assets date acquisition postacquisition exclusivity period straightline basis remaining retained profits losses comprehensive income book value amortised nonexclusivity period together goodwill arising acquisition group years straightline basis vaccines intangible assets recognises assets liabilities revenue expenses joint cost usually amortised exclusivity period plus operations accordance rights obligations years years exclusivity period granted inventories straightline basis asset lives reviewed appropriate adjusted annually inventories included financial statements lower cost including raw materials direct labour direct costs related production overheads net realisable value cost generally determined first first basis pre launch inventory held asset high probability regulatory approval product point provision made carrying value reduce recoverable amount provision reversed point high probability regulatory approval determined strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued accounting principles policies continued financial instruments trade receivables trade receivables measured accordance financial assets business model portfolio trade receivables financial assets measured amortised cost fair value held group portfolios three business comprehensive income fvtoci fair value models ifrs collect contractual cash flows profit loss fvtpl measurement basis factoring agreement place measured determined reference business model amortised cost sell contractual cash flows managing financial asset contractual cash flow trade receivables sold factoring agreement characteristics financial asset financial assets measured fvtpl collect sell trade receivables month expected credit loss ecl contractual cash flows trade receivables may sold allowance recorded initial recognition factoring arrangement measured fvtoci trade subsequent evidence significant increase credit risk receivables measured amortised cost carried asset allowance increased reflect full lifetime original invoice amount less allowances expected credit ecl realistic prospect recovery asset losses written expected credit losses calculated accordance expected credit losses recognised income statement simplified approach permitted ifrs using provision financial assets measured amortised cost fair matrix applying lifetime historical credit loss experience value comprehensive income apart equity trade receivables expected credit loss rate varies investments depending whether extent settlement trade receivables overdue also adjusted current equity investments appropriate reflect current economic conditions current equity investments comprise equity investments estimates future conditions purpose determining group holds intention sell may sell credit loss rates customers classified groupings short term acquired intention similar loss patterns key drivers loss rate measured fvtpl initially recorded fair value nature business unit location type remeasured subsequent reporting dates fair value customer unrealised gains losses recognised income statement dividend income recognised income trade receivable determined reasonable statement groups right receive payment expectation recovery written firstly established purchases sales current equity investments expected credit loss allowance available accounted trade date income statement investments subsequent recoveries amounts previously provided written credited income statement longterm investments comprise equity investments investments receivables discounted effect material limited life funds group elected designate majority equity investments measured fvtoci cash cash equivalents initially recorded fair value plus transaction costs cash held deposit accounts measured amortised cost remeasured subsequent reporting dates fair value investments money market funds held fair value unrealised gains losses recognised profit loss funds fail solely payments comprehensive income disposal equity investment principal interest sppi test gains losses deferred comprehensive income transferred directly retained borrowings earnings borrowings initially recorded amount proceeds investments limited life funds measured fvtpl received net transaction costs borrowings subsequently initially recorded fair value remeasured carried amortised cost difference subsequent reporting dates fair value unrealised gains proceeds net transaction costs amount due losses recognised income statement redemption recognised charge income statement period relevant borrowing dividends equity investments distributions funds recognised income statement groups right derivative financial instruments receive payment established derivative financial instruments used manage exposure market risks principal derivative instruments used gsk purchases sales investments accounted foreign currency swaps interest rate swaps foreign trade date exchange forward contracts options group hold issue derivative financial instruments trading speculative purposes derivative financial assets liabilities including derivatives embedded host contracts separated host contract measured fair value changes fair value derivative instruments qualify hedge accounting recognised immediately income statement strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued accounting principles policies continued hedge accounting deferred tax assets liabilities recognised temporary differences arise initial recognition derivatives designated hedging instruments goodwill initial recognition assets classified inception hedge relationship cash flow liabilities transaction business combination hedges net investment hedges fair value hedges affects neither accounting taxable profit loss changes fair value derivatives designated cash flow unrecognised deferred tax assets reassessed hedges recognised comprehensive income reporting date recognised extent extent hedges effective accumulated become probable future taxable profits allow cash flow hedge reserve ineffective portions recognised deferred tax asset recovered profit loss immediately amounts deferred cash flow uncertain tax position identified management hedge reserve reclassified income statement make judgement probable outcome hedged item affects profit loss hedged forecast assuming relevant tax authority full knowledge transaction purchase nonfinancial asset amount situation assessed economic outflow deferred cash flow hedge reserve transferred directly probable arise provision made best estimate equity included carrying value recognised liability estimating liability gsk applies risk nonfinancial asset based approach takes account appropriate net investment hedges accounted similar way probability group would able obtain cash flow hedges reclassified income compensatory adjustments international tax treaties statement hedged item affects profit loss estimates take account specific circumstances dispute relevant external advice changes fair value derivatives designated fair value hedges recorded income statement together discounting changes fair value hedged asset liability time value money material balances taxation discounted current values using appropriate discount rates unwinding discounts recorded finance income current tax provided amounts expected paid finance expense applying tax rates enacted substantively enacted balance sheet date tax charge assets liabilities held sale distribution period recognised income statement statement discontinued operations comprehensive income directly equity according accounting treatment related transaction disposal groups classified held sale distribution deferred tax provided full temporary differences arising carrying amount recovered principally sale tax bases assets liabilities carrying distribution shareholders rather continuing amounts financial statements deferred tax assets use available sale distribution present recognised extent probable future taxable condition sale distribution considered highly profits available temporary differences probable assets held assets held sale distribution utilised deferred tax provided temporary measured lower carrying amount fair value differences arising investments subsidiaries associates less costs sell distribute noncurrent assets included joint ventures except timing reversal assets held sale distribution depreciated temporary difference controlled probable amortised assets liabilities classified held sale temporary difference reverse foreseeable distribution presented current assets current liabilities future deferred tax provided using rates tax separately assets liabilities balance enacted substantively enacted balance sheet sheet date deferred tax assets liabilities offset discontinued operation component group legally enforceable right offset current tax assets disposed distributed classified held sale current tax liabilities relate income taxes distribution represents separate major line levied tax authority company business results discontinued operations presented subsidiaries intend settle current tax assets liabilities separately consolidated income statement net basis consolidated statement comprehensive income consolidated statement cash flows comparatives restated consistent basis strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued critical accounting judgements key sources estimation uncertainty preparing financial statements management required revenue recognised full highly probable make judgements items significant reversal amount cumulative revenue recognised financial statements estimates recognised occur amount turnover recognised assumptions affect amounts assets liabilities year performance obligations satisfied previous revenue expenses reported financial statements periods set note turnover segment information actual amounts results could differ estimates indication level sensitivity estimate following considered critical accounting future events could cause assumptions judgements key sources estimation uncertainty accruals based change could materially affect turnover future results group reported group turnover million taxation million tax charge year million estimates million december current tax payable million million noncurrent corporation tax payable gross turnover reduced rebates discounts allowances million million current tax recoverable product returns given expected given vary million million product arrangements buying groups arrangements purchasing organisations dependent upon judgement estimates submission claims time initial recognition group open tax issues number revenue sale accruals made time sale authorities management makes judgement whether estimated rebates discounts allowances payable returns sufficient information able make reliable estimate made based available market information outcome dispute insufficient information historical experience available provision made sales pharmaceutical vaccine products us sufficient information available estimating potential tax complex arrangements rebates discounts allowances liability gsk applies riskbased approach takes turnover commercial operations products us account appropriate probability group would million million recording able obtain compensatory adjustments deductions million million rebates international tax treaties estimates take account allowances returns discounts december specific circumstances dispute relevant external total accrual amounted million advice inherently judgemental could change million due nature accruals practicable substantially time dispute progresses new give meaningful sensitivity estimates due large volume facts emerge variables contribute overall rebates chargebacks returns revenue accruals december group recognised provisions million respect uncertain tax positions significant variability final outcomes million due number uncertain tax positions held group applies constraint measuring variable number jurisdictions relate element within revenue revenue recognised practicable give meaningful sensitivity estimates suitably cautious amount objective constraint uncertain tax position individually material group ensure highly probable significant reversal revenue occur uncertainties resolved factors affecting tax charge future years set constraint applied making suitably cautious estimates note taxation gsk continues believe made inputs assumptions used estimating variable adequate provision liabilities likely arise open consideration amounts estimated may assessments open issues exist ultimate liability fully reflect final outcome amounts subject matters may vary amounts provided change dependent upon amongst things types dependent upon outcome negotiations relevant buying group product sales mix constraints applied tax authorities necessary litigation proceedings recognising revenue mean risk material downward adjustment revenue next financial year low level accrual rebates returns reviewed adjusted regularly light contractual legal obligations historical trends past experience projected market conditions market conditions evaluated using wholesaler thirdparty analyses market research data internally generated information reasonably possible could significant adjustment within next months recognise additional revenue actual outcomes better cautious constrained estimates strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued critical accounting judgements key sources estimation uncertainty continued legal disputes pensions postemployment benefits legal costs year million million judgement december provisions legal disputes surplus defined benefit scheme arises amounted million million potential surplus arise committed future judgement contributions rights trustees prevent group obtaining refund surplus future considered management makes judgement whether sufficient determining whether necessary restrict amount information able make reliable estimate likely surplus recognised three uk schemes surplus outcome dispute legal expenses two uk schemes combined surplus arising claims group insufficient information million december million available provision made disclosure claim recognised pension surpluses totalling million given spread across five countries million across five estimated provisions take account specific countries gsk made judgement amounts circumstances dispute relevant external advice meet requirements recoverability inherently judgemental could change substantially estimates time dispute progresses new facts emerge details status various uncertainties involved significant costs providing pensions postemployment unresolved disputes set note legal proceedings benefits assessed basis assumptions selected management assumptions include future earnings companys directors taken legal advice pension increases discount rates expected longterm rates established provisions taking account relevant return assets mortality rates disclosed note facts circumstances matter accordance pensions postemployment benefits accounting requirements respect product liability claims related certain products sufficient history discount rates derived aa rated corporate bond yields claims made settlements enable management make except countries deep market corporate reliable estimate provision required cover unasserted bonds government bond yields used sensitivity claims analysis provided note pensions post employment benefits reduction discount rate group may become involved legal proceedings would lead increase net pension deficit respect possible meaningfully assess approximately million increase annual whether outcome result probable outflow pension cost approximately million similarly quantify reliably estimate liability cases increase discount rate would lead decrease appropriate disclosure cases would provided net pension deficit approximately million provision would made contingent liability decrease annual pension cost approximately quantified million ultimate liability legal claims may vary amounts reduction discount rate would lead provided dependent upon outcome litigation increase net pension deficit approximately proceedings investigations possible settlement million increase annual pension cost negotiations position could change time approximately million similarly increase therefore assurance losses result discount rate would lead decrease net pension outcome legal proceedings exceed deficit approximately million decrease amount provisions reported groups financial annual pension cost approximately million selection statements material amount different assumptions could affect future results group contingent consideration income statement charge contingent consideration million million december liability contingent consideration amounted million million amount million million related acquisition former shionogiviiv healthcare joint venture estimates contingent consideration included consideration payable business combination recorded fair value date acquisition fair values generally based riskadjusted future cash flows discounted using appropriate posttax discount rates fair values reviewed regular basis changes reflected income statement see note contingent consideration liabilities strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued new accounting requirements international tax reform pillar two model rules amendments amendments ias adoption ifrs insurance contracts amendments group adopted amendments ias certain ifrs accounting standards year ended introduced response oecds beps pillar two december material impact rules include results financial position group mandatory temporary exception recognition certain amendments ifrs accounting standards disclosure deferred taxes arising jurisdictional interpretations published mandatory implementation pillar two model rules december reporting periods disclosure requirements affected entities help users adopted early group amendments financial statements better understand entitys interpretations expected material impact exposure pillar two income taxes arising results financial position group future reporting legislation periods gsk applied mandatory exception amendments ias statement cash flows ifrs recognising deferred tax impact information financial instruments disclosures supplier finance impact pillar two model framework including arrangements require additional disclosure information impact effective tax rate set note group supplier finance arrangements disclosure 'taxation ' requirements apply annual reporting periods beginning january interim periods ending december exchange rates group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries joint ventures associates sterling period end rates translate net assets entities currencies influence translations relevant exchange rates average rates period end rates us us euro euro yen yen strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued turnover segment information operating segments reported based financial information provided chief executive officer responsibilities gsk leadership team glt gsk reports two segments commercial operations total rd members glt responsible segment originally gsk reported results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare however reporting operating segments changed demerger consumer healthcare two operating segments reportable comparative information retrospectively revised consistent basis change reportable segments rd investment essential sustainability business however segment reporting commercial operating profits exclude allocations globally funded rd total rd segment responsibility chief scientific officer reported separate segment operating costs segment includes rd activities across specialty medicines including hiv vaccines includes rd selling general administrative sga costs relating regulatory functions groups management reporting process allocates intragroup profit product sale segment sale recorded profit analyses presented basis turnover segment commercial operations product sales reported within three product groups vaccines specialty medicines general medicines commercial operations shingles meningitis rsv influenza established vaccines pandemic vaccines vaccines hiv respiratoryimmunology oncology pandemic specialty medicines respiratory general medicines general medicines total commercial operations strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued turnover segment information continued sales made three us wholesalers million million million million million million million million million respectively allocating finalcustomer discounts wholesalers revenue recognised year performance obligations satisfied previous periods totalled million million including million million impacting turnover arising changes prior year estimates rar returns rebates accruals million million milestone income million million royalty income recognised current year segment profit commercial operations research development segment profit corporate unallocated costs reconciling items segment profit operating profit total operating profit finance income finance costs gainloss disposal interest associates share aftertax profitslosses associates joint ventures profit taxation continuing operations taxation profit taxation year continuing operations reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring costs include impairments tangible assets computer software transactionrelated adjustments related significant acquisitions proceeds costs disposals products businesses significant legal charges expenses settlement litigation government investigations operating income royalty income items please refer detail reconciling items segment profit operating profit analysis adjusting items group financial review depreciation amortisation segment commercial operations research development segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued turnover segment information continued ppe intangible asset goodwill impairment segment commercial operations research development segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment commercial operations research development segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals net operating assets segment commercial operations research development segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures current equity investment derivative financial instruments current deferred taxation assets held sale excluding cash cash equivalents net assets commercial operations segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million geographical information uk regarded groups country domicile turnover location customer uk us rest world external turnover noncurrent assets location subsidiary uk us belgium rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables countries individually material external revenue noncurrent assets strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued operating incomeexpense upfront settlement income fair value remeasurements equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends fair value adjustments derivative financial instruments income february viiv healthcare reached agreement gilead sciences inc gilead settle global patent infringement litigation relating commercialisation gileads biktarvy concerning viiv healthcares patents relating dolutegravir antiretroviral medication used together medicines treat human immunodeficiency virus hiv terms global settlement licensing agreement gilead made upfront payment billion million viiv healthcare february addition gilead also pay royalty future us sales biktarvy respect bictegravir component future bictegravircontaining products sold us royalties payable gilead viiv healthcare february expiry viiv healthcares us patent october recorded royalty income income statement fair value remeasurement equity investments included loss million remeasurement groups retained investment haleon plc see details note 'current equity investments ' disposal businesses assets primarily includes milestone income disposal businesses assets includes milestone income reversal provisions longer required disposal businesses assets included net gain disposal rights royalty stream cabozantinib net gain disposal cephalosporin antibiotic brands sandoz fair value remeasurements contingent consideration recognised business combinations included net charge million related acquisition former shionogiviiv healthcare joint venture million net credit payable novartis related vaccines acquisition together fair value movements related hedging contracts charge million relating contingent consideration acquisition affinivax primarily relating unwind discount income primarily includes net income dividends related investments including million dividends received retained investment haleon plc strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals depreciation right use assets impairment right use assets amortisation intangible assets impairment intangible assets net reversals impairment tangible intangible assets held sale net reversals net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories shortterm lease charge lowvalue lease charge variable lease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange gainslosses include net gain million million loss million gain arising recycling exchange liquidation disposal overseas subsidiaries recycling exchange disposal overseas associates nil nil recycling exchange disposal overseas subsidiaries include recycling exchange disposal consumer healthcare subsidiaries reported profit taxation demerger discontinued operations included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements including attestation sarbanesoxley act audit companys subsidiaries total audit services auditrelated assurance services total audit services auditrelated assurance services assurance services provided auditor related agreed upon procedures assurance services outside statutory audit requirements audit related assurance services include nil million million due reporting accountant work performed preparation consumer healthcare demerger addition fees paid auditor respect gsk pension schemes audit strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average number persons employed group including directors year number number number manufacturing selling general administration research development total continuing operations discontinued operations total note consumer healthcare divested july shown discontinued operations table average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record compensation directors senior management members glt aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information remuneration directors given sections annual report remuneration labelled audited within pages strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued major restructuring costs within pharmaceuticals sector highly regulated manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing rd sites likely take several years complete major restructuring costs related specific boardapproved major restructuring programmes including integration costs following material acquisitions structural significant scale costs individual related projects exceed million january board approved separation preparation programme prepare separation gsk two companies programme largely complete acquisition sierra oncology july affinivax august board approved major restructuring programme integration significant acquisitions designed integrate achieve synergies june gsk acquired bellus health inc total restructuring costs million million million incurred following areas restructuring costs separation gsk two companies continued transformation central functions including gsk technology platforms interfaces deliver greater digital synergies simplification applications staff reductions integration acquisitions analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash chargescredit cash costs provision reversals million reflected provision releases mainly related separation preparation programme asset impairments million noncash charges million principally comprised fixed asset writedowns manufacturing administrative facilities accelerated depreciation asset lives shortened supply chain manufacturing network result major restructuring programmes charges settled cash include site closure costs consultancy project management costs analysis major restructuring charges programme follows cash noncash total separation preparation programme significant acquisitions legacy programmes cash noncash total separation preparation programme significant acquisitions legacy programmes analysis major restructuring charges income statement line follows cost sales selling general administration research development strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued finance income finance income arising financial assets measured amortised cost financial assets measured fair value profit loss net gains arising forward element forward contracts net investment hedge relationships finance income finance expense finance expense arising financial liabilities amortised cost net losses arising financial instruments mandatorily measured fair value profit loss retranslation loans reclassification hedges comprehensive income unwinding discounts provisions finance expense arising lease liabilities finance expense strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued associates joint ventures groups share aftertax profits losses associates joint ventures set share aftertax lossesprofits associates share aftertax losses joint ventures year group disposed investment joint venture nil consideration release related commitments future capital contributions resulting net million profit disposal may group agreed innoviva inc sell shares innoviva back innoviva million following disposal december december december group held significant individual associates summarised income statement information respect innoviva may set results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods based publicly available information figures include share innovivas turnover profit total comprehensive income date disposal turnover profit taxation total comprehensive income aggregated financial information respect gsks share associated undertakings joint ventures set share aftertax losses share comprehensive incomeexpense share total comprehensive incomeexpense groups sales associates joint ventures nil nil nil please refer balance sheet information note 'investments associates joint ventures ' strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge chargecredit respect prior periods current taxation deferred taxation gsk made corporate income tax payments globally billion billion million million uk corporation tax paid hmrc amounts corporate income tax include various business taxes borne gsk year deferred tax credits period reflect current year losses offset taxable profits future periods probable release deferred tax liabilities latter relates primarily unwind deferred tax liabilities intangible assets following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits permanent differences disposals acquisitions transfers permanent differences reassessments prior year current tax estimates reassessments prior year deferred tax estimates changes tax rates tax chargetax rate global biopharmaceutical company substantial business employment presence many countries around world impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant belgium japan adverse impact offset benefit intellectual property incentives uk patent box belgian innovation income deduction regimes provide reduced rate corporation tax profits earned qualifying patents claim incentives manner intended relevant statutory regulatory framework permanent differences disposals acquisitions transfers includes tax internal restructuring simplify group structure groups tax rate also influenced updates estimates prior period tax liabilities following closure open issues tax authorities various jurisdictions changes tax rates cumulative impact items reduction tax rate changes tax rates included credits relation enactment increase headline rate uk corporate income tax effective future tax charges therefore effective tax rate may affected factors acquisitions disposals restructurings location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world uk government substantively enacted legislation introducing global minimum corporate income tax rate effect line organisation economic cooperation developments oecd pillar two model framework anticipate rules restrict ability benefit innovation incentives uk belgium patent box regimes consequently underlying effective tax rate forecast increase around strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued taxation continued tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments total chargecredit equity statement comprehensive income items charged statement comprehensive income except tax share based payments issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines base transfer pricing policy arms length principle support transfer prices economic analysis reports however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies risk based approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgement respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million net increase recognised provisions driven reassessment estimates agreement number open issues tax authorities various jurisdictions amounts related discontinued operations whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues consider made appropriate provision periods open yet agreed tax authorities provision deferred tax liabilities million december million made respect taxation would payable remittance profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions deferred tax provided temporary differences million million arising unremitted profits management ability control future reversal consider reversal probable strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued taxation continued movement deferred tax assets liabilities pensions share accelerated intra post option net capital intangible contingent group employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposals rd credits utilisation transfer assets saledistribution december exchange adjustments creditcharge income statement creditcharge statement comprehensive income acquisitionsdisposals rd credits utilisation december deferred tax liabilities relation intangible assets predominately relate temporary differences arising result historic business combinations acquisitions within year predominantly relate bellus health see note 'acquisitions disposals ' group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset million million recognised tax losses relates trading losses deferred tax assets recognised extent group longrange forecasts indicate sufficient future taxable profits available utilise assets around net temporary differences included accrued expenses tax deduction available paid basis deferred tax asset liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses expiring available indefinitely december deferred tax assets recognised probable future taxable profit available utilise losses strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued earnings per share pence pence pence basic earnings per share continuing operations basic earnings per share discontinued operations total basic earnings per share diluted earnings per share continuing operations diluted earnings per share discontinued operations total diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts future exercise share options share awards treasury shares trustees waived rights cash dividends gsk shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total estimate fourth interim dividend disclosed annual report million million less dividend ultimately paid ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends demerger consumer healthcare effected gsk declaring interim dividend specie haleon plc shares fair value distribution million amounts recognised year follows cash dividends shareholders dividends specie shareholders haleon plc shares note strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held saledistribution cost december exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held saledistribution cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held saledistribution depreciation december exchange adjustments charge year disposals writeoffs transfer assets held saledistribution reclassifications depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held saledistribution impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held saledistribution reclassifications impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued property plant equipment continued weighted average interest rate capitalised borrowing costs year disposals writeoffs year included number assets nil net book value longer use business impairment losses principally arose decisions rationalise facilities calculated based fair value less costs disposal fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate specific segment country currency risk assets continue used group generally assessed part associated cash generating unit value use basis value use calculations posttax cash flows include impact future uncommitted restructuring plans improvements impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pre tax discount rate approximately net impairment reversals credited cost sales million net impairment losses million rd million net impairment losses million net impairment losses charged sga million million charging impairment losses million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply million impairment reversal credited cost sales million impairment reversal credited rd expenses million impairment reversal credited sga full impairment reversal million credited cost sales million million computer software reclassified assets construction intangible assets becoming ready use group assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded material impairments december million capitalised property plant equipment regarding transition lowercarbon propellant right use assets land plant buildings equipment vehicles total net book value january exchange adjustments additions business combinations additions depreciation transfer assets held saledistribution disposals impairments net book value december exchange adjustments additions business combinations additions depreciation transfer assets held saledistribution disposals impairments reclassifications net book value december group entered commitments lease contracts yet commenced see note 'commitments ' analysis lease liabilities set note net debt strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued goodwill cost january exchange adjustments additions business combinations note movements note transfer assets held saledistribution cost december net book value january net book value december goodwill allocated groups segments follows commercial operations total rd net book value december recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected risk adjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy rd segment evaluated arm 's length pricing model see assumptions details relating discounted cash flow models used impairment tests follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates jurisdiction period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate commercial operations pa pa rd pa pa commercial operations pa pa rd pa pa terminal growth rate exceed longterm projected growth rates relevant markets reflects impact future generic competition take account new product launches goodwill monitored impairment segmental level valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill group assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded material impairments strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued intangible assets computer licences patents indefinite life software amortised brands brands total cost january exchange adjustments capitalised development costs additions business combinations additions disposals asset writeoffs transfer assets held saledistribution reclassifications cost december exchange adjustments capitalised development costs additions business combinations additions disposals asset writeoffs transfer assets held saledistribution reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held saledistribution reclassifications amortisation december impairment january exchange adjustments impairment losses transfer assets held saledistribution reversal impairments disposals asset writeoffs impairment december exchange adjustments impairment losses transfer assets held saledistribution reversal impairments disposals asset writeoffs impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs carrying value december intangible assets impairments charged year following impairments million million resulting appraisal gsks assumptions related inlicences collaboration agreements carrying value december intangible assets impairment reversals charged year following impairment reversals nil million million individual intangible asset accounted material impairment strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued intangible assets continued patent expiry dates groups significant assets relevant set pages please refer note 'accounting principles policies ' groups accounting policy estimate useful life intangible assets exclusivity nonexclusivity periods amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents amortised brands etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows tesaro assets meningitis portfolio momelotinib camlipixant affinivax assets dolutegravir including cabotegravir iteos assets alector assets benlysta shingrix okairos bms assets curevac assets spero rsv relvarbreoanoro stiefel trade name wave life sciences ucb arrowhead dt fluarixflulaval vir assets others announcement december gsk wave life sciences ltd entered strategic collaboration january advance oligonucleotide therapeutics focusing novel genetic targets june gsk completed acquisition bellus health inc latestage biopharmaceutical company acquisition provides gsk access camlipixant refer note 'acquisitions disposals ' group consider reasonably possible changes key assumptions would cause recoverable amount intangible assets disclosed fall carrying values group assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded material impairments strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received net fair value movements comprehensive income impairment interest associates profitloss tax recognised consolidated income statement december year group disposed investment joint venture nil consideration please refer income statement information note 'associates joint ventures ' current equity investments investments investments measured measured fvtpl fvtpl current january additions net fair value movements profit loss disposals settlements exchange adjustments december current equity investments represent haleon plc shares held demerger consumer healthcare shares held trading measured fair value profit loss fvtpl based haleon plc share price changes fair value presented operating incomeexpense continuing operations groups investment haleon plc end december held glaxo group limited gsk scottish limited partnership gsk scottish limited partnership nil gsk scottish limited partnership nil esop trusts nil strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued investments investments investments designated investments designated investments measured measured measured measured fvtoci fvtpl fvtoci fvtpl noncurrent january exchange adjustments additions net fair value movements comprehensive income net fair value movements profit loss held sale disposals december noncurrent investments comprise noncurrent equity investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments recent financing rounds discounted cash flows underlying net assets net fair value movements include impact exchange losses million comprehensive income nil profit loss gains million comprehensive income nil profit loss investments include listed investments million million gsk elected designate majority equity investments measured fair value comprehensive income fvtoci significant investments held december crispr therapeutics ag fair value december million million vir biotechnologyinc fair value december million million fair value investment nimbus therapeutics llc disclosed significant investment december million december million investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest disposal equity investments measured fvtoci accumulated fair value movements reclassified fair value reserve retained earnings investments measured fvtoci fair value million million disposed year cumulative loss investments tax million gain million certain investments investments funds limited lives investments acquired intention sell measured fair value profit loss fvtpl significant investments held december sr one capital fund ib lp fair value december million million noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables amounts receivable insurance contracts held cash surrender value movements profit loss within receivables million million million million classified financial assets million million classified fair value profit loss remaining balance million million expected credit loss allowance immaterial december receivables include million relating carbonbased nature removal projects million strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued inventories raw materials consumables work progress finished goods part tcfd one climaterelated risks identified affects metered dose inhalers mdi impact recoverable value associated inventories held year end trade receivables trade receivables net loss allowance accrued income prepayments interest receivable employee loans advances receivables trade receivable balances nil due associates joint ventures significant component receivables comprises receivables indirect taxes million million significant balances within receivables royalties receivable million million amount receivable collaboration partners nil million loss allowance trade receivables january exchange adjustments charge year transfer assets held sale subsequent recoveries amounts provided utilised december total trade receivables balance million million considered credit impaired million million expected credit loss allowance applied amount purchased originated credit impaired within receivables million million million million classified financial assets nil nil classified held fair value profit loss december expected credit loss allowance million million recognised respect financial assets release expected credit loss allowance million nil reported profit loss year discussion credit risk practices please refer note 'financial instruments related disclosures ' strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued cash cash equivalents cash bank hand cash equivalents cash cash equivalents included million million available general use due restrictions applying subsidiaries held restrictions include exchange controls taxes repatriation million transferred assets held sale relating consumer healthcare demerged year see note 'acquisitions disposals ' assets held sale property plant equipment noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued trade payables trade payables wages salaries social security viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included nil nil due associates joint ventures group provides limited supplier financing arrangements certain suppliers amounts involved december material revenue recognised year included deferred income january million million customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers fully described group financial review december customer return rebate accruals included million million respect us commercial operations accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual amounts paid changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare currently exercisable pfizer may request ipo viiv healthcare time either gsk consent ipo offering completed within nine months pfizer could require gsk acquire shareholding amount liability put option held gross redemption basis derived internal valuation viiv healthcare business utilising discounted forecast future cash flow multiplesbased methodologies table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts increase sales forecasts decrease sales forecasts decrease sales forecast basis points increase discount rate basis points increase discount rate basis points decrease discount rate basis points decrease discount rate cent appreciation us dollar cent appreciation us dollar cent depreciation us dollar cent depreciation us dollar cent appreciation euro cent appreciation euro cent depreciation euro cent depreciation euro sales forecast viiv healthcare sales respect viiv healthcare put option accruals includes interest accrued financial liabilities amortised cost million million explanation accounting viiv healthcare set strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts euro medium term note london stock exchange euro medium term note london stock exchange us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange lease liabilities longterm borrowings us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note london stock exchange euro medium term note london stock exchange us us medium note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange longterm borrowings lease liabilities net debt strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued net debt continued current assets liquid investments classified financial assets amortised cost december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount million nil balances reported within cash cash equivalents original maturity three months less effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amounted million million respectively million noninterest bearing holdings amounted million million gsks policy regarding credit quality cash cash equivalents set note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme million million issue december million million gsk billion euro commercial paper programme million million issue december million million gsk billion threeyear committed facility billion billion day committed facility threeyear committed facility agreed february extended one year august september day committed facility agreed september facilities undrawn december weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december average effective preswap interest rate notes classified shortterm december longterm borrowings yearend gsk longterm borrowings billion billion billion billion fell due five years bilateral buyback outstanding sterling notes gsk repurchased euro medium term note euro medium term note average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging effective rates exclude impact oneoff premiums associated early repayment sterling notes pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note 'other provisions lease liabilities maturity analysis discounted lease liabilities recognised group balance sheet follows rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total lease liabilities strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit credit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years remeasurement movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rates pension increases longterm predictions based yield gap longterm indexlinked fixed interest government bonds uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using pri white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancy strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment physical asset allocation strategy three four uk plans returnseeking assets liabilitymatching assets buyin insurance contract purchased cover substantially obligations uk plan december value insurance contract million million asset allocation us plans currently set return seeking assets liabilitymatching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix returnseeking assets generate future returns liabilitymatching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property currency bank counterparty risk plan liabilities series future cash flows relatively long duration ias basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase long term inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities interest rate risk credit rate risk us partially hedged targets based accounting measure plan liabilities uk plans interest rate inflation hedging strategy place targets based economic measure plan liabilities climaterelated impacts along environmental social governance esg considerations financially material regard expected returns risk implications incorporation considerations investment policy subject local regulations fiduciary obligations uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme addition group operates number postretirement healthcare schemes principal one us uk defined benefit plans closed future accrual effective march result post closure accrued benefits active participants revalued line inflation rpi legacy glaxo wellcome plans cpi legacy smithkline beecham plans subject relevant caps arrangement rather capped pay increases april former defined benefits plans employees transferred defined contribution plans defined benefit plan participants still active april received defined pension contribution us cash balance pension plan closed future accrual january group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings na na na na na discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detailing effect changes assumptions provided analysis provided reflects assumption changes material impact results group strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income amounts included within past service costs uk included million million million augmentation costs arose major restructuring programmes strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised pensions postemployment benefits pension schemes deficit postretirement benefits event plan windup gsk believes uk pension scheme rules provide company right refund surplus assets following full settlement plan liabilities result net surplus uk defined benefit pension schemes recognised full fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio value funds asset class quoted market price million million liabilitiesassets category comprises cash mark market values derivative positions indexlinked gilts held part uk repo programme included government bonds related loan million december million million deducted within assets strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets asset ceiling restrictions present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions transfer assets held saledistribution benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions transfer assets held saledistribution benefits paid assets december final instalment cash funding technical provision deficits million identified december pension scheme valuations three gsk uk pension schemes paid march gsk transferred gsk consumer healthcare holdings limited gskchh c ordinary shares representing aggregate gsks interest gskchh three scottish limited partnerships slps providing funding mechanism separate gsk uk defined benefit pension scheme part steps relating demerger separation slps transferred applicable portion gskchh c ordinary shares haleon plc haleon consideration shares haleon time demerger slps together held shares representing total issued share capital haleon contributions collateralised creation three scottish limited partnerships slps three principal uk defined benefit pension schemes two benefiting current former glaxo welcome employees third benefiting current former smithkline beecham employees interest one slps time demerger scottish limited partnership general partner limited partners gsk scottish limited partnership gsk gp ltd gsk lp ltd berkeley square pension trustee company ltd acting behalf gsk pension scheme ceased limited partner effective june gsk scottish limited partnership gsk gp ltd gsk lp ltd berkeley square pension trustee company ltd acting behalf gsk pension fund ceased limited partner effective june gsk scottish limited partnership gsk gp ltd gsk lp ltd smithkline beecham pension plan trustee ltd acting behalf smithkline beecham pension plan ceased limited partner effective june strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued pension scheme slp interest received distribution slp regards net proceeds sales haleon shares dividend income haleon shares amount equal agreed threshold proceeds threshold million increased million notional interest payment amount fully funded cash funding technical provisions deficits three pension schemes shown december valuations december total cash contributions totalling million million million made towards proceeds threshold leaving outstanding amount due uk pension schemes cash contributions included million distributions dividends haleon shares slps schemes gsk uk pension schemes exited slp partnership june receipt proceeds threshold notional interest remaining economic interest slps held gsk lp ltd owned subsidiary gsk plc gsk controlled general partner slp employer contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions transfer assets held saledistribution benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions transfer assets held saledistribution benefits paid obligations december strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfunded movement net defined benefit liability follows january exchange adjustments service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest lossgain change demographic assumptions gainloss change financial assumptions experience lossgain employer contributions transfer assets held saledistribution expenses december remeasurements included within postretirement benefits detailed gain change demographic assumptions gainloss change financial assumptions experience gains defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued pensions postemployment benefits continued sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension post retirement costs detailed information determined taking account duration liabilities overall profile plan memberships increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation increase decrease increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation increase annual postretirement benefits cost increase postretirement benefits obligation strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised transfer assets held saledistribution additions business combinations reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes nature groups business number matters may subject negotiation litigation group involved substantial number legal many years litigation proceedings including various disputes including notification possible claims set appeal procedures often take many years reach resolution note legal proceedings provisions legal outofcourt settlement discussions also often disputes include amounts relating product liability antitrust protracted indemnified disputes result provision charge government investigations contract terminations self corresponding receivable insurance group potential settlement discussions number group may become involved significant legal disputes amounts provided based proceedings respect possible current assessment progress disputes meaningfully assess whether outcome result estimates million amount provided probable outflow quantify reliably estimate liability december settled within one year could result ultimate resolution discussion legal issues see note legal proceedings proceedings cases group would provide appropriate disclosures cases provision major restructuring programmes would made group two major restructuring net charge year million including reversals programmes separation preparation programme estimated insurance recoveries primarily related focused preparing separation gsk two provisions product liability cases commercial disputes companies largely complete plus significant various government investigations acquisitions programme focused integration recent acquisitions discount provision million million discount calculated using riskadjusted restructuring provisions primarily include severance costs projected cash flows riskfree rates return management made formal decision eliminate certain positions communicated groups respect product liability claims related certain products employees affected appropriate consultation procedures provision made sufficient history claims made completed appropriate provision made staff settlements enable management make reliable severance payments paid immediately estimate provision required cover unasserted claims determine probability outflow cash discount provisions increased million ultimate liability matters may vary amounts increased million provided dependent upon outcome litigation pension augmentation includes million relating proceedings investigations possible settlement defined benefit plan arising staff redundancies shown negotiations note pensions postemployment benefits groups position could change time therefore assurance losses result outcome legal proceedings exceed material amount amount provisions reported groups financial accounts strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued provisions continued employee related provisions given nature provisions amounts likely settled many years employee related provisions include obligations certain medical benefits disabled employees spouses provisions us included provisions provisions onerous contracts december provision benefits insurance provisions number provisions including amounted million million employee vehicle insurance regulatory matters benefits reflect variety provisions severance costs jubilee awards longservice benefits contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogiviiv novartis healthcare affinivax vaccines total january remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement exchange movement reserves initial recognition business combinations cash payments operating cash flows cash payments investing activities december remeasurement income statement exchange movement reserves cash payments operating cash flows cash payments investing activities december contingent consideration payable december million million expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture affinivax novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogiviiv healthcare contingent consideration liability discounted affinivax contingent consideration liability discounted novartis vaccines contingent consideration liability discounted commercialised products pipeline assets shionogiviiv healthcare novartis vaccines contingent consideration liabilities calculated principally based forecast sales performance specified products lives products affinivax contingent consideration based upon two potential milestone payments billion billion paid certain paediatric clinical development milestones achieved strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued contingent consideration liabilities continued table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogiviiv novartis shionogiviiv novartis increasedecrease financial liability lossgain healthcare affinivax vaccines healthcare affinivax vaccines income statement increase sales forecasts na na increase sales forecasts na na decrease sales forecasts na na decrease sales forecasts na na increase discount rate increase discount rate decrease discount rate decrease discount rate cent appreciation us dollar cent appreciation us dollar cent depreciation us dollar cent depreciation us dollar cent appreciation euro na na cent appreciation euro na na cent depreciation euro na na cent depreciation euro na na increase probability milestone success na na decrease probability milestone success na na sales forecast viiv healthcare sales respect shionogiviiv healthcare contingent consideration explanation accounting viiv healthcare set noncurrent liabilities accruals deferred income payables payables includes number employeerelated liabilities including employee savings plans contingent liabilities december contingent liabilities gsk present obligation result past event comprising guarantees items arising normal course business amounted million million december million million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow possible meaningfully assess whether outcomes result probable outflow quantify reliably estimate liability provision recorded descriptions significant legal disputes group party set note legal proceedings strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions postretirement benefits interest loans future finance charges leases lease contracts yet commenced commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts disclosed riskadjusted discounted increase intangible asset commitments mainly attributable new rd collaborations including collaborations wave life sciences usa inc shanghai hansoh biomedical co ltd gsk reached agreement trustees uk pension schemes make additional contributions million eliminate pension deficit identified december actuarial funding valuation prior consumer healthcare demerger gsk agreed collateralise commitment accelerate funding additional contributions refer note 'pensions postemployment benefits ' december nil million additional contributions unpaid included within total commitments million related nature based carbon removal projects support gsks net zero nature positive goals million related transition lowercarbon propellant table excludes amounts already capitalised financial statements year end strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued share capital share premium account share consolidation following completion consumer healthcare business demerger july gsk plc ordinary shares consolidated maintain share price comparability demerger consolidation approved gsk shareholders general meeting held july shareholders received new ordinary shares nominal value pence every existing ordinary shares nominal value pence earnings per share diluted earnings per share adjusted earnings per share dividends per share retrospectively adjusted reflect share consolidation periods presented years ordinary shares p preshare consolidation share ordinary shares p postshare consolidation premium number share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december impact share consolidation issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december december issued share capital shares held esop trusts shares held future exercise share options share awards shares held executive supplemental savings plan shares held treasury shares shares free issue issued shares fully paid shares authorised issue nominal carrying market values shares held esop trusts disclosed note employee share schemes movements equity retained earnings reserves amounted million december million million million million million related associates joint ventures cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates december exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates movement attributable continuing operations movement attributable discontinued operations december exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates december includes million reclassification consolidated income statement net exchange gains related demerger consumer healthcare business strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued movements equity continued analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement defined benefit plans tax remeasurement defined benefit plans fair value movements cash flow hedges total comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement defined benefit plans tax remeasurement defined benefit plans fair value movements cash flow hedges comprehensive expenseincome year continuing operations comprehensive expenseincome year discontinued operations total comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income statement items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement losses defined benefit plans tax remeasurement defined benefit plans comprehensive expenseincome year strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued movements equity continued information net investment hedges provided part note financial instruments related disclosures ' analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january exchange adjustments transferred income expenses year impairments equity investments transferred retained earnings year disposal equity investments net fair value movement year december exchange adjustments transferred retained earnings year disposal equity investments balances derecognised demerger net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december exchange adjustments transferred retained earnings year disposal equity investments reclassification cash flow hedges income statement hedging gainloss transferred nonfinancial assets net fair value movement year including tax ordinary shares acquired esop trusts writedown shares held esop trusts december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million noncontrolling interests total noncontrolling interests includes following individually material noncontrolling interests noncontrolling interests individually material viiv healthcare gsk holds viiv healthcare subgroup giving rise material noncontrolling interest summarised financial information available latest practicable date respect viiv healthcare subgroup follows turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued noncontrolling interests continued net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities increasedecrease cash bank overdrafts year financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million million million stated charging preferential dividends payable gsk pfizer charge million million million remeasurement contingent consideration payable consideration expected paid number years following amounts attributable viiv healthcare group included gsks financial statements share profit year attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet related party transactions december loan million nil index ventures loan million nil medicxi ventures lp remained due gsk cash distributions received investment medicxi ventures lp million medicxi ventures lp million december qura therapeutics llc liquidated investment associated commitment future contributions derecognised balance sheet immaterial gain less million recognised group significant related party transactions might reasonably expected influence decisions made users financial statements aggregate compensation directors glt given note employee costs strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions june gsk completed acquisition bellus health inc bellus effected plan arrangement arrangement pursuant canada business corporations act arrangement approved bellus shareholders june upon completion gsk acquired outstanding common shares bellus us per common share cash representing total equity value us billion billion acquisition provides gsk access camlipixant potential bestinclass highly selective px antagonist currently phase iii development firstline treatment adult patients refractory chronic cough rcc total net assets acquired intangible assets noncurrent equity investments right use assets trade receivables investments held current assets cash cash equivalents lease liabilities trade payables deferred tax liabilities noncontrolling interest goodwill total consideration provisional values identifiable assets liabilities acquired affinivax inc business combination updated finalisation fair value intangible assets resulting increase intellectual property million decrease goodwill million decrease deferred tax million amounts recognised december restated basis materiality business disposals gsk completed material business disposals associates joint ventures gsk completed material investments disposals associates joint ventures year cash flows business business acquisitions disposals cash consideration paid received net deferred consideration paid transaction costs cash cash equivalents acquireddivested cash outflowinflow strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued acquisitions disposals continued business acquisitions july gsk completed acquisition sierra oncology inc californiabased latestage biopharmaceutical company focused targeted therapies treatment rare forms cancer billion billion main asset momelotinib targets medical needs myelofibrosis patients anaemia total transaction costs million august gsk completed acquisition affinivax inc clinicalstage biopharmaceutical company based cambridge boston massachusetts focused pneumococcal vaccine candidates consideration acquisition comprised upfront payment billion billion adjusted working capital acquired paid upon closing two potential milestone payments billion billion paid upon achievement certain paediatric clinical development milestones estimated fair value contingent consideration payable million values provisional subject change total transaction costs million sales arising sierra oncology affinivax businesses included group turnover revenue expected regulatory approval received acquired assets gsk continues support ongoing development acquired assets consequently assets loss making regulatory approval assets received development assets integrated groups existing rd activities impracticable quantify development costs impact total profit taxation period ended december goodwill million million sierra oncology million affinivax expected deductible tax purposes recognised goodwill represents workforce place specific synergies available gsk business combinations goodwill allocated groups commercial operations rd segments refer note goodwill allocation methodology sierra oncology affinivax total net assets acquired intangible assets property plant equipment right use assets inventory trade receivables cash cash equivalents lease liabilities trade payables taxation goodwill total total cash fair value contingent consideration november gsk signed agreement buy noncontrolling interest glaxo saudi arabia ltd sar million million paid strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued acquisitions disposals continued demerger consumer healthcare business july gsk plc separated consumer healthcare business gsk group form haleon independent listed company separation effected way demerger gsks holding consumer healthcare business gsk shareholders following demerger haleon held aggregate gsk shareholders held gsk including shares received gsks consolidated esop trusts held certain scottish limited partnerships slps set provide collateral funding mechanism pursuant gsk provide additional funding gsks uk defined benefit pension schemes note 'pensions postemployment benefits ' aggregate ownership gsk including ownership esop trusts slps demerger measured fair value changes profit loss pfizer held haleon demerger ifric distributions noncash assets owners liability equity distribution measured fair value assets distributed dividend appropriately authorised longer entitys discretion liability equity movement associated gain distribution recognised q demerger distribution authorised occurred asset distributed ownership consumer healthcare business net carrying value consumer healthcare business consolidated financial statements including retained net amount attributable noncontrolling interest approximately billion end june gsks billion share shareholder loans made q advance preseparation dividends eliminated consolidated financial statements assets distributed reduced consumer healthcare transactions july principally included preseparation dividends declared settled end q july dividends included billion billion attributable gsk dividends funded consumer healthcare debt partially onlent q dividends billion billion attributable gsk available cash balances fair value ownership consumer healthcare business distributed billion measured reference quoted average haleon share price first five days trading fair value measured observable inputs considered representative fair value distribution date gain distribution fair value less book value attributable net assets consumer healthcare business billion recorded income statement additional gain billion remeasure retained book value fair value billion using fair value methodology used distributed shares gain distribution remeasurement retained stake upon demerger presented part discontinued operations future gains losses retained stake haleon recognised continuing operations addition reclassification groups share cumulative exchange differences arising translation foreign currency net assets divested subsidiaries offsetting net investment hedges reserves income statement billion total gain demerger consumer healthcare billion transactions presented profit discontinued operations fair value consumer healthcare business distributed fair value retained ownership haleon plc total fair value carrying amount net assets liabilities distributedderecognised carrying amount noncontrolling interest derecognised gain demerger exchange movements transaction costs reclassification exchange movements net investment hedge movements disposal overseas subsidiaries total gain demerger consumer healthcare consumer healthcare presented discontinued operation june disclosed interim financial statements consolidated income statement consolidated cash flow statement distinguish discontinued operations continuing operations comparative figures restated consistent basis financial information relating operations consumer healthcare period set following includes financial information july financial information differs purpose basis preparation historical financial information interim financial information included haleon prospectus published haleon march result whilst two sets financial information similar certain differences accounting disclosure ifrs strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued acquisitions disposals continued total results turnover expense profit tax taxation tax rate lossprofit taxation discontinued operations consumer healthcare gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation demerger discontinued operations noncontrolling interest discontinued operations earnings attributable shareholders discontinued operations earnings per share discontinued operations p p business disposals material business disposals business business business disposals disposals acquisitions demerger cash flows cash consideration net deferred consideration paid cash cash equivalents divestedacquired transaction costs paid cash outflowinflow cash consideration business acquisitions included million related business acquisition activity business acquisitions gsk completed material business acquisitions business disposals gsk made number business disposals net cash consideration received year million profit disposal businesses year million calculated follows total consideration cash consideration including currency forwards purchase adjustments deferred consideration total net assets sold property plant equipment cash cash equivalents net assets total costs deal costs reclassification exchange comprehensive income gain disposals strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued acquisitions disposals continued associates joint ventures may gsk agreed innoviva inc innoviva sell approximately million shares common stock innoviva back innoviva price per share raising gross proceeds approximately million following settlement transaction gsk longer hold innoviva stock see details note investment associates joint ventures cash flows associates joint business ventures disposals disposals cash consideration received net deferred consideration paid transaction costs cash cash equivalents divestedacquired cash outflowinflow adjustments reconciling total profit tax operating cash flows total profit tax continuing operations tax profits share aftertax profitslosses associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets profitloss sale investments associates profit sale equity investments changes working capital decreaseincrease inventories increase trade receivables increasedecrease trade payables increasedecrease receivables contingent consideration paid see note noncash increase contingent consideration liabilities increasedecrease payables decrease pension provisions sharebased incentive plans fair value adjustments operating cash flow continuing operations operating cash flow discontinued operations total cash generated operations strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued reconciliation net cash flow movement net debt net debt beginning year adjusted decrease cash bank overdrafts decrease liquid investments issue longterm loans repayment shortterm notes repayment ofincrease shortterm loans repayment longterm loans repayment lease liabilities investmentsdebt subsidiary undertakings acquired exchange adjustments noncash movements decreaseincrease net debt continuing operations decreaseincrease net debt discontinued operations total net debt end year january interest change reclass december exchange expense fair value ifications cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper europeanus mtn bank facilities lease liabilities debt due one year europeanus mtn bank facilities lease liabilities net debt interest payable derivative financial instruments total liabilities financing activities excluding cash cash equivalents overdrafts liquid investments strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued reconciliation net cash flow movement net debt continued january interest change reclass december exchange expense fair value ifications demerger cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts liquid investments attributed continuing operations liquid investments attributed discontinued operations debt due within one year commercial paper europeanus mtn bank facilities lease liabilities debt due within one year attributed continuing operations debt due within one year attributed discontinued operations debt due one year europeanus mtn bank facilities lease liabilities debt due one year attributed continuing operations debt due one year attributed discontinued operations net debt interest payable derivative financial instruments total liabilities financing activities excluding cash cash equivalents overdrafts liquid investments information significant changes net debt see note net debt strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures objective gsks treasury activities minimise net gsk access shortterm finance billion cost financial operations reduce volatility benefit billion us commercial paper programme million earnings cash flows gsk uses variety financial million issue december instruments finance operations derivative financial million million gsk access shortterm instruments manage market risks operations finance billion euro commercial paper programme derivatives principally comprise foreign exchange forward million million issue december contracts swaps used swap borrowings million million gsk billion three liquid assets currencies required group purposes well year billion billion day committed facility interest rate swaps used manage exposure committed facilities undrawn december financial risks changes interest rates financial gsk considers level committed facilities adequate instruments reduce uncertainty foreign currency given current liquidity requirements transactions interest payments gsk billion euro medium term note programme derivatives used exclusively hedging purposes relation december billion notes issue underlying business activities trading programme group also billion billion speculative instruments notes issue december us shelf registration gsks borrowings mature dates capital management gsks financial strategy supports groups strategic priorities put option owned pfizer viiv healthcare exercisable regularly reviewed board gsk manages reviewing liquidity requirements gsk considers sufficient capital structure group appropriate mix financing options available put option debt equity exercised capital structure group consists net debt market risk billion see note net debt total equity including items related noncontrolling interests billion see interest rate risk management consolidated statement changes equity gsks objective minimise effective net interest cost total capital including provided noncontrolling balance mix debt fixed floating rates time interests billion groups main interest rate risk arises borrowings group continues manage financial policies credit investments floating rates refinancing maturing profile particularly targets ratings least aa fixed rate debt changes interest rates affect moody'ssp cycle groups longterm credit future cash flows fair values financial instruments rating standard poors stable outlook policy interest rate risk management limits net amount moodys investor services moodys stable outlook floating rate debt specific cap reviewed agreed groups shortterm credit ratings p standard less annually board poors moodys respectively majority debt issued fixed interest rates liquidity risk management changes floating rates interest significantly gsks policy borrow centrally order meet anticipated affect groups net interest charge shortterm borrowings funding requirements strategy diversify liquidity including bank facilities exposed risk future sources using range facilities maintain broad access changes market interest rates majority cash financial markets day gsk sweeps cash liquid investments number global subsidiaries central treasury accounts foreign exchange risk management liquidity management purposes gsk utilises physical groups objective minimise exposure overseas notional cash pool arrangements appropriate location operating subsidiaries transaction risk matching local currency notional cash pools liquidity drawn currency income local currency costs possible foreign currency balances provide local funding foreign currency transaction exposures arising external central liquidity required balances actively internal trade flows selectively hedged gsks internal managed maintained appropriate levels balances trading transactions matched centrally intercompany notional pooling arrangements settled across payment terms managed reduce foreign currency risk currencies gross cash overdraft balances reported possible gsk manages cash surpluses borrowing december gsk billion borrowings requirements subsidiary companies centrally using forward repayable within one year held billion cash contracts hedge future repayments back originating cash equivalents liquid investments billion currency held centrally order reduce foreign currency translation exposure group seeks denominate borrowings currencies principal assets cash flows primarily denominated us dollars euros sterling borrowings swapped currencies required strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued borrowings denominated swapped foreign currencies change estimation techniques match investments overseas group assets may significant assumptions made current reporting treated hedge relevant assets forward period assessing loss allowance financial assets contracts major currencies also used reduce exposure amortised cost fvtoci since adoption ifrs groups investment overseas assets see net start reporting period investment hedges section note details treasuryrelated credit risk credit risk gsk sets global counterparty limits gsks banking credit risk risk counterparty default investment counterparties based longterm credit contractual obligations resulting financial loss group ratings moodys standard poors usage arises cash cash equivalents favourable limits actively monitored derivative financial instruments held banks financial gsk actively manages exposure credit risk reducing institutions well credit exposures wholesale retail surplus cash balances wherever possible part gsks customers including outstanding receivables strategy regionalise cash management concentrate group considers maximum credit risk december cash centrally much possible table sets million december million credit exposure counterparties rating liquid total groups financial assets investments cash cash equivalents derivatives exception investments comprising equity gross asset position derivative contract investments bear equity risk rather credit risk see considered purpose table although isda details groups total financial assets agreements amount risk net position december gsks greatest concentration credit risk counterparty table e sets groups billion wholesaler us billion financial assets liabilities offset basis wholesaler us see information groups credit risk exposure respect three largest us wholesaler customers strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued december million million cash categorised held unrated subinvestment grade rated counterparties lower bbbbaa exposure concentrated overseas banks used local cash management investment purposes including million saudi arabia saudi british bank million halk bank uk million nigeria held united bank africa zenith bank access bank stanbic ibtc bank million brazil held banco bradesco itau unibanco banco brasil caixa economica federal million banco de la produccion ecuador million bank balances deposits held bbbbaa rated counterparties million held bbbbaa rated counterparties including balances deposits million state bank india india banks used local investment purposes gsk measures expected credit losses cash cash equivalents function individual counterparty credit ratings associated month default rates expected credit losses cash cash equivalents thirdparty financial derivatives deemed immaterial loss experienced credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables credit ratings form basis assessment expected credit loss treasuryrelated balances held amortised cost bank balances deposits government securities bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities third party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities third party financial derivatives total gsks centrally managed cash reserves amounted billion concentration trade receivables reflective standard december available within three months market practice us pharmaceuticals sector includes billion cash managed group viiv significant portion sales made three wholesalers healthcare owned subsidiary group invested disclosed note 'turnover segment information ' centrally managed liquid assets bank deposits aaaaaa gsks assessment limited credit risk associated rated us treasury treasury repo money market funds customers aaaaaa rated liquidity funds groups credit risk monitoring activities relating wholesale retail credit risk wholesalers include review quarterly financial information standard poors credit ratings development outside us customer accounts gsk internal risk ratings establishment periodic groups trade receivables balance review credit limits us line pharmaceutical companies new customers subject credit vetting process group sells products small number wholesalers existing customers subject review least annually addition hospitals pharmacies physicians vetting process subsequent reviews involve obtaining groups sales three largest wholesalers amounted information including customers status government approximately sales us private sector entity audited financial statements credit bureau commercial operations business reports debt rating agency eg moodys standard poors december group trade receivables due reports payment performance history trade references three wholesalers totalling million industry credit groups bank references total trade receivables million group exposed concentration credit risk respect wholesalers one encounters financial difficulty could materially adversely affect groups financial results strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued trade receivables consist amounts due large number following methods assumptions used measure customers spread across diverse industries fair values significant financial instruments carried fair geographical areas ongoing credit evaluation performed value balance sheet financial condition accounts receivable investments equity investments traded active appropriate credit insurance purchased factoring market determined reference relevant stock arrangements put place exchange quoted bid price equity investments amount information obtained proportional level determined reference current market value exposure considered information evaluated similar instruments recent financing rounds discounted quantitatively ie credit score qualitatively ie cash flows underlying net assets judgement conjunction customers credit trade receivables carried fair value based invoiced requirements determine credit limit amount interest rate swaps foreign exchange forward contracts trade receivables grouped customer segments swaps options based present value similar loss patterns assess credit risk contractual cash flows option valuation models using receivables financial assets assessed individually market sourced data exchange rates interest rates historical forwardlooking information considered balance sheet date determine appropriate expected credit loss allowance cash equivalents carried fair value based net asset group believes credit risk provision value funds required excess allowance expected credit losses contingent consideration business acquisitions see note trade receivables divestments based present values expected future credit enhancements cash flows group uses credit enhancements including factoring following methods assumptions used estimate credit insurance minimise credit risk trade fair values significant financial instruments receivables group december million measured fair value balance sheet million trade receivables insured order receivables payables including put options carried protect receivables loss due credit risks amortised cost approximates carrying amount default insolvency bankruptcy liquid investments approximates carrying amount group entity assesses credit risk private cash cash equivalents carried amortised cost customers determine credit insurance required approximates carrying amount longterm loans based quoted market prices level factoring arrangements managed locally entities fair value measurement case european us used mitigate risk arising large credit risk medium term notes approximates carrying amount concentrations factoring arrangements nonrecourse case fixed rate borrowings floating rate bank fair value financial assets liabilities loans excluding lease liabilities shortterm loans overdrafts commercial paper approximates carrying amount short table presents carrying amounts maturity instruments fair values groups financial assets liabilities excluding lease liabilities december december fair values financial assets liabilities included price would received sell asset paid transfer liability orderly transaction market participants measurement date strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value notes financial assets measured amortised cost noncurrent assets b trade receivables b liquid investments cash cash equivalents financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables ab financial assets mandatorily measured fair value profit loss fvtpl current equity investments investments noncurrent assets ab trade receivables ab held trading derivatives designated ade effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value ade movements comprehensive income total financial assets financial liabilities measured amortised cost borrowings excluding obligations lease liabilities bonds designated hedging relationship bonds bank loans overdrafts commercial paper designated hedging relationship commercial paper borrowings total borrowings excluding lease liabilities f trade payables c provisions c noncurrent liabilities c financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities ac held trading derivatives designated ade effective hedging relationship derivatives designated effective hedging instruments fair value ade movements comprehensive income total financial liabilities excluding lease liabilities net financial assets financial liabilities excluding lease liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions contingent consideration liabilities noncurrent liabilities reconciled relevant notes pages strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued fair value investments gsk shares december employee share ownership plan esop trusts held gsk shares carrying value million million market value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations investments provide access biotechnology developments potential interest level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl current equity investments investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl current equity investments investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued movements year financial instruments measured using level valuation methods presented january exchange adjustments net losses recognised income statement net losses gains recognised comprehensive income contingent consideration related business acquisitions period settlement contingent consideration liabilities additions disposals settlements transfers level december total net losses million million attributable level financial instruments recognised income statement million million respect financial instruments held end year reported operating incomeexpense charges million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture remeasurement gain million million loss arose remeasurement contingent consideration payable acquisition novartis vaccines business acquisition affinivax resulted additon million contingent consideration level financial liabilities charges million million arising remeasurement contingent consideration liability year transfers million level financial instruments year transfers level financial instruments movements arising translation overseas net assets consolidation group accounts recorded exchange adjustments net gains losses include impact exchange movements financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies result acquisition affinivax contingent consideration payable million million recognised december consideration expected paid number years vary line achievement certain development milestones movements usdgbp exchange rate sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets scope ifrs following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ifrs relevant balance sheet amounts financial assets predominantly noninterest earning non financial instruments include tax receivables pension surplus balances prepayments outside scope ifrs non non amortised financial financial amortised financial financial fvtpl fvtoci cost instruments instruments total fvtpl fvtoci cost instruments instruments total trade receivables note noncurrent assets note trade receivables include trade receivables million million group portfolios three business models ifrs million million measured fvtpl held sell contractual cash flows receivables sold factoring arrangement million million measured fvtoci held either collect sell contractual cash flows receivables may sold factoring agreement million million measured amortised cost held collect contractual cash flows factoring agreement place strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued c trade payables provisions contingent consideration liabilities non current liabilities scope ifrs following table reconciles financial instruments within trade payables provisions contingent consideration liabilities noncurrent liabilities fall within scope ifrs relevant balance sheet amounts financial liabilities predominantly noninterest bearing nonfinancial instruments include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ifrs non non amortised financial financial amortised financial financial fvtpl cost instruments instruments total fvtpl cost instruments instruments total trade payables note provisions note contingent consideration liabilities note noncurrent liabilities note derivative financial instruments hedging programmes derivatives used economic hedging purposes speculative investments classified held trading designated effective hedging instruments presented current assets liabilities expected settled within months end reporting period otherwise classified noncurrent group following derivative financial instruments fair value fair value assets liabilities assets liabilities current cash flow hedges foreign exchange contracts net principal amount million million net investment hedges foreign exchange contracts net principal amount million million derivatives designated effective hedging instruments current foreign exchange contracts net principal amount million million embedded derivatives derivatives classified held trading total derivative instruments strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued fair value hedges december december group designated fair value hedges net investment hedges december certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro american usd singaporean sgd canadian cad japanese jpy foreign operations shown table carrying value bonds included million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges entered hedge foreign exchange exposure arising cash flows euro denominated coupon payments relating notes issued groups european medium term note programme hedge foreign currency payments due acquisitions collaboration licensing arrangements group manages cash flow interest rate risk using floatingtofixed interest rate swaps addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years current year balance reclassified finance costs life bonds foreign exchange risk current year group designated certain foreign exchange forward contracts swaps cash flow net investment hedges foreign exchange derivative financial assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet following tables detail foreign exchange forward contracts swaps outstanding end reporting period well information related hedged items hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments ensure economic relationship exists hedged item hedging instrument group enters hedge relationships critical terms hedging instrument match exactly terms hedged item qualitative assessment effectiveness performed changes circumstances affect terms hedged item critical terms longer match exactly critical terms hedging instrument group uses hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationships effect counterparty groups credit risk fair value foreign exchange forward contracts swaps reflected fair value hedged item attributable changes foreign exchange rates sources ineffectiveness emerged hedging relationships ineffectiveness recorded cash flow hedges nil ineffectiveness recorded net investment hedges nil periodic change value calculating average foreign net notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments cash flow hedges foreign exchange contracts buy foreign currency less months usd months months usd sell foreign currency less months eur strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued periodic change value calculating average foreign net notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments net investment hedges foreign exchange contracts sell foreign currency less months eur jpy usd months cad sgd borrowings less months eur months months jpy eur cumulative balance cash balance cash flow hedge periodic change value flow hedge reserveforeign reserve arising hedging calculating hedge currency translation reserve relationships hedge ineffectiveness continuing hedgesaccounting longer applied hedged items cash flow hedges variability cash flows highly probable forecast transaction net investment hedges net investment foreign operations periodic change value calculating average foreign net notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments cash flow hedges foreign exchange contracts buy foreign currency less months usd months eur months eur sell foreign currency less months eur strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued periodic change value calculating average foreign net notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments net investment hedges foreign exchange contracts sell foreign currency less months eur jpy months months cad sgd borrowings less months eur months eur months eur cumulative balance cash balance cash flow hedge periodic change value flow hedge reserveforeign reserve arising hedging calculating hedge currency translation reserve relationships hedge ineffectiveness continuing hedgesaccounting longer applied hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations nil million balances cash flow hedge reserve arise hedging relationships hedge accounting longer applied following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss amount reclassified balance sheet hedged line item amount line item future cash profit loss line item hedging hedge profit flows due balance gainslosses ineffectiveness loss longer hedged item reclassification due hedged sheet recognised recognised hedge expected affecting adjustment item affecting reclassification reserves profit loss ineffectiveness occur profit loss included balance sheet adjustment included included cash flow hedges variability cash flows finance finance intangible highly probable forecast income income assets transaction expense expense variability cash flows finance finance foreign exchange exposure income income arising euro denominated expense expense coupon payments relating debt issued net investment hedges net investment foreign finance operations income income expense expense strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued amount reclassified profit loss amount reclassified balance sheet hedged amount line item future cash line item line item hedging hedge profit flows due profit loss balance gainslosses ineffectiveness loss longer hedged item due hedged sheet recognised recognised hedge expected affecting reclassification item affecting reclassification reserves profit loss ineffectiveness occur profit loss adjustment balance sheet adjustment included included included cash flow hedges variability cash flows finance intangible highly probable forecast income assets transaction expense variability cash flows finance finance foreign exchange exposure income income arising euro denominated expense expense coupon payments relating debt issued net investment hedges net investment foreign finance discontinued operations income operations expense reclassified consolidated income statement demerger consumer healthcare business interest rate risk group manages cash flow interest rate risk using floatingtofixed interest rate swaps quarterly intervals difference fixed contract rates floating rate interest amounts calculated reference agreed notional principal amounts exchanged none swaps outstanding december december impact financial statements interest rate swaps interest rate risk element future debt issuance managed entering forward starting interest rate swaps effectively lock interest rates debt advance closed time issuing debt resulting gain loss held cash flow hedge reserve reclassified income statement interest payments debt impacted income statement forward starting interest rate swaps forward starting interest rate contracts exchanging floating interest fixed interest designated cash flow hedges hedge interest variability interest cash flows associated future fixed rate debt interest rate swaps interest rate swap contract assets liabilities presented applicable line derivative financial instruments either assets liabilities consolidated balance sheet million million balances cash flow hedge reserve arise hedge relationships hedge accounting longer applied following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item due line item amount profit hedged future profit loss hedging hedge loss cash flows due gainslosses ineffectiveness hedge longer hedged item reclassification recognised recognisedineffectiveness expected affecting adjustment reserves profit loss included occur profit loss included cash flow hedges prehedging longterm interest rates finance finance matured past income income expense expense strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued amount reclassified profit loss line item due line item amount profit hedged future profit loss hedging hedge loss cash flows due gainslosses ineffectiveness hedge longer hedged item reclassification recognised recognised ineffectiveness expected affecting adjustment reserves profit loss included occur profit loss included cash flow hedges prehedging longterm interest rates matured past finance finance income income expense expense e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross gross net financial related financial financial assets amounts assets liabilities liabilities per set liabilities assets set balance sheet balance sheet net december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gross gross financial financial net financial related assets liabilities assets amounts net liabilities assets offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings lease liabilities total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation us dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation us dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation us dollar cent appreciation euro cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation us dollar cent depreciation euro cent depreciation euro strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note 'net debt ' adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation us dollar cent appreciation euro cent appreciation euro yen appreciation yen yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation us dollar cent depreciation euro cent depreciation euro yen depreciation yen yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities basis points basis points movement eur usd sterling interest rates deemed material effect equity basis points basis points decrease eur usd sterling interest rates would equal opposite impact shown increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase us dollar interest rates basis points increase euro interest rates basis points increase euro interest rates strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provide analysis anticipated contractual cash flows including interest payable groups non derivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except lease liabilities interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows table provides analysis anticipated contractual cash flows groups derivative instruments excluding equity options give rise cash flows embedded derivatives material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments gross cash inflows gross cash outflows gross cash inflows gross cash outflows foreign exchange forward foreign exchange forward foreign exchange forward foreign exchange forward contracts swaps contracts swaps contracts swaps contracts swaps less one year gross contractual cash flows strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads gsk plc cost threeyear vesting period performance share plan whereby awards granted employees acquire shares ads gsk plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares gsk plc discounted price grants restricted share awards normally exercisable end threeyear vesting performance period awards normally granted employees acquire shares ads gsk plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details gsk share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based four measures threeyear performance period adjusted free cash flow tsr rd new product performance pipeline progress awards granted performance conditions based five measures threeyear performance period tsr pipeline progress profit measure sale measure esg environment fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million ads strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive sharebased payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount savingsrelated options outstanding share save plan share option schemes weighted number exercise price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares gsk plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts december shares held esop trusts held future exercise share options share awards shares held executive supplemental savings plan shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities shown percentage columns companies incorporated principal country operation except stated england scotland glaxo group limited gsk scottish limited partnership glaxo operations uk limited glaxo wellcome uk limited us glaxosmithkline capital plc affinivax inc glaxosmithkline export limited corixa corporation glaxosmithkline finance plc glaxosmithkline capital inc glaxosmithkline holdings limiteda glaxosmithkline holdings americas inc glaxosmithkline ihc limited glaxosmithkline llc glaxosmithkline intellectual property limited gsk equity investments limited glaxosmithkline intellectual property limited human genome sciences inc glaxosmithkline intellectual property limited stiefel laboratories inc glaxosmithkline intellectual property development limited tesaro inc glaxosmithkline intellectual property limited viiv healthcare company glaxosmithkline research development limited glaxosmithkline services unlimiteda others glaxosmithkline uk limited glaxo saudi arabia limited saudi arabia glaxosmithkline us trading limited glaxo wellcome manufacturing pte ltd singapore setfirst limited glaxosmithkline thailand limited thailand smithkline beecham limited glaxosmithkline australia pty ltd australia viiv healthcare finance limited glaxosmithkline brasil limitada brazil viiv healthcare uk limited glaxosmithkline far east bv taiwan viiv healthcare uk limited glaxosmithkline ilaclari sanayi ticaret turkey glaxosmithkline inc canada europe glaxosmithkline kk japan glaxosmithkline ag switzerland glaxosmithkline korea limited republic korea glaxo wellcome production sas france glaxosmithkline limited hong kong glaxosmithkline bv netherlands glaxosmithkline mexico sa de cv mexico glaxosmithkline biologicals sa belgium glaxosmithkline pakistan limited pakistan glaxosmithkline gmbh co kg germany glaxosmithkline pharmaceuticals limited india glaxosmithkline manufacturing spa italy gsk enterprise management co ltd china glaxosmithkline pharma gmbh austria gsk pharma vietnam company limited vietnam glaxosmithkline pharmaceuticals sa belgium id biomedical corporation quebec canada glaxosmithkline sa spain viiv healthcare kk japan glaxosmithkline spa italy viiv healthcare ulc canada glaxosmithkline single member aebe greece glaxosmithkline trading services limited republic irelandb gsk capital bv netherlandsb gsk services sp z oo poland gsk vaccines gmbh germany gsk vaccines srl italy jsc glaxosmithkline trading russia laboratoire glaxosmithkline france laboratorios viiv healthcare sl spain viiv healthcare gmbh germany viiv healthcare srl italy viiv healthcare sas france directly held whollyowned subsidiary gsk plc b tax resident uk subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk capital bv glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline finance plc gsk capital bv glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statements strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued legal proceedings group involved significant legal administrative december teva filed petition rehearing en proceedings principally product liability intellectual property banc court granted tevas petition rehearing tax antitrust consumer fraud governmental investigations threemember panel issued original decision significant matters tax matters august original panel issued rehearing opinion described group makes provision majority reinstated jurys damages award proceedings regular basis summarised note million gsks favour accounting principles policies note teva filed petition rehearing en banc provisions note also describes disclosure made rejected court appeals federal circuit proceedings provision legal expenses february july teva filed petition writ incurred provisions related legal claims charged certiorari supreme court united states seeking selling general administration costs group overturn federal court decision may us believe information amount sought plaintiffs supreme court denied tevas request certain issues remain known would meaningful respect legal resolved district court parties await proceedings due number factors including scheduling status conference limited stage proceedings entitlement parties appeal decision clarity theories liability dolutegravir proceedings damages governing law tivicaytriumeq december groups aggregate provision legal september viiv healthcare received paragraph iv disputes including tax matters described note letter lupin relating tivicay mg dosage oral taxation million assurance suspension challenging crystal form patent losses result outcome legal november viiv healthcare filed suit lupin proceedings materially exceed amount us district court district delaware march provisions reported groups financial statements parties reached settlement thereby concluding matter happen could material adverse impact results operations group reporting period juluca judgements incurred settlements entered june cipla sent viiv healthcare paragraph iv letter related juluca july viiv healthcare intellectual property filed suit cipla federal court delaware march parties reached settlement thereby concluding intellectual property claims include challenges validity matter enforceability groups patents various products processes well assertions noninfringement rsv patents loss cases could result loss patent june pfizer inc filed suit london high court protection product issue consequences challenging validity requesting revocation three gsk loss could significant decrease sales european patents relating rsv vaccine technology product could materially affect future results operations corresponding invalidity suits additional patents group filed district court hague netherlands coreg january frenchspeaking enterprise court brussels belgium march matters gsk initiated suit teva inducing gsk counterclaimed pfizers rsv vaccine infringes gsks infringement patent relating use carvedilol patents august gsk filed patent infringement suit coreg decreasing mortality caused congestive heart pfizer united states district court district failure june case proceeded jury trial us delaware alleging infringement four us gsk patents district court district delaware jury returned pfizers rsv vaccine abrysvo another two gsk patents verdict gsks favour awarding gsk lost profits added us litigation november reasonable royalties total award million march trial judge ruled posttrial motions filed trial uk action took place june decision teva found substantial evidence trial expected end q netherlands two support jurys finding induced infringement overturning separate firstinstance hearings scheduled first jury award gsk appealed october held january second scheduled divided panel court appeals federal circuit march belgium trial merits expected q reversed district courts ruling reinstated jury award first instance decision likely q trial date gsks favour us yet set gsk seeking monetary compensation pfizer pfizers infringing sales abrysvo gsks sales arexvy issue litigations strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued legal proceedings continued product liability gsk named defendant approximately plaintiffs several us state jurisdictions plaintiffs group currently defendant number product approximately plaintiffs filed delaware liability lawsuits delaware plaintiffs allege cancer five cancers pursued plaintiffs mdl proceeding avandia delaware court held general causation hearing two pending us class actions filed admissibility expert testimony cancers plaintiffs thirdparty payers assert claims racketeer decided pursue breast colorectal kidney prostate influenced corrupt organizations act rico state pancreatic lung bladder liver esophageal stomach consumer protection laws december third circuit january court appeals reversed summary judgements granted favour group remanded thirdparty payer cases california zantac litigation cases jccp jccp back district court discovery complete class court issued sargon ruling first case scheduled trial certification summary judgment briefing goetz court found plaintiffs experts causation completed hearing certain daubert motions relating opinions admissible presented jury experts held february gsk requested oral ruling applied goetz case affect argument class certification could scheduled state court cases june gsk reached thereafter confidential settlement goetz case october gsk announced reached confidential settlements zantac cantlayharper case well three remaining breast group contacted several regulatory cancer bellwether cases california february gsk authorities regarding detection nnitrosodimethylamine announced reached confidential settlement ndma zantac ranitidine products based information browne case filed california state court case available time correspondence regulators set begin trial february dismissed group made decision suspend release distribution settlements reflect gsks desire avoid distraction related supply dose forms zantac markets pending protracted litigation gsk admit liability outcome ongoing tests investigations also settlements continue vigorously defend based precautionary action group made decision initiate facts science zantac cases next voluntary pharmacyretail level recall zantac products case scheduled trial jccp boyd colorectal globally court set sargon hearing february trial date april additional bellwether cases jccp april european medicines agency ema set trial q q recommended suspension ranitidine medicines following publication emas recommendation company multiple trials state courts set dates communicated decision reenter market us including illinois texas florida first fda requested manufacturers withdraw ranitidine cases valadez colorectal scheduled trial products market april additional cases illinois trial dates cases texas florida group named defendant approximately yet firm trial dates although trials expected occur personal injury cases filed federal zantac multidistrict litigation mdl court proceeding southern district florida mdl plaintiffs originally identified different outside us two proposed class actions pending types cancers wished pursue plaintiffs subsequently gsk ontario quebec canada along class dropped cancers proceeded bladder action israel canada certification hearing held esophageal stomach liver pancreatic cancers although october british columbia proposed class action plaintiffs state courts continue pursue claims beyond first class action proceed certification designated cancers december court presiding hearing class action sought certify national class federal mdl proceeding granted defendants daubert may court dismissed proposed class action motions finding plaintiffs experts causation opinions manufacturer defendants appeal regarding whether zantac cause five cancers issue decision abandoned ontario action also mdl liver bladder pancreatic esophageal stomach discontinued also approximately individual unreliable thus inadmissible without expert causation actions filed canada opinions mdl court granted summary judgment gsk given complex ownership marketing zantac brand defendants mdl court found prescription overthecounter otc medicine many scientist outside litigation concluded years numerous claims involve several defendants result ranitidine causes cancer plaintiffs scientists within defendants served one another including litigation systemically utilized unreliable methodologies group notice potential indemnification claims failed use consistent objective sciencebased standards possible liabilities connected particularly zantac otc evenhanded evaluation data ruling effectively given current stage proceedings group dismissed approximately filed cases mdl meaningfully assess liability may binding claims census registry meaningfully assess liability parties relevant approximately plaintiffs includes plaintiffs indemnification provisions filed cases registry claimants appealed mdl decision eleventh circuit court appeals plaintiffs briefs due april following courts daubert decision entered final order dismissing medical monitoring consumer class actions based reasoning daubert holding plaintiffs filed notice appeal medical monitoring consumer class action cases strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued legal proceedings continued addition march department justice korea fair trade commission kftc also commenced doj sent group notice civil investigation proceedings regarding matter kftc hearings took opened allegations false claims act violations place july gsk korea found violation group related zantac june doj served applicable fair trade law kftc imposed fine civil investigative demand cid group formalising krw million approximately request documents group continues cooperate us electronic health records subpoena doj cid day new mexico attorney general filed lawsuit multiple defendants march group received subpoena including group alleging violations state consumer united states attorneys office western district protection false advertising statutes among claims virginia working united states department justice civil division seeking documents relating groups november mayor city baltimore filed electronic health record programmes group cooperating action group alleging zantac increased risk enquiry cancer andor caused cancer baltimore patients group failed warn concealed risks fact senate help enquiry expert discovery ongoing court set trial date group received letter dated january june majority members us senate health education labor pensions help committee initiating investigation zofran pricing inhalers treatment asthma group defendant product liability cases copd letter similar letters received number involving zofran pending multidistrict litigation mdl pharmaceutical companies requests information proceeding district massachusetts cases alleged pricing research treatment respiratory diseases children suffered birth defects due mothers patenting business practices group cooperating ingestion zofran andor generic ondansetron pregnancy enquiry related nausea vomiting plaintiffs asserted group sold zofran knowing unsafe pregnant women failed orange book challenge warn risks illegally marketed zofran offlabel november us federal trade commission ftc use pregnant women wrote group identified five patents challenging fda orange book listing dispute june mdl court granted groups motion process reserving right take action number summary judgment federal preemption grounds court companies also contacted ftc citing found fda fully informed relevant safety total patents five patent listings challenged information regarding zofran repeatedly rejected ftc group asked fda remove four patents attempt add birth defect warning label time orange book respect certain products court granted judgment group cases pending group 's position patents properly listed mdl approximately cases closed mdl time listing decision generic competition proceeding plaintiffs appealed decision january impacted previous listings delisted patents united states court appeals first circuit remain valid enforceable subsequent ftcs affirmed district courts decision favour group challenge group received letters us senator elizabeth remains one state court case four proposed class warren us congresswoman pramila jayapal us senator actions canada currently active amy klobuchar us senator tammy baldwin reiterating ftc position requesting information sales marketing regulation groups orange booklisted patents groups response groups marketing promotion pharmaceutical fda challenge process group cooperating vaccine products subject certain governmental enquiries investigations private lawsuits brought litigants antitrustcompetition various theories law certain governmental actions private lawsuits gsk korea proceedings fair trade laws brought group alleging violation competition august gsk korea indicted koreas antitrust laws monopoly regulation fair trade laws relation lamictal government tenders hpv cervarix pcv synflorix vaccines prosecutor alleged gsk purported classes direct purchasers filed suit us korea actions least one employees district court district new jersey alleging interfered tender process national group teva pharmaceuticals unlawfully conspired delay immunisation programme using straw bidders generic competition lamictal resulting overcharges purchasers entering allegedly anticompetitive former gsk korea employee also charged reverse payment settlement resolve patent infringement individual capacity prosecutor relation litigation separate count accuses group monopolising matter number wholesalers codefendants market proceedings february court rendered guilty verdict respect defendants gsk korea fined december trial judge granted plaintiffs class krw million approximately appeal certification motion certifying class direct purchasers proceedings ongoing group filed rule f motion court appeals third circuit challenging class certification decision april court appeals vacated lower courts grant class certification remanded issue back lower court analysis strategic report governance remuneration financial statements investor information gsk annual report notes financial statements continued legal proceedings continued october district court heard argument zejula royalty dispute plaintiffs renewed motion class certification remand october tesaro inc wholly owned subsidiary april district court denied plaintiffs motion gsk entered two worldwide patent license agreements class certification putative direct purchaser class leaving astrazeneca uk limited related niraparib later potential class brandonly purchasers plaintiffs moved approved zejula supplement expert report seek additional discovery support addition certain generic purchasers may astrazeneca filed lawsuit tesaro january district court denied plaintiffs motion high court england wales alleging tesaro failed supplement expert report seek additional discovery pay royalties due license agreements held issue generic purchasers already tesaro counterclaimed based calculated decided denied courts ruling decertification overpayment trial held week march parties conducted briefing class certification judgment entered group april ruling remaining brandonly purchasers plaintiffs also seeking current uses zejula generate royaltybearing sales add smaller category purchasers wording two license agreements june court appeal england wales granted february district court denied plaintiffs renewed groups request permission appeal april class certification motion series followon complaints judgment appeal heard january filed us district court eastern district february court appeal ruled groups favour pennsylvania groups alleged purchasers cases overturning trial courts judgment determining consolidated previously pending case zejula sales uses falling within licensed patents could district new jersey discovery ongoing deemed royaltybearing appropriate quantum royalties commercial corporate accord court appeals judgment may subject proceedings group involved certain contractual andor commercial disputes post balance sheet events acquisition aiolos bio inc january gsk announced entered agreement acquire aiolos bio inc aiolos clinical stage biopharmaceutical company focused addressing unmet treatment needs patients certain respiratory inflammatory conditions upfront payment us billion us million certain successbased regulatory milestone payments addition gsk also responsible successbased milestone payments well tiered royalties owed jiangsu hengrui pharmaceuticals co ltd hengrui transaction subject customary conditions including applicable regulatory agency clearances hart scottrodino act us subsequently closed february given timing closure transaction gsk expects disclose provisional accounting acquisition q results announcement disposal shares haleon plc january gsk completed sale million shares haleon plc equivalent haleon plcs issued share capital price pence per share raising gross proceeds million following sale gsk holds approximately million ordinary shares haleon plc representing issued share capital haleon plc strategic report governance remuneration financial statements investor information gsk annual report company balance sheet uk gaap including frs reduced disclosure framework december notes fixed assets investments e current assets trade receivables f cash bank total current assets trade payables g total current liabilities net current assets total assets less current liabilities provisions liabilities h noncurrent liabilities net assets capital reserves share capital j share premium account j reserves k retained earnings january profitloss year ordinary shares issued share optionaward schemes treasury shares transferred esop trust dividends specie dividends paid shareholders k equity shareholders funds financial statements pages approved board february signed behalf sir jonathan symonds chair gsk plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january profit total comprehensive income attributable shareholders treasury shares transferred esop trust dividends shareholders note dividends specie note shares issued employee share schemes december profit total comprehensive income attributable shareholders treasury shares transferred esop trust dividends shareholders note shares issued employee share schemes december strategic report governance remuneration financial statements investor information gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements key accounting judgements estimates description business key accounting judgements estimates required current year gsk plc parent company gsk major global biopharma group prevents treats disease b accounting policies vaccines specialty general medicines gsk focuses foreign currency transactions science immune system use new platform data technologies investing four core therapeutic areas foreign currency transactions recorded exchange infectious diseases hiv respiratoryimmunology oncology rate ruling date transaction foreign currency assets liabilities translated rates exchange ruling preparation financial statements balance sheet date financial statements prepared using dividends paid received historical cost convention modified include revaluation certain financial instruments going dividends paid received included financial concern basis prepared accordance financial statements period related dividends reporting standard reduced disclosure framework actually paid received uk accounting presentation companies act expenditure december comparative figures december expenditure recognised respect goods services received supplied accordance contractual terms permitted section companies act provision made obligation exists future liability income statement company presented respect past event amount annual report obligation reliably estimated company included group financial statements investments subsidiary companies gsk plc publicly available investments subsidiary companies held cost less following exemptions requirements ifrs provision impairment also includes capital applied preparation financial statements contribution relation movements contingent accordance frs consideration paragraphs b ifrs sharebased impairment investments payment carrying value investments reviewed impairment ifrs financial instruments disclosures indication investment might paragraphs ifrs fair value measurement impaired assessment method used compare paragraph ias presentation financial statements carrying value investment share net comparative information requirements respect assets value investment share paragraph iv ias valuation subsidiary based expected discounted cash paragraphs f b flows impairment charge recognised income ias presentation financial statements statement year concerned ias statement cash flows assets held saledistribution paragraph ias accounting policies changes noncurrent assets held disposaldemerger accounting estimates errors available immediate disposaldemerger present paragraph ias related party disclosures condition disposaldemerger highly probable requirement ias disclose related party expected completed within one year date transactions entered two members classification assets measured lower group carrying value fair value less cost disposal accounting convention standards trade receivables balance sheet prepared using historical cost trade receivables carried amortised cost less convention complies applicable uk accounting allowance expected credit losses expected credit losses standards calculated accordance approach permitted ifrs accounting principles policies majority balance within trade receivables amounts owed group undertakings preparation balance sheet conformity company applies general approach calculate generally accepted accounting principles requires expected credit losses receivable determined non management make estimates assumptions affect collectable written firstly expected credit reported amounts assets liabilities disclosure loss allowance available statement contingent assets liabilities date balance comprehensive income subsequent recoveries amounts sheet actual amounts could differ estimates previously provided credited statement balance sheet prepared accordance comprehensive income long term receivables discounted companys accounting policies approved board effect material described note b policies consistently sharebased payments applied unless otherwise stated company issues shares employees behalf subsidiary companies cash consideration strategic report governance remuneration financial statements investor information gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework treasury shares deferred tax measured average tax rates expected apply periods temporary purchase price paid treasury shares included differences expected realised settled deferred tax within retained earnings treasury shares transferred liabilities assets discounted esop trust fair market price date transfer cash consideration proceeds equal less financial guarantees purchase price paid company shares liabilities relating guarantees issued company proceeds treated realised loss proceeds exceed behalf subsidiaries initially recognised fair value purchase price excess purchase price subsequently measured higher transferred share premium account purchase price paid company shares determined use expected credit loss ecl measured used general weighted average price method approach taxation amount initially recorded less appropriate current tax provided amounts expected paid accumulated amortisation applying tax rates enacted substantively c operating profit enacted balance sheet date fee relating audit deferred tax provided full using liability method company charged operating profit temporary differences arising tax bases assets liabilities carrying amounts financial statements deferred tax assets recognised extent considered recoverable future taxable profits dividends directors declared four interim dividends resulting dividend year pence details see note 'dividends ' group financial statements demerger consumer healthcare business implemented gsk declaring interim dividend july follows dividend specie haleon plc shares distributed external shareholders dividend specie haleon plc shares distributed esop trusts e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline mercury limited shares gsk lp limited capital contribution relating sharebased payments contribution relating contingent consideration strategic report governance remuneration financial statements investor information gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework f trade receivables amounts due within one year debtors amounts owed group undertakings amounts due one year amounts owed group undertakings amounts owed group undertakings due within one year primarily include call account balance gsk finance plc unsecured repayable demand interest received sonia rate less per annum sonia rate less directors consider carrying amount amounts owed group undertakings approximates fair values provision expected credit loss recognised counterparty access sufficient funds assets fulfil future obligations amounts owed group undertakings past due increased credit risk experienced since initial recognition movement amounts owed group undertakings period reflected within notes f g primarily reflects receipt dividend income subsidiaries utilisation companys current account fund payment interim dividends g trade payables amounts due within one year creditors contingent consideration payable corporation tax amounts owed group undertakings company guaranteed debt issued certain subsidiary companies receives annual fee one subsidiaries aggregate company outstanding guarantees billion debt instruments billion financial guarantee contract liability million million included within creditors amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note f h provisions liabilities january charge year utilised december provisions relate number legal disputes company currently involved noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables details see note 'contingent consideration liabilities ' group financial statements strategic report governance remuneration financial statements investor information gsk annual report notes company balance sheet uk gaap including frs reduced disclosure framework j share capital share premium account share premium ordinary shares account number share capital issued fully paid january impact share consolidation issued employee share schemes ordinary shares acquired esop trust december issued employee share schemes ordinary shares acquired esop trust december december issued share capital shares held esop trusts held future exercise share options share awards shares held executive supplemental savings plan shares held treasury shares shares free issue issued shares fully paid shares authorised issue nominal carrying market values shares held esop trusts disclosed note employee share schemes k retained earnings reserves profit gsk plc year million million dividends paid million million included consumer healthcare business demerger dividend million effect million treasury shares transferred subsidiary company million retained earnings december stood million million million considered company available distribution million dividends shareholders paid reserves company considered available distribution december amounted million million reserves includes capital redemption reserve reserve reflecting historical contributions shares company issued satisfy share option awards granted employees subsidiary companies l group companies see pages complete list subsidiaries associates joint ventures significant shareholdings forms part financial statements gsk annual report investor information section commercial operations turnover three year record product development pipeline products competition intellectual property principal risks uncertainties share capital control dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms strategic report governance remuneration financial statements investor information gsk annual report financial record commercial operations turnover therapeutic area total us europe international growth growth growth growth cer cer cer cer shingles shingrix meningitis bexsero menveo rsv arexvy influenza fluarixflulaval established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix others vaccines ex covid pandemic vaccines pandemic adjuvant vaccines hiv dolutegravir products tivicay triumeq juluca dovato rukobia cabenuva apretude others respiratoryimmunology nucala benlysta oncology zejula blenrep jemperli ojjaara specialty medicines ex covid pandemic xevudy specialty medicines respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicines dermatology augmentin avodart lamictal general medicines total commercial operations strategic report governance remuneration financial statements investor information gsk annual report financial record continued commercial operations turnover therapeutic area total us europe international growth growth growth growth cer cer cer cer shingles shingrix meningitis bexsero menveo influenza fluarixflulaval established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix others vaccines ex covid pandemic vaccines pandemic adjuvant vaccines hiv dolutegravir products tivicay triumeq juluca dovato rukobia cabenuva apretude others respiratoryimmunology nucala benlysta oncology zejula blenrep jemperli specialty medicines ex covid pandemic xevudy specialty medicines respiratory arnuity ellipta anoro ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair trelegy ellipta ventolin respiratory general medicines dermatology augmentin avodart lamictal general medicines total commercial operations strategic report governance remuneration financial statements investor information gsk annual report financial record continued threeyear selected financial data record financial performance provided analysed accordance current reporting practice information included selected financial data except number employees adjusted results prepared accordance international accounting standards conformity requirements companies act also ifrs issued international accounting standards board group turnover geographic region us europe international group turnover product group vaccines specialty medicines general medicines vaccines turnover shingles meningitis rsv influenza established vaccines pandemic vaccines specialty medicines turnover hiv respiratoryimmunology oncology pandemic general medicines respiratory general medicines financial results total turnover profit taxation continuing operations profit taxation discontinued operations gainslosses demerger remeasurement discontinued operations distributed shareholders demerger profit taxation discontinued operations profit taxation year pence pence pence basic earnings per share continuing operations p p p basic earnings per share discontinued operations p p total basic earnings per share p p p diluted earnings per share continuing operations p p p diluted earnings per share discontinued operations p p total diluted earnings per share p p p strategic report governance remuneration financial statements investor information gsk annual report financial record continued threeyear selected financial data continued financial results adjusted turnover continuing operating profit continuing profit taxation continuing profit taxation reconciliation total adjusted operating profit last three years summarised follows total continuing operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelated items divestments significant legal items adjusted continuing operating profit reconciliation total adjusted earnings per share last three years summarised follows pence pence pence total continuing earnings per share p p p intangible asset amortisation p p p intangible asset impairment p p p major restructuring p p p transactionrelated items p p p divestments significant legal items p p p adjusted continuing earnings per share p p p return capital employed nm return capital employed calculated total profit taxation percentage average net assets year restated return capital employed calculated meaningful nm average net assets year included consumer healthcare demerged july balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition pharmaceuticals vaccines product development pipeline key inlicense alliance relationship third party approved viiv healthcare global specialist hiv company gsk submitted pfizer inc shionogi limited shareholders responsible phase evaluation clinical pharmacology usually conducted volunteers developing delivering hiv medicines phase ii determination dose initial evaluation efficacy conducted bla biological licence application small number patients maa marketing authorisation application europe large comparative study compound versus placebo andor established phase iii nda new drug application us treatment patients establish clinical benefit safety maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla oncology ojjaaraomjjara jak jak acvr inhibitor myelofibrosis approved ajan asep momelotinib jemperli antiprogrammed cell death protein dmmrmsih l endometrial cancer approved adec ajul dostarlimab receptor pd antibody l endometrial cancer combination iii zejula niraparib perioperative dmmrmsih colon cancer iii nonsmall cell lung cancer ii neoadjuvant dmmrmsih rectal cancer ii zejula poly adpribose polymerase parp l maintenance ovarian cancer combination iii niraparib inhibitor jemperli dostarlimab l maintenance non small cell lung cancer iii nsclc combination pembrolizumab iii blenrep adc targeting bcell maturation l multiple myeloma combination iii belantamab antigen pomalyst dexamethasone mafodotin l multiple myeloma combination iii velcade dexamethasone multiple myeloma combination anti ii cancer treatments platform study l multiple myeloma combination velcade revlimid dexamethasone cobolimab antitcell immunoglobulin mucin nonsmall cell lung cancer combination iii domain tim antibody jemperli dostarlimab docetaxel belrestotug antitigit nonsmall cell lung cancer combination ii jemperli platform study squamous cell carcinoma head neck ii combination jemperli gsk platform study antipvrig cancer anticd cancer xmt sting agonist adc cancer wholly owned mersana therapeutics belantamab bcell maturation antigen binder multiple myeloma dna polymerase theta inhibitor cancer adc targeting bh gynecologic malignancies hiv apretude hiv integrase strand transfer inhibitor hiv preexposure prophylaxis approved asep adec cabotegravir longacting hiv infection hiv broadly neutralising antibody hiv infection ii hiv maturation inhibitor hiv infection ii hiv capsid protein inhibitor hiv infection ii hiv capsid protein inhibitor hiv infection ii hiv integrase inhibitor hiv infection ii brand names appearing italics trade marks owned licensed gsk group companies footnotes nonregistrational gsk exclusive global license option codevelop commercialize candidate strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla infectious diseases arexvy recombinant protein adjuvanted respiratory syncytial virus prophylaxis adults approved ajun amay rsv vaccine vaccine years older respiratory syncytial virus prophylaxis older registration sjan sdec adult population years age gepotidacin triazaacenaphthylene bacterial type ii uncomplicated urinary tract infection uuti iii topoisomerase inhibitor urogenital gonorrhea gc iii bepirovirsen hbv antisense oligonucleotide chronic hepatitis b virus infection iii bexsero vaccine recombinant protein outer prevention invasive disease caused n iii membrance vesicle vaccine meninigitidis serogroup b individuals months age older us recombinant protein outer prevention invasive disease caused n iii men abcwy vaccine membrance vesicle glycoconjugate meninigitidis serogroups abcw vaccine adolescents years age tebipenem pivoxil antibacterial carbapenem complicated urinary tract infection cuti iii ibrexafungerp antifungal glucan synthase inhibitor invasive candidiasis iii ganfeborole leucyl trna synthetase inhibitor tuberculosis ii alpibectir ethionamide booster tuberculosis ii recombinant protein adjuvanted malaria prophylaxis plasmodium falciparum ii malaria fractional vaccine dose generalized modules membrane shigella diarrhea prophylaxis ii antigens gmma vaccine primeboost viral vector co treatment chronic hepatitis b infections ii therapeutic hbv sequentially administrated aims functional cure controlling adjuvanted recombinant proteins resolving clinical sequelae infection reducing need treatment recombinant protein outer prevention invasive disease caused n ii men abcwy nd membrance vesicle conjugated meninigitidis serogroup abcw gen vaccine adolescents children weeks age older live attenuated vaccine active immunization prevention ii varicella new strain varicella individuals months age older sanfetrinem cilexetil serine beta lactamase inhibitor tuberculosis ii recombinant proteinadjuvanted active immunization girls women boys ii hpvas vaccine men years prevention cancer genital warts precancerous dysplastic lesions girls boys caused human papillomavirus hpv targeted immunotherapy viral vector treatment chronic hepatitis b virus infection ii chbv aso combo adjuvanted recombinant proteins individuals years without decompensated direct acting antiviral gsk 's cirrhosis bepirovirsen maps pneumococcal valent paed prevention pneumonia invasive ii pneumococcal disease caused streptococcus pneumoniae serotypes included vaccine children aged weeks years maps pneumococcal valent prevention pneumonia invasive ii pneumococcal disease caused streptococcus pneumoniae serotypes included vaccine adults aged years older live attenuated vaccine active immunization prevention ii mmrv new strain measles mumps rubella varicella children months years age brand names appearing italics trade marks owned licensed gsk group companies strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla infectious diseases continued recombinant subunit adjuvanted cytomegalovirus cmv infection prophylaxis ii cmv vaccine females years age mrna vaccine active immunization prevention ii mrna seasonal flu influenza disease adults years older mrna vaccine active immunization prevent covid ii mrna covid disease caused sarscov individuals years older recombinant proteinadjuvanted treatment suppression recurrent ii therapeutic hsv genital herpes adults aged years older bivalent generalized modules invasive nontyphoidal salmonella ii ints typhimurium membrane antigens gmma vaccine enteritidis bivalent generalized modules invasive nontyphoidal salmonella typhoid ii ints typhimurium membrane antigens gmma vaccine fever enteritidis typhoid conjugate vaccine tcv typhi generalized modules membrane active immunization prevention ii gonorrhoea antigens gmma vaccine gonorrhea infection individuals aged years daplusiran hepatitis b virustargeted sirna chronic hepatitis b virus infection ii tomligisiran sequential combination fimh antagonist uncomplicated urinary tract infection uuti crk inhibitor visceral leishmaniasis proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis pik beta inhibitor viral copd exacerbations bivalent typhoid paratyphoid salmonella typhoid paratyphoid enteric salmonella typhoid conjugate fever paratyphoid papdpapd inhibitor chronic hepatitis b virus infection tlr agonist chronic hepatitis b virus infection p falciparum whole cell inhibitor malaria p falciparum whole cell inhibitor malaria brand names appearing italics trade marks owned licensed gsk group companies footnote transition activities underway enable progression partner strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla immunology respiratory nucala mepolizumab antiil copd iii depemokimab antiil longacting asthma iii chronic rhinosinusitis nasal polyps iii crswnp eosinophilic granulomatosis polyangiitis iii egpa hypereosinophilic syndrome hes iii latozinemab antisortilin monoclonal antibody frontotemporal dementia ftd due iii heterozygous mutations progranulin gene amyotrophic lateral sclerosis als ii frontotemporal dementia ftd due ii mutations corf gene camlipixant px receptor antagonist refractory chronic cough iii ventolin low carbon beta adrenergic receptor agonist asthma iii version metered dose inhaler benlysta belimumab antib lymphocyte stimulator systemic sclerosis associated interstitial lung ii monoclonal antibody disease anticcl osteoarthritis pain ii diabetic peripheral neuropathic pain ii al antisortilin monoclonal antibody alzheimer 's disease ii antiil atopic dermatitis ii antiil autoimmune disease transglutaminase tg inhibitor pulmonary fibrosis rnaediting oligonucleotide alpha antitrypsin deficiency antiil copd interferon pathway modulator systemic lupus erythematosus opportunity driven jesduvroq prolyl hydroxylase inhibitor anaemia chronic kidney disease approved afeb daprodustat linerixibat ileal bile acid transporter ibat cholestatic pruritus pbc primary biliary iii inhibitor cholangitis hsdb silencer nonalcoholic steatohepatitis nash ii dnmt inhibitor sickle cell disease brand names appearing italics trade marks owned licensed gsk group companies footnote phase iii start expected strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd spioltostiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair bevespi aerosphere device device brimica genuair avamysveramyst fluticasone furoate allergic rhinitis dymista xhance expired expired nasonex fluticasone gx nucala mepolizumab asthma crswnp egpa fasenra expired expired hes relvarbreo ellipta fluticasone furoate asthma copd symbicort foster vilanterol trifenatate budesonideformoterol nce nce generics fluticasone propionatesalmeterol device device generics beclomethasone formoterol generics atectura seretideadvair salmeterol xinafoate asthma copd symbicort foster expired expired fluticasone propionate budesonideformoterol diskus device diskus device generics fluticasone expired propionatesalmeterol hfadevice hfadevice generics beclomethasone formoterol generics atectura trelegy ellipta fluticasone furoate copd asthma breztri aerosphere trimbow vilanterol trifenatate nce nce umeclidinium bromide device device ventolin salbutamol sulphate asthma copd salbutamolsaba generics expired symbicort reliever prn hfadevice hfadevice marti airsupra us xevudy sotrovimab early treatment covid regencov bamlanivimab etesevimab evusheld central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi xr expired expired inovelon keppra generics keppra levetiracetam epilepsy briviact vimpat lamictal na na depakene depacon generics cardiovascular urogenital avodart duodart dutasteride benign prostatic hyperplasia generics finasteride alpha expired expired dutasteride tamsulosin bph blockers antibacterials augmentin amoxicillin trihydrate common bacterial infections generics oral na expired potassium clavulanate cephalosporins cefuroxime axetil cefixime cefpodoxime cefdinir cephalexin oral macrolides azithromycin clarithromycin unless otherwise stated patent expiry dates relate latest expiring new molecular entity patents relevant territory appropriate patent expiry dates include granted patent term extensions us granted supplementary protection certificates multiple countries eu uk paediatric exclusivity periods additional exclusivities example regulatory data protection types patents may exist listed table regulatory data protection expires us eu prn use required mart maintenance reliever therapy strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition continued pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu dermatology dermovate clobetasol propionate inflammatory skin conditions generics topical marketed expired betnovate betamethasone valerate corticosteroids like us cutivate fluticasone propionate mometasone furoate eumovate clobetasone butyrate methylprednisolone aceponate hydrocortisone oncology zejula niraparib ovarian cancer lynparza rubraca blenrep belantamab mafodotin relapsedrefractory multiple abecma carvykti tecvayli myeloma talvey elrexfio jemperli dostarlimab dmmrmsih recurrent keytruda imfinzilynparza advanced endometrial cancer dmmr solid tumours ojjaaraomjjara momelotinib myelofibrosis patients jakafi inrebic vonjo anemia immunoinflammation benlysta benlysta belimumab systemic lupus lupkynis saphnelo sc iv erythematosus lupus nephritis renal jesduvroq duvroq daprodustat anaemia chronic kidney evrenzo roxadustat approved disease vadadustat eu hiv apretude cabotegravir hiv prevention descovy truvada cabenuvavocabria cabotegravir rilpivirine hivaids descovy genvoya odefsey rekambys biktarvy rukobia fostemsavir hivaids trogarzo sunlenca dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy triumeq dolutegravir lamivudine hivaids descovy genvoya odefsey abacavir biktarvy tivicay dolutegravir hivaids isentress prezista symtuza reyataz biktarvy unless otherwise stated patent expiry dates relate latest expiring new molecular entity patents relevant territory appropriate patent expiry dates include granted patent term extensions us granted supplementary protection certificates multiple countries eu uk paediatric exclusivity periods additional exclusivities example regulatory data protection types patents may exist listed table strategic report governance remuneration financial statements investor information gsk annual report pipelines products competition continued vaccine products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu arexvy respiratory syncytial virus respiratory syncytial virus abrysvo vaccine vaccination bexsero meningococcal groupb meningitis group b trumenba vaccine prophylaxis boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexa diphtheria tetanus pertussis prophylaxis pentacel pediacel pentaxim expired expired pediarix polio hepatitis b diphtheria tetanus pertussis pentavac haemophilus influenzae type polio hepatitis b hexaxim hexyon b eu haemophilus influenzae type vaxelis b eu cervarix hpv virus like human papilloma virus gardasil silgard marketed expired particles vlps type us adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza intenza flumist qiv expired expired antigens virus subtypes prophylaxis vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza vaxigrip mutagrip expired expired antigens virus subtypes prophylaxis fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c meningitis group c w nimenrix menquadfi w conjugate prophylaxis vaccine priorix priorix live attenuated mmr measles mumps rubella mmr ii mmrvaxpro expired expired tetraa varilrix varicella mmrv chickenpox prophylaxis proquad varivax vaccines rotarix human rotavirus rix rotavirus prophylaxis rotateq expired expired strain synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar note marketed polysaccharide disease pneumonia acute us otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles unless otherwise stated patent expiry dates relate latest expiring new molecular entity patents relevant territory appropriate patent expiry dates include granted patent term extensions us granted supplementary protection certificates multiple countries eu uk paediatric exclusivity periods additional exclusivities example regulatory data protection types patents may exist listed table strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties outline principal risks uncertainties relevant litigation government investigations related gsks business financial condition operations may provisions may make unfavourable outcomes affect performance ability achieve objectives increases related costs insurance premiums could risks believe could cause actual also materially adversely affect financial results results differ materially expected historical results detail status various uncertainties operating biopharmaceutical sector carries various significant unresolved disputes potential litigation set inherent risks uncertainties may affect business note legal proceedingson must comply broad range laws regulations details regarding risk management framework apply research development manufacturing identify principal risks found pages testing approval distribution sales marketing incorporated section risks related pharmaceutical vaccine products affect cost environmental social governance esg product development time required reach market level principal risks including environmental sustainability likelihood successfully uninterrupted climate change managed six focus areas basis described esg performance report additional information climaterelated risk management rules regulations change government interpretation climaterelated financial disclosure pages policy evolves business activities develop nature particular risk may also alter changes regulatory uk regulations require description principal risks regimes may substantial alteration failure uncertainties explanation comply applicable laws regulations could materially managed mitigated description adversely affect financial results principal risks together summary impact manage risk across businesses listed similarly global business exposes us litigation order significance consistent principal government investigations including product liability litigation risks detailed pages patent antitrust litigation sales marketing litigation patient safety risk definition context risk gsk including third parties fails accountable safeguarding patients clinical trial appropriately collect assess follow report human safety participants receive medicines vaccines whether information including adverse events potential sources development marketed harm unforeseen gsk potentially fails appropriately act relevant event unfavorably shifts benefitrisk profile findings may affect benefitrisk profile medicine probable occurrence event fully discounted vaccine timely manner mitigate risk robust safety evaluation product risk management activities risk impact chief medical officer single point accountability gsk tolerate unfavourable benefittorisk profile benefitrisk decisionmaking crossfunctional safety patients use products important review teams continually assess new safety efficacy consequence ineffective pharmacovigilance potential information every gsk product throughout life cycle harm patients maintain robust processes global safety board leadership chief medical managing human safety information conducting timely safety officer head global safety reviews product safety signal detection ensuring appropriate measures established milestones every situation might place manage risks patients gsk also intends fully potential impact benefitrisk profile comply pharmacovigilance relevant regulations worldwide noncompliance could result inspection findings must operate complex restrictive regulatory scrutiny civil criminal sanctions either pharmacovigilance regulatory environment sometimes temporary permanent loss product marketing complicated variable requirements regulatory authorisation regularly review respond patient agencies regulatory complexity illustrated safety risks limit potential reputational damage loss instances regulatory agencies taking decisions safety trust patients healthcare providers productrelated medicines vaccines based externally available data litigation loss shareholder confidence may accessible marketing authorisation holder trend could inhibit ability make timely decisions take appropriate action relation safety products confirm refute conclusions asserted external parties potential extend beyond regulatory agencies nextgeneration digital health data held technology companies data custodians inaccessible industry andor regulatory agencies strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued patient safety continued many sources information might trigger took additional steps strengthen increase reporting related products andor adverse events safeguard patients enhance execution media coverage social media government health pharmacovigilance operational activities added risk authorities etc ineffective management patient safety risks management benefitrisk expertise global safety could result reputational damage loss trust organisation enhance ability define risk patients healthcare providers decline shareholder management strategy evolving portfolio confidence could also increase volume product complex risk minimisation measures may required related litigation including classaction lawsuits followed new system better enable us regularly faced gsk industry general track implementation effectiveness risk management plans transitioned simplified mitigating actions efficient approach collecting following reporting chief medical officer accountable patient safety human safety information including adverse events enterprise risk human safety matters collaboration potential sources continuing build capability across head global safety crossenterprise safety gsk staff hold accountability pharmacovigilance governance board oversees implementation control quality management system process framework including risk management global safety embedding simplified process managing board ensures address human safety proactively pharmacovigilance agreements safety clauses throughout products lifecycle global policy gsk third parties including strategic partners management human safety information requires employees immediately report issues relating safety products third party risk management framework supports us identifying training third parties may encounter human safety information product quality risk definition mitigating actions risk gsk third parties potentially fail ensure align extensive global network quality appropriate controls governance quality compliance professionals sitelevel senior management development commercial products place within business unit provide oversight assist compliance industry practices regulations delivery quality performance operational manufacturing distribution activities terms gsk compliance deliver management oversight product licenses supporting regulatory activities met hierarchy quality councils global head quality risk impact expanding quality management system good manufacturing practice audit quality assurance oversight failure ensure product quality could farreaching programme across rd ensure mitigate potential implications patient safety cause product launch delays product quality risk across endtoend process drug shortages product recalls regulatory legal implemented riskbased approach assessing financial consequences could materially managing third party suppliers provide materials used adversely affect gsks reputation financial results finished products including monitoring third party labs context independently checking goods expect contract manufacturers make products comply external environment product quality remains gsk standards regularly conduct audits provide us challenging increase supplier mergers supply assurance use key risk indicators support risk network create challenge influencing quality management activities provide leadership teams standards rapid advancement use digital quality councils integrated assessment product technologies artificial intelligence machine quality performance learning aiml within evolving regulatory framework introduces opportunity modernisation potential throughout continued actively manage impact product quality adequately controlled deployment plans align new annex guidance need adopt adapt new updated guidance manufacture sterile medicinal products context emerges threat cyberattacks data global equipment component supply chain constraints breaches across industry could risk integrity product effecting industry increasingly applying advanced quality data audit trail additionally gradual digital technologies insights drive scientific excellence divergence regulatory expectations inspections enhance modernise development manufacture particularly health authorities presents challenge testing products protect data actively sites prepare inspections retaining expertise contributing industry advocacy influence thinking biopharma deep capability support digital regulatory frameworks advancing technologies progression potential challenge highly support patient safety benefit access competitive environment strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued product quality continued collaboratively working pharma companies continue adapt procedures evolving industry trade associations respond questions expectations topic work mitigation plans ema completing safety evaluation use alongside regular engagement regulators times titanium dioxide medicines well identifying potential ensuring inspection readiness markets serve substitutes working industry monitor emerging risk factors regulatory intelligence guidance nitrosamines financial controls reporting risk definition lead double taxation profits taxed one country complexity tax regulations also means risk gsk fails comply current tax laws fails may occasionally disagree tax authorities report accurate financial information compliance technical interpretation particular area tax law tax accounting standards applicable legislation incurs charge included financial statements best estimate significant losses due treasury activities tax liability pending audits tax authorities expect risk impact continued focus tax reform driven initiatives oecd ec address tax challenges arising noncompliance existing new financial new esg digitalisation economy reporting disclosure requirements changes recognition income expenses could expose gsk together domestic initiatives around world may litigation regulatory action could materially result significant changes established tax principles adversely affect financial results failure comply increase tax authority disputes regardless merit changes substance application laws governing outcomes may costly divert management attention transfer pricing dividends tax credits intellectual property adversely impact reputation relationship key could also materially adversely affect financial results stakeholders laws regulations orders measures failure comply applicable laws regulations could restrict dealings certain countries governments result gsk investigated relevant government government officials entities individuals use agencies authorities andor legal proceedings financial institutions movement funds us government investigations litigation mitigating actions unpredictable regardless outcome may costly require significant management attention damage keep date latest developments financial reputation inconsistent application treasury policies reporting requirements reviewing updates regulators transactional settlement errors counterparty defaults working external auditor legal advisors could lead significant losses performing responding emerging risks financial results reviewed approved regional management context reviewed gsks group financial controller chief required laws various jurisdictions publicly financial officer cfo allows financial controller disclose financial results events could cfo assess evolution business time materially affect groups financial results regulators evaluate performance plan significant judgements routinely review financial statements listed companies reviewed confirmed senior management integrate compliance new revised existing accounting technical organisational transformation newly acquired regulatory requirements believe comply activities external risks risk assessments apply appropriate regulatory requirements concerning financial appropriate controls reviews statements disclosure material information including maintain control environment designed identify transactions relating business restructuring material errors financial reporting disclosure acquisitions divestitures however subject standardised global financial reporting operating model investigation potential noncompliance accounting design operating effectiveness key financial reporting disclosure requirements could lead restatements controls regularly reviewed management tested previously reported results significant penalties external third parties locations treasury group deals daily high value transactions mostly standard model apply minimum standard set controls foreign exchange cash management transactions reviewed management monitored transactions involve market volatility counterparty risk independently gives us assurance controls key groups effective tax rate reflects locations activities financial reporting disclosure processes operating value generate determine jurisdictions effectively global finance risk management controls profits arise applicable tax rates frmc group provides extra support significant may higher lower uk statutory rate transformations system deployment management may reflect regimes encourage innovation investment structural reorganisations add operational resources rd providing tax incentives changed could adapt programme timelines ensure processes controls affect gsks tax rate addition worldwide nature maintained significant changes disclosure operations means crossborder supply routes committee reporting board reviews gsks quarterly necessary ensure supplies medicines vaccines results annual report result conflicting claims tax authorities profits taxed individual countries strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued financial controls reporting continued throughout year consultation legal advisors relevant provide pragmatic constructive disclosure committee also determines whether necessary business input tax policy makers either directly disclose publicly information group stock industry trade bodies includes advocating reform exchange announcements treasury management group support economic growth job creation well needs meets regularly ensure liquidity interest rate patients key stakeholders tax affairs counterparty foreign currency transaction foreign currency managed global basis team tax professionals led translation risks managed line prudent global head tax work closely business approach detailed risk strategies policies adopted daytoday basis global tax team suitably qualified board counterparty exposure subject defined limits roles perform support training needs approved board credit rating individual provide date technical advice line counterparties responsibilities submit tax returns according statutory time limits engage proactively tax authorities ensure middle office within treasury monitor management tax affairs current entering continuous audit counterparty risk line agreed policy oversight programmes advance pricing agreements corporate compliance officer operating independently appropriate arrangements provide longterm certainty treasury details mitigation treasury risks tax authorities gsk tax treatment found pages manage tax risk robust business based full disclosure relevant facts seek internal policies processes training compliance resolve differences interpretation tax legislation programmes maintain open constructive relationships tax authorities cooperative manner exceptional cases tax authorities worldwide monitor government debate may resolve disputes formal proceedings tax policy key jurisdictions understand potential future changes tax law share informed point view legal matters risk definition supportive aspects external environment include increase focus corporate transparency advances risk gsk third parties potentially fail comply technology use data analytics also providing certain legal requirements development supply better platforms streamline processes detect potential commercialisation products operation business issues specifically relation requirements competition law antibribery corruption sanctions failure meet mitigation actions compliance legal standards particular areas group general counsel oversees accountable could lead increasing scrutiny enforcement legal matters principal risk enterprise antibribery government agencies corruption competition law sanctions control risk impact frameworks programmes designed ensure compliance applicable laws regulations building code failure mitigate legal risk could expose gsk associated culture business standards monitor adapt persons governmental investigation regulatory action evolving regulations business activities civil criminal liability may compromise gsks ability programmes include senior leader commitment setting supply products certain government contracts tone top addition failure manage legal risk could substantial implications gsks reputation credibility senior control frameworks based globally recognised leaders might erode investor confidence governance accepted principles include global policies written risk management future performance standards controls govern business activities give consequential negative impact share performance could rise risks mandate enhanced controls including also lead imposition significant financial penalties due diligence requirements sanctions screening specific imposition additional reporting obligations highrisk activities interactions government officials business development transactions context engagement third parties overall environment antibribery corruption regularly provide antibribery corruption competition competition law sanctions export controls remains law sanctions training employees relevant challenging continues strong enforcement complementary workers third parties accordance appetite bribery investigations prosecutions roles responsibilities risks face include particular focus conduct multinational companies aspects key risks annual mandatory training wherever operate focus sanctions export controls reinforce workforce clear expectations regarding competition law enforcements increased acceptable behaviours sanctions perspective seen penalties violations levied companies number different industries leverage data analytics use information merger control seen increasing intervention greater monitoring assurance activities key risk indicators divergence decisions policy enforcement agencies investigations speak channels identify specific areas financial penalties handed types case intervention drive continuous improvements often significant enhancements controls investigate allegations noncompliance take disciplinary action required permitted locally strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued legal matters continued dedicated teams responsible implementation continuously assess monitor understand risk evolution risk framework programmes anti exposure related risks including money laundering risk bribery corruption competition law sanctions actively consider implement improvements risk framework programmes based internal external learnings considering complexity geographic breadth risk commercial practices risk definition financially new productsindications carry uncertainty future success product development costly risk gsk third parties potentially engage lengthy uncertain carries potential failure commercial activities fail comply laws regulations stage even successful product development face industry codes internal controls requirements challenges launch competitors products risk impact pricing strategies could render assets less competitive support product innovation continued focus failure engage activities consistent letter inperson virtual engagement constant focus spirit law industry regulations groups patient approved medicine requirements relating sales promotion medicines vaccine obligation provide important information vaccines appropriate interactions healthcare healthcare community various ways always professionals hcps organisations patients responsible legal ethical manner legitimate transparent transfers value pricing competition antitrust regulations commercial appropriate product promotion ensures hcps access practices including trade channel activities business information need patients consumers tendering could materially adversely affect ability facts medicines vaccines require deliver strategy longterm priorities additionally may products prescribed recommended used result incomplete awareness riskbenefit profile manner provides healthcare benefit committed products possibly suboptimal treatment patients ethical responsible commercialisation products consumers governmental investigation regulatory action support purpose improve quality human life legal proceedings brought group governmental get ahead disease together private plaintiffs could result government mitigating actions sanctions criminal andor financial penalties practices found misaligned culture could evolved policies standards incrementally also result reputational harm dilute trust established ensure commercial activities undertake external stakeholders conducted behalf executed within established governance train employees relevant information context focus interactive learning elements behavioural science commercial activities worldwide must conform operate highly regulated extremely competitive high ethical regulatory industry standards local biopharma industry amongst peers make significant standards differ global ones apply product innovations technical advances intensify price stringent standards acquired company joint competition additional external factors include access venture partner differ global standards remediate limitations customers macroeconomic inflationary legacy policies implement revisions align dynamics pricing pressure across markets achieve businesses continue use internal control framework strategic objectives must continue develop commercially support assessment management risks viable new products sustain reliable supply deliver additional uses existing products address needs patients consumers hcps payers strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued commercial practices continued business unit risk management compliance boards allow fairmarket value payments made gsk manage risks across global incountry business activities expert practitioners speak innovative medicines oversee commercial activities monitoring vaccines restricted period products lifecycle programmes promotional materials activities must new competitive data published support reviewed approved according policies embedded global endtoend expert engagement standards conducted accordance local laws process rolled healthcare organisation hco process regulations requirements seek ensure created new standard operating procedure tenders materials activities fairly represent groups products updated external expert engagement operating procedure services necessary event misconduct strengthened interactive digital media channel disciplined employees including termination controls identification channels contract appliedenforced gsk 's senior leader contracting third party monitor channels across recoupment policy continued evolve incentive gsk drive consistent ways working efficiencies programme sales representatives better recognise strengthen controls automation use data reward individual effort nearly markets capped permitted report payments individual hcps variable pay element representatives compensation part commitment transparency responsible evaluated basis individual sales targets disclosure scientific patient engagement risk definition mitigating actions risk gsk third parties potentially fail engage chief medical officer cmo oversees nonpromotional externally gain insights educate communicate scientific patient engagement spe enterprise risk science medicines associated disease areas owner gsk code practice key internal policy provide grants donations legitimate transparent nonpromotional engagement activities activities include manner compliant laws regulations industry codes scientific interactions support medical education advice internal controls requirements seeking gathering insights unmet needs patients scientific communication research disease risk impact awareness healthcare support services patient support without controls place risk could result real perceived programs disguised promotion including offlabel prior process simplification continued global process authorisation promotion real perceived provision owners accountable endtoend process medical advice could lead reputational damage assigned simplified processes seeking advice content competitor complaints regulatory inspections subsequent approval medical information medical education corrective actions civil litigation accountability includes comprehensive oversight must fully appropriately engage externally bring process creation appropriate internal control patient benefit advance science innovation framework continuous evaluation process delivering strategy otherwise risk reducing trust improvement necessary public patients healthcare professionals payers regulators spe materials activities must reviewed approved governments according policies standards additional controls context review spe content implemented continue ensure content nonpromotional accurate fair objective scientific patient engagements diverse non balanced perceived promotion promotional activities directed healthcare professionals patients payers external stakeholders engagements modernised digital approach hcps aim improve patient care exchange provision embedded framework interactions patients knowledge use products related diseases patient organisations developed policy healthcare scientific patient engagement external stakeholder support services patient support programmes applied groups vital gsk researchbased biopharma internal principles activities internal framework company ambitious patients advance science software medical device established including medicine expert panel provides business owners multi disciplinary advice crossbusiness unit spe risk council expect activities scientifically sound accurate oversees spe activities reviews monitoring audit data conducted ethically transparently compliant spe network reviews maturity internal applicable codes laws regulations many control framework spe processes continuously industry local codes laws regulations improve internal controls systems networks identify apply privacy data integrity means measured emerging risks early support staff conduct activities risktaking rooted sound ethical considerations compliance gsks culture policies local laws principlesbased decisionmaking training communication regulations building effective risk management monitoring activities key managing risk management monitoring systems enabling full appropriate engagement strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued data ethics privacy risk definition mitigating actions risk gsk third parties potentially fail ethically general counsel gsks enterprise risk owner ero collect use reuse artificial intelligence data analytics chairs digital privacy governance board automation secure share destroy personal information oversees gsks overall data ethics privacy operating model accordance laws regulations internal controls gsk business area appointed risk owner requirements accountable overseeing privacy risks supported privacy leaders within business countries local risk impact data privacy laws require appointment data protection noncompliance data privacy laws globally could lead officer dpo gsk made appointments including harm individuals gsk could also damage trust eu dpo result gsks focus technology datadriven gsk individuals communities business partners science use aiml evolving global data strategy government authorities many countries increased ero appointed head digital privacy enforcement powers data protection authorities cybersecurity head dpc daytoday allowing impose significant fines restrict crossborder accountability designing implementing control data flows temporarily ban data processing many new framework national laws also enable individuals bring collective legal actions companies gsk failing follow head dpc leads global crossfunctional core team data privacy laws digital privacyqualified attorneys compliance professionals supported network privacy leaders within context business unitsfunctions privacy contacts locally wider data protection privacy legislation diverse limited legal compliance team gsk global data ethics global harmonisation simplification making challenging privacy framework based eu general data protection multinationals standardise approach compliance regulation deployed every market based factors governments enforcing compliance data protection including robustness local privacy legislation established privacy laws rigorously data protection authorities gsks footprint approach focus data protection privacy beyond countries deployed proportionate regulators also differs regions countries control framework set minimum privacy standards creates challenges global organisations seeking irrespective applicable legislation implement single harmonised global privacy programme core team responsible increases volume data processed advances operating improving centralised global data ethics technology resulted greater focus data privacy control framework governance ethical use personal information continuously assessing providing relevant compliance data privacy laws companies proportionate controls aid nondeployed markets seeking foster innovation artificial intelligence monitoring new changing laws adapting privacy new technologies faced evolving decisions global framework accordingly policymakers best promote trust systems avoid unintended outcomes harmful impacts deploying comprehensive training programme drive greater awareness accountability managing personal additionally number emerging laws concerning information across entire organisation localisation data restrictions international transfers legal regulatory expertise emerging technologies data security changing existing frameworks including artificial intelligence machine learning gsk previously relied upon increasing trend data sovereignty affects ability drive medical innovation ensure key gsk privacy network roles sufficient effectively operate internationally training experience carry roles effectively continuously improve processes issue identification global regulators eu uk us china also reporting handling monitoring core team process introducing legislation around use works business ensure build privacy controls artificial intelligence machine learning aiml existing new business initiatives well ensuring continues considerable uncertainty around final meet accountability obligations accordance version proposed laws global data protection privacy laws strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued research practices risk definition use wide variety biological materials discovery research development assets committed risk gsk third parties potentially fail ensuring research compliant terms conditions adequately conduct ethical credible preclinical licenses agreements authorisations acquire clinical research collaborate research activities compliant use transfer biological materials technologies laws regulations internal controls requirements convention biological diversity cbd nagoya risk impact protocol international community established global framework regulating access use genetic resources potential impacts risk include harm human nonhuman origin research development support subjects reputational damage failure obtain necessary equitable access fairness principles access regulatory approvals products governmental benefit sharing abs outlined cbd nagoya investigation legal proceedings brought gsk protocol also recognise importance appropriate governmental private plaintiffs product liability suits effective proportionate implementation measures claims damages loss revenue due inadequate patent national regional levels protection inability supply products regulatory action fines penalties loss product authorisation mitigating actions poor data integrity governance could compromise gsks research practices risk overseen enterprise rd efforts negatively impact reputation framework seeks strengthen governance across rd could materially adversely affect financial results leadership research practices enterprise risk damage trust patients customers owner management risk takes pragmatic approach context information sharing streamlining risk identification escalation ensuring ownership risk mitigation stays research involving animals raise ethical concerns many business cases however research involving animals way investigate effects potential new medicine living established office animal welfare ethics body humans animal research provides critical strategy risk oawesr led chief veterinary information causes mechanisms diseases officer oversees ensures humane therefore remains vital part research continually responsible care use animals conduct ethical seek ways minimise use animals reviews independent scientific reviews animal studies research development testing complying advocates application nonanimal alternatives regulatory requirements reducing impact oawesr provides framework animal welfare animals used human subject research critical assessing governance defines provides oversight animal care demonstrating safety efficacy use programmes promotes replacement refinement investigational products evaluating products reduction animal use research conducts quality approved assessments manages programme due diligence external animal research research includes clinical trials healthy volunteers patients adheres regulations high ethical medical ensuring implement maintain proper data governance scientific standards disclose results research controls remains important priority especially externally regardless whether reflect positively scientific strategy evolving take advantage breadth negatively products scientific community data example genomics artificial intelligence learn outcomes research also work machine learning aiml focus building data human biological samples fundamental integrity privacy usage controls internal control discovery development safety monitoring products framework quality assurance teams conduct audits provide independent business monitoring internal controls committed managing human biological samples rd organisation maintains controls prepublication accordance relevant laws regulations ethical procedures guard public disclosure patent principles manner respects interests sample applications filed addition lack data donors data pivotal rd strategy integrity preparing patent application data information maximising use data serve patients governing lead loss patent protection legal experts data accordance relevant laws regulations contractual collaborate rd support review process new obligations expectations culture across data ethics patent applications rd organisation also collaborates privacy information cyber security data integrity legal experts throughout development assets essential take account relevant thirdparty patent rights strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued environment health safety ehs risk definition function leaders ensure ehs control framework implemented effectively respective business area risk gsk third parties potentially fail ensure compliant applicable laws regulations appropriate controls governance organisation 's adequately resourced maintained communicated assets facilities infrastructure business activities including monitored every employee qualified contractor acting execution hazardous activities handling hazardous behalf gsk personally responsible ensuring materials release substances harmful environment follow applicable local standard operating procedures disrupts supply harms employees third parties riskbased proactive approach articulated global ehs environment policy detailed global ehs standards risk impact audit operations ensure compliance ensure hazards appropriately controlled design failure manage ehs risks could lead significant harm facilities equipment systems rigorous procedures people environment communities applied correctly put effective barriers place protect operate fines inability meet stakeholder expectations employees health safety regulatory requirements litigation regulatory action damage companys reputation could materially refreshed rebranded life saving rules adversely affect financial results across gsk global initiatives embed rules daily operations safety leadership experience training context continues across gsk using incident knowledge enhance gsk subject health safety environmental laws learnings build strong collaborative safety culture various jurisdictions laws impose duties protect contractor safety assessment deployed people environment communities support external expert review current gsk contractor operate management improving driver safety safer cars enhanced training mitigating actions gsk leadership team responsible ehs governance risk oversight ensure effective control framework inplace inuse manage ehs risks impacts legal compliance issues businesses includes assigning responsibility senior managers providing maintaining controls ensuring tiered monitoring governance processes place within business units information cyber security risk definition context risk gsk third parties potentially fail ensure external environment continues extremely appropriate controls governance identify protect challenging making hard keep pace increasingly detect respond recover cyber incidents sophisticated cyber security threats factors include increased unauthorised access disclosure theft unavailability geopolitical conflict digital nationalism rising frequency corruption gsk 's information key systems technology severity data breaches growing capability infrastructure accordance applicable laws regulations sophistication cyber threat actors additional tools like industry standards internal controls requirements generative ai propagate attacks gsks business relies operating highly connected information network internal risk impact external systems hold confidential research failure adequately protect information systems development manufacturing commercial workforce cyber security threats may cause harm patients financial data means systems information workforce customers disruption business andor loss continue targeted cyber security commercial strategic advantage regulatory sanction threat actors acceleration use digital data damage reputation analytics aiml cloud computing capabilities drive gsks pipeline performance productivity requires us continuously adapt strengthen controls defensive capabilities strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued information cyber security continued gsk also relies thirdparty contractors partners information cyber security governance suppliers face similar cyber security threats chief digital technology officer cdto leads emphasises focus third party risk management digital technology function includes ciso additionally hybrid working environments create larger cyber security office cdto enterprise risk owner complex attack surface cyber security threat actors information cyber security principal risk responsible exploit employees accessing company resources managing reporting risk enterprise risk plan various locations devices new threats vulnerabilities plan includes description risk context could arise assessment risk appetite treat risk mitigating actions actions need take manage line corporate internal control framework ciso responsible risk manage cyber security risk coordination across organisation developing use corporate enterprise risk management internal overseeing implementation controls monitoring control framework manage oversee information reporting enterprise risk plan board cyber security principal risk follow corporate audit risk committee oversee cyber security risk risk governance hierarchy risk reporting escalation oversight compliance council helps audit risk chief information security officer ciso heads cyber committee oversee cyber security risks security office responsible identifying putting strategies address ciso reports cyber security place controls measures help gsk mitigate manage risks throughout year cdto risk oversight cyber security risks includes actively monitoring compliance council audit risk committee initiating remediation actions respond cyber reporting covers external insights key risk indicators security intelligence threats also includes ongoing management actions updates implementing enterprise investment people process technology improve risk plan progress cyber maturity programme ability prevent detect respond recover escalations cyber security office analyses potential cyber cyber security incidents monitor risk using key risk security incidents supported internal experts gives indicators include tolerance thresholds reported monthly updates ciso ciso escalates cyber incidents business quarterly governance channels potential material impact chief compliance officer cdto turn escalates gsk also thirdparty security risk management leadership team company secretary triggering review programme assess cyber security risk selecting disclosure committee determine materiality boarding third parties like external partners suppliers material cyber security incidents subsequently escalated use widely accepted standards frameworks benchmark board audit risk committee internal environment controls help define security objectives desired security outcomes cyber security awareness training readiness standards frameworks evolve response cyber security awareness training programmes dynamic threat environment also rely external include phishing simulations monthly awareness campaigns frameworks including mandatory annual refreshers employees new hires national institute standards technology nist highrisk roles run quarterly phishing simulation tests cyber security framework measuring overall cyber related remedial trainings also offer optional training readiness maturity annual global event efforts aim increase cyber international organisation standardisations iso security awareness foster culture security general information technology controls everyones responsibility also run periodic crisis simulation sarbanesoxley sox assessment internal controls exercises targeted functions test response cyber security incidents also draw thirdparty consultants ' expertise processes assessing identifying managing cyber security risks compliance various governmental cyber security year cyber security maturity programme designed regulations reduce risk data compromised improved cyber security office guided general counsel security posture ability detect protect works stay abreast emerging government regulations respond recover malicious cyber activity also trends compliance expectations regarding cyber security created ai governance council includes ciso new regulatory guidance becomes available including assess manage information security risks around adopting us securities exchange commission 's rules cyber scaling ai gsk security related disclosures respond remedial compliancerelated actions strategic report governance remuneration financial statements investor information gsk annual report principal risks uncertainties continued supply continuity risk definition supply chain imperatives focus accelerating innovation use technology data transform way risk gsk third parties potentially fail deliver manufacture supply medicines vaccines drive continuous supply compliant finished product respond competitive advantage longterm strategic effectively crisis incident timely manner recover partnership rd focus talent skills needed sustain critical supply operations future addressing skills new technologies risk impact modalities brought vaccines medicines supply chains together one global supply chain recognise important continuity supply organisation leverage benefits highly skilled products patients rely supply disruption workforce continual business monitoring place assess lead sectorwide risk spread industrial relations product shortages product recalls challenges arising global cost living pressures keeping patients supplied medicines priority regulatory intervention reputational harm mitigating activities lost sales revenue risk management consequently need sophisticated endtoend supply chain medicines vaccine supply chains set ensure management robust crisis management business sustainable global supply gsk internal control framework continuity plans place respond drives approach risk management context designed identify emerging new risks support clear decision making risk oversight managed hierarchy operate supply chains continually evolving highly risk management compliance boards assure risk regulated environment single set global mitigation including identifying new emerging threats regulations governs manufacture distribution medicines must adhere requirements inventory management markets licence sell manufacture products supply chain governance committees medicines rely upon internal quality management system vaccines closely monitor inventory status delivery internal control framework ensure maintain licence products core commercial cycle links supply chain operate complex endtoend supply chains often involve forecasting commercial ambition designed third party suppliers active pharmaceutical ingredient reduce risk demand fluctuations manage temporary api manufacturers raw material suppliers shortages supply periodically review node third party logistics providers contract engineering firms supply chains ensure hold adequate safety stocks whilst integrated risk management sourcing balancing working capital put particular emphasis day day business processes emphasis third mitigating supply risks associated medicallycritical high party oversight external factors continued challenge supply revenue products new product launches example using continuity difficulties sourcing bioscience dual sourcing key products apis use monthly materials eased year performance management process across supply chains monitor business activity highlight adverse trends supply new constraint third party sterile manufacturing operations budget workforce capability capacity increases global competition contract manufacturing operations continue operate global business continuity supply chains rapidly changing geopolitical environment crisis management business continuity plans place increasing nationalism friction us china across supply chains include authorised response creates divergence global supply strategy recovery strategies key areas responsibility clear reacted designing supply routes derisk sourcing communication routes regularly use business continuity decisions use business continuity planning mitigate plans manage potential supply disruptions maintain supply continuity eg dual sourcing materials manufacturing sites crisis management plans place adapting supply routes meet regulatory expectations plans tested least annually ensure maintenance commercial late stage clinical supply chains core skills crisis management strategic report governance remuneration financial statements investor information gsk annual report shareholder information share capital control details issued share capital number shares articles association right holder vote held treasury december found note respect companys shares financial statements share capital share premium account interests voting rights ordinary shares listed london stock exchange lse also quoted new york stock exchange stated far company aware nyse form american depositary shares ads persons significant direct indirect holdings ads represents two ordinary shares details listed debt company information provided company pursuant listed refer note financial fca 's disclosure guidance transparency rules dtr statements net debt published regulatory information service companys website gskcom holders ordinary shares ads entitled receive dividends declared copy companys company received notifications accordance annual report elected also entitled attend dtr following notifiable interests voting rights speak appoint proxies exercise voting rights general companys issued share capital meetings company december february restrictions transfer limitations percentage percentage holding ordinary shares ads requirements total total obtain approval prior transfers ordinary shares voting voting voting voting ads carry special rights regard control rights rights rights rights company restrictions voting rights major blackrock inc shareholders voting rights per share dodge cox shareholders known arrangements percentage total voting rights date notification financial rights held person holder company shares known agreements restrictions share comprising indirect interest ordinary shares transfers voting rights holding qualifying financial instruments contracts difference shares acquired groups employee share plans comprising indirect interest ordinary shares rank equally shares issue special ads rights trustees employee share ownership plan trusts waived rights dividends shares held company acquired disposed interests trusts shares period review demerger haleon share consolidation share buyback programme reported previously july company completed board authorised issue allot ordinary demerger consumer healthcare business shares article companys articles association group details found wwwgskcomengb power article authority company haleoncmdtodemergerarchive july make purchases shares subject shareholder shareholders received four new gsk plc shares nominal value authorities sought annual basis annual pence every five gsk plc shares nominal general meeting agm shares purchased value pence company may cancelled held treasury shares used group reduced share holding haleon plc satisfying share options grants group 's employee course financial year ended december share plans information found note current equity programme covers purchases shares cancellation investments january group reduced held treasury shares accordance authority shareholding gsk holds approximately million renewed shareholders agm may ordinary shares haleon plc representing company authorised purchase maximum issued share capital haleon information found million shares note post balance sheet events determining specific share repurchase levels company exchange controls limitations considers development free cash flow year affecting holders treasury shares purchased since details shares purchased cancelled held treasury shares certain economic sanctions may force subsequently transferred treasury satisfy awards time time currently applicable laws groups employee share plans disclosed note decrees regulations force uk restricting import financial statements share capital share premium export capital restricting remittance dividends account company confirms currently payments holders companys shares intend make market purchases company nonresidents uk continue review potential future share buybacks similarly certain economic sanctions may line usual annual cycle subject return force time time limitations relating ratings criteria nonresidents uk english law companys market capitalisation share price trend three years ended market capitalisation based shares issue excluding december treasury shares gsk december billion date gsk th largest company market capitalisation ftse index share price january december increasedecrease high year low year table sets middle market closing prices companys share price decreased compares decrease ftse index year middle market closing share price february ku us strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued share capital control continued jan jan jan uk share price uk us share price us nature trading market following table sets periods indicated high low middle market closing prices companys ordinary shares lse ads nyse ordinary shares ads uk per share us per share high low high low february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december february strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued analysis shareholdings december number total total accounts accounts shares number shares holding shares held institutional corporate holders individuals corporate bodies guaranty nominees limited adr programme held treasury shares gsk jp morgan chase bank na depositary companys american depositary receipt adr programme companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name guaranty nominees limited february guaranty nominees limited held ordinary shares representing issued share capital excluding treasury shares february number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders dividends company pays dividends quarterly continues return adjusted share consolidation prior years cash shareholders dividend policy dividends adjusted remain essential component total shareholder return q ordinary dividend receivable ads holders calculated based exchange rate april cumulative gsk recognises importance dividends shareholders dividend receivable ads holders q q q june gsk investor update gsk set progressive dividend policy implemented expected dividend p per ordinary share guided percent payout ratio details dividends declared amounts investment cycle dividend policy total expected cash payment dates given note financial statements distribution respective dividend payout ratios gsk dividends remain unchanged dividend calendar dividends per share exdividend ads ex quarter date dividend date record date payment date table sets dividend per share per ads last five years dividend per ads translated q february february february april us dollars applicable exchange rates q may may may july year pence us q august august august october q november november november january q february february february april annual fee per ads per ads per quarter charged depositary amounts shown dividends paid per ads annual fee charged dividends declared paid respect p per share q p per share q p per share q dividend p per share declared q strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued financial calendar event date results announcements quarter results announcement may results announcements issued lse available annual general meeting may news service also sent us securities quarter results announcement july exchange commission sec nyse issued media made available website quarter results announcement october preliminaryquarter results announcement february financial reports annual report publication februarymarch company publishes annual report made annual report distribution march available website date publication shareholders may elect receive notification email information company including share ads publication annual reports registering price available website gskcom information made wwwshareviewcouk may also elect receive printed available website constitute part annual copy annual report contacting registrar equiniti report limited stock exchange announcement notifications copies previous annual reports available website provide shareholders service receive automatic printed copies also obtained registrar see email notifications publish stock exchange contact details announcement receive email notifications please sign announcements gskcom investors section annual general meeting annual general meeting agm held pm uk ads holders wishing attend meeting electronically time wednesday may royal lancaster refer agm notice details request proxy london lancaster terrace london w ty also appointment depositary jp morgan chase bank na broadcast live join electronically enable attend ask questions vote electronically business transacted meeting agm companys principal forum communication private shareholders addition formal agm ads holders reminded instruct business presentation ceo depositary way shares represented performance group future development ads voted completing returning opportunity questions asked board voting card provided depositary shares chairs boards committees available take voted questions relating roles documents display details access agm electronically articles association company directors attend person ask questions vote found service contracts applicable letters appointment notice annual general meeting agm notice directors company subsidiaries made available website gskcom around side letters relating severance terms pension march arrangements available inspection companys investors holding shares nominee service registered office made available inspection arrange service appointed proxy agm respect shareholding attend vote meeting electronically strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued tax information shareholders summary certain uk tax us federal income tax inheritance tax consequences holders shares ads citizens individual ukdomiciled otherwise shareholders may uk us set complete analysis liable uk inheritance tax transfer shares ads possible tax consequences purchase ownership exposure uk inheritance tax charge typically occurs sale securities intended general guide death asset owner however transfers shares holders advised consult advisers respect commercial sales within seven years death remain tax consequences purchase ownership sale relevant inheritance tax exposure death shares ads consequences state local tax transfers trust arrangement lifetime give rise laws us implications current ukus tax immediate inheritance tax charge conventions tax may charged amount value us holders ads generally treated owners shareholders estate reduced result transfer underlying shares purposes current ukus double way lifetime gift disposal less full market taxation conventions relating income gains income tax value case bequest death tax may charged convention estate gift taxes estate gift tax value shares date shareholders convention purposes internal revenue code death exposure uk inheritance tax us estate amended gift tax exists careful planning must undertaken uk shareholders understand opportunity utilise usuk estate gift double tax convention manage tax credits avoid summary applies uk resident shareholder double taxation holds shares capital assets overall exposure dependent specific taxation dividends circumstances situation also important note uk tax year uk resident individuals tax charges may arise jurisdictions bespoke advice entitled dividend tax allowance tailored individuals personal circumstances first dividends received tax year free tax therefore obtained tax professional dividends excess allowance taxed stamp duty stamp duty reserve tax basic rate taxpayers higher rate taxpayers additional rate taxpayers note april uk stamp duty andor stamp duty reserve tax sdrt dividend allowance reduced subject certain exemptions payable transfer shares rate rounded nearest uk resident shareholders corporation taxpayers case stamp duty consideration transfer note dividends payable ordinary shares generally notwithstanding provided instrument executed entitled exemption corporation tax pursuance agreement gave rise charge taxation capital gains sdrt instrument stamped within six years agreement including stamped exempt sdrt uk resident shareholders may liable uk tax gains charge cancelled sdrt already disposal shares ads paid repaid listed shares transferred disposals individuals uk tax year company connected transferor chargeable taxable capital gain accruing disposal shares ads consideration deemed less market taxed basic rate taxpayers value shares transferred market value override also allowable deductions individuals taxable income applies nonlisted shares transferred company year exceeds basic rate income tax banding note connected transferor consideration includes following use exemptions available individual issue shares taxpayer annual exempt amount us shareholders corporation taxpayers may entitled indexation summary applies shareholder citizen allowance applies reduce capital gains extent resident us domestic corporation person gains arise due inflation indexation allowance may otherwise subject us federal income tax net income reduce chargeable gain create allowable loss basis respect shares ads holds shares ads assets acquired january legislation capital assets resident uk uk tax purposes finance act freezes level indexation allowance hold shares purposes trade profession given calculating companys chargeable gains vocation carried uk branch value would apply disposal asset agency december assets acquired january onwards legislation finance act removes summary also address tax treatment indexation allowance disposal holders subject special tax rules banks tax exempt entities insurance companies dealers securities currencies persons hold shares ads part integrated investment including straddle comprised share ads one positions persons directly indirectly constructively companys stock vote value address tax treatment may applicable result international income tax treaties strategic report governance remuneration financial statements investor information gsk annual report shareholder information continued tax information shareholders continued taxation dividends information reporting backup withholding gross amount dividends received treated foreign dividends payments proceeds sale shares source dividend income us tax purposes eligible ads paid within us certain usrelated financial dividend received deduction allowed us corporations intermediaries subject information reporting may dividends ads payable us dollars dividends subject backup withholding unless us holder ordinary shares payable sterling dividends paid corporation exempt recipient provides taxpayer sterling included income us dollar amount identification number certifies loss exemption calculated reference exchange rate day occurred nonus holders generally subject dividends received holder subject certain information reporting backup withholding may exceptions shortterm hedged positions individual required provide certification nonus status eligible us holder subject us taxation maximum connection payments received amounts withheld federal rate plus applicable state local tax allowed refund credit holders us federal respect qualified dividends qualified dividend defined income tax liability provided required information us internal revenue service irs dividend furnished irs meets following criteria estate gift taxes must issued us corporation corporation estate gift tax convention us shareholder incorporated us possession corporation generally subject uk inheritance tax however us eligible benefits comprehensive income tax treaty holder may subject us federal estate gift tax deemed satisfactory published irs stamp duty dividends type listed irs dividends qualify uk stamp duty andor sdrt subject certain exemptions payable transfer shares ads custodian required dividend holding period met depositary rate amount consideration shares must owned days provided transferred sale value transferred holding period defined day consideration period begins days exdividend date day stock trades without dividend priced however stamp duty sdrt payable example stocks exdividend date october transfer agreement transfer ads transfers shares must held days period within clearance service notwithstanding august november year order clearance service operator made election count qualified dividend sa finance act broadly stamp dutysdrt charge arise transfer clearance dividends qualified subject taxation service transfers within system us federal graduated tax rates maximum rate change beneficial ownership would attract charge types dividends automatically excluded qualified dividends even meet requirements demerger share consolidation include limited summary certain uk us tax consequences respect capital gains distributions demerger haleon plc consolidation dividends bank deposits company 's share capital relevant companys shareholders resident case individuals dividends held corporation employee stock resident domiciled uk uk tax purposes ownership plan esop citizens resident us us tax purposes set dividends paid taxexempt corporations part circular relation demerger us state local tax rates qualified nonqualified share consolidation published june circular pages dividends may vary would assessed addition circular along information regarding federal tax rates communicated demerger share consolidation found gskcom demerger section taxation capital gains information tax base cost allocation assist uk generally us holders subject uk capital gains tax shareholders apportion base cost gsk plc subject us tax capital gains realised shares haleon plc shares uk capital gains tax purposes sale disposal shares ads gains long following demerger including worked example term capital gains subject reduced rates taxation found tax section gskcom demerger section individual holders shares ads held one year date shares vestedreleased short term capital gains subject taxation rates whereas longterm capital gains may subject rates state local tax rates capital gains may also apply strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may drip election form terms conditions drip choose reinvest dividends buy gsk shares information fees downloaded wwwshareviewcouk requested contacting equiniti dividend payment direct dividends paid directly bank building dividend bank mandate form downloaded bank account bank society account receive cash dividends must wwwshareviewcouk requested contacting equiniti mandate provide equiniti bank building society account details quick secure method payment dividend payment direct equiniti convert dividend local currency information overseas payment service bank account overseas send direct local bank account including information fees found shareholders overseas overseas payment service available approximately wwwshareviewcouk contacting equiniti payment service countries worldwide electronic communications shareholders may elect receive electronic notifications please register wwwshareviewcouk company communications including annual report dividend payments dividend confirmations availability online voting general meetings time gsk publishes shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view please register wwwshareviewcouk share balance movements update address dividend payment instructions register votes general meetings deduplication receive duplicate copies mailings may please contact equiniti publications mailings one account please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated information share dealing service including please note market form corporate sponsored nominee online information fees found trading hours telephone via postal dealing service provided wwwshareviewcoukdealing pm uk time equiniti financial services limited online transactions please log monday friday excluding wwwshareviewcoukdealing public holidays england wales telephone transactions please call uk outside uk lines open pm uk time monday friday excluding uk public holidays postal transactions please call request dealing form corporate sponsored convenient way manage shares without application form requested nominee account requiring share certificate service provides facility wwwshareviewcouk contacting equiniti hold shares nominee account sponsored company continue receive dividend payments attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts equiniti financial services limited provide eqi flexible details including information fees available isas isa hold gsk shares wwweqicouk requested calling equiniti customer experience team lines open pm uk time monday friday excluding uk public holidays lines open pm uk time monday friday excluding public holidays england wales please use country code dialling outside uk provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued shareholder services contacts continued ads depositary share scam alert adr programme administered jpmorgan receive unsolicited telephone call offering sell buy chase bank na shares please take extra care caller may part highly organised financial scam regular correspondence eq shareowner services uk shareholder please contact financial po box conduct authority wwwfcaorgukconsumers st paul mn consumer helpline delivery stock certificates overnight mail tel uk eq shareowner services tel outside uk centre pointe curve suite mendota heights mn lines open pm uk time monday friday except uk public holidays pm saturdays shareowneronlinecominformationalcontactus us outside us donating shares save children depositary also provides global invest direct direct ads gsk embarked ambitious global partnership purchasesale dividend reinvestment plan ads holders save children share expertise resources details enrol please visit wwwadrcom call aim finding innovative ways reduce number children helpline number obtain enrolment pack dying preventable diseases shareholders small number shares value contacts makes uneconomical sell may wish consider donating investor relations save children donated shares aggregated investor relations may contacted follows sold behalf save children use funds raised help reach goal uk obtain share donation form please contact registrar great west road equiniti managing donation sale uk shares brentford middlesex tw gs save children free charge tel provision share dealing details intended invitation us inducement engage investment activity advice share dealing walnut street obtained stockbroker independent financial adviser philadelphia pa tel us toll free tel outside us gsk response center tel us toll free tel outside us strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued us law regulation number provisions us law regulation apply section corporate responsibility company shares quoted nyse financial reports form ads sarbanesoxley requires ceo cfo complete nyse rules formal certifications confirming general nyse rules permit company follow uk reviewed annual report form f corporate governance practices instead applied based knowledge annual report form f us provided explain significant variations contains material misstatements omissions explanation contained form f accessed sec 's edgar database via website based knowledge financial statements nyse rules require us file annual interim written financial information fairly present material respects affirmations concerning audit risk committee arc financial condition results operations cash flows statement significant differences corporate dates periods presented annual governance report form f sarbanesoxley act responsible establishing maintaining disclosure controls procedures ensure material following number corporate accounting scandals information made known evaluated us congress passed sarbanesoxley act effectiveness controls procedures year sarbanesoxley wideranging piece legislation end results evaluation contained concerned largely financial reporting corporate annual report form f governance responsible establishing maintaining internal recommended sec company established control financial reporting provides reasonable disclosure committee committee reports ceo assurance regarding reliability financial reporting cfo arc chaired company secretary preparation financial statements external purposes members consist senior managers finance legal accordance generally accepted accounting corporate communications investor relations principles appropriate external legal counsel external disclosed annual report form f auditors sponsor bank internal experts invited changes internal controls financial reporting attend disclosure committees meetings periodically period covered annual report form f committee responsibility considering materiality materially affected reasonably likely affect information timely basis determining disclosure materially companys internal control financial information responsibility timely filing reporting reports sec formal review annual report annual report form f committee disclosed based recent evaluation met times including purpose receiving relevant internal control financial reporting external appropriate training auditor arc significant deficiencies material weaknesses design operation internal controls sarbanesoxley requires annual report form f financial reporting reasonably likely affect contains statement whether member arc adversely companys ability record process summarise audit committee financial expert defined rules report financial information fraud regardless sarbanesoxley statement relevant members materiality involving persons significant role arc charles bancroft included board committee companys internal control financial reporting information area corporate governance report group carried evaluation supervision biography participation management including additional disclosure requirements arise section ceo cfo effectiveness design operation section sarbanesoxley respect disclosure controls groups disclosure controls procedures procedures internal control financial reporting december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued us law regulation continued ceo cfo expect complete certifications group exports certain medicines iran via sales non report conclusions effectiveness disclosure us entities subsidiaries us entity controls procedures march following distributor iran pursuant specific licence issued certifications filed sec part groups office foreign assets control annual report form f group regularly receive information regarding section managements annual report identity distributor 's downstream customers intermediaries iran possible parties internal control financial reporting include entities hospitals pharmacies accordance requirements section owned directly indirectly iranian government sarbanesoxley following report provided persons entities sanctioned connection terrorism management respect companys internal control proliferation activities financial reporting defined rules af df us securities exchange act amended group regularly receive information regarding exchange act identity distributor 's downstream customers intermediaries establish proportion gross management responsible establishing maintaining revenue sales potentially attributable entities affiliated adequate internal control financial reporting iranian government parties sanctioned group internal control financial reporting designed disclosable activities result group reporting provide reasonable assurance regarding reliability entire gross revenues million net profits financial reporting preparation financial million group 's sales iran statements external purposes accordance ifrs hospitals medical facilities lebanon may management conducted evaluation effectiveness affiliated controlled hezbollah groups internal control financial reporting based designated united states pursuant executive framework internal control integrated framework order group deal directly issued committee sponsoring organisations hospitals facilities instead sells distributors treadway commission coso group unable establish proportion gross revenue changes groups internal control sales potentially attributable reportable activities result financial reporting materially group reporting entire gross revenues million affected reasonably likely materially affect net losses million group 's sales lebanon groups internal control financial reporting management assessed effectiveness internal control financial reporting december addition section r exchange act us law conclusion filed part groups annual generally restricts dealings us persons dealings report form f otherwise subject us jurisdiction certain countries deloitte llp audited consolidated financial territories subject comprehensive sanctions currently statements group year ended december crimea cuba socalled donetsk people 's republic iran also assessed effectiveness groups socalled luhansk people 's republic north korea syria internal control financial reporting auditing well government venezuela though standard public company accounting oversight country venezuela whole group engages board united states audit report filed activity certain jurisdictions assessed groups form f applicable licences exemptions section r exchange act believe group complies applicable us sanctions material respects laws complex section r exchange act requires issuers make continue evolve rapidly specific disclosure annual reports certain types dealings iran including transactions dealings governmentowned orcontrolled entities well dealings entities sanctioned activities related terrorism proliferation weapons mass destruction even activities prohibited us law involve us persons strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued donations political organisations political expenditure ensure consistent approach political contributions result definitions may cover legitimate business across group global policy introduced activities ordinary sense considered political voluntarily stop corporate political contributions donations political expenditure designed support political party independent election candidate period january december group made political donations eu noneu therefore notwithstanding policy organisations intend make donations eu political parties organisations incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act us continue expenditure support employeeoperated political action committee pac facilitates voluntary political donations eligible authority precautionary measure ensure gsk employees company subsidiaries inadvertently breach legislation pac controlled gsk decisions amounts recipients contributions governed pac board authorisation process expenditure directors contributions pac made year dates back agm held may following participating eligible employees exercising legal right introduction political parties elections pool resources make political contributions referendums act authority since renewed subject strict limitations us law total annually us us donated political organisations gsk employee pac english law requires prior shareholder approval political contributions eu political parties independent election candidates well eu political expenditure definitions political donations political expenditure political organisations used legislation however quite broad particular definition eu political organisations may extend bodies concerned policy review law reform representation business community special interest groups concerned environment company subsidiaries might wish support strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held gsk plc percentage held class share stated less unless otherwise stated subsidiary companies registered office tax resident country incorporation name security registered address wholly owned subsidiaries canada inc common armandfrappier boulevard laval hv canada canada inc common milverton drive suite mississauga lr h canada alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom adechsa gmbh ii ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland affinivax inc common corporation service company little falls drive wilmington de united states allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary town planning way ilupeju lagos nigeria allen pharmazeutika gesellschaft mbh ordinary wienerbergstrae wien austria austria beecham group plc ordinary b great west road brentford middlesex tw gs england ordinary beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesa quota rua dr antonio loureiro borges arquiparque miraflores produtos farmaceuticos e quimicos lda alges portugal beecham sa ordinary avenue fleming wavre belgium bellus health corp common corporation trust company corporation trust center orange street wilmington de united states bellus health inc common boulevard armand frappier laval qc hv canada biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey cascan gmbh co kg partnership capital prinzregentenplatz munich bavaria germany cellzome gmbh ordinary meyerhofstrasse heidelberg germany clarges pharmaceutical trustees limited ii ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little falls drive wilmington de united states corixa corporation common corporation service company little falls drive wilmington de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain duncan pharmaceuticals philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines etex farmaceutica ltda social capital av andrs bello costanera center torre piso providencia santiago chile glaxo group limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo new zealand pension plan trustee limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxo verwaltungs gmbh ordinary prinzregentenplatz munich bavaria germany glaxo wellcome farmaceutica limitada ordinary rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production ordinary rue franois jacob rueilmalmaison france strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxo wellcome vidhyasom limited liquidation ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd ordinary th floor dksh building preah monivong boulevard co sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room unit floor mid th east ring road chaoyang district beijing china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline gsk srl ordinary str dr nicolae staicovici nr opera center ii etaj sector bucureti romania glaxosmithkline ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline australia pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary rue de l'institut b rixensart belgium preference glaxosmithkline brasil limitada quotas estrada dos banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc n market street th floor wilmington de united states glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline gsk srl ordinary str dr nicolae staicovici nr opera center ii etaj sector bucureti romania glaxosmithkline ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline australia pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary rue de l'institut b rixensart belgium preference strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline brasil limitada quotas estrada dos banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc n market street th floor wilmington de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital av andrs bello torre piso providencia santiago regin metropolitana chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer holding bv ii ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline doo beogradnovi beograd liquidationordinary milutin milankovic j novi beograd belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline el salvador sa de cv ordinary municipio de san salvador departamento de san salvador el salvador glaxosmithkline eood ordinary nedelcho bonchev str sofia sofiya bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary ra av zona torre citibank nivel guatemala city guatemala glaxosmithkline holding ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street th floor wilmington delaware glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common milverton drive suite mississauga lr h canada class c preference glaxosmithkline insurance ltd ordinary co trinity corporate services ltd trinity hall cedar avenue hamilton hamilton hm bermuda glaxosmithkline intellectual property limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom glaxosmithkline intellectual property development limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom glaxosmithkline intellectual property holdings limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny b ordinary united kingdom glaxosmithkline intellectual property limited deferred gsk medicines research centre gunnels wood road stevenage sg ny ordinary united kingdom glaxosmithkline intellectual property management limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investments pty ltd ordinary level johnston street abbotsford victoria australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline limited ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline limited ii ordinary great west road brentford middlesex tw gs england glaxosmithkline llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline manufacturing spa ordinary viale dellagricoltura verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products kft ordinary budapest andrassy ut hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline mexico sa de cv ordinary av real mayorazgo piso colonia xoco alcaldia benito jurez ordinary b ciudad de mexico mexico glaxosmithkline nz limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxosmithkline oy ordinary porkkalankatu helsinki finland glaxosmithkline peru sa ordinary av vctor andrs belande n va principal n piso distrito de san isidro lima peru glaxosmithkline pharma ordinary vallensbk company house iii delta park dk valle denmark glaxosmithkline pharma gmbh ordinary wienerbergstrae wien austria austria glaxosmithkline pharmaceutical kenya limited ordinary po box likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary hz horizon penthouse powerhouse persiaran bandar utama bandar utama petaling jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary autopista florencia del castillo kilmetro siete oficentro terracampus edificio uno cuarto piso san diego cartago costa rica glaxosmithkline pharmaceuticals sa ordinary avenue fleming wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline philippines inc ordinary rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common corporation service company puerto rico inc co rvm professional services llc reparto mendoza humacao puerto rico glaxosmithkline republica dominicana sa ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline sl lp iiviii partnership great west road brentford middlesex tw gs england glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline trading services limited iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble regus lot b centre urbain nord tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered provisory stock victor solio montevideo montevideo uruguay glaxosmithkline us trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ca ordinary calle altagracia edificio pg piso mezzanina torre torre sur urbanizacion sorokaima la trinidad caracas venezuela bolivarian republic glaxosmithkline vietnam limited liability company ii equity capital metropolitan dong khoi street district th floor unit ho chi minh city vietnam glycovaxyn ag liquidation common grabenstrasse schlieren switzerland preferred preferred b preferred c groupe glaxosmithkline ordinary rue franois jacob rueilmalmaison france gsk biopharma argentina sa nominative non tucumn piso buenos aires caaa argentina endorseable ordinary gsk scottish limited partnership viii partnership lothian road festival square edinburgh scotland eh wj united kingdom gsk scottish limited partnership viii partnership lothian road festival square edinburgh scotland eh wj united kingdom gsk scottish limited partnership viii partnership lothian road festival square edinburgh scotland eh wj united kingdom strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia gsk capital bv iiiv ordinary great west road brentford middlesex tw gs gsk capital kk ordinary akasaka minatoku tokyo japan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management co ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investments limited units corporation service company interstate drive suite harrisburg pa united states gsk finance plc ordinary great west road brentford middlesex tw gs england gsk finance limited ordinary great west road brentford middlesex tw gs england gsk india global services private limited equity level luxor north tower bagmane capital business park outer ring road bangalore karnataka india gsk international holding finance bv ordinary van asch van wijckstraat h lp amersfoort netherlands gsk kazakhstan llp participation interest nursultan nazarbayev ave business center usko rd fl almaty kazakhstan gsk life sciences fze ordinary lb jebel ali freezone dubai united arab emirates gsk pharma india private limited equity battery house bhulabhai desai raod mumbai maharashtra india gsk pharma vietnam company limited chartered capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh vietnam gsk pharmaceutical trading sa ii ordinary bucharest costache negri street opera center one th floor discussions room district romania gsk psc poland sp z oo equal indivisible shares ul grunwaldzka pozna pol gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv ordinary hullenbergweg cl amsterdam netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota via fiorentina siena italy gsk vaccines srl quota via fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselring holzkirchen germany human genome sciences inc common corporation service company little falls drive wilmington de united states id biomedical corporation quebec common boul du parc technologique qubec qubec gp r canada instituto luso farmaco limitada ii quota rua dr antonio loureiro borges arquiparque miraflores alges portugal interpharma dienstleistungen gmbh quota wienerbergstrae wien austria austria jj technologies lc ii llc interests corporation service company shockoe slip nd floor richmond va united states jsc glaxosmithkline trading ordinary leningradskiy prospect building floor premises xv room moscow russian federation laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoires saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordinary av real mayorazgo piso colonia xoco alcaldia benito jurez ordinary b ciudad de mexico mexico laboratorios farmaceuticos stiefel portugal ltda ii ordinary rua dr antonio loureiro borges arquiparque miraflores alges portugal laboratorios stiefel de venezuela sa ordinary calle altagracia edificio pg nivel mezzanina piso mezzanina local torre sur urbanizacion sorokaima la trinidad caracas venezuela bolivarian republic laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii quota rua dr antonio loureiro borges arquiparque miraflores alges portugal maxinutrition limited liquidation ordinary co bdo llp temple square temple street liverpool l rh pt glaxo wellcome indonesia class jl pulobuaran raya kaviii class b dd kws industri pulogadung jatinegara cakung jakarta timur indonesia setfirst limited ordinary great west road brentford middlesex tw gs england strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued sierra oncology australia pty ltd ordinary co maddocks lawyers angel place level pitt street sydney australia sierra oncology canada ulc common suite west georgia street vancouver bc vb canada sitari pharma inc common corporation service company little falls drive wilmington de united states smith kline french portuguesa ordinary rua dr antonio loureiro borges arquiparque miraflores produtos farmaceuticos lda ii alges portugal smithkline beecham bangladesh private limited ii ordinary housea roadgulshan dhaka bangladesh smithkline beecham cork limited ordinary riverwalk citywest business campus dublin ireland smithkline beecham egypt llc quota amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham legacy h limited ordinary great west road brentford middlesex tw gs england smithkline beecham limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington de united states smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited ii stiefel gmbh co kg partnership capital prinzregentenplatz munchen germany stiefel laboratories legacy ireland limited ordinary unit building avenue cork airport business park cork ireland stiefel laboratories pte limited ordinary pioneer sector singapore stiefel laboratories inc common corporation service company little falls drive wilmington de united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary level johnston street abbotsford victoria australia stiefel research australia pty ltd ordinary level johnston street abbotsford victoria australia stiefel west coast llc llc interests corporation service company little falls drive wilmington de united states strebor inc common corporation service company little falls drive wilmington de united states tesaro bio gmbh liquidation ordinary poststrasse zug switzerland tesaro bio netherlands bv ordinary joop geesinkweg ab amsterdamduivendrecht netherlands tesaro development ltd ordinary clarendon house church street hamilton hm bermuda tesaro inc common corporation service company little falls drive wilmington de united states sydney ross co ii ordinary corporation service company princeton south corporate center suite charles ewing blvd ewing nj united states ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petaling jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome limited ordinary great west road brentford middlesex tw gs england effective name security ownership registered address subsidiaries effective interest less amoun pharmaceutical industries co sae monetary shares el salam city po box cairo egypt biddle sawyer limited equity dr annie besant road mumbai india british pharma group limited guarantee great west road brentford middlesex tw gs england galvani bioelectronics inc common corporation service company little falls drive wilmington de united states galvani bioelectronics limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny b ordinary united kingdom glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxoallenburys nigeria limited ii ordinary creek road apapa lagos pmb nigeria strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quota amoun street po box el salam city cairo egypt phivco llc llc interests corporation service company little falls drive wilmington de united states phivco llc llc interests corporation service company little falls drive wilmington de united states smithkline beechambiomed ooo participation interest leningradskiy prospect building floor premises xiv room moscow russian federation stiefel egypt llc ii quota amoun street po box el salam city cairo egypt viiv healthcare south africa proprietary ordinary flushing meadows building campus sloane street bryanston limited south africa viiv healthcare bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands viiv healthcare company common corporation service company little falls drive wilmington de united states viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare kk ordinary akasaka minatoku tokyo japan viiv healthcare limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny b ordinary united kingdom c ordinary preference ordinary deferred e cumulative preference viiv healthcare pty ltd ordinary level johnston street abbotsford victoria australia viiv healthcare puerto rico llc llc interests corporation service company puerto rico inc co rvm professional services llc reparto mendoza humacao puerto rico viiv healthcare srl quota viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary avenue fleming wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect building floor premises xiv room moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom viiv healthcare uk limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom viiv healthcare uk limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom viiv healthcare uk limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom viiv healthcare uk limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores alges portugal winster pharmaceuticals limited ordinary association avenue ilupeju industrial estate lagos po box nigeria effective name security ownership registered address associates glaxosmithkline landholding company inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines index ventures life vi jersey lp partnership interest esplanade st helier jersey je wg channel islands kurma biofund ii fcpr partnership interest rue royale th floor paris france longwood fund lp partnership interest prudential tower suite boylston street boston medicxi ventures lp partnership interest esplanade st helier jersey je wg channel islands joint ventures chiron panacea vaccines private limited liquidation equity shares th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india significant holdings axon therapies inc common walsh avenue santa clara ca united states series preference alpheus medical inc series preference hopkins place north oakdale minnesota usa series preference global farm sa shares mendoza ciudad autnoma de buenos aires argentina b shares c c shares shares longwood fund ii lp partnership interest prudential tower suite boylston street boston sanderling ventures vii lp partnership interest el camino real suite san mateo ca sr one capital fund ib lp partnership interest corporation service company little falls drive city wilmington county new castle delaware sr one capital opportunities fund lp partnership interest corporation service company little falls drive city wilmington county new castle delaware strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued group companies continued following uk registered subsidiaries take advantage audit exemption set within section companies act period ended december unless otherwise stated undertakings listed owned either directly indirectly gsk plc effective company name security ownership registered address number uk registered subsidiaries exempted audit burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england domantis limited ordinary gsk medicines research centre gunnels wood road stevenage sg ny united kingdom edinburgh pharmaceutical industries limited ii ordinary shewalton road irvine ayrshire ka ap united kingdom sc preference eskaylab limited ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxochem uk unlimited ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england gsk gp limited iv shares lothian road festival square edinburgh scotland eh sc b shares wj united kingdom gsk gp limited iv ordinary lothian road festival square edinburgh scotland eh sc wj united kingdom gsk lp limited iiv ordinary great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap united kingdom sc phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited ordinary great west road brentford middlesex tw gs england smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinary smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical services ordinary great west road brentford middlesex tw gs england limited smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ordinary great west road brentford middlesex tw gs england stiefel laboratories uk ltd ordinary great west road brentford middlesex tw gs england tesaro uk limited ordinary great west road brentford middlesex tw gs england wellcome foundation limited ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england accordance section c companies act company guarantee debts liabilities uk subsidiary undertakings december total sum debts liabilities million million key directly owned gsk plc ii dormant entity iii tax resident uk iv exempt regulation partnership accounts regulations requirement deliver registrar financial statements qualifying partnerships entity member accordance companies act v incorporated netherlands vi consolidated subsidiary accordance section companies act grounds dominant influence vii principal business address puerto rico viiiexempt provisions regulations partnership accounts regulation accordance exemptions noted regulation regulation strategic report governance remuneration financial statements investor information gsk annual report glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company gsk plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group gsk plc subsidiary undertakings gsk gsk plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance code strategic report governance remuneration financial statements investor information gsk annual report statutory disclosures continued index access major restructuring costs accounting principles policies movements equity acquisitions disposals net debt adjustments reconciling total profit tax operating new accounting requirements cash flows nominations corporate governance committee report annual general meeting noncontrolling interests approach tax noncontrolling interests viiv healthcare assets held sale nonexecutive directors fees associates joint ventures nonfinancial sustainability information statement audit risk committee report notes financial statements business model operating profit cash cash equivalents intangible assets cash generation conversion investments ceos statement noncurrent assets chairs statement noncurrent liabilities chairs governance statement operating incomeexpense climaterelated financial disclosure provisions commitments culture people continuous engagement key decisions external environment consolidated balance sheet longterm priorities consolidated cash flow statement pensions postemployment benefits consolidated income statement performance consolidated statement changes equity pharmaceutical products competition intellectual consolidated statement comprehensive income property contingent consideration liabilities pipeline contingent liabilities post balance sheet events corporate governance presentation financial statements corporate responsibility committee report principal group companies critical accounting judgements key sources principal risks uncertainties estimation uncertainty property plant equipment critical accounting policies reconciliation net cash flow movement net debt demerger consumer healthcare business registrar directors senior management related party transactions directors interests shares reliable supply directors report remuneration committee chair 's annual statement directors statement responsibilities remuneration governance dividends remuneration report donations political organisations political reporting framework expenditure research development earnings per share responsible business employee costs right use assets employee share schemes risk management environment science committee report ethical standards section statement exchange rates share capital control finance expense share capital share premium account finance income share consolidation financial calendar shareholder information financial instruments related disclosures shareholder services contacts financial performance summary specialty medicines financial position resources task force climaterelated financial disclosures general medicines taxation glossary terms tax information shareholders goodwill board group companies threeyear selected financial data group financial review trade payables gsk leadership team trade receivables gsk plc parent company accounts uk gaap treasury policies independent auditors report trust innovation turnover segment information inventories us law regulation investments associates joint ventures using data responsibly investor relations vaccines key performance indicators vaccine products competition intellectual property legal proceedings viability statement gsk gsk plc incorporated glaxosmithkline brand names appearing italics throughout report trade marks either owned andor licensed gsk associated companies plc english public limited company trade marks property respective owners december formed merger printed sustainably uk pureprint carbonneutral company glaxo wellcome plc smithkline fsc chain custody iso certified environmental management system recycling dry waste beecham plc gsk acquired two english printed arena eco ew smooth wood free uncoated paper ecf companies december part fsc certification made recycled fibre merger arrangements effective may glaxosmithkline plc changed name gsk plc july gsk plc separated consumer healthcare business gsk group form haleon independent download pdfs listed company annual report form f shares listed london stock esg performance report exchange new york stock exchange fullyear fourth quarter results gskcom cautionary statement regarding forwardlooking assumptions basis preparation related assumptions gsks updated revenue operating statements guidance outlooks profit operating margin cash flow outlooks document groups reports published guidance outlooks expectations read revenue outlook margin expectations filed furnished us securities exchange together guidance outlooks assumptions dolutegravir loss exclusivity also factor commission sec written information cautionary statements annual report divestments product exits announced date well released oral statements made public group 's q earnings release material costs investment new product launches f l gou rot ou k ur ine pg b sy ct uo rr r eo em nn eb ene xth pa efl cf r awf ia oh r ne g l oor ro fu k oip n g c asa say tst c e oo fn e ft ua n tti un r g efo iv erw e v ea nhrd te p cn ee ro r tiu il ni n ai n sg su mh e p tg ou ni ad sna adn b c f ooe ur f tr h e th ae ca g rn ord eo u cpu ot nhlo oao msk ms ic f dr eth e p l ra en la ged n us nr lt e tnd od rel r r nu si uans ck lc ceha ese td ss smj u w fas oht e c ed h fa ca hrl hee ae r si psi sn k r ec tal bu id nad j dus el vs te ea oe b f ps mf eso ce er h np n ct ne tn lh eia n dl investor identify statements fact environment healthcare sector including regarding potential future sales contribution blenrep relate strictly historical current facts existing possible additional governmental legislative excluded use words anticipate estimate expect regulatory reform different markets intend project plan believe target competitive landscape group operates notwithstanding guidance outlooks words terms similar meaning connection delivery revenues financial benefits expectations still uncertainty whether discussion future operating financial current portfolio development pipeline assumptions guidance outlooks expectations performance particular include statements restructuring programmes achieved including based assumptions relating future actions prospective products product guidance outlined p wfp n tctp hi mcr io n tp e sv ta nia ln ettl g ses g ed af n u n lp ct odru io r f e u sp guc ne uctsr c lh af ts lm rrl ye ela e g ue bc lf le l g p aor rtr ts ir oc e e nes x eu srp dl e h nnn cgs n lf e u ic ndu nir vhr gce ie c n ueo ot nn u ra dddtn c ea rn cee e thxh n epe es g ee c ra op ar ul n ta pii onn sngn pi sn rapg ose dsa r u u cs h tu e sm r n nep gt mo un ad ta e ea n r rs ic ia aw e l l e ia mnl nl eea rrs g rd u eo pv rp si tde ar ea nn ct qdi n u og sp itu ir opo npfi st ly r f b toall ts hi su e l n yd ek u rt e sa te om e n v e wa yr ir ea te hng g e v e e x n c aho sn n hg e e c bran set e os yn ua et ts l aoc ru r kbr e ren fec ey r market abuse regulation uk listing rules disposals material litigation investigation costs notice regarding limitations director liability disclosure transparency rules financial company save already recognised english law conduct authority group undertakes obligation provisions made change uk companies act safe harbour limits update forwardlooking statements whether groups shareholdings viiv healthcare liability directors respect statements result new information future events otherwise assumptions also assume material changes omissions directors report see reader however consult additional disclosures healthcare environment unexpected significant strategic report remuneration report group may make documents changes pricing result government competitor english law directors would liable publishes andor files sec readers wherever action guidance factors divestments company third party one located take note disclosures product exits announced date reports contained errors result recklessness accordingly assurance given outlooks knowing misstatement dishonest concealment particular expectation met investors assumptions gsks updated revenue operating material fact would otherwise liable pages cautioned place undue reliance forward profit operating margin cash flow outlooks inclusive comprise looking statements revenue outlook margin expectations directors report pages inclusive comprise f f e cn aso h c pr uie tw soor ea e rr snr aat et cn h r tl u ftk h ao ek lc rr tn g ee ong r rbd us e lu ut tiya sp nn c tc ce n ole uam r ddu te ia fh nn fi oe gn et ns r g sea mh r isr oo n ae su vm es e epu ris n ib tn cj le r lho ysc n st ff h r drw oao mh tla c c us tr hhs nu p ur em r se enlp c tb ei e co e r oo us f l r ae po v hv j pl e uu e rcn st ol ho te u pg e ah ds mr l sba v oan enir fs b il p hef en e aps na peo n l ia df pc n ee ei e sa sx le icc l p n rbl esu ibe e rs pt en di fv ode ft r f l oy tfii ot fu r osa rt lfs h ihr f os io esu om rm pr fu b ue di g et r rps lt uo h c oa gwe u sn erd r ee r nv enl ni dgv c ae ua vcr ln ar ay ind cto oe k c f r ny es u u th ot p p ir e r oa ea hr nt cn ee e ted g lm r mi pc sgu r il inr te ne ase hp tcer ao ctr n nt oit eo n n e p cir nnd ae di p n oap rno ca e r c lg w st ao te w r h ca c ohnh nec ot e ssto f eh p w w e r r e h l h p vi ac ioi da bn h r en ic tlh si ddl tu es biv hni se yv r e l seb l f uc l e bi cao e h e hnm n e sc l ad e br wr js ewe c n expressed implied forwardlooking statement underlie expectations also website factors include limited assessed purpose riskadjusted basis gsks website wwwgskcom gives additional information discussed principal risks uncertainties described material interruptions group notwithstanding references make pages annual report forward supply groups products successful delivery annual report gsks website none looking statements made behalf group ongoing planned integration restructuring plans information made available website constitutes speak date made based material mergers acquisitions disposals part annual report shall deemed upon knowledge information available material business development transactions material incorporated reference herein directors date report litigation investigation costs company save already recognised provisions number nonifrs measures used report made share repurchases company performance business measures defined change shareholdings viiv healthcare pages reconciliation adjusted results gsk assumes premature loss exclusivity key total results set pages products period information document constitute offer sell invitation buy shares gsk plc invitation inducement engage investment activities past performance relied upon guide future performance nothing annual report construed profit forecast unite science technology talent get ahead disease together head office registered office gsk plc great west road brentford middlesex tw gs united kingdom tel registered number